Acute Coronary Syndromes by unknown
Acute Coronary Syndromes
Edited by Mariano E. Brizzio
Edited by Mariano E. Brizzio
This book has been written with the intention of providing an up-to-the minute 
review of  acute coronary syndromes. Atherosclerotic coronary disease is still a 
leading cause of death within developed countries and not surprisingly, is significantly 
rising in others. Over the past decade the treatment of these syndromes has changed 
dramatically. The introduction of novel therapies has impacted the outcomes and 
surviving rates in such a way that the medical community need to be up to date almost 
on a “daily bases”. It is hoped that this book will provide a timely update on acute 
coronary syndromes and prove to be an invaluable resource for practitioners seeking 
new and innovative ways to deliver the best possible care to their patients.
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Antiplatelet Therapy in Cardiovascular  
Disease – Past, Present and Future 
Mariano E. Brizzio 
The Valley Heart and Vascular Institute, Ridgewood, New Jersey 
USA 
1. Introduction 
Platelet activity has a very important role in the pathogenesis of atherosclerosis disease. In 
addition to being part of the coagulation system, they contribute to all phases of the 
atherosclerosis process (1) The “intervention” in the platelet activity has been played a 
central role in the treatment of coronary artery disease (CAD) (2). 
Aspirin is considered the foundation antiplatelet therapy for patients at risk of 
cardiovascular events. However, in the last few decades many different agents were 
introduced to have a more effective antiplatelet action and improve treatment outcomes in 
coronary syndromes. 
In this chapter you will find a systematic review of all the antiplatelet agents available: 
mechanism of action, pharmacokinetics, side effects, evidence of effectiveness and their use 
in clinical settings. A special emphasizes will point out agents that are in investigational 
stage and what are the future perspectives. 
1.1 Platelet mechanisms of action 
Platelets play a critical role in the normal coagulation system by “preventing” bleeding after 
blood vessels are damaged.  In addition they contribute to different phases of the atherosclerotic 
process (1). Rupture of a previously formed atherosclerotic plaque exposes collagen, smooth-
muscle cells and von Willebrand factor (vWF) all of which trigger platelet activation and 
massive aggregation (3). The result of this accumulation of platelets is thrombosis. Acute 
coronary syndrome (ACS) is a consequence of the occlusion of an atherosclerotic vessel by the 
thrombotic process.  As described before, collagen and vWF in addition to thromboxane A2 
(TXa2), thrombin and adenosine diphosphate (ADP) are the most powerful platelet activators 
(4).  When a platelet is activated a conformational change occurs in a receptor located in the 
platelet membrane called glycoprotein IIb/IIIa which promotes platelet aggregation (5).  
Antiplatelet agents that target critical steps of the thrombotic mechanism described above 
have been developed in the last three decades.  However, treatment with these agents can 
sometimes increase the risk of “undesirable” bleeding complications (6). 
2. The traditional anti-platelet agents 
Many anti-platelet agents have been tested and used as an effective treatment in arterial 
thrombosis. Acetyl salicylic acid, commonly known as aspirin was the first anti-platelet 
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agent used and proven to be effective to reduce the incidence of myocardial infarction and 
stroke in many high risk vascular patients (2).The recurrence of vascular events in 
patients treated with aspirin alone ranges between 10 – 20% within five years of the initial 
event (2-7).  
Aspirin is effective by blocking the synthesis of TXa2, a powerful platelet activator.  
In the last decade, the thienopyridines such as clopidogrel have been used to improve 
outcomes in the treatment of ACS.  This anti-platelet agent irreversibly blocks the P2Y12 
receptor, precluding the platelet activation by ADP (2).  Its anti-platelet mechanism of action 
clearly differs from aspirin.  In the majority of cardiovascular patients the combination of 
clopidogrel and aspirin has additive beneficial effects when compared with clopidogrel or 
aspirin alone (8).  Clopidogrel also has some limitations, which have prompted the 
development of newer anti-platelet agents which interact at different sites of the coagulation 
cascade. 
The following figure reflects the site of action of the common antiplatelet agents (figure 1)  
3. The thromboxane A2 antagonist 
Dipyridamole (Persantine) acts as a thromboxane synthase inhibitor, therefore lowering the 
levels of TXA2 and thus stops the effects of TXA2 as a platelet activator (9). 
Also can causes systemic vasodilation when given at high doses over a short period of time. 
The latter, due to the inhibition of the cellular reuptake of adenosine into platelets, red blood 
cells and endothelial cells leading to increased extracellular concentrations of adenosine (9). 
It also inhibits the enzyme adenosine deaminase, which normally breaks down adenosine 
into inosine. This inhibition leads to further increased levels of extracellular adenosine, 
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Protease-activated receptor 1 antagonist 
Vorapaxar 
Direct thrombin Inhibitor 
Bivalirudin 
Modified release dipyridamole is used in conjunction with aspirin (under the trade names 
Aggrenox in the USA or Asasantin Retard in the UK) in the secondary prevention of stroke 
and transient ischemic attack. This practice has been confirmed by the ESPRIT trial (9). A 
triple therapy of aspirin, clopidogrel and dipyridamole has been investigated, but this 
combination led to an increase in adverse bleeding events (10). 
Via the mechanisms mentioned above, when given as 3 to 5 min infusion it rapidly increases 
the local concentration of adenosine in the coronary circulation which causes vasodilation. 
Vasodilation occurs in healthy arteries, whereas stenosed arteries remain narrowed. This 
creates a "steal" phenomenon where the coronary blood supply will increase to the dilated 
healthy vessels compared to the stenosed arteries which can then be detected by clinical 
symptoms of chest pain, electrocardiogram and echocardiography when it causes ischemia. 
Flow heterogeneity (a necessary precursor to ischemia) can be detected with gamma cameras 
and SPECT using nuclear imaging agents such as Thallium-201 and Tc99m-Sestamibi (9). 
Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane 
induced platelet aggregation and vasoconstriction (11). As of 2010, it is being tested for the 
secondary prevention of acute thrombotic complications in the Phase III clinical trial. 
However, the recent publication of the finalized trial PERFORMS shown no clinical 
advantage in comparison with patients with aspirin monotherapy in preventing strokes (12). 
At the time of this publication its use in clinical practice is not approved in the USA. 
4. Other P2Y 12 antagonist 
Ticlopidine an anti-platelet drug in the thienopyridine family inhibits platelet aggregation 
by altering the function of platelet membranes by irreversibly blocking ADP receptors. This 
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prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding 
to fibrinogen (13).  It is used in patients in whom aspirin is not tolerated, or in whom dual 
anti-platelet therapy is desirable (in combination with Aspirin).  Because it has been 
reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and 
neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is 
felt to have a much lower hematologic risk (14). 
Prasugrel, a novel thienopyryridine was approved for clinical use in the USA by the Food 
and Drug Administration (FDA) in 2010.  Unlike clopidogrel, which undergoes a two-step, 
CYP450-dependent conversion to its active metabolite, prasugrel only requires single-step 
activation.  Prasugrel is a more potent platelet inhibitor with faster action and inhibition.  
Also, it has been estimated that due to its “easy metabolism” its genetic resistance is less 
likely (15). In other words, prasugrel has a significantly lower incidence of hypo-
responsiveness in comparison with clopidogrel (15). However, the risks of bleeding in these 
patients are greater than clopidogrel (16). 
Ticagrelor is the most novel class of anti-platelet drugs, the cyclopentytriazolopyrimides, 
which also inhibit the P2Y12 receptor as the thienopyryridines.  However, it has a simpler 
and faster metabolism (rapid onset of action) high potency and most importantly 
reversibility (17). The latter, makes this drug safer in regards of bleeding complications. 
Cangrelor, an ATP analog, is an investigational intravenous anti-platelet drug. This agent 
has biphasic elimination and possesses the advantages of high potency, very fast onset of 
action and very fast reversibility after the discontinuation (16).This gives a considerable 
advantage over other ADP antagonist in patients who might need immediate surgery. 
However, after initial treatment, patients who received intravenous infusion of Cangrelor 
often require continued treatment with one of the oral P2Y12 antagonists, something that 
one must take into consideration (16).  
5. Glycoproteins IIb/IIa antagonist 
Abciximab, more known as the ReoPro is an antibody against glycoprotein IIb/IIIa receptor.  It 
had a lot of popularity within interventional cardiologist 10 years ago.  It is barely used today.  
It was replaced by newer IV agents. Abciximab has a plasma half-life of about ten minutes, with 
a second phase half-life of about 30 minutes. However, its effects on platelet function can be 
seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein 
IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated (18). 
Tirobiban (Aggrastat) is a synthetic, non-peptide inhibitor acting at glycoprotein (GP) IIb/IIIa 
receptors.  It has a rapid onset and short duration of action after proper intravenous 
administration.  Platelet activity returns to normal 4 to 8 hours after the drug is withdrawn (19). 
Eptifibatide (Integrilin) is the newer anti-platelet drug which inhibits the glycoprotein IIb/IIIa 
inhibitor.  It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and 
reversibly binds to platelets.  Eptifibatide has a short half-life, 3 to 5 hours after the 
discontinuation platelet activity recovers to normal levels (20).The drug is the third inhibitor of 
GPIIb/IIIa that has found broad acceptance within interventional cardiologists nowadays. 
6. Proteasa-activated receptors antagonist 
Vorapaxar (formerly SCH 530348) is a thrombin receptor (PAR-1) antagonist based on the 
natural product himbacine.  It is an experimental pharmaceutical treatment for acute coronary 
syndrome as a very powerful platelet inhibitor (21).In January 2011, the clinical trial was 
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halted for patients with stroke and mild heart conditions due to safety reasons. It is unknown 
if it will continue.  
7. Direct thrombin inhibitors 
Bivalirudin (Angiomax) is a specific and reversible intravenous direct thrombin inhibitor.  
Clinical studies demonstrated consistent positive outcomes in patients with stable angina, 
unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-
segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized 
trials (22).  Coagulation times and platelet activity return to baseline approximately 1-6 hour 
following cessation of bivalirudin administration (23). 
8. Conclusions 
Antiplatelet therapy plays a crucial role in the treatment of coronary patients.  The continuous 
introduction of new agents is geared to improve results in patient ongoing percutaneous 
coronary interventions.  However, the side effects of theses should be monitored closely.  In 
the end, the ideal management of patients with acute coronary syndrome should be to be a 
collaborative effort between cardiologist and surgeons to assure the best outcomes possible. 
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halted for patients with stroke and mild heart conditions due to safety reasons. It is unknown 
if it will continue.  
7. Direct thrombin inhibitors 
Bivalirudin (Angiomax) is a specific and reversible intravenous direct thrombin inhibitor.  
Clinical studies demonstrated consistent positive outcomes in patients with stable angina, 
unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-
segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized 
trials (22).  Coagulation times and platelet activity return to baseline approximately 1-6 hour 
following cessation of bivalirudin administration (23). 
8. Conclusions 
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introduction of new agents is geared to improve results in patient ongoing percutaneous 
coronary interventions.  However, the side effects of theses should be monitored closely.  In 
the end, the ideal management of patients with acute coronary syndrome should be to be a 
collaborative effort between cardiologist and surgeons to assure the best outcomes possible. 
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1. Introduction 
Seeing is believing, but the reverse, namely, disbelieving the unseen may often go against 
the spirit of scientific exploration. This is particularly true for nano-scale objects 
interacting almost invisibly with biological cells, tissues or organs. Interestingly many of 
the biological sub-cellular components (e.g. proteins, DNA)have nano-scale dimension. 
The apparently innocent (chemically inactive) and tiny particulate matter originating from 
various natural or artificial sources (e.g., pollutant) have been shown to be toxic at 
different  physiological levels. The famous saying by Jeevaka, the legendary physician of 
the Jataka tales,  that there is no herb in the world that is not a drug, however follows. 
What is toxic in some context have important therapeutic value elsewhere. Nanoparticles 
do interfere with the thrombo-static equilibrium. While this shift on one hand is a matter 
of concern, it may provide us a tool to handle or diagnose diseases in which such 
equilibrium is shifted. One of the finest models to test this dual aspect of the nano-scale 
objects is Acute Coronary Syndrome (ACS), a leading cause of death in the global 
scenario. What is known today regarding the effect of nanoscale objects may really be a 
tip of iceberg and with the advent of smarter nanoparticles one may think of more 
versatile use of nanotechnology in the management of ACS.  
2. Role of platelets in Acute Coronary Syndrome (ACS) 
ACS is a complex and multi-factorial disease (Badran et al., 2009). ACS is an umbrella like 
term which includes mainly three diseases i). ST elevated myocardial infarction (STEMI), 
ii). Non ST elevated myocardial infarction (NON STEMI), and iii) unstable angina. The 
patho-physiological event of ACS can be divided into four phases: 
a. Atherosclerotic plaque formation. 
b. Rupture of an unstable plaque. 
c. The acute ischemic event. 
d. Long term risk of recurrent coronary event. 
2.1 Platelet basic physiology 
Platelets play a pivotal in manifestation of ACS. Platelets are discoid in shape, with 
approximate number density 150,000-300,000/µl, and dimension of the order of 2000-4000 
nm.  Derived from megakaryocyte (figure 1) (Thompson, 1986) they contain mitochondria, 
peroxisomes, endoplasmic reticulum. They also contain granules and glycogen bodies. 
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Granules occur as i) dense granules (δ), ii) alpha granules (α). Dense granules mainly 
contains ATP, ADP, serotonin etc., whereas alpha granules contain fibronectin, fibrinogen, 
platelet activation factor (PAF) etc. (Marcus et al, 1966; Flaumenhaft et al, 2005). Ca++, one of 
the most important factors for platelet action, is stored in endoplasmic reticulum and 
released into the cytoplasm, during platelet activation (Nesbitt et al, 2003). Open canalicular 
system (OCS) is a channel like protrusion inside the platelet where granules release their 
contents (Escolar & White, 1991). Recently role of mRNA and mi-RNA has been shown to 
play important roles in platelet aggregation (Calverley et al, 2010; Rowley et al, 2011; 
Nagalla et al, 2011).  
 
 
Fig. 1. Precursor megakaryocyte and progenitor platelets: Represents microscopic image 
(20X) of a megakaryocyte in the bone marrow. Platelets generated from the megakaryocyte 
can be seen in 12 o’clock position of the megakaryocyte.  
When exposed to agonists, platelets become activated and this is followed by an 
aggregatory response (Patscheke, 1979). In systemic blood flow platelets remain in resting 
phase, without being activated (Marcus et al, 1991). Physiological agonists like collagen, 
thrombin, ADP, ATP etc. are not associated with the normal blood flow. Even if a trace 
amount of ADP and ATP are present, they are broken down by the phosphatase activity of 
CD39 (Marcus et al, 1997). At wound site, sub endothelial layers get ruptured. Hence Von 
Willebrand factor (vWf) and collagen get exposed causing activation of platelets (Nyman , 
1980; Tschopp et al., 1980). After the primary phase of activation and aggregation, platelet 
granules are released, this leads to enhancement of local concentration of agonists (e.g. 
granule secreted ADP, ATP, serotonin etc.). This triggers irreversible secondary phase 
platelet aggregation with fibrinogen, which is further followed by cessation of bleeding 
(Decie and Lewis 2003) (figure 2).  
 




Fig. 2. Schematic diagram of platelet activation and aggregation. In the resting conditions 
platelets, maintain their discoid form and flow in circulation. Upon injury, platelets become 
exposed to sub-endothelial collagen and vWf (1) adhered on it (2). This is followed by 
activation and shape changes (3). The next phase is granules release and  secondary phase 
aggregation (4) and lastly the stable platelet plaque forms(5). 
The detailed mechanism of platelet function depends on the complex intracellular signalling 
pathways. This leads to platelet activation by simulating a series of physiological events. 
Briefly, after binding of agonists, the corresponding receptors trigger downstream signalling 
cascades and initiates Ca++ mobilisation from endoplasmic reticulum. Platelet granules 
release (α and δ), platelet shape change and the thromboxane A2 (TXA2) production then 
follows. The cumulative effects of these events initiate activation of fibrinogen receptor 
(GPIIbIIIa) and triggering of primary phase  aggregation. The released granules-content 
(ADP, ATP etc.) along with TXA2 activate other resting platelets resulting the secondary 
phase aggregation (Kroll & Schafer, 1989; Ashby, 1990) (figure 3). The important signalling 
molecules that help the above process through a complex interplay among different G-
protein coupled receptors, integrin receptors, second messengers, kinases, phosphatise and 
Ca++ mobilisation etc (Dorsam & Kunapuli, 2004; Wu e al., 2006,2010;  Roberts et al.,2004; 
Karniguian et al., 1990; Farndale, 2006; Spalding et al., 1998; Patscheke , 1980; Clifford et al., 
1998; Hoffman et. al. 2009).  
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Fig. 3. Schematic diagram of agonists induced platelet activation. Binding of agonists with 
corresponding receptors, triggers downstream signalling cascade, and causes mobilisation 
of intracellular Ca++. The initial Ca++ flux branches itself into three major signalling events: 
A (alpha and dense granules release), B (platelet shape change), C (TXA2 production).  The 
three signalling events cumulatively determine the activation and aggregation. The released 
chemicals (ADP,ATP etc) from granules and the TXA2, further activates other resting 
platelets and initiates the secondary phase of aggregation.    
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2.2 Platelet in ACS 
It may be contextual to focus on the pathological role of platelets in ACS. Platelet thrombosis 
plays a central role in the pathogenesis of Acute Coronary Syndrome (ACS) by the 
formation of thrombi at the site of the ruptured atherosclerotic plaque (figure 4) (Massberg  
et al., 2003; Kottke-Marchant, 2009; Lakkis et al., 2004).  
 
 
Fig. 4. Flow chart illustrating the role of  platelets in thrombus formation. 
Thus, the main therapeutic regime for the treatment of ACS is use of anti-platelet drug that 
inhibits platelet hyper aggregation (Faxon, 2011; Guha et al., 2009; Aragam & bhatt, 2011; 
Born & Patrono, 2006). Table 1 describes a list of such drugs, while their mode of action is 
illustrated in figure 5.    
In the normal platelet aggregation process, downstream signalling induces fibrinogen receptor 
activation (GpIIbIIa). GpVI is the collagen receptor. P2X1 is the receptor of ATP and acts as 
Ca++ channel. P2Y1 is high affinity ADP repector and P2Y12 is low affinity ADP receptor, 
where the former one is Gq and the later one is Gi coupled. Gz coupled alpha 2a are adrenergic 
receptors for epinephrine, where Gs coupled PGI2R are the receptors of prostaglandin I2 (PGI2) 
or prostaglandin E1 (PGE1), these being inhibitory receptors. Protease-activated receptor 1 
(PAR1), protease-activated receptor 4 (PAR4), are coupled with Gq and G13 these being the 
receptors of thrombin. Thromboxane A2 (TxA2) receptor TP is also coupled with Gq and G13. 
Released TxA2 (b in figure 5) and ADP (a in figure5 ) further act on their corresponding 
receptors. The second messengers and other signalling mediators include, (DAG) 
diacylglycerol ;  (PLCβ)  phospholipase C β ;  (PKC) protein kinase C; (PIP2)  
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Mode of Action Name of the drugs 
Cyclo-oxygenase inhibitors (COX1), (1) Aspirin 
P2Y12 receptor inhibitors(2) Clopidogrel, Prasugrel, Ticlopidine 
Phosphodiestarase inhibitors(3) Cilostazole 
Glycoprotein GPIIbIIIa inhibitors(4) Abciximab, Eptifibatide, Tirofiban 
Adenosine uptake inhibitors(5) Dipyridamole 
Table 1. List of anti-platelet drugs – their mode of action and generic names. The most 
common drugs are described in the first two rows.  
 
 
Fig. 5. Target sites for anti-platelet drugs in platelet signalling pathway- different 
downstream signalling pathways are shown. The drug targets described in Table 1 are 
represented by the corresponding numbers (see text for elaboration).  
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phosphotidylinositol-4,5-biphosphate; (PLCγ) phospholipase C γ; (PLCβ) phospholipase C γ; 
(IP3) inositol triphosphate; (IP3R) inositol triphosphate receptor; (PP) protein 
phosphorylation; (PLA2) Phospholipase A2; (AA) arachidonic acid; AkT and Rap1B (which 
are serine /threonine kinase), (PI3K) phosphatidylinositol 3-kinase; (AC) adenylyl cyclase; 
(PKA) phosphokinase A; (cAMP) cyclic adenosine mono phosphate; (VASP) vasodialator 
stimulated phosphor protein; (P160 ROCK) a Rho activated kinase,  (MLCK) myosine light 
chain kinase, (LIM-K) LIM kinase; (PGG2) prostaglandin G2; (PGH2) prostaglandin H2; (PL) 
membrane phospholipids; (COX1) cyclooxygenase 1; (TS) thromboxane synthetase and 
(PDEIII) phosphor di-esterase III. As platelets are the key player in ACS, any extra-
physiological environmental materials that can alter platelet signalling circuit  is of great 
challenge in combating the disease. This is the context where nanotechnology can come in 
picture. 
3. Nano-interface 
Nanotechnology has the potential to interfere with basic biological mechanisms because of 
their tunable electrical, magnetic and optical properties, and small size ( Chen et al., 2005; 
Gobin et al., 2007; Fu et al., 2007). This tunability makes them potential tool in diagnostics 
(e.g. bio-imaging) therapy and a smart combination of both of these properties (Smith et al., 
2008; Peng et al., 2000; Li et al., 2003; Murry et al., 2000). 
Some of advancement of nanotechnology inspired application include improved imaging 
contrast agents by SPIONS (super-paramagnetic iron oxide nanoparticles), targeted 
delivery of drugs, molecular chaperons and agents to kill specific cancer cells (Yu et al., 
2011; Petkar et al., 2011; Patra et al., 2007). Another exclusive application involve magnetic 
induction (radio frequency) heating or laser induced heating of designer particles, with 
desirable material and shape attributes (Peterman et al., 2003; Plech et al., 2004).  The 
hyperthermic killing of tumor cells, is one of the most important examples (Rao et al., 
2010; Huff et al., 2007). The recently reported chaperon properties of nanoparticles can 
also have important biomedical potential (Singha et al., 2010). Interestingly there are only 
few report on  haematological (Elias & Tsourkas 2009; Baker, 2009; Walkey et al., 2009; 
Wickline et al., 2005) and cardiological applications (Lanza et al., 2006; Iverson et al., 2008) 
of nanotechnology.  
4. Nanotechnology in ACS and platelet contexts 
Nanotechnology is important in ACS because of several reasons. A simple application is 
imaging of plaques, conventional methods being grossly inadequate for such purpose 
(Nikolas, 2009; Wicklinea & Lanza, 2003). Secondly, the targeted delivery of therapeutic 
agents using nanoparticles to the areas of injured or dysfunctional vascular wall that 
inhibit the plaque progression is of significant importance in the ACS context (Nikolas, 
2009). 
Furthermore, nanoparticle based assay can be used for the detection of myocardial injury in 
patients with ACS (Wilson et al., 2009). In the therapeutic regime , an important use of 
nanotechnology is  to increase the amount of HDL in circulation interning  delivery of 
cholesterol to liver, thus minimizing the risk associated with ACS (Luthi et al., 2010). 
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Fig. 6. Diverse applications in nanotechnology 
In most of the above mentioned cases (diagnosis, drug delivery or treatment) the 
primary entry route of nanoparticle is through circulation where they interact directly 
with blood cells. Conversely exposure to  unwanted nanoparticles (e.g. gas phase 
exhaust from car or industry ) inhaled by human, that can penetrate the alveolar space 
and interfere with circulation may lead to cardiovascular diseases ( Yamawaki & Iwai, 
2006; Mohmmad et al., 2011; Chen et al., 2008). In both cases such interaction deserves a 
special attention.  
In case of ACS patients, if nanoparticles activate platelets then they may induce life 
threatening alarm. Till now there are a number of papers (Geys et al., 2008; Oberdörster et 
al., 2007; Deb et al., 2007,2011; Wiwanitkit et al., 2009; Radomski et al., 2005; Shrivastava et 
al., 2009; Koziara et al., 2005;  Mayer et al., 2009; Li et al., 2009; Ramtoola et al., 2010; 
McGuinnes et al., 2010; Nemmar et al., 2003; Gulati et al., 2010; Cejas et al., 2007; Wilson et 
al., 2010; Rückerl et al., 2007) about the effect of nanoparticles on platelets (Table. 2.) 
where most of the citations show that nanoparticles can induce platelet aggregation. What 
makes a nanoparticle pro-aggregarory (Geys et al., 2008; Oberdörster et al., 2007; Deb et 
al., 2007,2011; Wiwanitkit et al., 2009; Radomski et al., 2005; Mayer et al., 2009; McGuinnes 
et al., 2010; Nemmar et al., 2003; Cejas et al., 2007; Wilson et al., 2010; Rückerl et al., 2007; 
Miller et al., 2009),  inert (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 2010) or even 
anti-platelet in nature (Shrivastava et al., 2009; Koziara et al., 2005; Miller et al., 2009) is of 
great importance in development of  ACS based nano-drugs, risk assessment in ACS , and 
also in evaluating  resistance to ACS related drugs (Guha et al., 2009; Jogns et al., 2006; 
Michelson et al., 2006). 
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TYPE OF NANOMATERIALS EFFECT ON PLATELETS 
Carbon NP 
Carbon nanoparticle (C60)
Standard urban particulate matter
Multiwall carbon nanotube
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Carboxylated Polystyrine Latex NP (-ve )
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E78 NPs














Aerosol Ultra fine particlesAmbient Particulate Matter
Activation 
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Table 2. Nanoparticle effects on platelets – the Table enlists how the platelet response varies 
with variation in nano-material as well as the corresponding nano-surface configuration. NP 
is nanoparticle. 
5. Platelet nanoparticle interaction – A deeper insight 
A different paradigm of nanotechnology application has recently got considerable  interest. 
How thrombotic response is modulated by nanoparticles has recently become a new paradigm 
in nano-medicine. Till today, the exact mechanisms of how nano-surface exposure or uptake of 
nanoforms alter the platelet response are not known. Most of the metallic nanoparticles, 
carbon nanoparticles, aerosol and polymer nanoparticles induce platelet aggregation (Mayer et 
al., 2009; McGuinnes et al., 2011). A few nanoparticles remain inert for platelet or induce anti-
platelet effect (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 2010). Interestingly in case of 
some polymer nanoparticles, surface conjugation induces varying response to platelets 
(McGuinnes et al 2010). One needs deeper insights in induced platelet signalling to explain 
such varying response to nanoparticles with a characteristic surface property.  
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some polymer nanoparticles, surface conjugation induces varying response to platelets 
(McGuinnes et al 2010). One needs deeper insights in induced platelet signalling to explain 
such varying response to nanoparticles with a characteristic surface property.  
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As mentioned earlier, anti-platelet drug therapy is the most important therapeutic regime 
for ACS patients. A major fall-out of the conventional therapeutic approach is the sizable 
incidence of drug resistance among ACS patients (Guha et al., 2009; Jogns et al., 2006; 
Michelson et al., 2006). There are indications that nanotechnology can help diagnosis of drug 
resistance (Deb et. al. 2011).  
Again, metallic nanoparticles can induce platelet aggregation depending on the 
physiological state of the platelets. For a given nano-drug   such response can show inter 
individual variations, and there is evidently a scope of judging the safety of such drugs 
depending on the extent of induced alteration in platelet function.  It may be important to 
note that under certain conditions nanoparticles can be hazardous to both normal 
individuals as well as ACS patients. Table 3 summarises the overall ACS risk associated 
with nanoparticles : 
 
Phenomenon Risk Factors 
< 60 nm nanoparticle. Safe in context to thrombotic risk. 
Resting platelets + nanoparticle. No thrombotic risk. 
Anti-platelet drug like clopidogrel or reo-
pro. No thrombotic risk. 
Rupture plaque (where vascular bed is 
open) + Nanoparticle of any size. High thrombotic risk. 
Some special surface modification tunable 
Table 3. Overview of thrombotic risk factors of nanoparticles.   
5.1 Excitability of the nanoparticle mediated pro-aggregatory response 
Metallic nanoparticle (made of gold, copper, iron, cadmium sulphide and quantum dots) 
induced platelet aggregation is intriguing as the profile change of such aggregation fully 
depends on the physiologic conditions of the platelets (e.g. pre-activation) (Deb et al., 2007, 
2011; Geys et al., 2008). Non-metallic carbon nano-tube or polymer based nanoparticles on 
the other hand induce platelet aggregation  without any pre-activation, their pro-
aggregatory effect depends mainly on hydrophobic collapses (Radomski et al., 2005) or 
charge-charge interaction among platelets and nanoparticles (McGuinnes et al., 2010). At 
critical concentrations of ADP or in presence of a threshold shear force, which mildly 
activates the platelets, they  become most sensitive to nano-particles (figure 7). In other 
words, the nanoparticles in such cases serve as agonists. On the other hand, when platelets 
are in resting condition  most of the metallic nano-forms seems to be inert.  
Unlike optimal size response (of nanoparticles) observed in case of cancer cells, the nano- 
response in platelets increases monotonically with decreasing size of nanoparticles (Deb et 
al., 2011). This phenomenon occurs also in case of polystyrene nanoparticles  (Mayer et al., 
2009). This size attribute is similar to entry of the nanoparticles through inhalation. Smaller 
the size of the nanoparticle, lesser in the efficiency of the clearance by alveolar macrophages, 
which in turn increases their (nanoparticle) deposition in alveolar cell leading to entry into 
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Fig. 7. Nanoparticle Size Response.  Gold Nanoparticle induced platelet response [see Deb et. 
al. 2007,2011] is dependent on nanoparticle size, smaller particle showing aggregatory effects.  
Though the exact molecular mechanism of metallic-nanoparticle platelet interaction is yet to 
be established, systemic response like release of platelet granules (both α and δ) have  been 
observed in presence of nano-particles. In presence of apyrase (scavenge ADP released from 
δ granules), or anti-platelet drug clopidogrel (block P2Y12 purinergic receptors, thus inhibit 
secondary wave of aggregation, which is the signature of granules release) nano-particle 
induced aggregation inhibited. In presence of Arg-Gly-Asp-Ser (RGDS) (a tetra-peptide, 
which binds to fibrinogen receptor GpIIbIIIa, mimicking the anti-platelet drug Reo-Pro), 
nano induced platelet aggregation is again inhibited. This reflects that nanoparticles 
induced aggregation is not due to any physico-chemical agglomerate formation. 
Consequently, metallic nano-forms are unlikely to activate platelets from patients  under 
anti-platelet drug therapy (Deb et al., 2011). Alternatively, conjugation of anti-platelet drugs 
(or combined administration of such drugs) can help to reduce the thrombotic risk of 
nanoparticle based drug formulation.   
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5.2 Platelet Response as a measure for nano-safety 
In the suspended condition, metallic nanoparticle induced platelet aggregation is highly 
dependent on the local ADP concentration. A  transition  of deaggregation to aggregation 
occurs at a threshold concentration of ADP. Interestingly, nanoparticle effect is most 
pronounced at this threshold concentration (Deb et al., 2007). This threshold nano-response 
is perhaps a manifestation of primary triggering of granules release which undergoes an 
auto-catalysis, ultimately  leading to aggregation.   
As there is a considerable variation of platelet aggregation among individuals, the threshold 
ADP concentration and extent of enhancement of aggregation induced by the nanoparticle 
have an individual specific fingerprint. The parameters thus can be used as nano-safety 
indices. Higher the threshold value and lower the nanoparticle induced aggregation, safer is 
the nano-drug (Deb et al., 2011). 
5.3 Nanoparticles and antiplatelet drugs 
Aspirin and Clopidogrel are most widely used anti-platelet drugs for ACS .In many cases dual 
antiplatelet drug (both Aspirin and Clopidogrel) therapy is used for patient safety (Born et al, 
2006, Guha et al., 2009, Faxon 2011, Aragam et al., 2011)  Despite the benefits of dual 
antiplatelet therapy, many patients still suffer from cardiovascular disease due to resistance to 
such drugs. The drug resistance also increases the risk of the recurrent occurrence of ACS 
(Guha et al., 2009; Jogns et al., 2006; Michelson et al., 2006). It is thus important to have a quick 
sensor that will assess the resistance to aspirin or clopidogrel in patients in one step and also 
assess the equivalence of the drug effects with respect to variations in geographic populations 
(which may correspond to genetic variations of patient population) and variations in effective 
drug dose among different drug manufacturers (Deb et al., US patent application, 2011). 
Interestingly among the ACS patients, one’s showing resistance to the conventional anti-
platelet drugs (e.g. aspirin or clopidogrel) respond differentially to gold nanoparticle 
(~20nm) as compared to one’s responding to it. This differential response can be used as a 
convenient classifier of  responders and non responder to antiplatelet drugs (see figure 8).  
5.4 Nano-material nano-surface and  nano-response 
Though most of the nano induced response is pro-aggregatory in nature, a few reports 
Mention inert nature of some nanoparticles (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 
2010). As most of the nano-particles induce platelet aggregation, so it can be said the 
aggregatory nature of nano surface depends on its diameter rather than its component 
material. But this conjecture is not applicable to all nano-forms. Charged surface (aminated - 
positively charged or carboxylated - negatively charged) polystyrene latex nano-forms are 
capable of inducing platelet aggregation, whereas unmodified latex beads are unable to do 
so. Interestingly, the modes of aggregation for positive and negatively charged 
nanoparticles are different. For carboxylated nanoparticle the aggregation is due to the 
upregulation of surface adhesion molecules, whereas aminated nanoparticles alter the 
platelet membrane and interact with the anionic phospholipid  (Mayer et al., 2009; 
McGuinnes et al., 2010). Though both of the charged particles are capable of inducing 
platelet aggregation, the negatively charged larger particles (larger than 60nm) are shown to 
be  less toxic in the platelet activation context (Mayer et al., 2009).The lesser toxicity of the 
such particle is probably due to less entry and charge repulsion between nano particles and 
platelets. Human cell derived nanoparticles that actually accentuate platelet granules 
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release, inhibit platelet aggregation. This paradox is possibly due to the reduction of 
platelet-platelet interaction in presence of nanoparticle (Miller et al., 2009). Negatively 
charged Polyethylene glycol (PEG) coated nanoparticles from Microemulsion precursor 
(PEG-E78) induces platelet inhibition (Koziara et al., 2005). Importantly, in both pro-
aggregatory or antiplatelet responses , the nanoparticles are effective inducer when added in 
the pre-incubation stage. Neither the inhibition nor the aggregatory response are observed 
once the aggregation is initiated by an agonist (Koziara et al., 2005; Deb et al. 2007, 2010). 
Similar argument holds good for anti-platelet effect of silver nanoparticles prepared with a 
certain surface attributes (Shrivastava et al., 2009). Silver nanoparticles with a different 
surface conjugations again show pro-aggregatory effects (Deb et al., 2011 (in press)).  
 
 
Fig. 8. Nanosensor for Drug Resistance in ACS [89]-Using Nanoparticle effect to discriminate 
between responder and non-responder of antiplatelet drugs (e.g. aspirin and clopidogrel).  
The important question that crops up here is whether in the platelet context it is the nano-
surface conjugation or the nano-material that play the lead role. It follows that by modulating 
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The important question that crops up here is whether in the platelet context it is the nano-
surface conjugation or the nano-material that play the lead role. It follows that by modulating 
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the nano-surface, one can tune the thrombotic level, the desirable level depending on the 
patient status. For ACS, the desired state is a nanoform that attenuates the  aggregatory 
response, and in case of hemorrhage the situation may be complimentary in nature.  
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1. Introduction 
The widespread application of catheter-based interventions, and chronic treatment have 
contributed to improved long-term prognosis in patients with acute ST-elevation 
myocardial infarction (STEMI) 1-5. Despite these indisputable achievements, a large number 
of individuals remain at substantial risk of severe first attack, recurrent disease and death. 
Patients with unstable angina were classified into three groups according to short-term risk 
of death or nonfatal myocardial infarction6, and the results of noninvasive tests and the 
corresponding approximate mortality rates were reported 7. 
Disruption, fissure, or erosion of an atherosclerotic plaque, with residual mural 
thrombus (RMT) has a fundamental role in the pathogenesis of acute coronary 
syndromes (ACS) 8-12. Most of occlusive thrombi had a layered structure indicating an 
episodic growth by repeated mural deposits 13, 14. Morphological studies indicated that 
plaque complications remained clinically silent days or weeks before the fatal event 15-18. 
A RMT predisposes patients to recurrent thrombotic vessel occlusion 15, 16, 17, and plaque 
disruption, fissure or erosion with thrombus contributes to plaque development and 
progression 18. Therefore, a marker that predicts disrupted, fissured or eroded plaque 
and the coronary thrombus may have practical clinical applications. The diagnosis of 
these lesions has been tried by several methods 19. However, plaque disruption itself is 
asymptomatic, and the associated RMT is usually clinically silent 20. To the best of our 
knowledge, markers as a sign of a disrupted, fissured or eroded plaque and a coronary 
thrombus are not available.  
Scavenger receptor-mediated endocytosis of oxidized low-density lipoprotein by 
macrophages has been implicated in the pathogenesis of atherosclerosis. The differentiation 
of scavenger receptor A negative (SRA－) monocytes in peripheral blood (PB) into SRA 
positive (SRA+ ) macrophages was believed to take place in atherosclerotic lesions by 
stimulation of macrophage-colony stimulating factor (M-CSF) 21-24, and it was reported that 
freshly isolated blood monocytes were negative for SRA 25. We surmised that plaque content 
might be exposed to the blood stream after disruption of plaque, and SRA－ monocytes 
might differentiate into SRA+ cells in PB by stimulation of M-CSF contained in plaque 
content, and that increased SRA+ cells in PB might be a useful indication of disrupted, 
fissured or eroded plaque and coronary thrombus.  
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Although several scavenger receptors, such as SRA, CD36, scavenger receptor-B1, CD68 and 
Lox-1 have been shown to bind oxidized low-density lipoprotein, SRA and CD36 are 
responsible for the preponderance of modified low-density lipoprotein uptake in 
macrophages 26. In our study, we evaluated the utility of SRA, since SRA antigen is 
restrictedly expressed on macrophages 26, but CD36 is expressed not only on macrophages 
and monocytes but also on B lymphocytes. 
We reported that the SRA index［number of SRA+ cells in 10 high power fields (HPF, ×400) 
of peripheral blood (PB) smear, upper limit: <30］ greater than 30 was considered to be a 
useful indication of disrupted, fissured or eroded plaque and coronary thrombus 27, 28 . In 
this paper, we described the composition of occlusive coronary thrombi obtained from 
patients with acute ST-elevation myocardial infarction (STEMI), the relationship between 
the SRA index and these thrombi, and the utility of SRA index as an indication of disrupted, 
fissured or eroded plaque and coronary thrombus in patients with ACS.  
2. Study subjects 
Eight autopsy cases with acute myocardial infarction, 393 patients with STEMI and 79 
patients with unstable angina (UA) were examined. Patients with STEMI were treated with 
percutaneous intracoronary thrombectomy during primary angioplasty. High-sensitivity C-
reactive protein (h-CRP), creatine kinase (CK) and creatine kinase-MB isozyme (CK-MB) 
were examined in patients with STEMI. PB from 43 apparently healthy men and women in 
their 20s was examined as a control. 
3. Thrombectomy procedure 
On admission, all patients were treated with 162 mg aspirin (Ebis, Osaka, Japan), and they 
underwent percutaneous coronary intervention of the infarct-related artery through the 
femoral access route with a 6F guiding catheter. Thrombectomy was performed with a 
RescueTM catheter (Boston Scientific, Natick, MA, USA) or a TVAC catheter (NIPRO, Osaka, 
Japan). Aspirated blood and intracoronary material were collected in a collection bottle, 
which was equipped with a filter. Stent implantation was performed in 386 patients and all 
patients were treated with antithrombotic therapy.  
4. Tissue processing and histopathological methods 
Autopsy was performed 2 or 3 hours after death. Thrombi and organs were fixed in 10 % 
neutral formalin and embedded in paraffin, and examined using hematoxylin and eosin, 
and phosphotungstic acid hematoxylin (PTAH) sections. Papanicolaou-stained smears and 
paraffin-embedded sections were used for the immunohistochemical and 
immunocytochemical examination, which was performed with the simple stain MAX-PO 
method (NICHIREI Co., Tokyo, Japan) and with diaminobenzidine as the chromogen using 
mouse monoclonal anti-human glycoprotein 1b (CD42b, a platelet marker, 1:100; Novo 
Castra, Newcastle upon Tyne, UK), and mouse monoclonal anti-human SRA (CD204, a 
macrophage SRA marker, 1:200; Trans Genic Inc., Kumamoto, Japan) antibodies. An antigen 
retrieval method using citrate buffer and microwave heating was employed. As a negative 
control, the primary antibody was substituted by phosphate-buffered saline, and a positive 
stain was not observed in these controls. 
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5. Cytological methods 
I believe that the method of cytological examination of peripheral blood is my original 
method 29. Briefly, red blood cells were lysed with lysing reagent (826 mg of NH4CL + 3.7 
mg of EDTA-4Na + 100 mg of KHCO3 in 100 ml H2O), then nucleated cells were 
suspended in isotonic sodium chloride solution, and the suspensions containing about 
5x106 nucleated cells were smeared on glass slides using Auto smear CF-12 (Sakura Seiki, 
Tokyo, Japan). Cells that did not adhere to the glass slides were gently washed away 
with 95% ethanol solution. Smear preparations were fixed in 95% ethanol solution and 
stained with the Papanicolaou method. A smear preparation of PB is shown in figure 1. 
About one million and two hundred thousand nucleated cells were smeared in one slide. 
Nucleated cells are smeared evenly and precise nuclear structures are excellently 
preserved. About one thousand nucleated cells were observed in one high power field 






Fig. 1. A cytological preparation of peripheral blood stained with the Papanicolaou method. 
About one million and two hundred thousand nucleated cells are smeared in one slide. 
Papanicolaou stain. 
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Fig. 1. A cytological preparation of peripheral blood stained with the Papanicolaou method. 
About one million and two hundred thousand nucleated cells are smeared in one slide. 
Papanicolaou stain. 
  








Fig. 2. About one thousand nucleated cells are observed in one high power field (×400). 
Nucleated cells are smeared evenly and precise nuclear structures are excellently preserved. 
Papanicolaou stain. 
6. Definitions 
Thrombi were classified into 4 groups according to previously published definitions 
considering age and constituents of thrombus13, 30 : 1) an eosinophilic mass with neo- 
vascularization (organizing thrombus: OT), 2) a structureless eosinophilic (hyalin) mass 
(fibrin-rich thrombus: FT), 3) Thrombus containing significant quantities of platelets, 
erythrocytes, fibrin and leukocytes (mixed thrombus: MT), and 4) tightly packed but 
individually discernible platelets (platelet thrombus: PT). In this paper, we defined MT and 
FT as RMT. Plaque components were identified based on the presence of foamy 
macrophages, cholesterol crystals, collagen tissue, and/or calcification. Since the aspirated 
material was fragmented, and PT seemed to be the freshest thrombus, contact between PT 
and other types of thrombus (PT and MT: P-M, PT and FT: P-F,) and contact between PT and 
plaque content (P-C) were examined in all cases to investigate the process of coronary 
occlusion. Cases were classified into 3 groups according to the composition of the thrombus: 
group A, containing PT only and P-C; B, a MT only, P-M and P-C+P-M; C, P-F, P-M+P-F, P-
C+P-F, and P-C+P-M+P-F. SRA+ cells in PB that had the same size and nuclear shape as 
blood monocytes were defined as SRA+ cells. The SRA index was defined as the number of 
SRA+ cells in 10 HPFs of PB smear samples. Based on the SRA index of apparently healthy 
people in their 20s, we temporarily set the normal upper limit of the SRA index at 30 27.  
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7. Autopsy cases 
P-C was observed in 4 autopsy cases, P-M in 3 and P-M + P-F in 1. Numerous emboli of PT 
were observed in peripheral small arteries and capillaries of the infarct-related artery in 6 
cases. SRA index exceeded 30 in 5 cases. A typical case with acute myocardial infarction is 
presented in figure 3 to 7. This patient is a forty-three year old male. He died suddenly. 
Postmortem examination revealed disruption of the plaque and occlusive thrombus in the 
left anterior descending artery (Figure 3). Thrombus is composed of platelet thrombus and 
mixed thrombus + fibrin-rich thrombus (Figure 4 and 5). Platelet thrombus was adhered on 
the inner side of mixed thrombus + fibrin-rich thrombus (Figure 4). Immunohistochemistry 
for CD 42b revealed that platelet thrombus was deeply stained than mixed thrombus + 
fibrin-rich thrombus (Figure 4). Fibrin mesh is contained in mixed thrombus + fibrin-rich 
thrombus but not in platelet thrombus (figure 5). SRA+ cells are infiltrated in mixed 
thrombus + fibrin-rich thrombus but not in platelet thrombus (Figure 6). Numerous emboli 
of fragments of platelet thrombi were observed in small arteries and capillaries at the distal 











Fig. 3. Plaque disruption (arrow) and thrombus formation in the left anterior descending 
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7. Autopsy cases 
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the inner side of mixed thrombus + fibrin-rich thrombus (Figure 4). Immunohistochemistry 
for CD 42b revealed that platelet thrombus was deeply stained than mixed thrombus + 
fibrin-rich thrombus (Figure 4). Fibrin mesh is contained in mixed thrombus + fibrin-rich 
thrombus but not in platelet thrombus (figure 5). SRA+ cells are infiltrated in mixed 
thrombus + fibrin-rich thrombus but not in platelet thrombus (Figure 6). Numerous emboli 
of fragments of platelet thrombi were observed in small arteries and capillaries at the distal 











Fig. 3. Plaque disruption (arrow) and thrombus formation in the left anterior descending 
artery of the patients who died suddenly. Thrombus is composed of platelet thrombus (P) 
and mixed thrombus + fibrin-rich thrombus (P+M). hematoxylin and eosin. 
  





Fig. 4. Serial section of figure 1. Platelet thrombus is deeply stained than mixed thrombus + 
fibrin-rich thrombus, and adhered on the inner side of mixed thrombus + fibrin-rich 
thrombus. Immunochemistry for CD42b.  
 
 
Fig. 5. Serial section of figure 1. Fibrin mesh is contained in mixed thrombus + fibrin-rich 
thrombus but not in platelet thrombus . phosphotungstic acid hematoxylin stain. 
 




Fig. 6. Serial section of figure 1. Scavenger receptor A positive cells are infiltrated in mixed 
thrombus + fibrin-rich thrombus but not in platelet thrombus. Immunochemistry for 
scavenger receptor A. 
 
 
Fig. 7. Numerous emboli of fragments of platelet thrombi are observed in small arteries and 
capillaries at the distal portion of the left anterior descending artery. Immunohistochemistry 
for CD 42b. 
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8. Patients with STEMI 
8.1 SRA index and CK, CK-MB, h-CRP 
Abnormally increased levels of CK and CK-MB were observed in 53.8 % and 55.6% cases 
respectively at the hospitalization, and all cases showed abnormally high levels of CK and 
CK-MB within 24 hours after hospitalization. There was a strong correlation between CK 
and CK-MB (r=0.986), but no correlation between the SRA index and CK (r=0.025), CK-MB 
(r=0.005), and h-CRP(r=0.085) were seen (all, Student’s t-test).  
8.2 Pathological findings of thrombus 
Thrombus was observed in 389 (99%) of the 393 patients, plaque contents alone were detected 
in 2, and neither thrombus nor plaque contents was identified in 2. In 270 patients, only 
thrombus was found; and both thrombus and plaque content were identified in 119. PT was 
found in 387 of 389 (99.5%) patients, MT in 269 (69.2%), FT in 57 (14.7%), and OT in 29 (7.5%). 
Results of the histopathological examination of thrombus are shown in table 1. RMT was 
detected in 300 (77.1 %) patients (Table 1). One type of contact was detected in 285 (73.3 %) 
patients, 2 types in 61 (15.7 %) and 3 types in 12 (3.0 %), and PT, or MT alone was found in 29 
and 2 patients respectively. Contact between PT and OT was not observed. There was no 
gradual morphological transition from PT to MT or FT, but there were gradual transitions 
from MT to FT, and FT to OT in some cases. 
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Table 1. Brief title: Relationships between contact patterns of thrombus and SRA index at 
hospitalization1. 
                                                 
1P: Platelet thrombus. P-C: Contact between platelet thrombus and plaque content. M: Mixed thrombus. 
P-M: Contact between platelet thrombus and mixed thrombus. P-F: Contact between platelet thrombus 
and fibrin-rich thrombus. 
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Eighty-nine patients were classified into group A, 243 into group B, and 57 into group C 
(Table 1). Typical findings of group A (P-C) are shown in figure 8. Macrophages in plaque 
content were positive for SRA, and SRA positive cells were not found in platelet thrombus. 
Figure 9 to 12 are typical findings of group B (P-M). Platelet thrombus is adhered on the 
mixed thrombus (Figure 9, 10), and fibrin mesh is not observed in platelet thrombus (Figure 
11). SRA positive cells are infiltrated into mixed thrombus along the boundary zone (Figure 
12). Typical findings of group C (P-F) are shown in figures 13 and 14. SRA positive cells are 
diffusely infiltrated in fibrin-rich thrombus (Figure 14). Fragments of PT are frequently 
found in MT in many cases (Figure 15). SRA+ cells infiltrated into 147 (54.6%) of 269 MT. 
These cells and SRA+ cells in PB were nearly equal in size, and infiltrated into MT along the 
boundary zone between PT and MT in most cases. SRA+ cells were diffusely infiltrated into 
all FT and OT. Some of these SRA+ cells were large in size. Foam cells in plaque content were 















Fig. 8. Contact between platelet thrombus (P) and plaque content (C).  
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Fig. 8. Contact between platelet thrombus (P) and plaque content (C).  
  











Fig. 10. Serial section of figure 9. Platelet thrombus is strongly stained. Immunochemistry 
for CD42b. 
 






Fig. 11. Serial section of figure 9. Fibrin mesh is not observed in platelet thrombus. 




Fig. 12. Serial section of figure 9. Scavenger receptor A positive cells infiltrate into mixed 
thrombus along the boundary zone. Immunochemistry for CD204. 
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for CD42b. 
 






Fig. 11. Serial section of figure 9. Fibrin mesh is not observed in platelet thrombus. 




Fig. 12. Serial section of figure 9. Scavenger receptor A positive cells infiltrate into mixed 
thrombus along the boundary zone. Immunochemistry for CD204. 
  










Fig. 14. Serial section of figure 13. Scavenger receptor A positive cells infiltrate into fibrin-
rich thrombus. Immunochemistry for CD204. 
 









Fig. 15. Small fragments of platelet thrombus (P) are intermingled with mixed thrombus (M). 
8.3 SRA+ cells in PB 
SRA+ cells were observed in all control cases and in all patients with STEMI and UA. 
Neither SRA+ large macrophages nor foamy cells could be observed in PB of all examined 
cases. SRA index of control cases ranged 1 to 24 (mean±SD=11.1±7.5). The relationships 
between SRA index and contact patterns of thrombus at hospitalization were shown in 
table 1. At hospitalization, SRA index exceeded 30 in 276 of 393 patients with STEMI 
(Figure 16). Thrombus was identified in all these patients with more than 30 SRA index. 
PT was identified in 274 (99.3 %), and RMT in 230 (83.3 %) cases. From the viewpoint 
thrombus, SRA index exceeded 30 in 230 of 300 (76.7 %) cases with RMT and 46 of 89 (51.7 
%) cases with PT alone (Table 1). The percentage of patients with a SRA index more than 
30 was significantly lower in group A patients than other groups of patients (P<0.001). 
Significant differences were observed between group A and B, and A and C (both, 
P<0.001).  
Peripheral blood of 109 of 117 patients with less than 30 SRA index at hospitalization were 
examined repeatedly, and SRA index of all 109 cases exceeded 30 within 2 to 3 days after 
hospitalization. The maximum SRA indices of STEMI patients during 3 days after 
hospitalization were significantly higher than those of STEMI patients at hospitalization. 
The SRA index of 60 of 79 UA (75.9%) cases were 30 or more at hospitalization. The 
differences in the SRA index were not significant between STEMI and UA (Table 2, P=0.218, 
Welch’s test). 
  










Fig. 14. Serial section of figure 13. Scavenger receptor A positive cells infiltrate into fibrin-
rich thrombus. Immunochemistry for CD204. 
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Table 2. The scattered plots of the SRA index of controls, AMI, UA. 
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9. Differentiation of SRA+ cells in PB 
It is reported that freshly isolated blood monocytes were negative for SRA 25; however, a few 
reports have indicated that SRA－monocytes can differentiate into SRA+ cells in PB by 
various stimuli 32, 33, 34. SRA+ cells were observed in all control cases. We , therefore, 
surmised that a small number of SRA－ monocytes differentiated into SRA+ cells in PB of 
healthy men and women by various stimuli. Fuster et al. classified the progression of 
coronary atherosclerotic diseases into five phases 35. Phase 1 is represented by a small plaque 
that is present in most people under the age of 30 years. We set the normal upper limit of the 
SRA index at 30 27, since plaque disruption, fissure, or erosion and RMT might not develop 
in healthy men and women in their 20s, and SRA index of these control cases ranged 1 to 24 
(mean±SD=11.1±7.5).  
We considered two possibilities on the pathophysiologic mechanisms underlying the 
differentiation of SRA+ cells in patients with STEMI (myocardial infarction or plaque 
disruption, fissure or erosion). With the recognition that atherosclerosis is an inflammatory 
process 36, h-CRP has been evaluated as a potential tool for predicting the risk of AMI 37, 38, 39, 
and CK and CK-MB are good markers of myocardial injury. Macrophages are known to 
arise from monocytes, and become larger over twice as large as monocytes with 
differentiation. SRA－monocytes became positive for SRA after 5 days in culture with M-CSF 
40, and differentiated into large macrophages by 10 days 41. Cytokines elevate in PB after 
insult 42. Myocardial infarction is severe insult, so SRA+ cells may increase in PB as a result 
of myocardial infarction. However, differentiation of SRA+ cells in PB was not considered to 
result from myocardial injury, because there was no correlation between SRA indices and 
CK, CK-MB, and h-CRP. 
The differentiation of SRA－ monocytes into SRA+ macrophages was believed to take place in 
atherosclerotic lesions by stimulation of M-CSF 21-24. Disruption, fissure or erosion of an 
atherosclerotic plaque is generally recognized as a proximate event responsible for the 
development of the ACS 8-12. The SRA index of the patients with less than 30 SRA index at 
hospitalization rapidly increased, and the SRA index of all these STEMI patients exceeded 
30 within 2 to 3 days. We therefore surmised that SRA－ monocytes might differentiate into 
SRA+ cells as the result of exposure of plaque content that contains M-CSF to the blood 
stream.  
10. Coronary occlusion 
Examinations of aspirated material have focused on thrombus age 31, 43, 44. Rittersma et al. 
classified thrombi into 3 groups: fresh (< 1 day), lytic (1 to 5 days), and organized thrombus 
(> 5 days) 31. However it is hard to understand the constituents of thrombus by this 
classification. PT and some MT seem to correspond to fresh thrombus, and some MT and FT 
to lytic thrombus. PT was detected in 387 (99.5 %) of 389 patients, MT in 269 cases (69.2 %) 
and FT in 57 (14.7 %). SRA+ cells infiltrated into all FT and 147 (54.6 %) of 269 MT, but not 
PT. These SRA+ cells in PB were thought to be infiltrated into MT, since SRA+ cells 
infiltrated in MT along the boundary zone between PT and MT (luminal side of the coronary 
artery). From these findings, PT was considered to be most fresh thrombus, and infarct-
related coronary artery was totally and rapidly occluded by the formation of PT. 
Using their computer-assisted extracorporeal-perfusion system, Badimon et al.45 and Lassila 
et al.46 found that platelet deposition increased significantly with increased stenosis. Sudden 
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coronary occlusion was often preceded by a period of plaque instability and thrombus 
formation, initiated days or weeks before the onset of symptoms 15-18, and total coronary 
occlusion of the infarct-related artery always results from the growth of RMT 44, 47 - 49. 
Considering these reports and the histopathological findings of thrombi, PT was thought to 
be formed abruptly as a result of severe coronary stenosis due to sudden extrusion of 
atheromatous debris into vessel lumen in 43 group A patients with a SRA index less than 30 
at hospitalization, and due to gradual growth of RMT in group B and C patients. The 
percentage of patients with SRA index more than 30 at hospitalization was significantly 
lower in group A patients than other groups of patients. This finding seemed to support the 
theory, since the SRA index exceeded 30 about 2 days after plaque disruption27. 
11. The fate of platelet thrombus 
RMT was observed in 300 of 389 STEMI cases. Meshwork of fibrin was observed in RMT, so 
RMT was thought not to be fragile. RMT predisposes patients to recurrent thrombotic vessel 
occulusion15-17, and plaque disruption, fissure or erosion with thrombus contributes to 
plaque development and progression18. Gradual growth of RMT plays an important role on 
the increased stenosis of coronary artery, and total occlusion of coronary artery by platelet 
thrombus.  
Meshwork of fibrin was not contained in platelet thrombus. Consequently, platelet 
thrombus was considered to be very fragile. Fragments of platelet thrombus were frequently 
observed in mixed thrombus and numerous emboli of fragments of platelet thrombus were 
observed in small arteries and capillaries at the distal portion of the infarct related artery of 
autopsy cases. Platelet thrombus was considered to repeat formation and disintegration 
with the gradual growth and lysis of RMT, and numerous emboli of fragments of platelet 
thrombus at the distal portion of the infarct related artery may repeatedly injure cardiac 
myocytes .  
12. SRA index and vulnerable plaque 
Disruption, fissure, or erosion of an atherosclerotic plaque, with RMT has a fundamental 
role in the pathogenesis of acute coronary syndromes (ACS) 8-12. 
In general, in case of AMI, a direct relationship between the onset of plaque disruption and 
acute transmural ischemia is assumed; however pathological studies of autopsy 13, 14 and 
thrombectomy 18, 31, 43 materials indicated that plaque disruption, fissure or erosion with 
RMT remain clinically silent days or weeks before the fatal event. The SRA index of the 
patents with less than 30 SRA index at hospitalization exceed normal level within 2 to 3 
days. These findings indicated that SRA index rapidly increases in AMI patients after plaque 
disruption, erosion, or fissure. A SRA index more than 30 was observed in patients with 
multiple organ dysfunction syndrome50. Therefore, SRA index more than 30 was not a 
specific finding to ACS. SRA index exceeded 30 in 230 of 300 (76.7 %) cases with RMT and 
46 of 89 (51.7 %) cases with PT alone, and 276 of all 389 cases at hospitalization. Thrombus 
was identified in all 276 patients with a SRA index more than 30 at hospitalization. PT was 
detected in 99.3 % and RMT in 83.3 % of these patients. SRA index did not exceed 30 in 
healthy control cases. SRA index of these 276 patients was surmised to exceed 30 before the 
onset of STEMI. The SRA indices of 75.9 % of unstable angina cases were more than 30 at 
hospitalization 27. The pathophysiological substrate of the unstable angina is now considered 
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to be common with the acute myocardial infarction. We, therefore, believe that the abnormal 
increase of SRA+ cells is considered to be a useful finding to gather the presence of disrupted 
or fissured or eroded plaque, PT, and probably RMT in patients with UA. 
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Considering these reports and the histopathological findings of thrombi, PT was thought to 
be formed abruptly as a result of severe coronary stenosis due to sudden extrusion of 
atheromatous debris into vessel lumen in 43 group A patients with a SRA index less than 30 
at hospitalization, and due to gradual growth of RMT in group B and C patients. The 
percentage of patients with SRA index more than 30 at hospitalization was significantly 
lower in group A patients than other groups of patients. This finding seemed to support the 
theory, since the SRA index exceeded 30 about 2 days after plaque disruption27. 
11. The fate of platelet thrombus 
RMT was observed in 300 of 389 STEMI cases. Meshwork of fibrin was observed in RMT, so 
RMT was thought not to be fragile. RMT predisposes patients to recurrent thrombotic vessel 
occulusion15-17, and plaque disruption, fissure or erosion with thrombus contributes to 
plaque development and progression18. Gradual growth of RMT plays an important role on 
the increased stenosis of coronary artery, and total occlusion of coronary artery by platelet 
thrombus.  
Meshwork of fibrin was not contained in platelet thrombus. Consequently, platelet 
thrombus was considered to be very fragile. Fragments of platelet thrombus were frequently 
observed in mixed thrombus and numerous emboli of fragments of platelet thrombus were 
observed in small arteries and capillaries at the distal portion of the infarct related artery of 
autopsy cases. Platelet thrombus was considered to repeat formation and disintegration 
with the gradual growth and lysis of RMT, and numerous emboli of fragments of platelet 
thrombus at the distal portion of the infarct related artery may repeatedly injure cardiac 
myocytes .  
12. SRA index and vulnerable plaque 
Disruption, fissure, or erosion of an atherosclerotic plaque, with RMT has a fundamental 
role in the pathogenesis of acute coronary syndromes (ACS) 8-12. 
In general, in case of AMI, a direct relationship between the onset of plaque disruption and 
acute transmural ischemia is assumed; however pathological studies of autopsy 13, 14 and 
thrombectomy 18, 31, 43 materials indicated that plaque disruption, fissure or erosion with 
RMT remain clinically silent days or weeks before the fatal event. The SRA index of the 
patents with less than 30 SRA index at hospitalization exceed normal level within 2 to 3 
days. These findings indicated that SRA index rapidly increases in AMI patients after plaque 
disruption, erosion, or fissure. A SRA index more than 30 was observed in patients with 
multiple organ dysfunction syndrome50. Therefore, SRA index more than 30 was not a 
specific finding to ACS. SRA index exceeded 30 in 230 of 300 (76.7 %) cases with RMT and 
46 of 89 (51.7 %) cases with PT alone, and 276 of all 389 cases at hospitalization. Thrombus 
was identified in all 276 patients with a SRA index more than 30 at hospitalization. PT was 
detected in 99.3 % and RMT in 83.3 % of these patients. SRA index did not exceed 30 in 
healthy control cases. SRA index of these 276 patients was surmised to exceed 30 before the 
onset of STEMI. The SRA indices of 75.9 % of unstable angina cases were more than 30 at 
hospitalization 27. The pathophysiological substrate of the unstable angina is now considered 
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to be common with the acute myocardial infarction. We, therefore, believe that the abnormal 
increase of SRA+ cells is considered to be a useful finding to gather the presence of disrupted 
or fissured or eroded plaque, PT, and probably RMT in patients with UA. 
13. References 
[1] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic 
therapy for acute myocardial infarction: a quantitative review of 23 randomised 
trials. Lancet 2003;361:13-20. 
[2] Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockede after myocardial 
infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737.  
[3] Latini R, Tognoni G, Maggioni AP, et al. For Angiotensin-converting Enzyme Inhibitor 
Myocardial Infarction Collaborative Group.Clinical sffects of early angiotensin-
converting enzyme inhibitor treatment for acute myocardial infarction are similar 
in the presence and absence of aspirin: systematic overview of indivifual data 
from96712 randomized patients. J A Coll Cardiol 2000;35:1801-07.  
[4] Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atovastatin on early recurrent 
ischemic events in acute coronary syndromes: the MIRACL study: a randomized 
controlled trial. JAMA 2001;285:1711-18. 
[5] Antithrombotic trialists’ Collaboration. Collaborative meta-analysis of randomized trials 
of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in 
high risk patients. BMJ 2002;324:71-86. 
[6] Gibbons RJ, BaladyGJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise 
testing: summary article: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Committee to Update the 
1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531-40.  
[7] Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, Part II. 
Mayo Clin Proc 2009;84:1021-36.  
[8] Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary 
thrombosis : characteristics of coronary atherosclerotic plaques underlying fatal 
occulusive thrombi. Br Heart J 1983;50:127-34. 
[9] Davies MJ, Thomas AC. Plaque fissuring－ the cause of acute myocardial infarction, 
sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-73. 
[10] Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress 
distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4. 
[11] Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors 
and plaque morphology in men with coronary disease who died suddenly. N 
Engl J Med 1997;336:1276-82. 
[12] Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Effect of risk factors 
on the mechanism of acute thrombosis and sudden coronary death in women. 
Circulation 1998;97:2110-6.  
[13] Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to 
infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis 
with peripheral embolization culminating in total vascular occlusion. Circulation 
1985;71:699-708. 
  
Acute Coronary Syndromes 
 
42
[14] Mailhac A, Badimon JJ, Fallon JT, et al. Effect of an eccentric severe stenosis on 
fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. 
Relative contribution of fibrin(ogen) and platelets. Circulation 1994;90:988-96.  
[15] Hackett D, Davie G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute 
myocardial infarction: value of combined thrombolytic and vasodilatory therapy. N 
Engl J Med 1987;317:1055-9. 
[16] Davies SW, Marchant B, Lyons JP, et al. Irregular coronary lesion morphology after 
thrombolysis predicts early clinical instability. J Am Coll Cardol 1991;18:669-74. 
[17] Ohman EM, Topol EJ, Califf RM, et al. An analysis of the cause of early mortality after 
administration of thrombolytic therapy. Cor Art Dis 1993;4:957-64. 
[18] Burke AP, Kolodgie FD, Farb A, et al. Healed plaque rupture and sudden coronary 
death. Evidence that subclinical rupture has a role in plaque progression. 
Circulation 2001;103:934-40. 
[19] MacNeill BD, Lowe HC, Takano M, Valentin F, Ik-Kyung J. Intravascular modalities for 
detection of vulnerable plaque. Arterioscler Thromb Vasc Biol 2003;23:1333-42.  
[20] Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC. Factors influencing the 
presence or absence of acute coronary artery thrombi in sudden ischemic death. 
Eur Heart J 1989;10:203-8. 
[21] Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression 
of granulocyte and macrophage colony-stimulating factors by modified low-
density lipoproteins. Nature 1990;344:254-7. 
[22] Liao F, Andalibi A, Qiao J-H, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a 
common pathway mediating oxidative stress, inflammatory gene induction, and 
aortic fatty streak formation in mice. J Clin Invest 1994;94:877-84. 
[23] Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage 
colony-stimulating factor gene expression in vascular cells and in experimental and 
human atherosclerosis. Am J Pathol 1992;140:301-16. 
[24] Rosenfeld ME, Ylä-Herttula S, Lipton BA, Ord VA, Witztum JL, Steinberg D. 
Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions 
of rabitts and humans. Am J Pathol 1992;140:291-300. 
[25] Takeya M, Tomokiyo R, Jinnouchi K, et al. Macrophage scavenger receptor: Structure, 
function and tissue distribution. Acta Histochem. Cytochem 1999;32:47-51. 
[26] Kunjathoor VV, Febbraio M, Poderz EA, et al. Scavenger receptor A-I/II and CD36 are 
the principal receptors responsible for the uptake of modified low density 
lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-8.  
[27] Emura I, Usuda H, Fujita T, Ebe K, Nagai T. Increase of scavenger receptor-A- positive 
monocytes in patients with acute coronary syndromes. Pathology International 
2007;57:502-508. 
[28] Emura I, Usuda H, Fujita T, Ebe K, Nagai T. Scavenger receptor A index anfd coronary 
thrombus in patients with acute ST elevation myocardial infarction. Pathology 
International 2011;61:351-355. 
[29] Iwao Emura. High incidence of apoptosis in peripheral blood of myelodysplastic 
syndrome patients determined by Papanicolaou-stained preparations. Laboratory 
Hematology 2003;9:42-6.  
 
Physiopathology of the Acute Coronary Syndromes 
 
43 
[30] Rittersma SZH, van der Wal AC, Koch KT, et al. Plaque instability frequently occurs 
day or weeks before occlusive coronary thrombosis. A pathological thrombectomy 
study in primary precutaneous coronary intervention. Circulation 2005; 111: 1160-5. 
[31] Konishi Y, Okamura M, Konishi N, et al. Enhanced gene expression of scavenger 
receptor in peripheral blood monocytes from patients on cuprophane 
haemodialysis. Nephrol Dial transplant 1997;12:1167-72. 
[32] Villanova JG, Lucena JLD, Arcás NF, Engel AR. Increased expression of scavenger 
receptor type I gene in human peripheral blood from hyperlipidemic patients 
determined by quantitative additive RT-PCR. Biochimica et Biophysica Acta 
1996;1300:135-41.  
[33] Geng Y-j, Kodama T, Hansson GK. Differential expression of scavenger receptor 
isoforms during monocyte-macrophage differentiation and foam cell formation. 
Arterioscler Thromb 1994;14:798-806.  
[34] Fuster V, Badimon L, Badimon JJ, Cheserbo JH. The pathogenesis of coronary artery 
disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.  
[35] Ross R. Atherosclerosis －an inflammatory disease. New Engl J Med 1999;340:115-26. 
[36] Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relationship of C-reactive protein and 
coronary heart disease in the MRFIT nested case-control study : Multiple Risk 
Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.  
[37] Koenig W, Sund M, Frohlich M. et al. C-rfeactive protein, a sensitive marker of 
inflammation, predicts future risk of coronary heart disease in initially healthy 
middle-aged men : results from the MONICA(monitoring Trends and 
Determinants in Cardiovascular Disease) Augsberg Cohort Study, 1984 to 1992. 
Circulation 1999;99:237-42.  
[38] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 
2002;105:35-1143. 
[39] Naito M, Kodama T, Matsumoto A, Doi T, Takahashi K. Tissue distribution, 
intracellular localization, and in Vitro expression of Bovine macrophage scavenger 
receptor. Am J Pathol 1991;139:1411-23 
[40] Young DA, Lowe LD, Clark SC. Comparison of the effects of IL-3, granulocyte-
macrophage colony- stimulating factor, and macrophage colony-stimulating factor 
in supporting monocytes differentiation in culture. J Immunol 1990;145:607-15. 
[41] Sakamoto K, Arakawa H, Mita S, et al. Elevation of circulating interleukin 6 after 
surgery: Factors influencing the serum level. Cytokine 194;6:181-186. 
[42] Henriques de Gouveia R, van der Wal AC, van der Loos CM, Becker AE. Sudden 
unexpected death in young adults.Discrepancies between initiation of acute plaque 
complications and the onset of acute coronary death. Eur Heart J 2002; 23: 1433-40. 
[43] Murakami T, Mizuno S, Takahashi Y, et al. Intracoronary aspiration thrombectomy for 
acute myocardial infarction. Am J Cardiol 1998; 82: 839-44. 
[44] Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: 
platelet thrombi grow on the apex of stenotic severely injured vessel wall. 
Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.  
[45] Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet 
deposition on severely damaged vessel wall in flowing blood. Effects of different 
stenoses on thrombus growth. Arteriosclerosis 1990; 10: 306-15. 
  
Acute Coronary Syndromes 
 
42
[14] Mailhac A, Badimon JJ, Fallon JT, et al. Effect of an eccentric severe stenosis on 
fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. 
Relative contribution of fibrin(ogen) and platelets. Circulation 1994;90:988-96.  
[15] Hackett D, Davie G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute 
myocardial infarction: value of combined thrombolytic and vasodilatory therapy. N 
Engl J Med 1987;317:1055-9. 
[16] Davies SW, Marchant B, Lyons JP, et al. Irregular coronary lesion morphology after 
thrombolysis predicts early clinical instability. J Am Coll Cardol 1991;18:669-74. 
[17] Ohman EM, Topol EJ, Califf RM, et al. An analysis of the cause of early mortality after 
administration of thrombolytic therapy. Cor Art Dis 1993;4:957-64. 
[18] Burke AP, Kolodgie FD, Farb A, et al. Healed plaque rupture and sudden coronary 
death. Evidence that subclinical rupture has a role in plaque progression. 
Circulation 2001;103:934-40. 
[19] MacNeill BD, Lowe HC, Takano M, Valentin F, Ik-Kyung J. Intravascular modalities for 
detection of vulnerable plaque. Arterioscler Thromb Vasc Biol 2003;23:1333-42.  
[20] Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC. Factors influencing the 
presence or absence of acute coronary artery thrombi in sudden ischemic death. 
Eur Heart J 1989;10:203-8. 
[21] Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression 
of granulocyte and macrophage colony-stimulating factors by modified low-
density lipoproteins. Nature 1990;344:254-7. 
[22] Liao F, Andalibi A, Qiao J-H, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a 
common pathway mediating oxidative stress, inflammatory gene induction, and 
aortic fatty streak formation in mice. J Clin Invest 1994;94:877-84. 
[23] Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage 
colony-stimulating factor gene expression in vascular cells and in experimental and 
human atherosclerosis. Am J Pathol 1992;140:301-16. 
[24] Rosenfeld ME, Ylä-Herttula S, Lipton BA, Ord VA, Witztum JL, Steinberg D. 
Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions 
of rabitts and humans. Am J Pathol 1992;140:291-300. 
[25] Takeya M, Tomokiyo R, Jinnouchi K, et al. Macrophage scavenger receptor: Structure, 
function and tissue distribution. Acta Histochem. Cytochem 1999;32:47-51. 
[26] Kunjathoor VV, Febbraio M, Poderz EA, et al. Scavenger receptor A-I/II and CD36 are 
the principal receptors responsible for the uptake of modified low density 
lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-8.  
[27] Emura I, Usuda H, Fujita T, Ebe K, Nagai T. Increase of scavenger receptor-A- positive 
monocytes in patients with acute coronary syndromes. Pathology International 
2007;57:502-508. 
[28] Emura I, Usuda H, Fujita T, Ebe K, Nagai T. Scavenger receptor A index anfd coronary 
thrombus in patients with acute ST elevation myocardial infarction. Pathology 
International 2011;61:351-355. 
[29] Iwao Emura. High incidence of apoptosis in peripheral blood of myelodysplastic 
syndrome patients determined by Papanicolaou-stained preparations. Laboratory 
Hematology 2003;9:42-6.  
 
Physiopathology of the Acute Coronary Syndromes 
 
43 
[30] Rittersma SZH, van der Wal AC, Koch KT, et al. Plaque instability frequently occurs 
day or weeks before occlusive coronary thrombosis. A pathological thrombectomy 
study in primary precutaneous coronary intervention. Circulation 2005; 111: 1160-5. 
[31] Konishi Y, Okamura M, Konishi N, et al. Enhanced gene expression of scavenger 
receptor in peripheral blood monocytes from patients on cuprophane 
haemodialysis. Nephrol Dial transplant 1997;12:1167-72. 
[32] Villanova JG, Lucena JLD, Arcás NF, Engel AR. Increased expression of scavenger 
receptor type I gene in human peripheral blood from hyperlipidemic patients 
determined by quantitative additive RT-PCR. Biochimica et Biophysica Acta 
1996;1300:135-41.  
[33] Geng Y-j, Kodama T, Hansson GK. Differential expression of scavenger receptor 
isoforms during monocyte-macrophage differentiation and foam cell formation. 
Arterioscler Thromb 1994;14:798-806.  
[34] Fuster V, Badimon L, Badimon JJ, Cheserbo JH. The pathogenesis of coronary artery 
disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.  
[35] Ross R. Atherosclerosis －an inflammatory disease. New Engl J Med 1999;340:115-26. 
[36] Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relationship of C-reactive protein and 
coronary heart disease in the MRFIT nested case-control study : Multiple Risk 
Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.  
[37] Koenig W, Sund M, Frohlich M. et al. C-rfeactive protein, a sensitive marker of 
inflammation, predicts future risk of coronary heart disease in initially healthy 
middle-aged men : results from the MONICA(monitoring Trends and 
Determinants in Cardiovascular Disease) Augsberg Cohort Study, 1984 to 1992. 
Circulation 1999;99:237-42.  
[38] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 
2002;105:35-1143. 
[39] Naito M, Kodama T, Matsumoto A, Doi T, Takahashi K. Tissue distribution, 
intracellular localization, and in Vitro expression of Bovine macrophage scavenger 
receptor. Am J Pathol 1991;139:1411-23 
[40] Young DA, Lowe LD, Clark SC. Comparison of the effects of IL-3, granulocyte-
macrophage colony- stimulating factor, and macrophage colony-stimulating factor 
in supporting monocytes differentiation in culture. J Immunol 1990;145:607-15. 
[41] Sakamoto K, Arakawa H, Mita S, et al. Elevation of circulating interleukin 6 after 
surgery: Factors influencing the serum level. Cytokine 194;6:181-186. 
[42] Henriques de Gouveia R, van der Wal AC, van der Loos CM, Becker AE. Sudden 
unexpected death in young adults.Discrepancies between initiation of acute plaque 
complications and the onset of acute coronary death. Eur Heart J 2002; 23: 1433-40. 
[43] Murakami T, Mizuno S, Takahashi Y, et al. Intracoronary aspiration thrombectomy for 
acute myocardial infarction. Am J Cardiol 1998; 82: 839-44. 
[44] Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: 
platelet thrombi grow on the apex of stenotic severely injured vessel wall. 
Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.  
[45] Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet 
deposition on severely damaged vessel wall in flowing blood. Effects of different 
stenoses on thrombus growth. Arteriosclerosis 1990; 10: 306-15. 
  
Acute Coronary Syndromes 
 
44
[46] Nagata Y, Usuda K, Uchiyama A, Uchikoshi M, sekiguchi Y, Kato H, Miwa A, Ishikawa 
T. Characteristics of the Pathological images of coronary artery thrombi according 
to the infarct-related coronary artery in acute myocardial infarction. Circ J 2004; 68: 
308-14. 
[47] Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34. 
[48] Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic 
myocardium. Cardiovasc Res 2004; 61: 498-511. 
[49] Emura I, Usuda H. Histopathological and cytological examination of autopsy cases with 
multiple organ dysfunction syndromes. Pathology International 2010;60:443-51. 
4 
Evolution of Biochemical Diagnosis of Acute 
Coronary Syndrome – Impact Factor of High 
Sensitivity Cardiac Troponin Assays 





In patients with acute thoracic pain and non-conclusive acute myocardial infarction 
electrocardiogram (non-STEMI), the biochemical diagnosis is an essential tool for its correct 
treatment. The study of the chosen biomarker for cardiac injury has raised interest during 
decades. The appearance of immunoassays to assess cardiac troponin I or T has reached 
great improvements in the diagnosis, evolution and prognosis of the Acute Coronary 
Syndrome (ACS), as well as in risk stratification of these patients and in patients with 
chronic cardiac diseases as heart failure or cardiomyopathies. Regarding the analytical 
sensitivity of the methods that evaluate cardiac troponin I or T these improvements have 
made possible to measure accurately very tiny seric concentrations of the protein (high 
sensitivity troponin) (hs-Tn). This fact, being positive in principle sometimes induces to 
reconsider if tiny seric concentrations of isolated troponin I or T are not due to acute 
myocardial infarction but to a less severe source which affects the myocardiocite, this will 
oblige us to assess the clinical presentation in depth.  
2. Diagnostic criteria of acute coronary syndrome – Biochemical markers – 
History background and evolution 
Thoracic pain is one of the most frequent reasons for attending the emergengy room at 
hospitals. About 10% of these patients will be diagnosed Acute Myocardial Infarction. The 
clinical syntoms and the electrocardiogram can not always differentiate between a patient 
suffering from acute myocardial infarction or an angina. Electrocardiogram is only 
diagnostic in 40% of the patients. That is why in processes of acute coronary ischemia 
different from infarction with rising of segment ST, (infarction no Q or without rising of ST, 
unstable angina), the use of biochemical markers can be the only criteria to identify the 
existence of myocardial necrosis, being necessary for infarction diagnosis, treatment, 
evolution and prognosis. 
The biochemical diagnosis of acute coronary syndrome has had remarkable changes over 
the last few years. During years the enzymatic profile (creatine kinase, activity of the 
isoenzime CKMB, aspartate aminotransferase and lactate deshidrogenase) has been the 
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biochemical method chosen for the diagnosis of acute coronary ischemia. The criteria of the 
WHO (WHO 1979 ) was followed until 1999, being the catalytic activity of creatine kinase 
MB isoenzyme (CKMB) the marker chosen. In fact, according to the WHO to reach the 
diagnosis of acute myocardial infarction (AMI) two of the following three criterias must be 
fulfilled: precordial pain with evolution longer than 30 minutes, specific electrocardiograph 
changes and elevation of catalityc activity of creatine kinase (CK) and its isoenzime MB 
(CKMB). 
However, during the 1990s more sensitive and specific cardiac markers are marketed and 
beginning to be used in order to detect the disease, such as the protein concentration of 
isoenzime MB (CKMBmass) or Troponin. 
In September 2000 the criteria which defines acute myocardial infarction (AMI) was 
reviewed and a consensus document was published (European Society of Cardiology/ American 
College of Cardiology Committe 2000) between The Joint European Society of Cardiology and 
The American College of Cardiology where they give great importance to the alterations of 
cardiac markers: Troponin or CKMBmass (no activity) for the diagnosis of the disease, 
together with symptoms of ischemia or alterations in the electrocardiogram (ECG). In fact, 
the main criteria to establish the diagnosis of acute myocardial infarction is to verify the 
gradual release of troponin or CKMBmass, (typical curve of fast rising-descent), together 
with at least one of the following alterations: a) ischemic syntoms; b) development of 
pathological Q waves in ECG; c) indicative changes of ischemia (variations of the segment 
ST,T)  
2.1 Cardiact troponin: Biochemical bases  
Troponin is one of the myofibrilar proteins of the skeletal muscle and its function is to 
regulate muscular contraction in relation with calcium ion (Figure 1). The thick filament of 
the muscle is formed by myosin and the thin filament by actin, troponin and tropomyiosin. 
Only actin and myosin are contractile proteins; troponin and tropomyosin are regulatory. 
Troponin is composed by three peptides called troponin T, troponin I and troponin C. 
Troponin T is regulatory of tropomyosin; troponin I (inhibitory), inhibits the union actin-
myosin; troponin C is the receptor of calcium so when linking calcium disappears the 
inhibition of troponin I on tropomyosin forming the shuttles actin-myosin and activating the 
contraction.  
The theory currently accepted for the mechanism of muscular contraction involves the ATP-
asic activity (two molecules of ADP and inorganic phosphorus) present in the heads of 
myosin (figure 1). In repose myosin does not contact actin as the sarcplasm does not have 
enough calcium to produce the contraction, and calcium regulates the ATP-asic activity. 
During the contraction when receiving the nervous signal calcium is released to the 
sarcoplasm, this calcium joins immediately to the centers of union of calcium to troponin, 
inducing a structure change which allows the heads of actin and myosin to link forming an 
angle of about 90ºC. The release of the phosphorus molecule of the complex actin-myosin-
ADP involves a structure change which makes actin slide (power strike) and adopt a 45ºC 
angle on myosin. This movement produces at the same time a release of ADP. For each actin 
myosin union provoked by the union of two calcium molecules to troponin C, at least two 
ATP molecules are needed and to carry two calcium molecules from the cytosol to reticule 
an ATP molecule is required (Galán A. 2000).  
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ADP: Adenosin diphosphate 
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Fig. 1. Scheme of the process of muscular contraction and involvement of myofibrilar and 
contractile proteins of the skeletal muscle (Galán A. 2000).  
The different kinds of muscles of the organism present different characteristics of 
contraction, this is due to the structural differences genetically determined in some 
myofibrilar proteins. Three isoforms have been described for troponin I and T which present 
structural differences codified by genes located in three different crhomosomes. So for 
troponin I (figure 2) there are two isoforms of the skeletal muscle one of slow contraction 
and another one fast and a specific shape of the cardiac muscle. The cardiac isoform has 31 
suplementary aminoacids at the N-terminal end of the polypeptide chain and besides it 
differs from skeletal isoforms as it shows in the tracts of the primary sequences of the 
protein, a heterogeneity of 69% for the central tract (residues 30 to 110) and 44% for the 
terminal tract (110-215) which seems to be more stable because of the protection carried out 
by the subunit C terminal. Troponin T also shows three isoforms codified by genes located 
in three different chromosomes, one of them is specific for myocardium. The myocardial 
isoform has an elevated polymorphism provoking isoforms which express in injured 
myocardial tissue, adult and fetal. Troponin C, however, is identical in both kinds of muscle. 
(Galán A. 2004).  
This fact confers troponin the qualification of cardiac marker of maximum cardiospecificity 
unlike creatine kinase, creatine kinase MB and myoglobine which co-express in the skeletal 
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biochemical method chosen for the diagnosis of acute coronary ischemia. The criteria of the 
WHO (WHO 1979 ) was followed until 1999, being the catalytic activity of creatine kinase 
MB isoenzyme (CKMB) the marker chosen. In fact, according to the WHO to reach the 
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muscle and in the myocardium. Some specific anti-bodies have been patented in opposition 
to troponin T and cardiac Troponin I so that they can be recognised by specific 
immunoassays. Troponin forms (I and T) of skeletal and cardiac muscle: a) Are codified by 
different genes; b) Have structures which are clearly differentiated; c) Are recognised by 
specific immunoassays. 
That is why the assessment of troponin T or troponin I favours the specific recognition of 
myocardial damage even in the presence of concomitant skeletal muscle damage. Therefore 
only troponin molecules fulfil the cardiospecificity criteria. This cardiospecificity guarantees 
that the detection of a cardiac troponin molecule in plasma is indicative of myocardial 
injury. 
 























Fig. 2. Isoforms of Troponin I: In the figure we can see two isoforms of skeletal muscle, one 
of slow contraction and another one fast and a specific form of cardiac muscle. The cardiac 
isoform has 31 suplementary aminoacids at the end N-terminal of the polypeptide chain, 
besides it differs from skeletal isoforms as it shows in the tracts of the primary sequence of 
the protein a heterogeneity of 69% for the central tract (residues 30 to 110) and 44% for the 
terminal tract (110-215) which seems to be more stable because of the protection carried out 
by the subunit C terminal (Galän A 2004).  
We confirmed the absence of crossed reactions (Galán A. 2002) for an Immunoassay 
Troponin I (cat. nº RF421 Dade Behring) using the Dimension RxL automatic analyzer (Dade 
Behring, Newark, Delaware, USA). The cardiospecificity of troponin I was verified using 
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myocardial and skeletal muscle (quadriceps, biceps) tissue. Troponin I was measured in 
myofibrillar and cytosolic fraction. The absence of troponin I in skeletal muscle was 
corroborated: the concentration of troponin I in biceps and quadriceps was not detected (< 
1% of the values obtained in myocardial tissue). The troponin I concentration in the 
myofibrillar fraction of cardiac tissue was 7.2 mg/g protein and only 4% of total troponin 








































Fig. 3. Tissue specificity for the troponin I method. The figure shows the lack of 
crossreactivity of troponin I with skeletal muscle. No troponin I concentrations in the crude 
extract of biceps and quadriceps were detected. The troponin I concentration in the 
myofibrillar fraction of cardiac tissue was 7.2 mg/g protein and in the cytosolic fraction 0.3 
mg/g protein. (Galán A. 2002) 
This fact helps to understand the double diagnostic window of troponin: The small fraction 
dissolved in cytoplasma of the cardiomyocites, which has relative precociousness (>6 hours) 
in the detection of cellular injuries (similar to other cytoplasmatic proteins) and the majority 
fraction which is the one linked to tropomyosin complex in structure and only appears in 
plasma after cellular irreversible damage and after 40 hours from occurring and remains 
elevated till 10-15 days after the injury, being then used as late marker of myocardial 
necrosis (figure 4)  
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Fig. 4. Plasmatic levels of cardiac markers after ischemic process: Double diagnostic window 
of Troponin 
2.2 Comparative characteristics of troponin with other cardiac markers 
Myoglobine and CKMB are located in the cellular cytoplasma which favours a fast exit of the 
molecule out of the cell and therefore an early appearance in systemic circulation. Troponin 
has a small fraction in cellular cytoplasma but most of it is found in deep tissue, as part of 
tropomyosin complexes. On the other hand either myoglobin or CK-MB co-express in skeletal 

















MIOGLOBIN Heart  muscle 




CK-MB Heart  muscle 
Skeletal muscle     






   
Heart  muscle 
 







Heart  muscle 
 





Table 1. Molecular Weight and cellular and tissue location. 
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Myoglobin and CK isoforms are the earliest markers and with the fastest elimination. CKMB 
is cytosolic but it has higher PM than Myoglobin so it takes it longer to appear and clear the 
plasma. Troponin, due to its double location has a wide diagnostic window (from 6 hours to 






















2 -4 6 -8 18-2 4 houres
MIOGLOBIN 2 -3 6- 9 18-2 4 houres
CK-M B 4 -6 10- 18 1-2  days  
T ROPONIN I >6 10- 24 5 -10 days  
T ROPONIN 
T 
>6 10- 24 5 -12 days  
 
  
Table 2. Cardiac marker Kinetics. 
Cardiac troponin has a small fraction (6% for T and 3% for I) dissolved in cytoplasma of the 
cardiomyocites. This confers the early detection of cellular damage similar to that of other 
cytoplasmatic proteins, even better than the isoenzime MB of creatine kinase because its 
molar mass is lower (33.000 g/mol para la T y 23.500 g/mol para la I). Nevertheless, the 
majority fraction, approximately 90%, is linked in structure to the tropomyosin complex and 
only appears in plasma after irreversible cellular damage and 40 hours after occurring. 
Besides, as it remains in plasma for a long time it can also be used as late marker of 
myocardial necrosis. 
Because of all of this, the excellent cardiospecificity and sensitivity of troponin for the 
detection of myocardial necrosis, together with its wide diagnostic window (from 6-12h to 5-
10 days for troponin I and from 6-12 hours to 5-15 days for troponin T) have revolutionised 
in the latest years the approach of patients with acute coronary syndrome as a lot of studies 
have demonstrated its usefulness in the diagnosis of myocardial necrosis as well as in the 
prognostic stratification of these patients in the first hours of evolution. 
2.3 Problem of the methods to assess troponin. Solutions taken. Guidelines for 
clinical practice 1999 and 2001 
In the beginning of working with troponin, either physician or biochemists wondered : Is 
troponin so useful?, Which troponin method is the right one? (Troponin T or Troponin I), 
What cut-off must we choose?, What marker or markers must be selected?, What intervals 
must be used? 
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troponin so useful?, Which troponin method is the right one? (Troponin T or Troponin I), 
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must be used? 
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At present there are black spots in the analytical management of the methods which assess 
troponin as the election for cut-off or the lack of standardization of the different methods 
available in the market (Wu Alan HB 2001), (Apple FS, 2001) and the low analytical 
sensitivity of the methods among others. These factors may cause confusion in the election 
of the method as well as in the clinical interpretation of the results (Table 3). 
 
• The choice of cutoff
• Lack of Tn I method’s estandarization
• Low sensitivity of methods
These factors may cause confusion
in the interpretation of results
 
Table 3. Technical problems in management troponin methods. 
To try to help and encourage us to use troponin, in 1999 appeared the first Guidelines for 
Clinical Practice in the use of troponin published by the National Academy of Clinical 
Biochemistry (NACB) to establish analytical and clinical recommendations (Wu AHB 1999) 
and in 2001 the standardization committee of cardiac markers of the International 
Federation of Clinical Chemistry (IFCC) opted for troponin as election marker for 
myocardial necrosis and establishes recommendations of analytical and pre-analitical 
quality for the assays of Tn, ( Panteghini M 2001), encouraging the clinical laboratories to 
use it and inducing the manufacturers to improve the analytical quality of the methods of 
assessment of the protein. 
An example of the problems was the discrepancy arisen when establishing the cut-offs 
according to the criteria of the different scientific societies: The NACB suggests using the 
ROC curves of sensitivity and diagnostic specificity choosing two cut-offs (AMI and 
myocardial damage) or just one cut-off of myocarid damage. Another alternative is to 
establish Reference Values in normal population and apply 95th percentile as the National 
Academy of Clinical Biochemistry (NACB) suggests or 99th percentile as the American 
College of Cardiology suggests (ACC). 
Another important problem is the election of the method (table 4). There is only one 
method in the market to measure TnT and innumerable methods to measure Tn I. The 
results of the different methods which measure Tn I are not overlapping, which generates 
doubts about its election. This variability of results does not occur with TnT methods as 
there is only one TnT immunoanalisis marketed. However, TnT values are not 
overlapping either with the methods which measure Troponin I. The molecular structure 
of TnI favours its heterogeneity. In serum there is variability of forms of TnI by oxidation, 
phosphorilation or protelisis affecting the interaction with anti-bodies in the assays. 
Besides, the heterogeneity in plasma of the different forms of troponin is another reason 
that makes it difficult to select the method. In blood we can find tissular forms of troponin 
making binary or ternary troponin complexes and free cytosolic forms (Figure 5). 
Therefore the anti-bodies used in the immunoassays of TnI detect different epitopes in 
free and complexed forms. 
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• Heterogeneity in plasma of the different forms of troponin
– Tissular forms:
binary troponin complexes  (I +C)
ternary troponin complexes (T+I+C)
– Free cytosolic forms  (I and T)
• There is any reference material to standardize marketed troponin
methods
• The antibodies used in the immunoassays of TnI detect different 
epitopes in free and complexed forms.  
Table 4. Reasons difficult the election of the method. 
 
 
Fig. 5. Scheme of the release in blood of cardiac sub-units of troponin after acute myocardial 
infarction (according to Wu y cols.) (Galan2004). 
So the main problem regarding the methods that assess troponin is the lack of 
standardization (Figure 6). As a consequence of that there is no transferring of the results 
among the different commercial methods which assess this protein, what creates confusion 
due to the analytical and clinical variability of the results. This makes it difficult to choose 
the best method.  
The absence of a material of reference which standardizes the methods means that the 
results obtained can not be transferred. The methods will have a different cut-off, variations 
in the limit of the cut-off, as well as imprecisions. On the other hand at low levels close to 
the reference values the coefficients of variation are elevated. 
The most suitable solution in the long run, as it is a difficult matter, to solve this problem is 
to obtain international reference material, a topic in which scientific societies as IFCC and 
AACC (American Society of Clinical Chemistry) among others have been working on since 
2001. This would standardize the methods and the transferring of the results would be 
achieved. What would not be unified is the variation of anti-bodies every manufacturer 
uses. The problem is not completely solved as the reference material obtained, more 
suitable, was elaborated by a sub-committee of standardization of the AACC in 
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collaboration with the National Institute of Standards and Technology (NIST) and certified 
in 2006 as standard reference material SRM # 2921. This reference material achieves 
commutability only with 50% of the commercial methods which assess troponin. In any 
case, the standardization of the measurement methods of troponin is not finished yet, which 
involves wide analytical variations noticed among the different immunoassays marketed 












































Fig. 6. Analitical problems of the methods which assess troponin: Absence of 
standardization of the methods. 
The immediate solution the user must opt is: Choose the immunoassay which best adapts 
the infrastructure of the centre (central laboratory, emergency laboratory, or at the patients’ 
side) (bear in mind the analytic system available) and demand the manufacturers the 
technical documentation about what their method measures. The black spots must be 
evaluated by the user itself. In case that the imprecision of the chosen method does not fulfil 
the NABC indications at the point of diagnostic decision, the improvement of the method 
must be claimed to the manufacturer. 
Another important shortage of the initial methods of quantification of troponin is its relative 
sensitivity (figure 7)  
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Figure 7. PROBLEM OF INITIAL TROPONONIN METHODS 
uncertainty in the diagnostic sensitivity 
of necrosis detection.
High coefficients of variation at levels
near of the lower limit of the reference values
 
Fig. 7. Problem of initial troponin methods. 
In general the methods of assessment of troponin showed elevated values in the limits of 
detection, limits of quantification far from the reference values, high imprecisions in the 
limits of quantification, cut-off and reference values, which provokes uncertainty in the 
diagnostic sensitivity of necrosis detection.  
That is why the goals of analytic quality of the different scientific societies have been: 
Recommend the use of methods to assess troponin with the maximum analytical sensitivity 
to increase the diagnostic sensitivity of the test in myocardial necrosis as well as avoiding 
the problems arising because of the lack of standardization of methods. 
2.4 Guidelines of clinical practice 2007 
In 2007, The Joint ESC/ACF/AHA/ WHF Task Force 2007 (Thygesen 2007) published 
the last Guidelines of Clinical Practice on the recommendations of the biochemical 
diagnosis of the detection of ACS and re-define the criteria for Myocardial Infarction 
establishing a universal definition of AMI. The recommendation (class I) state: In 
presence of clinical evidence (symptoms or alterations in ECG), concentrations of seric 
troponin higher than 99th percentile of the interval of reference of the method (with 
optimal analytic precision CV<10%), are indicative of myocardial necrosis. If troponin is 
not available the measurement of CKMB-mass is another acceptable alternative. The 
extraction of blood must be carried out at patient’s admission and 6 – 9 hours after 
admission.  
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collaboration with the National Institute of Standards and Technology (NIST) and certified 
in 2006 as standard reference material SRM # 2921. This reference material achieves 
commutability only with 50% of the commercial methods which assess troponin. In any 
case, the standardization of the measurement methods of troponin is not finished yet, which 
involves wide analytical variations noticed among the different immunoassays marketed 
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the infrastructure of the centre (central laboratory, emergency laboratory, or at the patients’ 
side) (bear in mind the analytic system available) and demand the manufacturers the 
technical documentation about what their method measures. The black spots must be 
evaluated by the user itself. In case that the imprecision of the chosen method does not fulfil 
the NABC indications at the point of diagnostic decision, the improvement of the method 
must be claimed to the manufacturer. 
Another important shortage of the initial methods of quantification of troponin is its relative 
sensitivity (figure 7)  
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Fig. 7. Problem of initial troponin methods. 
In general the methods of assessment of troponin showed elevated values in the limits of 
detection, limits of quantification far from the reference values, high imprecisions in the 
limits of quantification, cut-off and reference values, which provokes uncertainty in the 
diagnostic sensitivity of necrosis detection.  
That is why the goals of analytic quality of the different scientific societies have been: 
Recommend the use of methods to assess troponin with the maximum analytical sensitivity 
to increase the diagnostic sensitivity of the test in myocardial necrosis as well as avoiding 
the problems arising because of the lack of standardization of methods. 
2.4 Guidelines of clinical practice 2007 
In 2007, The Joint ESC/ACF/AHA/ WHF Task Force 2007 (Thygesen 2007) published 
the last Guidelines of Clinical Practice on the recommendations of the biochemical 
diagnosis of the detection of ACS and re-define the criteria for Myocardial Infarction 
establishing a universal definition of AMI. The recommendation (class I) state: In 
presence of clinical evidence (symptoms or alterations in ECG), concentrations of seric 
troponin higher than 99th percentile of the interval of reference of the method (with 
optimal analytic precision CV<10%), are indicative of myocardial necrosis. If troponin is 
not available the measurement of CKMB-mass is another acceptable alternative. The 
extraction of blood must be carried out at patient’s admission and 6 – 9 hours after 
admission.  
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These Guidelines are in accordance with the latest analytic recommendations for the use 
of troponin published in 2007 by the National Academy of Clinical Biochemistry (NACB) 
and the Committee of standardization of Cardiac Markers of the IFCC (NACB 2007) 
which state that: To establish reference values 99th percentile must be applied on a 
population of at least 120 subjects exempt from myocardial damage. It is required that the 
imprecision of the method in the 99th percentile chosen is lower or equal to a coefficient of 
variation of 10%.  
3. Methods of new generation: High-sensitivity assays 
The recommendations of these Clinical Guidelines have induced the manufacturers to 
market methods which assess the protein with higher reliability. This has provoked the 
appearance in the market of a new generation of immunoassays which assess troponin.  
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Fig. 8. New generation of troponin methods. 
(Figure 8) They are methods with elevated analitic sensitivity and their goal is to detect the 
99th percentile of the limit of the detection, quantification limit and normal population with 
high analitic precision being able to fulfil the recommendations of the scientific societies. 
The goal of these methods is to be able to know with reliability the early diagnosis of the 
necrosis and the stratification of myocardial risk. There is a recent publication of Jaffé 2010 
which collects the characteristics of analytic sensitivity of all the methods of troponin in the 
market (table 5, ref Jaffé 2010).  
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cTn at 99th 
percentile 
(ug/L) 





Abbott AxSYM ADV (2nd) 0.02 0.04 15.0 0.16 
Abbott ARCHITECT <0.01 0.028 15.0 0.032 
Abbott i-STAT 0.02 0.08# 16.5 0.10 
Beckman Coulter Access 
Accu (2nd) 0.01 0.04 14.0 0.06 
bioMerieux Vidas Ultra 
(2nd) 0.01 0.01 27.7 0.11 
Innotrac Aio! (2nd) 0.006 0.015 14.0(at 19 ng/L) 0.036 
Inverness Biosite Triage 0.05 <0.05 NA NA 
Inverness Biosite Triage (r) 0.01 0.056 17.0 NA 
Mitsubishi Chemical 
PATHFAST 0.008 0.029 5.0 0014 
Ortho Vitros ECi ES 0.012 0.034 10.0 0.034 
Radiometer AQT90 0.0095 0.023 17.7 0.039 
Response Biomedical 
RAMP 0.03 <0.1 18.5 0.21 
Roche E170  0.01 <0.01 18.0 0.03 
Roche Elecsys 2010 0.01 <0.01 18.0 0.030 
Roche Cardiac Reader <0.05 <0.05 NA NA 
Siemens Centaur Ultra 0.006 0.04 10.0 0.03 
Siemens Dimension RxL 0.04 0.07 20.0 0.14 
Siemens Immulite 2500 
STAT 0.1 0.2 NA 0.42 
Siemens Immulite 
1000Turbo 0.15 NA NA 0.64 
Siemens Stratus CS 0.03 0.07 10.0 0.06 
Siemens VISTA 0.015 0.045 10.0 0.04 
Tosoh AIA II  0.06 <0.06 8.5 0.09 
NA= not assayed 99th = 99th percentile; 10% CV = Concentration measured with a 10% of total 
imprecision measured as coefficient of variation (CV); (r) = revised assay submitted to FDA per 
Inverness. Table can be consulted at http://www.ifcc.org/PDF/ScientificActivities/Committees/C-
SMCD/cTn_Assay_Table_v091209.pdf. Version updated September 12, 2009 
Table 5. Analytical characteristics of the current cardiac troponin I and T assays. (source) 
Troponinas ultrasensibles en el dolor torácico y los síndromes coronarios agudos. ¿un paso 
hacia delante? A.S. Jaffé y J.Ordoñez-Llanos. Rev Esp Cardiol, 2010; 63(7)763-68  
There are only 4 of them which fulfil the recommendations of the Guidelines for Clinical 
Practice into effect at present (Thygesen 2007) , (NCB 2007) (CV< 10% in 99th percentile). 
However, at present there is no recommendation in any Clinical Guideline which classifies 
high sensitivity methods. Apple et al 1999 have suggested a classification to differentiate such 
methods. They use two criterias a) coefficient of variation in 99th percentile and b) percentege 
of values detected in reference population. For a method to be ultra-sensitive must have 
CV<10% in 99th percentile and detect troponin in less than 50% of the reference population. 
  
Acute Coronary Syndromes 
 
56
These Guidelines are in accordance with the latest analytic recommendations for the use 
of troponin published in 2007 by the National Academy of Clinical Biochemistry (NACB) 
and the Committee of standardization of Cardiac Markers of the IFCC (NACB 2007) 
which state that: To establish reference values 99th percentile must be applied on a 
population of at least 120 subjects exempt from myocardial damage. It is required that the 
imprecision of the method in the 99th percentile chosen is lower or equal to a coefficient of 
variation of 10%.  
3. Methods of new generation: High-sensitivity assays 
The recommendations of these Clinical Guidelines have induced the manufacturers to 
market methods which assess the protein with higher reliability. This has provoked the 
appearance in the market of a new generation of immunoassays which assess troponin.  
 
Figure 8.  New Generation of Troponin methods
High- sensitivity assays
To detect the Tn
99 percentile of the reference interval, with
HIGH PRECISION ANALYTICAL
Reliably detected
early diagnosis of necrosis and
risk stratification




Fig. 8. New generation of troponin methods. 
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Practice into effect at present (Thygesen 2007) , (NCB 2007) (CV< 10% in 99th percentile). 
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CV<10% in 99th percentile and detect troponin in less than 50% of the reference population. 
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Table 6 (from Jaffé 2010) holds the classification of the methods available in the market to 
assess troponin according to the criteria of Apple 1999. None of the 16 methods mentioned in 
















Current available assays (generation) 
Abbott AxSYM ADV (2nd) 40 15.0 Clinically <50% 
Abbott ARCHITECT 28 15.0 Clinically <50% 
Abbott i-STAT 80 16.5 Clinically <50% 
Beckman Coulter Access 
Accu (2nd) 40 14.0 Clinically 50-75% 
bioMerieux Vidas Ultra (2nd) 10 27.7 Not acceptable <50% 
Innotrac Aio! (2nd) 15 14.0 (at 19 ng/L) Clinically <50% 
Inverness Biosite Triage <50 NA NA <50% 
Inverness Biosite Triage (r) 56 17.0 Clinically Unknown 
Mitsubishi Chemical 
PATHFAST 29 5.0 Guideline
 <50% 
Ortho Vitros ECi ES  34 10.0 Guideline <50% 
Radiometer AQT90 23 17.7 Clinically <50% 
Response Biomedical RAMP <100 18.5 Clinically <50% 
Roche E170  <10 18.0 Clinically <50% 
Roche Elecsys 2010  <10 18.0 Clinically <50% 
Roche Cardiac Reader  <50 NA NA <50% 
Siemens Centaur Ultra  40 10.0 Guideline <50% 
Siemens Dimension RxL  70 20.0 Clinically <50% 
Siemens Immulite 2500 
STAT 200 NA NA <50% 
Siemens Immulite 1000 
Turbo NA NA NA <50% 
Siemens Stratus CS  70 10.0 Guideline <50% 
Siemens VISTA  45 10.0 Guideline <50% 
Tosoh AIA II  <60 8.5 Guideline <50% 
Research high-sensitive assays 
Beckman Coulter Access hs-
cTnI 8.6 10.0 Guideline >95% 
Roche Elecsys hs-cTnT 13 8.0 Guideline >95% 
Nanosphere hs-cTnI 2.8 9.5 Guideline 75-95% 
Singulex hs-cTnI 10.1 9.0 Guideline >95% 
Table 6. Classification of the current and the high-sensitive cTn assays according criteria of 
Apple 2009.(source) Troponinas ultrasensibles en el dolor torácico y los síndromes 
coronarios agudos. ¿un paso hacia delante? A.S. Jaffé y J.Ordoñez-Llanos. Rev Esp Cardiol, 
2010; 63(7)763-68  
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From these results it is important to point out that the most sensitive methods (research 
high-sensitivity assays) that is, with concentration values under 99th percentile and with 
better imprecisions in such percentile, are the ones which show higher proportion of healthy 
subjects (between 75-95% or >95%) which exceed the value of normality established for the 
method  
4. Repercussion of high sensitivity troponin methods in the management of 
patients with ACS – Proposal of interpretation in clinical practice 
The appearance of this new generation of high sensitivity troponin methods is going to 
modify the classical diagnostic interpretation of precordial pain we have been making 
until now as their goal is to be able to measure much smaller protein concentrations than 
the ones conventional methods are able to measure now. So it will be necessary to learn 
again and become familiar with the management of the marker. These new myocardial 
necrosis biomarkers going to appear in the blood stream hours earlier than if the marker 
is measured using conventional methods. These ones can only detect troponin 6-9 hours 
after clinical symptoms whereas using high sensitivity troponin the necrosis can be 
diagnosed earlier, as it starts being detected in blood three hours after pain. In a similar 
way the exclusion of acute myocardial infarction will also be earlier and considering the 
negligible amount of troponin which can be detected it will also increase the prediction of 
adverse clinical events. There are studies which confirm this fact. As the sensitivity of the 
methods has increased, it has been found a remarkable increase of the diagnostic 
sensitivity in the early detection of AMI using all, methods of high sensitivity troponinT 
and conventional Tn T methods (Giannitsis E,2010, Giannitsis E,2010 b) or troponin I 
(Kavasak PA 2009. Wilson 2009). 
These characteristics which theoretically just show benefits can cause diagnostic confusion 
of an acute coronary syndrome because ultrasensitive troponin elevations are not only 
due to an acute process as they are also found in sub-acute processes and other cardiac 
diseases. High sensitivity troponin methods detect a minimum injury of the non-ischemic 
cardiomiocites, due to cardiac disorders (myocardial injuries such as myocarditis, 
pericarditis among others or the increase of the cardiac size as in cardiac insufficiency, left 
ventricular hypertrophia among others) or to other sort of diseases as for example 
pulmonary edema , sepsis or ictus can cause the release of hsTn into the systemic 
circulation. That is why not only the ischemic injury but also a wide range of other 
alterations can be associated with elevated high sensitivity troponin values. Besides, most 
of these elevations predict an adverse evolution in these patients, being , in this case, the 
clinic criterias the only way to reach a diagnosis. This causes confusion in the 
interpretation of troponin, which has traditionally been associated with the acute 
coronary syndrome being its elevation essential when the patient has acute thoracic pain, 
having or not elevation of the ST segment in electrocardiogram. Using conventional 
methods the finding of troponin values over the reference interval, in processes which do 
not fit with an acute coronary syndrome, induced us to look into the cause, which 
habitually was not explained. The appearance of high sensitivity methods make us change 
our criteria as although the reason for the output into the bloodstream of small amounts 
of the protein, which were not detected by conventional methods, is not known exactly, in 
processes which do not fit with acute ischemia its find represents a very useful data for 
the prognosis of the patient. 
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The appearance of this new generation of methods to assess troponin induces us to 
continue with the research in the management of these biomarkers, whose future is 
promising, in order to optimize and learn its management, and until new Guidelines in 
Clinical Practice appear and reach a consensus on the best way to use and interpret the 
results, we must be cautious in the application of high sensitivity troponin in clinical 
practice methods. 
That is why the best thing to do (table 7) before implementing a method in clinical practice 
is to assess comprehensively and establish the reference values in better defined 
populations, using more strict inclusion criteria, setting up patterns of evolution changes to 
differentiate an ischemic patient from a patient with troponin elevations due to stable 
disease or underlying to new pathologic entities different from acute coronary syndrome. 
The knowledge this data for each of the methods assessing ultrasensitive troponin is an 
essential tool for the correct use and clinical interpretation of the results. Not to have such 
data well defined and established makes the diagnostic interpretation difficult and can 
cause confusion  
 
1. Establishing reference values (99 th percentil discriminator at CV <10%) 
2. Establishing the increase value of high sensitivity troponin discriminator of Acute 
Coronary Syndrome (∆ Tn discriminator). 
Table 7. Mandatory requirements for the use of a high sensitivity troponin method in 
clinical practice 
4.1 Establishing reference values of the method 
As it can be seen in table 7 when there is an increase in the analytical sensitivity of the 
troponin tests, there are more people with troponin concentration over the 99th percentile. 
So, individuals with cardiovascular risk as hypertension, dislipemia, diabetes, renal 
insufficiency, cardiac insufficiency among others. This fact can make the clinical 
interpretation of the test difficult. That is why when evaluating a high sensitivity troponin 
method we must be especially cautious when establishing the reference values (table 8). 
The selection of the individuals to be included as reference population must be much 
more selective, considering much more strict inclusion criteria. The most important 
exclusion criteria to bear in mind are: pregnancy, current cold or infection, chronic 
inflammatory disease, patients treated for cardiac disease or lipid management, diabetes, 
family history of cardiovascular disease, smoking, high blood pressure or treated for high 
blood pressure, increased C-reactive protein, o interleukin-6 among others. The number of 
subjects to study must be at least 120 and 99th percentile will be applied. The imprecision 
of the method in the 99th percentil chosen must be lower or equal to a coefficient of 
variation of 10% (NACB 2007). We must bear in mind that the value of the 99th percentile 
chosen must be higher than the value measured by the method with an imprecision lower 
than 10% (99th percentil discriminator). We could expect that if we carried out again 
reference values in the methods mentioned in tables 5 and 6, with more restrictive 
inclusion criteria applied , especially in the ones called (research high-sensitivity assays), 
the percentage of detectable troponin in normal subjects, exempt from cardiovascular 
pathology, would decrease. 
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Number of patients  Mínimum de 120 subjects 
Exclusion criteria  
- pregnancy  
- infection  
- chronic inflammatory disease 
- subjets treated for cardiac disease or lipid management  
- diabetes  
- subjects with family history of cardiovascular disease  
- smoking  
- high blood pressure  
- increased C-reactive protein or interleukin-6 
statistic 99th percentile 
Precision  CV< 10% in 99th percentile 
Table 8. Requirements to establish reference values of high sensitivity troponin methods 
4.2 Establish the value of increase of high sensitivity troponin discriminator of acute 
coronary syndrome 
As a result of all the above mentioned it is easy to understand the difficulty in interpreting a 
value of basal high sensitivity troponin in patients who go to the emergency room with 
precordial pain and without conclusive alterations in the electrocardiogram. From the 
biochemical point of view, the only way to help to distinguish if a high sensitivity troponin 
elevation is due to an acute ischemia process or if the origin is a sub-acute cardiac disease or 
chronic, as it happens with congestive cardiac insufficiency or cardiomyiopaties among 
others, is to perform serial troponins, as the Guidelines for Clinical Practice in 2007 
recommended (Thygesen 2007, NACB 2007). Nevertheless, given the early of the appearance 
of high sensitivity troponin (3 hours after pain) as well as its high sensitivity in detection, 
the basal determination and the determination 6-9 after pain would not be the protocol to 
choose. With these new generation of troponins, the advisable to distinguish if we are facing 
an acute necrosis process or an underlying ischemia of a chronic process, is to establish a 
value of the increase of troponin discriminator of acute coronary syndrome (∆ Tn 
discriminator). To obtain this data the increase in the variation of troponin should be 
assessed for a 3-hour interval, in a group of patients who suffer from an acute coronary 
syndrome and in another group patients who suffer a chronic process. In the acute ischemia 
there will be a significant increase of basal troponin compared with the one carried out 
between 3 and 6 hours later. In chronic processes the increase in troponin between 3 and 6 
hours compared with basal troponin will be much lower. Once the Tn discriminator for a 
determined method is obtained, in clinical practice the scheme in figure I could be applied, 
which will help us confirm an acute myocardial infarction, at an earlier stage than with 
traditional methods, or to look for other causes of the increase in troponin. 
The correct establishment of the increase evolution of high sensitivity troponin for an acute 
coronary syndrome, together with the strict study of normality values will clarify the 
advantages of this new generation of methods for the early diagnosis of acute coronary 
syndrome, as well as it will significantly benefit in the stratification of the risk, not only in 
patients with acute coronary syndrome but also patients who suffer from other myocardial 
injuries or increase of cardiac size among other causes. 
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Number of patients  Mínimum de 120 subjects 
Exclusion criteria  
- pregnancy  
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- chronic inflammatory disease 
- subjets treated for cardiac disease or lipid management  
- diabetes  
- subjects with family history of cardiovascular disease  
- smoking  
- high blood pressure  
- increased C-reactive protein or interleukin-6 
statistic 99th percentile 
Precision  CV< 10% in 99th percentile 
Table 8. Requirements to establish reference values of high sensitivity troponin methods 
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The correct establishment of the increase evolution of high sensitivity troponin for an acute 
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Fig. 9. Clinical significance of hsTn using troponin increase ACS discriminator. Proposal for 
the use of high sensitivity troponin in clinical practice. 
5. High sensitivity troponin in patients with heart failure 
Heart failure (HF) is a growing public health problem with high morbidity and mortality 
(Rosamond W 2008) . Natriuretic peptides are the election markers for diagnosis and risk 
stratification of patients with Heart failure ( Braunwald E 2008) . Cardiac troponin are detected 
in an important proportion of patients suffering from acute or chronic HF. The mechanism of 
cardiac damage and appearance in Tn plasma, acute or chronic HF is not exactly known. The 
levels of troponin in plasma are associated with the increase of the risk of morbility and 
mortality either in acute or chronic HF giving prognostic information (Parentini 2008). Cardiac 
troponin is detected in a significant portion of patients with acute and chronic Heart Failure. 
However, the incidence of detection depends on the sensitivity of the assay used. Latini et al ( 
Latini 2007) ,. measured Plasma troponin T in 4053 patients with chronic HF enrolled in the 
Valsartan Heart Failure Trial (Val-HeFT). Troponin T was detectable in 10.4% of the 
population with the conventional cTnT assay (detection limit < or = 0.01 ng/mL) compared 
with 92.0% with the new hsTnT assay (< or = 0.001 ng/mL). Detectable cTnT predicts adverse 
outcomes in chronic HF. (High sensitivity Troponin T (hsTnT) is a novel biomarker that 
provides prognostic information in several clinical settings as heart failure. 
6. Conclusions 
In view of all the above mentioned we can conclude that the biochemical diagnosis of ACS 
continues being a current affair and continues envolving. The process of troponin has not 
finished yet. The appearance of high sensitivity methods seems to be promising. They help 
to diagnose ACS much earlier and obtain higher stratification of the risk than convencional 
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methods. Besides, it will let us know about the prognostic evolution of other pathologies 
such as chronic cardiac insufficiency as well as cardiovascular events in stable coronary 
disease. Nevertheless, to achieve the efficiency that the test deserves we have to learn, again 
to use and interprete the results of ultra-sensitive troponin. It is necessary to consolidate and 
establish firmly the dynamic changes of troponin concentrations to interprete the results 
accurately.  
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1. Introduction  
Cardiovascular diseases remain the leading cause of morality in the western world. The aim 
of this chapter is to understand the pathogenesis of acute coronary syndromes from 
atherosclerotic plaque formation, to plaque progression and vascular remodeling, to plaque 
destabilization, to ultimately plaque rupture or erosion and thrombus formation.  
A cascade of interacting factors leads to plaque formation, progression, fraglisation, and 
rupture. 
Features associated with plaque rupture are: large eccentric soft lipid core, thin fibrous cap, 
inflammation in the cap and adventitia, increased plaque neovascularity, and outward or 
positive vessel remodeling. 
Vasospasm is a separate mechanism for developing ACS without plaque rupture or erosion 
will not be discussed in this chapter. 
2. Atherosclerosis 
Atherosclerosis is a chronic disease that can remain asymptomatic through decades. It is 
enhanced by modifiable and non modifiable risk factors and consists of intra intimal 
accumulation of intra cellular and extracellular oxidized LDL, macrophages, T cells, smooth 
muscle cells, proteoglycan, collagen, calcium, and necrotic debris. Low endothelial shear 
stress can contribute to atherosclerotic plaque formation, vulnerabilisation, and rupture. 
Intimal accumulation of oxidized LDL-C, called fatty streaks constitutes the earliest 
histopathologic stage of atherosclerosis. 
Adhesion molecules expressed by endothelial cells mediate the rolling and adhesion of 
circulating leukocytes on the endothelial surface. Chemoattractant chemokines promote 
transmigration of leukocytes into the intima. Monocytes infiltrate beneath the endothelium, 
differentiate to macrophages, phagocytose the oxidized LDL-C and transform into foam 
cells. Foam cells produce cytokines, growth factors, reactive oxygen species and matrix-
degrading enzymes, sustaining atherosclerosis progression. The intensity of oxidized LDL-C 
accumulation in the subendothelial space is a major stimulus for the ongoing inflammatory 
process. The accumulation of lipid-laden foam cells constitute the intermediate lesions or 
pathologic intimal thickening, which evolve through several stages of progression.  
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3. Arterial remodeling 
Arterial remodeling involves a cascade of structural and morphological changes of a vessel 
wall in response to various stimuli including changes in blood flow and pressure, and acute 
injury; all three are common findings in atherosclerotic plaques.  
Two types of coronary arterial remodeling have been described: 
- Negative remodeling: defined as local shrinkage, negative remodeling is more often 
seen in patients with stable angina and is associated with smaller plaque areas. It might 
be seen in arterial wall healing after injuries such as balloon injury, that could be mainly 
related to vascular wall contracture and consequent luminal narrowing. The biological 
events involved in this wound healing involve complex series of interacting growth 
factors, integrins and proteases.  
- Positive or outward remodeling:  defined by a compensatory increase in local vessel 
size in response to increasing plaque burden minimizing the degree of luminal stenosis. 
Positive remodeling characterizes unstable vulnerable plaques.  
There are studies demonstrating that plaque rupture occurs in insignificant, mildly 
occlusive plaques, this could be explained by positive remodeling: the increase in total 
arterial area that accompanies plaque accumulation. Large positive remodeled plaques 
while paradoxically protecting against luminal narrowing, are more susceptible to 
mechanical forces that lead to plaque rupture and an unstable clinical presentation.  
The pathogenesis of arterial remodeling is not fully understood and remains debated. Many 
hypotheses have been advanced.  
Arterial wall neovascularisation of atherosclerotic plaques seems to have a potential role in 
modulating lesion formation and structural changes of the arterial wall, by nourishing the 
growing plaque. Various angiogenic growth factors and receptors are implicated in 
coronary wall angiogenesis such as   VEGF/VPF, estrogen, interleukin 8, bFGF, and aFGF; 
the role of TNF-α and TGF-β remains controversial. 
Angiotensine II via AT1 receptors is another trigger of plaque neovascularisation and 
remodeling. 
Activation of NADPH oxidase by various triggers such as Angiotensine II and mechanical 
stretch promotes ROS production and ROS-mediated pathways leading to vascular remodeling.  
In addition Low ESS leads to inflammation of the wall beneath the plaque and shift of the 
extracellular matrix balance toward degradation. Within such an environment the internal 
elastic lamina undergoes severe fragmentation, and the atherosclerotic process extends into 
the media degrading the collagen and elastin fibers, thereby promoting arterial expansion 
and outward remodeling. 
Human studies using intravascular ultrasound confirmed that outward or positive 
remodeling is more common at culprit lesion sites in patients with unstable angina, whereas 
inward or negative remodeling is more common in patients with stable angina.  
 
Pathogenesis of positive arterial remodeling 




Table 1. This table summarizes factors contributing to positive plaque remodeling that is 
associated with unstable plaque. 
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4. Plaque destabilisation 
Typically a vulnerable plaque is described as having a thin fibrous cap and a rich superficial 
lipid core. Weakening of the fibrous cap is due mainly to accelerated degradation of 
collagen and other matrix components.  
Many factors contribute to plaque vulnerabilisation: 
4.1 Inflammation 
Inflammation cells such as activated monocytes and macrophages and, to a lesser degree, T 
cells play a crucial role in destabilizing the fibrous cap tissue and, therefore, enhance the risk 
of plaque rupture.  
Adhesion molecules such as VCAM-1 as well as chemokines such as MCP-1 recruite 
inflammatory cells into the atherosclerotic plaques. Inflammatory cells are activated in the 
vessel wall by oxidized lipids and cytokines such as M-CSF. 
Adventitial neovasculature also enhances inflammatory cells entry and recruitement inside 
the atherosclerotic lesion.  
Many mediators secreted by plaque macrophages could be involved in fibrous cap 
weakening including: 
- Interleukin (IL)-18: also called interferon gamma-inducing factor, is a proinflammatory 
cytokine secreted by plaque macrophages. Increased serum IL-18 may be an 
independent predictor of cardiovascular mortality.  
- Matrix Metalloproteinases (MMP): mainly MMP-2 (Gelatinse A), MMP-9 (Gelatinase B), 
and MMP-8 (Collagenase), released from activated macrophage foam cells, directly 
mediate matrix degradation of the plaque fibrous cap. Oxidized LDL containing 
arachidonic and linoleic acid  upregulates the expression of metalloproteinase, while 
HDL reverses this effect. 
- Tissue factor: expressed by macrophages is the main initiator of thrombogenesis.  
Inflammation usually concerns the entire coronary circulation not only the culprit lesion. 
This fact explains why patients with acute coronary syndrome may have multiple 
vulnerable plaques. 
 
Mechanisms of Angiotensine II mediated plaque weakening  
Upregulation of IL6 gene 
Upregulation of MMP genes 
Activation of mitogen-activated protein kinase cascades 
Activation of tyrosine kinases 
Stimulation of neovascularisation  
Table 2. This table summarizes the leading mechanisms of Angiotensine II mediated 
atherosclerotic plaque weakening 
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Pathogenesis of positive arterial remodeling 




Table 1. This table summarizes factors contributing to positive plaque remodeling that is 
associated with unstable plaque. 
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4. Plaque destabilisation 
Typically a vulnerable plaque is described as having a thin fibrous cap and a rich superficial 
lipid core. Weakening of the fibrous cap is due mainly to accelerated degradation of 
collagen and other matrix components.  
Many factors contribute to plaque vulnerabilisation: 
4.1 Inflammation 
Inflammation cells such as activated monocytes and macrophages and, to a lesser degree, T 
cells play a crucial role in destabilizing the fibrous cap tissue and, therefore, enhance the risk 
of plaque rupture.  
Adhesion molecules such as VCAM-1 as well as chemokines such as MCP-1 recruite 
inflammatory cells into the atherosclerotic plaques. Inflammatory cells are activated in the 
vessel wall by oxidized lipids and cytokines such as M-CSF. 
Adventitial neovasculature also enhances inflammatory cells entry and recruitement inside 
the atherosclerotic lesion.  
Many mediators secreted by plaque macrophages could be involved in fibrous cap 
weakening including: 
- Interleukin (IL)-18: also called interferon gamma-inducing factor, is a proinflammatory 
cytokine secreted by plaque macrophages. Increased serum IL-18 may be an 
independent predictor of cardiovascular mortality.  
- Matrix Metalloproteinases (MMP): mainly MMP-2 (Gelatinse A), MMP-9 (Gelatinase B), 
and MMP-8 (Collagenase), released from activated macrophage foam cells, directly 
mediate matrix degradation of the plaque fibrous cap. Oxidized LDL containing 
arachidonic and linoleic acid  upregulates the expression of metalloproteinase, while 
HDL reverses this effect. 
- Tissue factor: expressed by macrophages is the main initiator of thrombogenesis.  
Inflammation usually concerns the entire coronary circulation not only the culprit lesion. 
This fact explains why patients with acute coronary syndrome may have multiple 
vulnerable plaques. 
 
Mechanisms of Angiotensine II mediated plaque weakening  
Upregulation of IL6 gene 
Upregulation of MMP genes 
Activation of mitogen-activated protein kinase cascades 
Activation of tyrosine kinases 
Stimulation of neovascularisation  
Table 2. This table summarizes the leading mechanisms of Angiotensine II mediated 
atherosclerotic plaque weakening 
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4.2 Renin-angiotensin system 
There is evidence of angiotensin converting enzyme (ACE), angiotensine II, and AT1 
receptors within the plaque.  An increased activity of ACE was found within culprits lesions 
in the setting of acute coronary syndromes, probably related to a local secretion. 
Angiotensine II increases the likelihood of  plaque progression and rupture via AT1 
receptors by regulating the gene expression of various bioactive substances mainly 
interleukine 6  (IL6), metalloproteinases, and other growth factors and cytokines. 
Angiotensine II also activates multiple intracellular signaling cascades (mitogen-activated 
protein kinase cascades, tyrosine kinases, and various transcription factors) in coronary 
endothelial and smooth muscle cells. 
In addition Angiotensine II enhances plaque neovascularisation.  
4.3 Hemodynamical factors mainly shear stress 
4.3.1 Definitions  
- Endothelial shear stress (ESS): tangential force derived by the friction of the flowing 
blood on the endothelial surface. It is the product of the shear rateat the wall and the 
blood viscosity. 
- Shear rate: The spatial gradient of blood velocity from areas at the arterial wall toward 
areas at the center of the lumen (dv/dy, where dv is change in flow velocity and dy is 
change in radial distance from the wall). 
Physiologically, the shear rate decreases at the center of the lumen and gradually 
increases toward the wall. 
- Blood viscosity: A principal property of blood related to its internal friction that causes 
blood to resist flow. Hematocrit is the major determinant of blood viscosity. 
Although the entire vasculature is exposed to the atherogenic effects of the systemic risk 
factors such as hyperlipidemia, cigarette smoking, hypertension, diabetes mellitus, and 
genetic predisposition, atherosclerotic lesions form at specific regions of the arterial tree, 
such as in the vicinity of branch points, the outer wall of bifurcations, and the inner wall of 
curvatures, where disturbed flow occurs and ESS is low. 
Low ESS induces endothelial dysfunction by reducing the bioavailability of nitric oxid via a 
decrease in eNOS messenger ribonucleic acid and protein expression, thereby exposing the 
endothelium to the atherogenic effect of local and systemic risk factors. Nitric oxide is a key 
component of normal vascular tone, characterized by strong anti-inflammatory, 
antiapoptotic, anti-mitogenic, and anti-thrombotic properties. In addition, low ESS 
downregulates prostacyclin, another endothelial vasodilatory substance and upregulates 
endothelin-1,  a potent vasoconstrictive and mitogenic molecule.  
Low ESS also promotes subendothelial deposition and accumulation of LDL-C by increasing 
mitotic and apoptotic activity of endothelial cells and inducing conformational changes of 
endothelial cells from fusiform to polygonal shape, widening thereby the junctions between 
endothelial cells.  
Gene expression as well as post-transcriptional activity of the major oxidative enzymes at 
endothelial cell membranes are enhanced by low ESS, leading to the production of reactive 
oxygen species within the intima. 
In addition gene expression of several adhesion molecules, chemoattractant chemokines and 
proinflammatory cytokines are upregulated by low ESS. 
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Mechanisms of low ESS mediated plaque weakening 
Endothelial dysfunction: 
 Decreases eNOS 
 Downregulates Prostacycline synthesis  
 Upregulates Endotheline-1 synthesis  
LDL-C  sub-intimal uptake and accumulation 
Promotes inflammation  
Promotes oxidative stress 
Table 3. This table summarizes the contribution of low ESS to plaque weakening.  
4.4 Strenuous exercise  
Strenuous exercise especially among those who exercise infrequently and have multiple 
cardiac risk factors, is associated with increased temporary risk of plaque rupture and 
myocardial infarction via increase wall stress due to rapid increase in heart rate and blood 
pressure, coronary vasospasm, increased flexing of epicardial coronary arteries, deepening 
of existing plaque fissures, and catecholamine induced platelet aggregation.   
4.5 In vivo detection of vulnerable plaque with optical coherence tomography 
Optical coherence tomography (OCT) is recently developed imaging modality, using infra 
red light and characterized by the higher existing resolution (axial resolution: 10-15μm) 
allowing a microscopical description of the atherosclerotic plaque in vivo within the 
coronary arteries. OCT is validated for the detection of vulnerable plaque wich is typically 
characterized by: 
- Thin fibrous cap < 65 μm 
- Rich lipid core: when lipid is present within two or more quadrants of the plaque. 
- Microchannels in case of plaque neovascularisation.   
 
 
Fig. 1. Fibrous cap assessment with OCT: fibrous cap is a signal rich layer separating the lumen 
from the signal poor underlying lipid core. Fibrous cap is measured at its thinest segment. 
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Fig. 1. Fibrous cap assessment with OCT: fibrous cap is a signal rich layer separating the lumen 
from the signal poor underlying lipid core. Fibrous cap is measured at its thinest segment. 
  







Fig. 2. OCT showing a thick fibrous cap, calcified plaque. Calcium is seen as a homogeneous 





Fig. 3. OCT showing a lipid rich plaque. Lipid is seen as a heterogeneous signal poor region 
with irregular edges. 
 


















Fig. 4. Adventicial and subintimal increazed neovascularization characterizes unstable 
plaque and can be detected in vivo with OCT. Neovessels or microchannels are seen as no-
signal tubulo-luminal structure without a connection to the vessel lumen and recognized on 
≥ 3 consecutive cross sectional OCT images. 
5. Plaque rupture 
As previously explained the fibrous cap rupture results from an imbalance between 
synthesis and breakdown of extracellular matrix collagen and other matrix components 
leading to thinning of the cap, predisposing the cap to spontaneous rupture or rupture in 
response to a variety of triggers. Plaque rupture primarily occurs in yellowish plaques with 
an increased lipid core and thin fibrous cap. Rupture of the thin fibrous cap exposes blood 
flow to the lipid core. The lipid core is believed to be highly thrombogenic when exposed to 
circulating blood. The enhanced thrombogenicity of the lipid core has been attributed to the 
high levels of functionally active tissue factor most likely derived from the death of 
macrophages inside the plaque. In addition to tissue factor, oxidized lipids in the lipid core 
may also directly stimulate platelet aggregation. 
The thrombus is usually occlusive in STEMI and nonocclusive in NSTEMI.  Episodes of 
plaque disruption and thrombosis may be subclinical and do not always result in acute 
coronary syndrome. Healing process may play an integral role in the progression of 
atherosclerosis, having the potential to cause sudden plaque growth.  
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Fig. 5. (A)- Coronary angiogram showing ostial occlusion (TIMI 0 flow) of the left ascending 
artery responsible of acute STEMI; (B)- OCT performed in the same patient after thrombo-
aspiration and restauration of a TIMI 3 flow, shows the site of plaque rupture, defined  by a 







Fig. 6. Rupture site detected with OCT (right) in the setting of NSTEMI. The coronary 
angiogram (left) shows a subocclusion of the segment 2 of the right coronary artery. 
 










Fig. 7. (A)- Coronary angiogram showing occlusion of the segment 1 of right coronary artery 
in a patient presenting with STEMI; (B)- OCT performed after thrombo-aspiration showed 






Fig. 8. Red thrombus in the setting of ACS is seen with OCT as hypersignal  protusion 
within the lumen, however, unlike white thrombus, red thrombus is characterised by a 
signal attenuation  and posterior signal free shadowing due to the backscatering properties 
of the red blood cells wich are highly present in red thrombus. 
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Fig. 8. Red thrombus in the setting of ACS is seen with OCT as hypersignal  protusion 
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signal attenuation  and posterior signal free shadowing due to the backscatering properties 
of the red blood cells wich are highly present in red thrombus. 
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6. Plaque erosion 
Plaque erosion usually occurs in younger patients, women and smokers.  
Culprit lesion do not have a large lipid core but instead have a proteoglycan-rich matrix, a 
deep lipid core, the prevalence of inflammation is lower with less macrophages and T cells 
and more smooth muscle cells compared to culprit lesions in plaque ruptures. Plaque 
erosion is defined as acute thrombus in direct contact with the intimal plaque without 
rupture of a lipid pool. The plaque luminal surface is irregular and eroded. 
Thrombus resulting from plaque erosion has been reported to be 20% to 40% of all coronary 
thrombi. The precise mechanisms of thrombosis in this entity are not known.  
Thrombosis in such cases might be triggered by an enhanced systemic thrombogenic state 
such as enhanced platelet aggregability, increased circulating tissue factor levels, and 
depressed fibrinolytic state. In addition activated circulating leucocytes may transfer active 
tissue factor by shedding microparticles and transferring them onto adherent platelets.  
Virmani et al have also identified yet another pathological variant where a calcified nodule 
within the plaque erodes through the surface of the plaque leading to thrombosis.  
7. Abbreaviations 
ACS Acute coronary syndrome 
LDL-C Low density lipoprotein cholesterol  
ESS Endothelial shear stress 
VEGF Vascular endothelial growth factor  
VPF Vascular permeability factor  
FGF Fibroblast growth factor  
TNF   Tumor necrosis factor  
TGF Transforming growth factor  
AT1 Angiotensine  type 1 
IL Interleukine  
MMP Matrix  metalloproteinase 
NADPH Nicotinamide Adenosine Dinucleotide Phosphate 
VCAM Vascular cellular adhesion molecule 
ROS Reactive oxygen species 
MCP Monocyte Chemotactic Protein 
CSF Colony stimulating factor  
ACE Angiotensine converting enzyme 
HDL High density lipoprotein 
eNOS Endothelial nitric oxide synthase  
OCT Optical coherence tomography 
TIMI Thrombolysis In Myocardial Infarction 
STEMI ST elevation myocardial infarction  
NSTEMI Non ST elevation myocardial infarction 
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1. Introduction 
Acute coronary syndrome is a clinical condition of partial or total obstruction of blood flow 
in the coronary artery due to acute thrombus formation. Culprit vessel, coronary artery 
segment within which the site of origin of thrombus formation lies, is occupied by eroded or 
ruptured atherosclerotic plaque. Direct contact between circulating blood constituent and 
atherosclerotic plaque content owing to loss of endothelial cell barrier orchestrates the 
haemostasis events, i.e. thrombus formation and coagulation activation. Evolved within 
years of human life span, atherosclerotic undergoes three main steps: initiation, progression 
and finally complication (Libby, 2002).   
Atherosclerotic plaque development involves cellular and molecular interactions as well as 
blood flow dynamic alterations in the affected area. Although these steps affect all 
individual, some gather the risk factors to develop progression and complication of 
coronary atherosclerotic lesion faster and more prominent than others. Given the dynamic 
nature of these steps, understanding several mechanisms engage in every step will provide 
insight into therapeutic approach. Here, we review the last two steps of coronary 
atherosclerotic plaque development, with the focus in the role of platelets, anucleated cells 
being the target for therapeutic advancement in atherosclerosis and acute coronary 
syndrome.   
2. Formation of atherosclerotic plaque 
The earliest event of atherosclerosis formation is the retention of apolipoprotein B–
containing lipoproteins from circulation into subendothelial of the arterial wall (Tabas et al., 
2007). This particular lipoprotein interacts with subendothelial proteoglycan through ionic 
affinity and hence instigates lipoprotein retention in the intimal layer, the innermost part of 
the arterial wall (Borén et al., 1998; Skalen et al., 2002). During this stage, the tendency of 
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retention of lipoprotein depends greatly on sustained plasma level of apolipoprotein B-
containing lipoproteins and, in the lesser degree, lipoprotein size, charge, and composition 
as well as endothelial permeability (Tabas et al., 2007). Three classes of lipoproteins have 
apolipoprotein B as integral constituent: very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), and low density lipoproteins (LDL) (Sniderman et al., 1991). 
Among them, LDL has the biggest apolipoprotein B proportion and is the most likely to 
interact with subendothelial proteoglycan  (Sniderman et al., 1991).  
Modification of LDL apolipoprotein B entrapped in intimal layer by oxidative mechanism 
results in oxidative LDL (oxLDL) (Stocker & Keaney, 2004). Smooth muscle cells, endothelial 
cells and macrophages are capable to modify LDL via oxidative modification (Diaz et al., 
1997). OxLDL is susceptible to scavenging macrophages and gives rise to the generation of 
cholesterol-laden foam cells (Stocker & Keaney, 2004). OxLDL continuously activates 
adjacent endothelial cells. Activated endothelial cells express adhesion molecules on their 
luminal surfaces which attract inflammatory cells from circulation, mainly monocytes and 
lymphocytes which transmigrate to intimal layer. The blend of inflammatory and resident 
vascular cells promotes the formation of atherosclerotic plaque. Arterial smooth muscle cells 
proliferate and migrate to the intimal layer in response to several growth factors releasing 
from chronic inflammation microenvironment in the intimal layer (Libby, 2002). Smooth 
muscle cells form a layer which envelopes the core of “inflammatory nidus” at the 
endothelial site, produce and release collagen and thus shape the so called fibrous cap. 
Below the cap, “inflammatory nidus” continuously attracts circulating LDL, modifies it and 
recognizes it as antigen which attracts more inflammatory cells.     
Atherosclerotic plaque mainly composes of two constructions which undergo dynamic 
changes: fibrous cap and lipid-rich core. The theories of how plaque originated have been 
proposed. Response-to-injury theory proposes the initial step in atherogenesis is endothelial 
denudation due to injurious substance or forces leading to alteration of normal vascular 
homeostatic properties (Ross, 1993). Injury to endothelial cells enhances endothelial 
permeability and adhesiveness for leukocytes to attach and migrate into subendothelial. 
Here inflammation occurs and macrophage recruitment and platelet adhesion and 
aggregation take place, which promote procoagulant tendency of the plaque. Response-to-
retention theory suggests LDL retention into subendothelial is the initial event and the 
prerequisite for plaque to form (Tabas et al., 2007). Endothelial injury does not play 
important role in this process, since plasma LDL is capable to cross normal endothelial cells 
through transcytosis mechanism and retains in subendothelial (Simionescu & Simionescu, 
1993). Subsequent events are monocyte recruitment and lipid-laden macrophage formation 
which initiate subendothelial inflammation (Tabas et al., 2007).  Oxidative modication 
theory indicates that to initiate plaque formation, subendothelial LDL should be modified 
chemically in order to attract macrophages’ scavenger receptor and be internalized to form 
foam cells (Stocker & Keaney, 2004). Native plasma LDL can enter subendothelial and is 
taken up by resident vascular cells via LDL receptor-mediated endocytosis. This native LDL 
does not initiate an inammatory response and is not phagocytosed by monocytes, thus 
does not induce atherosclerosis (Torzewsky & Lackner, 2006).  
As the plaque progress, fibrous cap is thinner and turn out to be fragile due to the imbalance 
of extracellular matrix metabolism, the infiltration of the fibrous cap by macrophages and 
foam cells, and the calcification process (Burnier et al., 2009). All of these contribute to 
fibrous cap weakening and lost its protective role. Once fibrous cap lose its integrity, it 
 
Plaque, Platelets, and Plug – The Pathogenesis of Acute Coronary Syndrome 
 
79 
exposes thrombogenic plaque to circulation. Platelets, around 150,000 until 450,000 per 
millilitre circulate in the blood without contacting endothelial cells, adhere to exposed site, 
are activated and initiate the event to seal the broken plaque surface. Unfortunately, this 
process gives rise to thrombus formation and acute coronary syndrome.   
3. Activated platelet promotes progression of the plaque 
Putative notion that platelets have role merely in the complicating stage of atherosclerosis 
has recently been challenged by several evidence indicating the wider involvement of 
platelets in both early and late atherosclerosis steps (Ruggeri, 2002; Gawaz et al., 2005). In 
histopathology study of human atherosclerosis, platelets were observed in the lesions, both 
in the free form and derivative form being phagocytozed by foam cells and macrophages 
(Sevitt, 1986). Platelet patrols the blood circulation ensuring the integrity of endothelial cells. 
Once this integrity disrupts, platelets expose to subendothelial component and rapidly 
undergo activation to form haemostasis thrombus; this is the case of plaque erosion or 
rupture in acute coronary syndrome. However, intact yet activated endothelial cells can also 
promote platelet activation, this is the case of progressed atherosclerosis plaque.  
3.1 Role of platelet in progressed plaque dynamic 
Advanced responses to modified apolipoprotein B-containing LDL through chronic and 
maladaptive inflammation, macrophage and foam cell apoptotic and plaque necrotic 
formation are representatives of progressed plaque (Tabas et al., 2007). Endothelial cells 
lining the plaque are continuosly under activated state and express adhesion molecules and 
chemoattractant mediator in their surface. Monocytes and lymphocytes are attracted and 
adhere to these molecules and mediators, enter subendothelial and advance inflammatory 
state in the “inflammatory nidus” of the plaque (Lusis, 2000).  
The histomorphology of progressed plaque is characterized by the presence of large lipid-
rich necrotic core, and a thin brous cap. Fibrous cap composes mainly of extracellular 
matrix produced by vascular smooth muscle cells (Lusis, 2000). Supportive function of 
fibrous cap relies on the integrity of this matrix which is maintained through fine balance 
between matrix production and degradation (Ross, 1993). In progressed plaque, the matrix 
degradation activity is increased in line with inflammatory activity in the “inflammatory 
nidus” of the plaque below the cap. Macrophage-derived proteases degrade extracellular 
matrix, thus weaken fibrous cap (Ross, 1993).  
Necrotic core of progressed plaque is derived from foam cells that endure apoptosis and 
necrotic. Initially, necrosis core is an acellular lipid-rich core, which predominantly consist 
of deposited lipids, such as cholesterol esters and free cholesterol derived mostly from retain 
LDL particles (Lusis, 2000). High toxicity of LDL oxidation and formation of reactive oxygen 
species damage the surroundings vascular cells, including foam cells (Madamanchi et al., 
2005). The death of foam cells discharges extracellular lipids and cell debris into adjacent 
environments, thus promotes necrotic core formation (Lusis, 2000). Necrotic core enlarges 
and, in addition to free cholesterol, composes of cholesterol crystals, hyalinized hemorrhage 
and foam cell necrotic remnants (Virmani et al., 2000). Intimal calcifications, resulting from 
advance lipid oxidation and inflammatory cytokine reaction which modify osteogenic 
regulatory genes to promote osteogenesis, scatter in the base of necrotic core adjacent to the 
medial layer (Virmani et al., 2000; Abedin et al., 2004). Neovascularization in the intimal and 
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medial layer is another hallmark of progressed plaque (Fleiner et al., 2004). Hyperplastic 
network of vasa vasorum and ectopic neovascularization of the plaque are associated with 
intimal thickening, lipid contents and the degree of inammation (Fleiner et al., 2004). The 
extent of these microvessels delivers a channel for entry of inflammatory cells into the 
plaque, boosting inflammation even more (Lusis, 2000). This blood vessel networks are 
fragile and prone to rupture and create an outward expansion of intraplaque hemorrhage 
that may overwhelm the integrity of the fibrous cap (Dickson & Gottlieb, 2003). 
Thrombogenic property of lipid-rich necrotic core is determined by its collagen and tissue 
factor content. Two important direct platelet agonists dwell in the lipid-rich core, i.e 
lysophosphatidic acid which mediates platelet shape change during thrombus formation 
and collagen which induces platelet adhesion and aggregation (Lusis, 2000). Tissue factor, 
another major thrombogenic subtrate in the lipid-rich core, is released by endothelial cells, 
smooth muscle cells, monocytes and macrophages or foam cells (Moons et al., 2002). The 
most abundant tissue factor site is in the necrotic core (Moons et al., 2002).  Tissue factor 
activates coagulation cascade and promotes thrombus stabiliy through fibrin network 
formation. Platelets are also capable in releasing tissue factor which give a hint of their role 
in supporting coagulation process (Zillmann et al., 2001). 
3.2 Platelet-endothelial interaction promotes progressed plaque 
Platelets have two storage granules, alpha and dense granules. Alpha granules contain 
adhesion molecules, chemokines, coagulation and brinolysis proteins, growth factors, 
and other proteins (Linden & Jackson, 2010). Dense granules contain molecules such as 
calcium, magnesium, phosphate and pyrophosphate, adenosine and guanosine 
triphosphate, adenosine and guanosine diphosphate and serotonin (Linden & Jackson, 
2010). These granules develop in megakaryocytes, the progenitor cell of platelets. Platelet 
also contains lysosomes which have ubiquitous lysosomal membrane proteins: LAMP-1, 
LAMP-2, and CD63 (LAMP-3), acid hydrolases, cathepsins and other proteins (King & 
Reed, 2002). 
In the alpha granules, platelet-specific proteins are synthesized only in megakaryocytes and 
deliver to platelets which undergo proteolytic upon platelet activation, which include 
platelet factor 4 (PF-4) and β-thromboglobulin (King & Reed, 2002). Platelet-selective 
proteins are synthesized principally by megakaryocytes but also in fewer number by few 
other cells and found in a larger concentration in platelets than plasma. These platelet-
selective proteins include coagulation factor V, thrombospondin, P-selectin, and von 
Willebrand factor (King & Reed, 2002).  
It is expected that platelets keep away from contact with vascular walls or other blood 
cellular components. Under steady laminar blood stream, platelets tend to flow away 
from endothelial cell surface area, avoiding connection with endothelial cells. 
Furthermore, intact and inactivated endothelial cell prevent platelet to adhere to its 
surface. Endothelial cells control platelet activity through inhibitory mechanisms 
involving cyclooxigenase 2 (Cox-2), prostacyclin or prostanoid synthetic systems (Gawaz, 
2006). However, activated endothelial cells are capable to capture platelets and activated 
them, even without any endothelial damage (intact endothelial cells). Activated platelets 
will express several molecules, release their granule contents and stimulate surrounding 
cells, thus promoting plaque progression.  
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3.2.1 Rolling and adhering of platelet to endothelial cell surface 
During inflammation, endothelial cells are activated and change their phenotype becoming 
prone to be adhesive for platelets (Gawaz, 2006). In vitro experiment showed that platelets 
adhere to activated human umbilical vein endothelial cells (HUVEC) which is mediated by 
fibrinogen, fibronectin and von Willebrand factor bound to platelets and endothelial cell 
receptors, ICAM-1, integrin αvβ3 and GPIb (Bombelli et al., 1998). In vivo experiment 
discloses that loose contact between platelets and activated endothelial cells precedes a 
tighter adhesion (Frenette et al., 1995). Rolling of platelets to activated endothelial cell is 
mediated by endothelial P-selectin and constitutively-expressed platelet P-selectin 
glycoprotein ligand 1 (PSGL-1) (Frenette et al., 1995; Frenette et al., 2002).  
P-selectin is a type-1 membrane glycoprotein with a C-type lectin domain and is stored in 
the Weibel-Palade bodies of endothelial cells and alpha granules of platelets (Furie & Furie, 
1995). It rapidly translocate to cell membrane upon endothelial cell or platelet activation 
(Frenette et al., 2002). PSGL-1 is an adhesion molecule primarily expressed in myeloid cells 
and T cells and functions as the main P-selectin ligand which mediates interactions between 
myeloid cells and endothelial cells as well as between myeloid cells and platelets 
(Vandendries et al., 2004). In the study of apoE-knock-out and the P-selectin gene deletion 
mice, atherosclerotic lesion development was significantly delayed, indicating the role of P-
selectin as a key adhesion receptor in promoting advanced atherosclerosis (Dong et al., 
2000). In early atherogenesis, it is likely that intact endothelial cells activate quiescent 
platelets through rolling mechanism via endothelial cell P-selectin and platelet PSGL-1 
interaction. Endothelial cells coating atherosclerotic plaque are constantly under activated 
state, thus expressed P-selectin and attract platelets. P-selectin-expressed activated platelets 
bind to activated endothelial cells in a greater amount than non-activated platelets do.  
In addition to platelet PSGL-1, platelet GP1bα is capable to interact with endothelial P-
selectin and mediate platelet rolling (Gawaz et al., 2006). GP1bα is a component of  GP Ib-
IX-V complex which comprises four polypeptides: GP Ibα, GP Ibβ, GP IX, and GP V (Romo 
et al., 1999).  GP Ib-IX-V complex bind to subendothelial von Willebrand factor, exposed 
when endothelial cell disrupted and initiate thrombosis. GP1α contains von Willebrand 
factor–binding site and molecular structure nearly similar to PSGL-1 (Romo et al., 1999). 
Consequently, during endothelial cell activation, in addition to P-selectin, von Willebrand 
factor are also released from Weibel Palade body to the surface cell membrane. Both 
endothelial cell P-selectin and von Willebrand factor become the target for platelet GP1bα 
(Theilmeier et al., 2002). A study using mice deficient of von Willebrand factor showed some 
level of protection from atherosclerosis thus elucidated the role of von Willebrand factor on 
plaque formation and progression in intact endothelial cells (Methia et al., 2001).  
3.2.2 Tight adhesion of platelet to endothelial cell surface 
P-selectin-mediated loose contact is subsequently changed by tighter connection involving 
endothelial cell integrin, αvβ3 and platelet integrin, αIIbβ3 (Langer & Gawaz, 2008). 
Ligation of platelet GPIbα to endothelial cell von Willebrand factor during platelet rolling 
lead to activation of platelet integrin (Kasirer-Friede et al., 2002). Integrins are ubiquitous 
transmembrane α/β heterodimers that mediate cell-matrix and cell-cell interactions 
(Bennet, 2005). Platelets express 3 members of the β1 subfamily (αIIβ1, αvβ1, and 
αvIβ1) and 2 members of the β3 subfamily (αvβ3 and αIIbβ3) (Bennet, 2005). An αIIbβ3 
is the most important integrin on platelets (Gawaz et al., 1991). In vitro and in vivo studies 
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medial layer is another hallmark of progressed plaque (Fleiner et al., 2004). Hyperplastic 
network of vasa vasorum and ectopic neovascularization of the plaque are associated with 
intimal thickening, lipid contents and the degree of inammation (Fleiner et al., 2004). The 
extent of these microvessels delivers a channel for entry of inflammatory cells into the 
plaque, boosting inflammation even more (Lusis, 2000). This blood vessel networks are 
fragile and prone to rupture and create an outward expansion of intraplaque hemorrhage 
that may overwhelm the integrity of the fibrous cap (Dickson & Gottlieb, 2003). 
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3.2 Platelet-endothelial interaction promotes progressed plaque 
Platelets have two storage granules, alpha and dense granules. Alpha granules contain 
adhesion molecules, chemokines, coagulation and brinolysis proteins, growth factors, 
and other proteins (Linden & Jackson, 2010). Dense granules contain molecules such as 
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3.2.1 Rolling and adhering of platelet to endothelial cell surface 
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show that platelet αIIbβ3 and endothelial cell αvβ3, mediate firm contact between platelets 
and activated endothelial cells (Bombeli et al., 1998; Maasberg et al, 1999). By forming a 
bridge to fibrinogen, αIIbβ3 promotes arrest of platelets to adhesion molecules, intercellular 
adhesion molecule-1 (ICAM)-1, and to αvβ3 on activated endothelial cells (Bombeli et al., 
1998; von Hundelshausen & Weber, 2007). Fibrinogen links platelet fibrinogen receptor on 
the surface of αIIbβ3 to the endothelial cell αvβ3 and forms the firm platelet adhesion to 
activated endothelial cells (Gawaz et al., 1991).  
 
 
Fig. 1. Rolling of platelets to endothelial cells is mediated by platelet PSGL-1 and GP1bα 
bind to endothelial cell von Willebrand factor and P selectin. 
It is worth mentioning that interaction between platelets and activated endothelial cells is 
not sufficient to promote thrombus formation. However, platelet adhesion to endothelial 
cells contributes to the progression of the plaque. Platelets mediate such effects through 
releasing products following adhesion and activation. The contents of storage granules are 
liberated upon platelet activation. It is estimated more than 300 proteins are secreted from 
activated platelets, which act in an autocrine or paracrine manner to modulate cell signaling 
and mediate the plaque progression (Coppinger et al., 2004).   
Endothelial cell chemotactic, adhesion, and proteoliytic capacities are altered by paracrine 
modulation of substances released by adherent activated platelets. Here are the lists of 
platelet contents released upon adhesion and activation : (1) adhesion proteins (e.g., P-
selectin, vitronectin, fibrinogen, fibronectin, von Willebrand factor, thrombospondin and 
αIIbβ3), (2) growth factors (e.g., PDGF, TGF-β, EGF and bFGF), (3) chemokines (e.g. 
RANTES, PF-4 and epithelial-neutrophil activating protein 78 (ENA-78)), (4) cytokine-like 
factors (e.g. IL-1β, CD40 ligand and β-thromboglobulin) and (5) coagulation factors (e.g. 
factor V, factor XI, PAI-1, plasminogen and protein S) (Gawaz et al., 2005). 
In vitro study revealed that activated platelets coincubated with cultured endothelial cells 
gave rise to a secretion of MCP-1 and surface expression of ICAM-1 and αvβ3 on endothelial 
cells, which is mediated by an IL-1-dependent mechanism (Gawaz et al., 2000). MCP-1 is an 
effectual chemotactic factor for monocytes and ICAM-1 is an adhesion molecule which 
advocates monocyte and neutrophil recruitment to endothelial cells. This study emphasized 
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the important role of IL-1β on mediating endothelial cell activity upon platelet activation. 
IL-1 is the prototypic cytokine released by inflammatory cells and three members of the IL-1 
gene family have been identified: IL-1, IL-1β, and IL-1 receptor antagonist (IL-1RA) (von 
Hundelshausen & Weber, 2007). Platelet activation induces rapid and persistent synthesis 
and release of IL1β and converts endothelial cell phenotype to become more adhesive to 
circulating neutrophils (Lindemann et al., 2001). Inhibition of β3 integrin attenuated the 
synthesis of platelet IL-1β, indicating firm adhesion of platelet to endothelial cells is 
prerequisite for IL-1β sustained secretion (Lindemann et al., 2001).  
 
 
Fig. 2. Tight adhesion of platelets to endothelial cells is mediated by platelet αIIbβ3 bind to 
endothelial cell αvβ3, bridged by fibrinogen, and ICAM-1. This results in release of platelet 
contents (blue dots) which mediates endothelial activated molecules (green dots) expression,    
Upon activation, platelet expresses CD40 ligand (CD40L) which ligates CD40 expressed by 
activated endothelial cells (Henn et al., 1998). Platelet CD40L and endothelial cell CD40 
interaction amplifies the release of IL-8 and MCP-1 from endothelial cells and enhances 
the expression of endothelial cell adhesion receptors including E-selectin, VCAM-1, and 
ICAM-1 (Henn et al., 1998). In vivo study using mice deficient of platelet CD40L shows that 
platelet CD40L accelerate plaque formation and progression, mainly due to prevention of 
leukocyte recruitment (Lievens et al., 2010). This study implicates that platelet CD40L is 
important for recruitment of monocytes, neutrophils and lymphocytes during plaque 
intitiation and progression. Ligation of CD40L on endothelial cells promotes endothelial cell 
tissue factor expression, thus enhances a procoagulant phenotype on endothelial cells 
(Slupsky et al., 1998). Furthermore, it implicates in both the generation and secretion of 
matrix metalloproteinase-9 (MMP-9) and protease receptor urokinase-type plasminogen 
activator receptor (uPAR), thus promotes proteolytic activity on endothelial cells (May et 
al., 2002). Tight adhesion of platelet to endothelial cell via αIIbβ3 binding enhances platelet 
CD40L upregulation and matrix degradation (May et al., 2002). This endothelial-mediated 
matrix degradation is important in digestion of fibrous cap, thus promotes imbalance of 
matrix production and degradation and subsequently weakens the cap. This contributes to 
loss of cap protection and threatens plaque in rupture-prone condition. 
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activated endothelial cells (Henn et al., 1998). Platelet CD40L and endothelial cell CD40 
interaction amplifies the release of IL-8 and MCP-1 from endothelial cells and enhances 
the expression of endothelial cell adhesion receptors including E-selectin, VCAM-1, and 
ICAM-1 (Henn et al., 1998). In vivo study using mice deficient of platelet CD40L shows that 
platelet CD40L accelerate plaque formation and progression, mainly due to prevention of 
leukocyte recruitment (Lievens et al., 2010). This study implicates that platelet CD40L is 
important for recruitment of monocytes, neutrophils and lymphocytes during plaque 
intitiation and progression. Ligation of CD40L on endothelial cells promotes endothelial cell 
tissue factor expression, thus enhances a procoagulant phenotype on endothelial cells 
(Slupsky et al., 1998). Furthermore, it implicates in both the generation and secretion of 
matrix metalloproteinase-9 (MMP-9) and protease receptor urokinase-type plasminogen 
activator receptor (uPAR), thus promotes proteolytic activity on endothelial cells (May et 
al., 2002). Tight adhesion of platelet to endothelial cell via αIIbβ3 binding enhances platelet 
CD40L upregulation and matrix degradation (May et al., 2002). This endothelial-mediated 
matrix degradation is important in digestion of fibrous cap, thus promotes imbalance of 
matrix production and degradation and subsequently weakens the cap. This contributes to 
loss of cap protection and threatens plaque in rupture-prone condition. 
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PF-4, stored in platelet alpha granules, is the most abundant protein secreted by activated 
platelets. In histopathological study on human carotid atherosclerotic, PF-4 accumulates 
within macrophages of the plaque in the early lesion and continues to accumulate in foam 
cells and neovascular endothelial cells as lesion progressed (Pitsilos et al., 2003). PF-4 is 
deposited on the endothelial cell surface and retained by subendothelial proteoglycan 
(Aidoudi & Bikfalvi, 2010). PF-4 can activate endothelial cells by stimulating E-selectin 
expression (Yu et al., 2005). In vitro study indicates that PF-4 inhibits apolipoprotein B-
containing LDL catabolism and facilitates retension of LDL on cell surface (Sachais et al., 
2002). PF-4 blocks LDL uptake by LDL receptor expressed by vascular wall cells, thus 
increases its retention and prolongs its residence time in the vascular space which allows 
apolipoprotein-B to be modified and increases ox-LDL deposition (Nassar et al., 2002).  
RANTES, secreted by activated platelets, triggers monocyte arrest and recruitment under 
flow conditions in vitro and in perfused carotid arteries (von Hundelshausen et al., 2001). 
Platelet P-selectin is important mediator of RANTES upregulation, indicates that RANTES is 
secreted during platelet rolling to endothelial cells (Schober et al., 2002). In atherosclerotic 
lesions and injury of apolipoprotein-E deficient mice, RANTES is expressed on endothelial 
cells (von Hundelshausen et al., 2001). Endothelial cells should have been modified by IL-1β, 
in order to receive the deposition of RANTES (Weyrich et al., 2002).  Taken together, 
platelet-generated RANTES involves in atherosclerosis early in the beginning and more 
prominently in the plaque progression by modulating intimal hyperplasia and monocyte 
recruitment (Schober et al., 2002). Initial knowledge of ENA-78 activity is that this CXC 
chemokine superfamily member is synthesized and secreted by activated endothelial cells 
which give a proadhesive activity for neutrophils (Walz et al., 1997).  Activated platelet 
expresses ENA-78 which attract leukocyte to adhere the endothelial cells (Schober et al., 
2002). Furthermore, activated platelet-induced IL-1β action can stimulate endothelial cells to 
secret ENA-78 which encourage endothelial cell adhesiveness (Weyrich et al., 2002).   
3.3 Platelet-leukocyte interaction enhances progressed plaque 
Migration and recruitment of leukocytes into atherosclerotic plaque are essential steps of 
atherosclerosis progression. Leukocytes are captured and begin rolling on P-selectin 
expressing-endothelial cells. Leukocytes express PSGL-1 which engages in leukocyte rolling 
and attachment to P-selectin. Similar to that of platelet, P-selectin-mediated leukocyte 
binding to endothelial cells is a loose contact. This connection mediates rolling of leukocytes 
on the endothelial surface without firm attachment.   
In addition to direct contact between leukocytes and endothelial cells, activated platelets 
interact with leukocyte as well. Among leukocytes, monocytes and lymphocytes are the first 
to be involved in atherogenesis and plaque progression.   
3.3.1 Activated platelets bind and promote monocyte activation and transmigration  
Monocytes are predominant leukocytes lodge in atherosclerotic plaque.  Adherent platelets 
efciently mediate monocyte rolling and arrest, even at high shear rate. Monocyte rolling is 
mediated by P-selectin on activated platelets and PSGL-1, constitutively expressed on 
monocytes (Kuijper et al., 1998). CD15, expressed by  monocytes, has also been shown to 
bind platelet P-selectin (Larsen et al., 1990).  
The initial connection between platelet P-selectin and monocyte PSGL-1 and CD15 is a loose 
attachment, and within rapid periode it leads to elevated expression of the monocyte 
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integrin αMβ2 (membrane-activated complex 1 (Mac-1)) and makes tighter adhesion which 
support binding to platelet (Neumann et al., 1999). Monoctyte Mac-1 has several counter-
receptors expressed on activated platelet, such as GP1b, JAM-3 and ICAM-2 (Simon et al., 
2000; Santoso et al., 2002; Diacovo et al., 1994).  
Platelet junctional adhesion molecule (JAM) supports platelet chemokine deposition and 
promotes monocyte recruitment (von Hundelshausen & Weber, 2007). JAM-3 is identified as 
a counter-receptor on platelets for the monocyte Mac-1 and mediates platelet-monocytes 
interactions (Santoso et al., 2002). Mac-1 is also able to bind indirectly to platelet αIIbβ3 
linked by soluble fibrinogen bridge (Gawaz et al., 1991). Furthermore, several protein-
receptor complexes mediate platelet-monocyte adhesion, such as thrombospondin which 
form a bridging of the CD36-CD36 interaction in both monocytes and platelets, CD40L on 
the platelet which attach to monocyte CD40 and monocyte triggering receptor expressed on 
myeloid cell 1 (TREM-1) to platelet-expressed TREM-1 ligand (Van Gils et al., 2009).  
The attachment of activated adherent platelets to monocytes induces monocyte activation 
through shedding, expressing and releasing fungsional proteins. Interaction between 
platelets and monocytes increases the expression and activity of chemotaxis (MCP-1 and 
MIP-1α), proteolysis (uPAR and MMP), thrombosis (tissue factors), activation (TNF-α and 
IL-8) and adhesion (Mac-1 and VLA-4) factors on monocytes as well as potentiates 
monocyte to macrophage differentiation (Gawaz et al., 2005). In this respect, platelet-
monocyte interaction provides an atherogenic environment at the vascular wall that 
supports plaque formation and regression (Gawaz et al., 2005). Similar to adherent platelets, 
activated platelets circulating in blood stream can affect endothelial cell and leukocyte 
phenotype (Huo et al., 2003). Circulating activated platelets are detected in the blood of 
patients with atherosclerotic conditions, such as acute coronary syndromes (Sarma et al., 
2002), stable coronary disease (Furman et al., 1998), and diabetes mellitus (Broijersen et al., 
1998).   
In vitro study shows that platelet P-selectin increases monocytoid cell adhesion to 
endothelial cells (Theilmeier et al., 1999). In vivo study using apoE-knock-out mice reveals 
that circulating activated platelets, through platelet P-selectin, promote monocyte 
recruitment to atherosclerotic plaque and accelerate the formation of atherosclerotic lesions 
(Huo et al., 2002). Platelet P-selectin-mediated interactions lead to deposition of platelet-
derived proinflammatory factors, RANTES and PF-4, to the vessel wall and monocytes, 
resulting in activation of monocyte integrins, increased monocyte recruitment and accelerate 
atherosclerosis (Huo et al., 2002). Inversely, at low levels, activated endothelial cells express 
PSGL-1 and bind P-selectin on platelets and monocytes, thus mediating monocyte tethering 
and platelet recruitment to the endothelial cells (Da Costa Martins, 2007). 
Not only do adherent platelets form tight binding to monocyte, but also circulating 
activated platelets attach to monocyte and form platelet monocyte complex (PMC). PMC 
reflected great capacity of platelet activation and in lesser extent, monocyte activation (Van 
Gils et al., 2009). Activated platelets bind via P-selectin to its receptor on monocytes, PSGL-
1, and form complexes (Van Gils et al., 2009). PMCs mediate monocyte tethering and 
adhering to endothelial cell surface, making adherent monocyte-PMC cluster and promoting 
monocyte, and probably platelet,  transmigration into subendothelial plaque lession (Da 
Costa Martins et al., 2004).  PMC high adhesive capability to activated endothelial cell is due 
to increasing integrin activation on monocyte and subsequently, increasing cell adhesion to 
fibronectin, VCAM-1 and ICAM-1 (Da Costa Martins, 2006). Monocytes transmigrate into 
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fibronectin, VCAM-1 and ICAM-1 (Da Costa Martins, 2006). Monocytes transmigrate into 
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the atherosclerotic plaque, and change phenotype, becoming macrophages which express 
scavenger receptors and digest oxLDL to become foam cells (Libby & Aikawa, 2001).  
 
 
Fig. 3. Activated platelets recruit monocytes via platelet P selectin binding to monocyte 
PSGL-1 and CD15, subsequently stabilized by monocyte Mac-1 bind to counter receptors in 
platelets thus promoting monocyte adhesion and transmigration into subendothelial.  
Monocytes are the main source of tissue factor, an important determinant of thrombogenic 
plaque (Lindmark et al., 2000). Along with more monocyte recruitment, macrophage 
proliferation and tissue factor production intensify, filling the plaque with inflammatory 
and thrombogenic material which promote plaque progression. 
3.3.2 Activated platelets bind and promote lymphocyte activation and transmigration  
Lymphocyte transmigration from circulation to atherosclerotic plaque follows three steps: 
selectin-mediated rolling, integrin-modulated adhesion and transmigration. The 
transmigration of all lymphocyte populations, i.e. T cells, B cells, and natural killer cells, are 
enhanced by activated platelets (Li, 2008). Activated platelets interact with lymphocytes 
through binding between platelet P-selectin and lymphocyte PSGL-1 forming  a loose 
contact, which subsequently induces clustering of αL integrin and enhances lymphocyte 
firm adhesion via ICAM-1 binding (Atarashi et al., 2005). Among lymphocytes, T cells have 
stronger adhesive capacity than B cells, indicates that T cells are selectively recruited in 
mediation of P-selectin expressing cells (Li, 2008) Enhancement of  T cell adhesion on 
subendothelial matrix is mediated by activated platelets through formation of platelet–T cell 
conjugates and via ligations of P-selectin, CD40L and αIIbβ3 integrins (Li, 2008).  
In progressed atherosclerotic plaque, T cells make up nearly 10% to 20% of the cell 
population and assemble at sites which are prone to rupture and cause fatal thrombosis 
(Hansson et al., 2002). Most of the T cells in atherosclerotic lesions is T helper (CD3+ and 
CD4+) and T-cell antigen receptor positive (TCRβ+), which indicate a function of 
recognition of antigens presented by macrophages or dendritic cells (Hansson et al., 2002). 
They modulate cell mediated immunity through secretion of interferon (IFN-γ), IL-2, and IL-
22 (Hansson et al., 2002). IFN-γ inhibits smooth muscle cell new collagen synthesis, which is 
essensial in supporting fibrous caps, thus weakens brous cap and promotes rupture-prone 
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plaque (Libby et al., 2010). Smooth muscle cells in the rupture-prone plaque express HLA-
DR which is susceptible to IFN-γ action (Libby & Aikawa, 2001). Furthermore,  activated T 
cells induce production of MMP and tissue factor, mediated by CD40-CD40L binding, which 
enhances the thrombogenicity of the plaque lipid-rich core (Libby  et al., 2010).   
4. Activated platelet plays important role in coronary atherothrombosis  
Arterial thrombosis is the acute complication that develops on the chronic atherosclerosis 
lesion, i.e. atherothrombosis, and in the coronary artery it causes acute coronary syndromes, 
during which blood flow through coronary segment is partially or totally obstructed. 
Platelets are prominent constituents of the thrombi that occlude the lumen of arteries. In this 
regard, atherothrombosis is a term that describes the combination of acute, a complication, 
and chronic, a progression, events of arterial disease (Ruggeri, 2002). Platelets are involved 
in both processes, through promoting plaque progression and participating in ruptured 
plaque-driven thrombus formation (Ruggeri, 2002).  
Inducing event of acute coronary syndrome is plaque rupture or erosion. Rupture of fibrous 
cap lining the plaque is account for 60–65% of occlusive thrombi and erosion of endothelial 
cells lining the plaque is responsible for the rest 35–40% (Dickson & Gottlieb, 2003). In the 
rupture-prone atherosclerotic plaque, brous cap maintains protective role for the integrity 
of the plaque and provides a barrier between the thrombogenic material in the necrotic core 
and circulating blood components, mainly platelets and coagulation factors (Libby & 
Aikawa, 2001). As plaque progressed, leukocyte-driven inflammation is heightened in the 
intimal layer. Inflamed leukocytes can hinder biosynthesis of collagen from smooth muscle 
cells and can themselves overexpress collagen-degrading proteinases which in turn give the 
condition of the imbalance between collagen synthesis and degradation, thus weakening the 
fibrous caps and lead to plaque rupture (Libby & Aikawa, 2001). Furthermore, leukocytes 
participate in augmentation the production of the procoagulant factor, primarily tissue 
factor, in plaque lesion and give rise to the high thrombogenicity of the plaque’s lipid core 
(Libby et al., 2010). In addition to intrinsic factor within plaque, vessel lumen shear stress 
contribution for rupture of the plaque is considerate as well, since lumen restricted-area 
surrounding the plaque causes a local rising in blood flow velocity. Wall shear rate may 
exceed considerably at the edge of a severe occlusion in a coronary artery. High shear stress 
may specifically enhance platelet reactivity to matrix extra cellular of plaque (Ruggeri, 2002).    
The main trigger for the formation of a thrombus is the loss of the endothelial cell barrier 
and exposure of thrombogenic subendothelial extracellular matrix components with 
circulating blood. The response of platelets to this event can be divided into three successive 
but closely integrated phases: adhesion, activation and aggregation (Ruggeri, 2002). Several 
indices of activated platelets in the circulating blood are increased in patients with coronary 
artery disease and acute coronary syndromes, such as platelet surface molecule expression, 
platelet-monocyte aggregates, platelet-neutrophil aggregates and soluble proteins releasing 
upon platelet activation, mainly soluble CD40L (sCD40L) (Linden et al., 2007; Setianto et al., 
2010). 
4.1 Platelet tethering and adhesion initiate atherothrombosis   
Erosion or rupture of the plaque poses circulating platelets, some of them have already 
activated, with highly thrombogenic extra cellular matrix components of the lipid core 
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the atherosclerotic plaque, and change phenotype, becoming macrophages which express 
scavenger receptors and digest oxLDL to become foam cells (Libby & Aikawa, 2001).  
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plaque (Libby et al., 2010). Smooth muscle cells in the rupture-prone plaque express HLA-
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cells induce production of MMP and tissue factor, mediated by CD40-CD40L binding, which 
enhances the thrombogenicity of the plaque lipid-rich core (Libby  et al., 2010).   
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lesion, i.e. atherothrombosis, and in the coronary artery it causes acute coronary syndromes, 
during which blood flow through coronary segment is partially or totally obstructed. 
Platelets are prominent constituents of the thrombi that occlude the lumen of arteries. In this 
regard, atherothrombosis is a term that describes the combination of acute, a complication, 
and chronic, a progression, events of arterial disease (Ruggeri, 2002). Platelets are involved 
in both processes, through promoting plaque progression and participating in ruptured 
plaque-driven thrombus formation (Ruggeri, 2002).  
Inducing event of acute coronary syndrome is plaque rupture or erosion. Rupture of fibrous 
cap lining the plaque is account for 60–65% of occlusive thrombi and erosion of endothelial 
cells lining the plaque is responsible for the rest 35–40% (Dickson & Gottlieb, 2003). In the 
rupture-prone atherosclerotic plaque, brous cap maintains protective role for the integrity 
of the plaque and provides a barrier between the thrombogenic material in the necrotic core 
and circulating blood components, mainly platelets and coagulation factors (Libby & 
Aikawa, 2001). As plaque progressed, leukocyte-driven inflammation is heightened in the 
intimal layer. Inflamed leukocytes can hinder biosynthesis of collagen from smooth muscle 
cells and can themselves overexpress collagen-degrading proteinases which in turn give the 
condition of the imbalance between collagen synthesis and degradation, thus weakening the 
fibrous caps and lead to plaque rupture (Libby & Aikawa, 2001). Furthermore, leukocytes 
participate in augmentation the production of the procoagulant factor, primarily tissue 
factor, in plaque lesion and give rise to the high thrombogenicity of the plaque’s lipid core 
(Libby et al., 2010). In addition to intrinsic factor within plaque, vessel lumen shear stress 
contribution for rupture of the plaque is considerate as well, since lumen restricted-area 
surrounding the plaque causes a local rising in blood flow velocity. Wall shear rate may 
exceed considerably at the edge of a severe occlusion in a coronary artery. High shear stress 
may specifically enhance platelet reactivity to matrix extra cellular of plaque (Ruggeri, 2002).    
The main trigger for the formation of a thrombus is the loss of the endothelial cell barrier 
and exposure of thrombogenic subendothelial extracellular matrix components with 
circulating blood. The response of platelets to this event can be divided into three successive 
but closely integrated phases: adhesion, activation and aggregation (Ruggeri, 2002). Several 
indices of activated platelets in the circulating blood are increased in patients with coronary 
artery disease and acute coronary syndromes, such as platelet surface molecule expression, 
platelet-monocyte aggregates, platelet-neutrophil aggregates and soluble proteins releasing 
upon platelet activation, mainly soluble CD40L (sCD40L) (Linden et al., 2007; Setianto et al., 
2010). 
4.1 Platelet tethering and adhesion initiate atherothrombosis   
Erosion or rupture of the plaque poses circulating platelets, some of them have already 
activated, with highly thrombogenic extra cellular matrix components of the lipid core 
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which contains several adhesive molecules such as collagen, von Willebrand factor, laminin, 
bronectin and thrombospondin (Andrews & Berndt, 2004). These molecules, once exposed, 
provide ligands for various activated platelet surface receptors. Under low shear rate 
condition, such as in vein and large artery flow, the molecules bind to platelet receptors are 
collagen, fibronectin and laminin, whereas under higher shear rates, such as in small arteries 
and atherosclerotic vessel, collagen and von Willebrand factor are principal molecules to 
mediate platelet slackening, tethering and adhesion (Andrews & Berndt, 2004). The early 
step of atherothrombosis is tethering of platelets to the surface of rupture plaque and is 
accomplished through the interaction between platelet GPIbα and collagen-bound von 
Willebrand factor (Ruggeri, 2002) and platelet GPVI and collagen (Andrews & Berndt, 2004).  
GPIbα is the major ligand-binding subunit of GPIb-IX–V or von Willebrand factor receptor 
and, in addition to binding site for von Willebrand factor, contains partially overlapping 
binding sites for the leukocyte integrin Mac-1, α-thrombin, and P-selectin expressed on 
activated platelets or activated endothelial cells (Andrews & Berndt, 2004). GPVI is a 
collagen receptor of the immunoglobulin superfamily that forms a complex with the FcR g-
chain at the cell surface in human and mouse platelets (Andrews & Berndt, 2004). 
Von Willebrand factor, stored both by alpha granules of platelets or Weibel-Palade body of 
endothelial cells, is an adhesive glycoprotein found in circulating blood or subendothelial 
matrix (Andrews & Berndt, 2004). Circulating von Willebrand factor, which amount is much 
higher than that in subendothelial matrix, can be immobilized in exposed collagen via 
collagen binding site and become the substrate for platelet GP1bα (Massberg et al., 2003). In 
addition to collagen-bound, circulating von Willebrand factor can also be immobilized by 
forming the multimeric connection to matrix-bound, platelet-bound or subendothelial von 
Willebrand factor (Ulrichts et al., 2005). Immobilized von Willebrand factor is capable to 
catch circulating platelets via binding with platelet GPIbα (Andrews & Berndt, 2004). 
Ligation of non-activated platelet GPIbα with collagen-bound von Willebrand factor is not 
stable enough and is intended mainly to slow down platelets and maintain them in the 
rupture site, where subsequently platelets will be activated through various receptors, 
mainly integrin, and stable adhesion is formed.  
 
 
Fig. 4. Plaque rupture exposes platelets to thrombogenic collagen which attract them to 
adhere via platelet GPVI bind to collagen and GP1bα bind to collagen-bound von 
Willebrand factor, initiate thrombus formation. 
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In addition to collagen-bound von Willebrand factor, collagen itself can capture non-
activated circulating platelets through platelet GPVI. However, GPVI has only a low afnity 
for collagen which makes GPVI, same as GPIbα, incapable to mediate stable platelet 
adhesion. Ligation of GPVI during the initial contact between platelets and subendothelial 
collagen provides an activation signal through platelet integrins, αIIbβ3 and α2β1, which is 
essential for subsequent stable platelet adhesion and aggregation (Gawaz, 2004). Although 
not tightly adherent, this early adhesion of platelets is of adequate affinity to facilitate arrest 
at high shear rate, leading ultimately to much more stable integrin-mediated adhesion 
(Andrews & Berndt, 2004). 
4.2 Platelet activation and aggregation enhance atherothrombosis  
Platelet activation and aggregation are the ensuing steps that occur within minutes, marked 
by the accumulation of platelets into the haemostatic thrombus (Ruggeri, 2002). Collagen-
bound von Willebrand factor and platelet GPIbα interaction convey signal activation of 
platelet integrin αIIbβ3 to undergo conformational changes which are compulsory for firm, 
irreversible platelet resting on the subendothelial matrix surface (Gawaz, 2004). 
Conformational changes of αIIbβ3 enable an exposure of fibrinogen binding site which form 
cross linking with αIIbβ3 on different platelets by brinogen bridge (Andrews & Berndt, 
2004). Similarly, ligation of GPVI shifts platelet αIIbβ3 and α2β1 from a low to a high affinity 
state and contributes to stable platelet adhesion (Gawaz, 2004). Until this step, stable 
adhesion of platelets is promoted by irreversible binding of platelet αIIbβ3 to collagen-
bound von Willebrand factor and platelet α2β1 to uncoated collagen. The integrin-
dependent stable adhesion of platelets consequently leads to activation of adherent platelets.  
Activated platelets are receptive to wide range of agonists or stimulants and adhesive 
proteins. They express surface receptors, which, upon activation by agonists and adhesive 
proteins, stimulate internal signaling pathways that lead to further platelet activation, 
degranulation, and capacity enhancement to bind with other adhesive proteins or platelets. 
Transmembran receptors are the main agonist-stimulated receptor families and greatly 
activated during thrombus formation. The important platelet receptors in this class are 
thrombin receptors (protease activation receptor (PAR-1 and PAR-4), ADP receptors (P2Y1, 
and P2Y12) and integrins (mainly αIIbβ3) (Freedman, 2005). 
Activation of platelets by thrombin through PAR-1 and PAR-4 receptors results in calcium 
flux, platelet shape change, and stimulation of a variety of platelet-signaling pathways 
(Freedman, 2005). Importantly, thrombin-PAR receptor interaction leads to activation of 
integrin αIIbβ3 receptor complex through inside-out signalling (Freedman, 2005).  
In non-activated platelets, αIIbβ3, the most abundant platelet integrins, has a very low 
afnity for its ligands (Cosemans et al., 2008). However, platelet activation remarkably 
increases the capacity of αIIbβ3 to attach to its ligands, particularly brinogen, brin, 
bronectin and von Willebrand factor (Cosemans et al., 2008). These soluble adhesive 
proteins are immobilized and are attached to activated αIIbβ3 on the surface of activated 
adherent platelets and become the substrate for more non-activated circulating platelet 
recruitment and aggregation (Ruggeri, 2002). The interaction of circulating platelets with 
adherent platelets carries on through activated αIIbβ3 cross linking between platelets 
bridged by soluble fibrinogen, thus form the platelet aggregates (Gawaz, 2004). Platelet 
activation increases the surface density of αIIbβ3, thus more soluble fibrinogen attach and 
bridge other platelets, makes cross linking and allows continuing platelet aggregation and 
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activation increases the surface density of αIIbβ3, thus more soluble fibrinogen attach and 
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thrombus growth. The inhibiton of interaction of platelet αIIbβ3 - von Willebrand factor and 
αIIbβ3 - fibrinogen by αIIbβ3 antagonists, i.e tirofiban, abciximab and eptifibatide, is of 
potentially benefit in acute settings of coronary atherothrombosis, due to inhibition of 
platelet aggregation, thrombus growth  and stability.  
 
 
Fig. 5. Adhesion and activation of platelets form stable plug via platelet αIIbβ3 bind to 
collagen-bound von Willebrand factor and platelet α2β1 bind to collagen, thus stimulate 
release of platelet surface receptors (blue dots) receptive to agonists and adhesive proteins.  
In addition to integrin activation, several means of activation responses of platelets include: 
mobilization of cytosolic calcium, secretion of ADP, shedding and secretion of CD40L, 
released of tromboxane A2 (TxA2) and formation of pseudopods which support an effective 
sealing of the denuded plaque area (Cosemans et al., 2008; Gawaz, 2004). ADP, secreted by 
dense granules of activated platelets, stimulates platelets in autocrine loop through its 
receptors, P2Y1 and P2Y12. P2Y1 activation mediates platelet shape change and initiates 
platelet aggregation by mobilization of intracellular calcium (Andre et al., 2003). P2Y12 
activation by ADP signal mediates inhibition of adenylyl cyclase and stabilizes platelet 
aggregates as well as participates in the firm adhesion by activating αIIbβ3 (Andre et al., 
2003). Persistent signal to keep P2Y12 in active state is of paramount important to prevent 
platelet disaggregation and to maintain αIIbβ3 in its active conformation (Cosemans et al., 
2008). In addition to autocrine loop, ADP also works in paracrine mechanism by stimulating 
and recruiting non activated circulating platelets and inducing them to undergo aggregation 
with adherent platelets (Gawaz, 2004). Antagonist for P2Y12, i.e ticlopidine and clopidogrel, 
has already been widely used in acute coronary syndrome.  
CD40L, expressed and released by activated platelets, binds to activated αIIbβ3 and 
contributes in supporting platelet aggregate stability (Andre et al., 2002). Upon platelet 
activation, the cytosolic CD40L protein is exocytosed to the platelet plasma membrane from 
where it is also shed and release into circulation in soluble form, sCD40L (Andre et al., 2002). 
These transmembran and soluble forms are detected to be elevated in patients with acute 
coronary syndrome (Aukrust et al., 1999; Garlichs et al., 2001; Setianto et al., 2010). Both 
transmembrane and soluble CD40L can form a cluster with platelet αIIbβ3 and lead to more 
platelet activation and enhance thrombus formation and stabilization (Andre et al., 2002).  
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TxA2 is made from arachidonic acid and is secreted by activated adherent platelets. It 
strengthen the activation process after the release into the extracellular space and create 
platelet feedback activation by acting as autocrine and paracrine manner on its thromboxane 
platelet receptor (Gawaz, 2004). TxA2 has a vasoconstricting activity and thus favors 
formation of the thrombus by slowing down the blood flow (Gawaz, 2004).  Aspirin induces 
a complete and permanent inhibition of platelet TxA2 production through the inactivation 
of cyclooxygenase. In addition to αIIbβ3-mediated stability, several other adhesion and 
signaling receptors contribute to thrombus stability, such as PECAM-1, JAM-A, JAM-C, 
ESAM, CD226, and  Epf kinases/ephrins, which is enable the tight contact of one platelet 
with receptors on adjacent platelets (Brass et al., 2005).  
5. Conclusion 
Platelet is a key maker for progression of atherosclerotic plaque. Its ability to interact with 
activated endothelial cells and leukocytes, provide the milieu of inflammation and 
thrombus-prone environment in atherosclerotic plaque. Platelet, with relatively similar 
pattern, captures monocyte and lymphocyte and grants them the path to transmigrate into 
atherosclerotic plaque. Platelet is a central player during coronary plaque rupture. It starts 
and nurtures coronary thrombus formation and stabilization. Platelet-based therapeutic 
modalities for atherosclerosis and acute coronary syndrome are still in progressed studies 
with some of them yield beneficial effect while others inconclusive.  
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αIIbβ3 - fibrinogen by αIIbβ3 antagonists, i.e tirofiban, abciximab and eptifibatide, is of 
potentially benefit in acute settings of coronary atherothrombosis, due to inhibition of 
platelet aggregation, thrombus growth  and stability.  
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collagen-bound von Willebrand factor and platelet α2β1 bind to collagen, thus stimulate 
release of platelet surface receptors (blue dots) receptive to agonists and adhesive proteins.  
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dense granules of activated platelets, stimulates platelets in autocrine loop through its 
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These transmembran and soluble forms are detected to be elevated in patients with acute 
coronary syndrome (Aukrust et al., 1999; Garlichs et al., 2001; Setianto et al., 2010). Both 
transmembrane and soluble CD40L can form a cluster with platelet αIIbβ3 and lead to more 
platelet activation and enhance thrombus formation and stabilization (Andre et al., 2002).  
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TxA2 is made from arachidonic acid and is secreted by activated adherent platelets. It 
strengthen the activation process after the release into the extracellular space and create 
platelet feedback activation by acting as autocrine and paracrine manner on its thromboxane 
platelet receptor (Gawaz, 2004). TxA2 has a vasoconstricting activity and thus favors 
formation of the thrombus by slowing down the blood flow (Gawaz, 2004).  Aspirin induces 
a complete and permanent inhibition of platelet TxA2 production through the inactivation 
of cyclooxygenase. In addition to αIIbβ3-mediated stability, several other adhesion and 
signaling receptors contribute to thrombus stability, such as PECAM-1, JAM-A, JAM-C, 
ESAM, CD226, and  Epf kinases/ephrins, which is enable the tight contact of one platelet 
with receptors on adjacent platelets (Brass et al., 2005).  
5. Conclusion 
Platelet is a key maker for progression of atherosclerotic plaque. Its ability to interact with 
activated endothelial cells and leukocytes, provide the milieu of inflammation and 
thrombus-prone environment in atherosclerotic plaque. Platelet, with relatively similar 
pattern, captures monocyte and lymphocyte and grants them the path to transmigrate into 
atherosclerotic plaque. Platelet is a central player during coronary plaque rupture. It starts 
and nurtures coronary thrombus formation and stabilization. Platelet-based therapeutic 
modalities for atherosclerosis and acute coronary syndrome are still in progressed studies 
with some of them yield beneficial effect while others inconclusive.  
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1. Introduction 
Acute coronary syndrome(ACS) and acute aortic dissection(AAD) are life-threatening 
conditions which can be difficult to differentiate in the emergency room because of the 
similarity of clinical presentations. In addition, ACS can be caused in AAD as a complication 
of the dissecting process. Usual form of ACS is caused by an obstruction of the epicardial 
coronary arteries, which is initiated with the rupture of an unstable atherosclerotic plaque 
complicated with subsequent thrombus formation(Libby , 2001). On the other hand, ACS 
secondary to AAD is caused by malperfusion of the coronary artery by an obstruction of the 
orifice as a complication of the dissecting process. If AAD is compicated with ACS, 
prognosis becomes worse and the treatment of choice may be totally different from usual 
ACS. Medications and procedures which are usually used in cases of ordinary ACS, such as 
Heparin, antiplatelets, thrombolytic agents and catheter interventions, may be harmful in 
ACS secondary to AAD. So it is of great importance to make a correct diagnosis of ACS 
secondary to AAD for better treatment and survival. 
2. Acute coronary syndrome in patients with acute type A aortic dissection 
2.1 Incidence 
Incidence of coronary involvement in AAD has been reported to be 1.8-11.3%(Hirst, 1958 ; 
Hagan, 2000 ; Kawahito, 2003 ; Neri, 2001 ; Spittel, 1993) . Incidence may vary according to 
the different study population(autopsy, surgical patients or non-selected patients in the 
emergency room). We recently evaluated the incidence of coronary malperfusion in 159 
patients with type A AAD who presented to the emergency room within 12 hours from 
the onset and found that 9.4 % had coronary malperfusion(Hirata, 2010). On the contrary, 
the incidence of the AAD in ACS is not so frequent. In the large studies dealing with 
prehospital thrombolysis, 0.3-0.33% of the patient was erroneously diagnosed as having 
usual ACS who later proved to have AAD(Wilcox,1988 ; European Myocardial Infarction 
Group, 1993). 
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Group, 1993). 
  




There are four possible mechanisms for coronary malperfusion in AAD(Ashida, 2000 ; 
Cambria, 1988; Massetti, 2003 ; Neri, 2001 ; Shapira, 1998,) 
1. buldging of the dissected false lumen producing occlusion of the coronary artery orifice 
(Figure 1 A). 
2. a retrograde extension of the dissection into the coronary arterial wall resulting in 
obstruction (Figure 1 B) 
3. disruption or detachment of the coronary artery from the aortic root(Figure 1 C). 
4. dynamic obstruction of the coronary orifice by flail intimal flap(Figure 1 D). 
 
 
Fig. 1. Four possible mechanisms for coronary malperfusion in cases of acute type A aortic 
dissection. Mechanisms A to D correspond to mechanisms 1) to 4) in the text. See text in 
detail (modified from Neri E et al. Proximal aortic dissection with coronary artery 
malperfusion. J Thorac Cardiovasc Surg 2001 ; 121 : 552-560 with permission).  
Distribution of the each mechanism has not been well defined. In our 
experience（Hirata,2010）, among 10 patients in whom actual mechanism of coronary 
malperfusion was identified during surgery, 5 patients had mechanism 1), 3 patients had 
mechanism 2) , and 2 patients had mechanism 3). Identification of the mechanism for 
coronary malperfusion is potentially important in relation to the therapeutic options 
described later. 
2.3 Clinical pictures and electrocardiographic changes 
Compared with patients of AAD without ACS, those with ACS had more severe clinical 
presentation as manifested with a higher incidence of cardiac tamponade and initial 
shock vital signs(Hirata K, 2010). The prognosis was also worse(Kawahito,2003; Metha 
2002). If the right coronary artery is involved, ST segment elevation in the inferior leads 
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is seen. Simultaneous ST elevation in leads V1-V3 may be seen as a result of obstruction 
of the conus branch or the right ventricular branch (Figure 2). If the left main trunk(LMT) 
is involved, elevation of the ST segment in leads aVR and aVL with diffusse ST 






Fig. 2. Twelve-lead ECGs obtained from a 56-year-old male with type A AAD. This patient 
had shock (initial systolic blood pressure was 60mmHg), cardiac tamponade and mild aortic 
regurgitation. An ECG showed sinus pause with ectopic atrial escape rhythm, marked ST 
elevation in both inferior and precordial leads. This patient had disruption of the orifice of 
right coronary artery but the orifice of left main trunk was intact. Simultaneous ST elevation 
in inferior and anterior leads reflected involvement of the conus branch or right ventricular 
branch due to obstruction of the orifice of the right coronary artery. A horizontal arrow 
indicates 1 second and a vertical arrow indicates 1 mV (same in Figure 3). Reproduced with 
permission(Hirata K et al. Electrocardiographic changes in patients with type A acute aortic 
dissection. J Cardiol 2010;56:147-153). 
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Fig. 3. Twelve-lead ECGs obtained from a 46-year-old female with type A AAD associated 
with Marfan syndrome. Note that ST segment was elevated in leads aVR and aVL, and 
diffuse severe ST depression was also seen. This patient had acute pulmonary edema due to 
severe acute aortic valvular regurgitation. Initial systolic blood pressure was preserved 
(120mmHg). A transesophageal echocardiogram showed flail intimal flap in the ascending 
aorta. The dissection was extended beyond the orifice of the left main trunk. Bentall surgery 
and coronary reconstruction were performed. Reproduced with permission(Hirata K et al. 
Electrocardiographic changes in patients with type A acute aortic dissection. J Cardiol 
2010;56:147-153). 
We recently reported that acute electrocardiographic changes(either ST depression and or T 
wave inversion) were rather common in patients with type A AAD even if there was no 
involvement of the coronary artery(Table 1, Hirata 2010). Only 27% of the patients with type 
A AAD had normal ECG. These observations were consistent with others(Hagan, 2000). 
Those acute ECG changes were closely associated with initial shock state(BP<90mmHg) and 
cardiac tamponade in our experience of 159 patients(Hirata K, 2010).  
Pre-existing chronic coronary artery disease has been reported to coincide in some patients 
with type A AAD. In the international registry of AAD, Hagan et al reported that, among 
464 patients, 4.3% had previous history of bypass surgery and 7.7% had evidence of old 
myocardial infarction(Hagan, 2000). Creswell et al. found that about one-third of the 
patients showed one or more coronary artery lesions greater than 50% with a coronary 
angiography (Creswell, 1995). At present, in type A AAD, the contribution of preexisting 
chronic coronary disease on clinical presentation, acute ECG change and needs for 
concomitant bypass surgery has not been well defined.  
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Chronic ECG abnormalities such as left ventricular hypertrophy with or without strain 
pattern, bundle branch block, etc. were also common in patients with type A AAD. 
 
Acute change 79(49.7)
ST elevation (0.1mV) 13(8.2) 
ST depression 54(34.0)
 0.1 mV and < 0.2 mV 28(17.6) 
 0.2 mV and < 0.3 mV 18(11.3) 












Both acute and chronic 21(13.2)
Normal 43(27.0)
AVB: Atrioventricular block (second degree), Af: Atrial fibrillation, PAC: Premature Atrial 
Contraction, PVC: Premature Ventricular Contraction, LVH: Left Ventricular Hypertrophy, BBB : 
Bundle Branch Block, Values are expressed as number(%). Reproduced with permission(Hirata K et al. 
Electrocardiographic changes in patients with type A acute aortic dissection. J Cardiol 2010;56:147-153) 
Table 1. ECG changes in type A AAD(n=159) 
2.4 Differentiation between acute coronary syndrome secondary to acute type A 
aortic dissection and usual form of acute coronary syndrome 
Regardless of the difference of the mechanism, the results of coronary malperfusion is 
myocardial ischemia in both usual form of ACS and ACS secondary to AAD. So it is 
impossible to differentiate usual form of ACS from ACS secondary to AAD with 
electrocardiographic findings. At present, differential diagnosis is dependent on the clinical 
suspicion based on difference of clinical pictures, confirmed with imaging modalities such as a 
CT scan and an echocardiogram. Shirakabe et al. tried to differentiate AAD and ACS using 
scoring system utilizing clinical idexes obtainable in emergency room. Presence of back pain, 
mediastinal widening on chest X-ray, aortic regurgitation and aortic dilatation(>30mm) were 
closely associated with AAD（Shirakabe,2008）. They found that AAD can be differentiated 
from ACS at sensitivity of 93.1% and specificity of 77.6%, when more than 3 of the 4 features 
were positive. We found that ECG change in AAD is closely associated with initial shock vital 
sign(BP<90mmHg) and cardiac tamponade（Hirata, 2010）. To perform a trans-thoracic 
echocardiography at bedside in the emergency room appeared to be very important in ACS 
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Chronic ECG abnormalities such as left ventricular hypertrophy with or without strain 
pattern, bundle branch block, etc. were also common in patients with type A AAD. 
 
Acute change 79(49.7)
ST elevation (0.1mV) 13(8.2) 
ST depression 54(34.0)
 0.1 mV and < 0.2 mV 28(17.6) 
 0.2 mV and < 0.3 mV 18(11.3) 












Both acute and chronic 21(13.2)
Normal 43(27.0)
AVB: Atrioventricular block (second degree), Af: Atrial fibrillation, PAC: Premature Atrial 
Contraction, PVC: Premature Ventricular Contraction, LVH: Left Ventricular Hypertrophy, BBB : 
Bundle Branch Block, Values are expressed as number(%). Reproduced with permission(Hirata K et al. 
Electrocardiographic changes in patients with type A acute aortic dissection. J Cardiol 2010;56:147-153) 
Table 1. ECG changes in type A AAD(n=159) 
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echocardiography at bedside in the emergency room appeared to be very important in ACS 
  
Acute Coronary Syndromes 
 
104 
patients in whom underlying AAD is a possible cause of ACS. Those patients include abrupt 
onset with back pain, shock vital signs, mediastinal widening(ratio of greater than 30%), 
pericardial effusion, aortic regurgitation, and aortic root dilatation(>30mm). If there is a flail 
intimal flap, the diagnosis of AAD can be made at bedside 
3. Treatment options for acute coronary syndrome secondary to acute type A 
aortic dissection 
3.1 Surgery 
If ACS secondary to AAD is erroneously diagnosed as usual form of ACS and received 
thrombolysis or catheter interventions, those patients may have an increased risk of 
developing harmful sequelae such as rupture of the aorta resulting in bleeding or cardiac 
tamponade（Blankenship, 1989; Butler 1990; Eriksen, 1992; Kamp,1994; Melchior,1993）. 
Surgical treatment to improve coronary malperfusion and underlying dissecting process at 
the same time is the most important and vital(Kawahito,2003; Neri,2001). Replacement of 
the dissected ascending aorta(sometimes beyond the arch) with artificial vessel prosthesis is 
necessary. If coronary involvement is seen, simultaneous bypass surgery or repair of the 
involved coronary artery may be required. Especially, if coronary malperfusion is due to 
mechanism 2) and 3), bypass surgery is mandatory(Figure 1 B and C). In mechanism 1), 
decompression of the false lumen may be sufficient enough to restore coronary 
perfusion(Figure 1A). In mechanism 4), removal of the flap with ascending aortic 
replacement may be effective and bypass may not be necessary(Figure1 D). Needless to say, 
aortic valve replacement is necessary, if the aortic valve regurgitation is severe. 
3.2 Percutaneous catheter intervention 
There have been several case reports of successful percutaneous catheter intervention (PCI) 
for ACS secondary to AAD. Barabas et al. reported a case of intermittent obstruction of the 
LMT in whom deployment of a stent in LMT was very effective to improve unstable 
hemodynamic (Barabas,2000). The patient was later sent to surgery as a definitive treatment. 
In their case, the diagnosis of ACS secondary to AAD was not made before the catheter 
intervention. The presence of AAD was diagnosed during the procedure and unplanned 
stenting was performed as an emergency bridge to surgery. Yunoki et al. reported a rare 
case of type A AAD in whom the right coronary orifice obstruction resulted in acute inferior 
and right ventricular myocardial infarction(Yunoki, 2010). Initially, the patient was sent for 
catheter intervention as having an usual form of ACS. During the procedure, AAD was 
diagnosed and the stent was deployed at the orifice of the right coronary artery. The patient 
was carefully followed medically and at one year, a false lumen in the ascending aorta had 
been resolved.  
3.2.1 Report of a case 
We recently experienced a case of ACS secondary to AAD in whom, emergency stenting in 
the LMT was intentionally necessary. The patient was a 56-year-old female who presented 
to the emergency room of Okinawa Hokubu Hospital complaining of chest pain. Initial 
systolic blood pressure was 60 mmHg and heart rate was 80 beats per minutes. A chest X 
ray showed mediastinal widening. A bedside echocardiography and a CT scan confirmed 
type A AAD(Figure 4). ECG showed ST elevation in aVR, aVL and V5-6. The patient 
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developed repetitive episodes of ventricular fibrillation requiring multiple cardioversion 
and cardiopulmonary resuscitation. The patient was intubated and was taken to the 
catheterization laboratory. A percutaneous cardiopulmonary support equipment(PCPS) was 
inserted and emergency catheter intervention was performed as a last resort, because the 
hospital was not equipped for emergency cardiovascular surgery. A coronary angiography 
showed obstruction of the LMT with a dissecting hematoma(Figure 5). A bare metal stent 
was deployed at LMT. Shortly after, the patient’s hemodynamic condition improved and the 
patient was transferred to Okinawa Chubu Hospital (with a support of PCPS). Emergency 
surgery (CABG on LAD and ascending aortic replacement) was performed. At the time of 
surgery, the surgeons noticed the ischemia of the small bowel and the part of the small 
bowel was also resected. The patient’s condition improved temporarily, but unfortunately 
the patient died of pan-peritonitis secondary to intestinal ischemia and necrosis. In this 
particular patient, emergency left main stenting was the last resort in the situation of very 












Fig. 4. A: A CT scan image showing severe narrowing of the left main coronary artey 
(between arrows)due to the extension of the dissecting hematoma. B: The ostium of the right 
coronary artery was not obstructed. T : True lumen, F: False lumen. 
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Fig. 5. Coronary angiograms before(A) and after(B) stenting the left main coronary artery. 
Note the severe narrowing of the orifice of the left main coronary artery resulting in poor 
visualization of both left anterior descending and circumflex artery. After stenting the left 
main tract became wide open and TIMI 3 flow was restored in both left anterior descending 
and circumflex arteries. A:Left anterior oblique view. B:Left anterior oblique and cranial 
view. 
3.2.2 Current shortcomings of catheter intervention 
Current shortcomings of PCI for ACS secondary to AAD include the followings: 
1. Although PCI may be temporarily effective to improve coronary malperfusion, it has no 
effects on the ongoing dissection process itself. So the surgical approach to the 
dissecting process may be inevitably necessary 
2. Medications used after PCI, such as antiplatelets or heparin, may result in increased risk 
of bleeding, rupture or cardiac tamponade. 
3. To insert and to advance the guiding catheter in the injured aortic lumen may result in 
further injury of the aortic wall(sometimes, the true lumen is so shrunk and deformed). 
In addition, the guiding catheter may be erroneously inserted into the false lumen 
4. Intra-aortic balloon pumping may be contraindicated and the safety of PCPS is not 
established. 
5. If the mechanism of coronary malperfusion is due to mechanism 3), to pass the 
guidewire across the obstruction is impossible because there is no continuity of the wall 
of the coronary artery(Figure 1 C). 
6. If the malperfusion is due to mechanism 4), deploying a stent in the orifice is not 
effective(Figure 1D). 
So, at present, ACS secondary to AAD should be treated with surgery in most cases. PCI 
may be effective in selected cases as a bridge to definitive surgery.  
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Recognition and appropriate management of ASC secondary to AAD is very important. 
Because the mechanism of coronary malperfusion is totally different from usual ACS, the 
treatment of choice is also very different. Making a correct diagnosis regarding underlying 
dissection is very important. 
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Atypical Presentation in Patients with  
Acute Coronary Syndrome 
Hyun Kuk Kim and Myung Ho Jeong 
The Heart Center of Chonnam National University Hospital, Gwangju,  
Korea 
1. Introduction 
Chest pain has been reported as a cardinal clinical feature among the patients with acute 
coronary syndrome (ACS). However, several patients exhibit the atypical or no symptom on 
initial evaluation. Atypical symptom was defined as the absence of chest pain before or 
during admission, and may have included gastrointestinal or respiratory symptoms such as 
dyspnea, nausea, vomiting, and abdominal discomfort.  
Patients who present without chest pain are frequently misdiagnosed, and less likely to 
receive optimal treatment for ACS. Consequently, greater in-hospital morbidity, and 
mortality are noted. Therefore, understanding the factor associated with atypical 
presentations may help in the earlier detection and treatments in patients with ACS.  
Prior to discussing the risk factor, clarifying the concept of symptom in patients with ACS is 
needed to figure out this theme. In this manuscript, atypical presentation is used 









Fig. 1. Definition of atypical presentation; 1 or 1+2 
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2. Definition of clinical presentation 
2.1 Ischemic chest pain 
There are several features that tend to distinguish ischemic chest pain from non-cardiac 
pain. 
 Quality – patients with ischemic pain often describe more as a discomfort than pain. 
Typical pain is expressed by terms include squeezing, tightness, pressure, constriction, 
strangling, burning, heavy weight on chest. It is not generally described as sharp, knife-
like, stabbing, and pins. 
 Site – ischemic pain is a diffuse discomfort that may be difficult to localize. The 
sensation is often located in the retro-sternal area but may be felt in the epigastrium, 
back, arms, or jaw. Pain radiating to the upper extremities is highly suggestive of 
ischemic pain. 
 Onset – ischemic pain is described as having a crescendo pattern (wax and wane), and 
is typically gradual in onset.  
 Provocation and relieving factors – ischemic pain is usually developed by situations 
such as exercise, emotional stress which increases cardiac oxygen demands. Chest pain 
that is reproduced on respiration, coughing, position change, palpation is often 
associated with not-ACS disease. Relief of pain after administration of nitroglycerin or 
gastro-intestinal cocktails (GI cocktails; viscous lidocaine and antacid) could not 
guarantee the cardiac or gastric origin pain.  
2.2 Atypical chest pain and presentation 
The following characteristics were considered as more non-ischemic chest discomfort. 
 Sharp or knife like pain related to respiration, coughing 
 Reproduced pain by movement or palpation 
 Localized pain with one finger 
 Radiating pain into the lower extremities or above the mandible 
 Pain lasting for days or a few seconds 
Atypical presentation was defined as the absence of chest pain before or during admission, 
and may have included gastrointestinal or respiratory symptoms such as dyspnea, nausea, 
vomiting, and abdominal discomfort. The prevalence of this presentation was 8.4% in the 
Global Registry of Acute Coronary Events (GRACE), 33% in the National Registry of 
Myocardial Infarction 2 (NRMI-2) and the dominant symptoms in these patients were 
dyspnea, nausea, syncope (Fig.2). 
3. Clinical characteristics and prognosis with atypical symptom 
In NRMI-2 report, patients with atypical presentation had a longer delay before hospital 
seek (mean, 7.9 vs. 5.3 hours), were less likely to be diagnosed with a myocardial infarction 
on admission (22% vs. 50%), and were less likely to be treated with optimal medical therapy 
[aspirin (60% vs. 85%), β-blocker (28% vs. 48%), heparin (53% vs. 83%)] and to receive 
thrombolytic therapy or primary percutaneous coronary intervention (25% vs. 74%).6 Its 
results were similar with GRACE report. Not surprisingly, in-hospital mortality rates were 
much higher in patients with atypical presentation in both registry data (NRMI-2, 23% vs. 
9%; GRACE 13% vs. 4%). Moreover, in-hospital complications were developed more in 
atypical presentation group.  
 








Fig. 2. Dominant symptom among patients with atypical presentation (Adopted from 
Brieger D, et al. Chest. 2004;126: 461-9) 
4. Risk factors of atypical presentation 
In NRMI-2 registry, Variables such as older age, gender, race, and co-morbidities (diabetes, 
stroke, heart failure) were considered as a risk factor for atypical symptom (Table.1), and 
many studies have described the association of aging, gender, and diabetes mellitus. 
 
Variables Odds Ratio (95% confidential interval) 
Nonwhite 1.05 (1.03-1.07) 
Women 1.06 (1.04-1.08) 
Diabetes mellitus 1.21 (1.19-1.23) 
Age (10-year interval) 1.28 (1.26-1.28) 
Prior stroke 1.43 (1.40-1.47) 
Prior heart failure 1.77 (1.74-1.81) 
 
Table 1. Independent risk factor for atypical presentation (Adopted from Canto J.G, et al. 
JAMA. 2000;283:3223-9) 
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much higher in patients with atypical presentation in both registry data (NRMI-2, 23% vs. 
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Fig. 2. Dominant symptom among patients with atypical presentation (Adopted from 
Brieger D, et al. Chest. 2004;126: 461-9) 
4. Risk factors of atypical presentation 
In NRMI-2 registry, Variables such as older age, gender, race, and co-morbidities (diabetes, 
stroke, heart failure) were considered as a risk factor for atypical symptom (Table.1), and 
many studies have described the association of aging, gender, and diabetes mellitus. 
 
Variables Odds Ratio (95% confidential interval) 
Nonwhite 1.05 (1.03-1.07) 
Women 1.06 (1.04-1.08) 
Diabetes mellitus 1.21 (1.19-1.23) 
Age (10-year interval) 1.28 (1.26-1.28) 
Prior stroke 1.43 (1.40-1.47) 
Prior heart failure 1.77 (1.74-1.81) 
 
Table 1. Independent risk factor for atypical presentation (Adopted from Canto J.G, et al. 
JAMA. 2000;283:3223-9) 
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4.1 Women  
Atypical presentation in ACS was observed more commonly in women than men in large 
cohort studies (Table 2). Women with coronary heart disease are older by 10 years and 
have more risk factors than men. It might be due to lack of early recognition and 
management.  
There are several differences between men and women in presentation. Women were less 
likely to have typical angina, rated their pain as more intense, used different words to 
describe it (more burning, sharp), and reported more non-pain-related symptoms than 
men. They experienced pain and other sensations in the neck area more frequently. 
Another feature of chest pain in women is that angina being induced by rest, sleep, 
mental stress instead of or addition to physical exertion. Psychosocial factors might also 
affect symptom presentation and diagnostic approach in women. For example, a history 
of anxiety disorders is associated with a lower probability of significant angiographic 
disease among women with chest pain symptoms. As women underestimate their own 
risk of coronary artery disease, diagnostic approach by physician could be altered less 
aggressively than men. Compared with men, women are less likely to perform cardiac 
monitoring, cardiac enzyme measurement, electrocardiogram, cardiac consultation, 
admission to a coronary care unit, undergo less coronary angiography, angioplasty, and 
bypass surgery. 
 
Study name Study years Sample size 
Atypical symptom (%) 
Men Women 
GRACE 1999-2002 20881 7.3 10.6 
NRMI-2 1994-1998 434877 28.6 38.6 
Alabama UA registry 1993-1999 4167 50.2 53.0 
United kingdom 1995 2096 17.6 24.6 
Worcester MI study 1986-1988 1360 18.0 23.0 
Worcester MI study 1997-1999 2073 30.9 45.8 
26 hospitals, CCU Israel 2000 2113 18.7 29.7 
Croatia 1990-1995 1996 12.4 20.3 
Olmsted County 1985-1992 2271 25.0 19.0 
Cumulative   27.4 37.5 
Table 2. Prevalence of atypical presentation in large cohort 
 
Atypical Presentation in Patients with Acute Coronary Syndrome 
 
113 
4.2 Diabetes mellitus  
Some patients with diabetes mellitus (DM) have a blunted perception of ischemic chest pain, 
which could result in atypical presentation. The suggested mechanisms of this phenomenon 
are as follows; 1) autonomic neuropathy, 2) prolongation of the anginal perceptual 
threshold. 
Sympathetic denervation diabetic patients have evidence of a significant reduction in MIBG 
uptake, most likely on the basis of autonomic dysfunction. Furthermore, diabetic patients 
with silent myocardial ischemia have evidence of a diffuse abnormality in 
metaiodobenzylguanidine (MIBG) uptake, suggesting that abnormalities in pain perception 
may be linked to sympathetic denervation. Similar finding has also been observed with 
positron emission tomography. Moreover, regional heterogeneity in sympathetic 
denervation could result in potentially life-threatening myocardial electrical instability that 
may lead to life-threatening arrhythmias. 
Another mechanism of abnormal perception is prolongation of the angina perceptual 
threshold during exercise. Anginal perceptual threshold (the time from onset of 0.1 mV of 
ST segment depression to onset of angina during treadmill exercise) is prolonged in diabetic 
patients with coronary artery disease. The permissive effect of a prolonged anginal 
perceptual threshold on exercise capacity is undesirable as reflected by its correlation with 
ischemia at peak exercise (r = 0.6, p less than 0.001): the longer the threshold, the greater the 
exercise capacity and the more severe the ischemia. 
4.3 Age and atypical presentation  
Advanced age is an important predictor of atypical presentation and poor prognosis. Recent 
study in Korea examined and compared the risk factor associated with atypical presentation 
according to the age parameter. In this study, diabetes and hyperlipidemia significantly 
predicted atypical symptom in relatively young (<70 years) age group. Otherwise, co-
morbid conditions such as stroke or chronic obstructive pulmonary disease were the 
positive predictors in relatively old age group (>70 years) (Table 3). 
 
 Younger (n=49) Adjust OR (95% CI) P 
Older (n=41) 
Adjust OR (95% CI) P 
Female gender 0.861 (0.576-1.769) 0.069 0.721 (0.780-2.599) 0.385 
Hypertension 0.740 (0.712-1.875) 0.352 0.628 (0.780-2.599) 0.208 
Diabetes 2.494 (1.108-4.014) 0.023 0.841 (0.416-1.515) 0.719 
Hyperlipidemia 0.486 (0.285-0.828) 0.006 0.840 (0.438-1.611) 0.465 
Co-morbidity 2.029 (0.889-4.633) 0.093 3.315 (1.357-8.729) 0.001 
Smoking 0.595 (0.345-1.025) 0.061 0.575 (0.255-1.297) 0.157 
ACS type 1.243 (0.675-1.235) 0.883 1.041 (0.744-1.417) 0.877 
Constant 0.162 <0.001 0.258 0.001 
Table 3. Predicting factors on atypical presentation in younger and older patients (Adopted 
from Hwang S.Y, et al. J Korean Med Sci. 2009;24:789-94) 
5. Conclusions  
ACS patients with atypical presentation are under-diagnosed and under-treated high risk 
group. Several clinical risk factors could be helpful in prediction of ACS in this group. 
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Health care providers should have more concerns about the presence of ACS in patients 
who have these risk factors. 
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1. Introduction 
Patients with coronary artery disease (CAD) who suffer persistent symptoms and reduced 
quality of life while receiving medical therapy are considered for revascularization.1  
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are 
the most common methods of revascularization for symptomatic CAD.  These two 
interventions can reduce ischemic symptoms such as angina or dyspnea,2 thus  improving 
the ability to undertake physical training. Shorter length of hospitalization,3 earlier return to 
work,4 and better life adaptation5 were reported in patients undergoing PCI.  However, the 
incidence rate of restenosis following PCI is higher than CABG,6 and PCI patients who 
required further interventions outnumbered the patients who underwent CABG.7-8 A recent 
meta-analysis study found that the mortality rate and the rate of revascularization were 
significantly lower in the CABG group than the PCI group (9.9% vs 24.5%).9 In a subgroup 
analysis, the 5-year mortality rate of DM patients was also lower in the CABG group.  
In the era of drug-eluting stent (DES), the Synergy between PCI with Taxus and Cardiac 
Surgery (SYNTAX) trial10 found that major adverse cardiovascular events rates at 12 months 
were significantly higher in the PCI group (17.8% vs 12.4%), and the rate of 
revascularization was lower in the CABG group (5.9% vs 13.5%), but stroke was 
significantly higher in the CABG group (2.2% vs 0.6%). However, the application of new 
surgical technique, such as off-pump CABG (OPCAB) may reduce the rate of stroke after 
surgery. In general, CABG remains the method of choice in patients with left main disease, 
multivessel disease, especially in diabetic patients, or patients with left ventricular 
dysfunction, in the event of failure of PCI, and in-stent restenosis.11 Although the procedure 
risk is higher for patients receiving CABG, the extent of revascularization is more 
complete,12 and hence the potential of training is higher than patients with PCI. The 
objective of this study is to review the effect of exercise training program in patients with 
CABG. 
2. Principle of exercise training 
Exercise is a major component for patients with CAD.  Cardiac rehabilitation (CR) 
usually beginning during hospitalization (phase I, inpatient), followed by a supervised 
outpatient program lasting 3-6 months (phase II), and continuing in a lifetime 
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Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are 
the most common methods of revascularization for symptomatic CAD.  These two 
interventions can reduce ischemic symptoms such as angina or dyspnea,2 thus  improving 
the ability to undertake physical training. Shorter length of hospitalization,3 earlier return to 
work,4 and better life adaptation5 were reported in patients undergoing PCI.  However, the 
incidence rate of restenosis following PCI is higher than CABG,6 and PCI patients who 
required further interventions outnumbered the patients who underwent CABG.7-8 A recent 
meta-analysis study found that the mortality rate and the rate of revascularization were 
significantly lower in the CABG group than the PCI group (9.9% vs 24.5%).9 In a subgroup 
analysis, the 5-year mortality rate of DM patients was also lower in the CABG group.  
In the era of drug-eluting stent (DES), the Synergy between PCI with Taxus and Cardiac 
Surgery (SYNTAX) trial10 found that major adverse cardiovascular events rates at 12 months 
were significantly higher in the PCI group (17.8% vs 12.4%), and the rate of 
revascularization was lower in the CABG group (5.9% vs 13.5%), but stroke was 
significantly higher in the CABG group (2.2% vs 0.6%). However, the application of new 
surgical technique, such as off-pump CABG (OPCAB) may reduce the rate of stroke after 
surgery. In general, CABG remains the method of choice in patients with left main disease, 
multivessel disease, especially in diabetic patients, or patients with left ventricular 
dysfunction, in the event of failure of PCI, and in-stent restenosis.11 Although the procedure 
risk is higher for patients receiving CABG, the extent of revascularization is more 
complete,12 and hence the potential of training is higher than patients with PCI. The 
objective of this study is to review the effect of exercise training program in patients with 
CABG. 
2. Principle of exercise training 
Exercise is a major component for patients with CAD.  Cardiac rehabilitation (CR) 
usually beginning during hospitalization (phase I, inpatient), followed by a supervised 
outpatient program lasting 3-6 months (phase II), and continuing in a lifetime 
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maintenance stage in minimally supervised or unsupervised setting (phase III). 
According to the recommendations of American College of Sports Medicine,13 patients 
with CABG should perform aerobic exercise 3-5 times per week and 20-60 minutes for 
each session, at the intensity of 40-80% of v O2peak. Strength training is suggested to 
perform 2-3 times per week at the intensity of 40-50 % of maximal voluntary contraction 
with 10-15 repetitions.  
For the coronary patients, exercises with moderate intensity have been shown to improve 
functional capacity, and it may provide greater safety during unsupervised training.  Lower 
intensity exercise training also increases the acceptance of exercise program, particularly 
unfit and elderly patients. Therefore, some oriental conditioning exercises deserve more 
attention because they are less intense, easily accessible, low cost and therefore suitable for 
implementation in the community. 
3. Benefits of exercise training 
3.1 Cardiorespiratory fitness 
Cardiac rehabilitation exercise training improves exercise capacity, without significant 
complications or other adverse effects. Peak oxygen uptake is the best indicator for 
cardiorespiratory fitness, and attaining a high v O2peak requires integration of high levels of 
pulmonary, cardiovascular and neuromuscular function. In patient with CAD, the level of 
v O2peak is also a good predictor for mortality rate. Kavanagh et al.14 reported exercise test 
data for 12,169 male rehabilitation candidates, and found the most powerful predictor of 
cardiac and all-cause mortality was v O2peak. Values of <15, 15 to 22, and >22 mL·kg-1·min-1 
yielded respective hazard ratios of 1.00, 0.62, and 0.39 for cardiac deaths and 1.00, 0.66, and 
0.45 for all-cause deaths.  Additionally, the mortality rate might decrease 9% for each 1 
mL·kg-1·min-1 increase of v O2peak.14 For patients with CABG, previous studies reported 
10.5%-48.2% increase of v O2peak in outpatient CR, and the increase of absolute value was 
1.9-6.6 mL·kg-1·min-1 (Table 1),15-32 depended on different exercise protocol and the initial 
level of fitness.  
 
Study Patients Intervention Outcomes 
Haennel et al15 
(1991) 
24 men 
9-10 wk after CABG 
Cycle training (n=8): cycling 
24 min, 3 times/wk for 8 wk 
Hydraulic circuit training 
(HCT, n=8): 24 min circuit 
training 3 times/wk for 8 wk
Control (n=8) 
v O2peak between baseline and 8 
wk: 
Cycling: 21.4 vs 25.7 mL·kg-1·min-1 
(20.1%) 
HCT: 21.2 vs 23.6 mL·kg-1·min-1 
(11.3%) 
Cardiac output between baseline 
and 8 wk: 
Cycling:14.3 vs 16.8 L·min-1 
(17.5%) 
HCT: 13.1 vs 15.1 L·min-1 
(15.3%) 
Engblom et al16 
(1992) 
171 men 
2 mon after CABG 
Rehabilitation group (n=93) 
3- wk exercise followed by  
2-day refresher for 8 m  
Reference group (n=78) 
Maximal work load increased in 
both groups, but the increase is 
greater in rehabilitation group 
than in reference group 12 months 
post-operatively. 
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Study Patients Intervention Outcomes 
Dubach et al17 
(1995) 
42 men 
1 mon after CABG 
Exercise group (n=22): 
walking 1 h twice daily for 1 
m, followed by 1 m of usual 
care 
Control group (n=20): usual 
care for 1 m, followed by 
walking 1 h twice daily for  
1 m 
v O2peak between baseline and 1 
mon: 
Ex: 22.6 vs 24.5 mL·kg-1·min-1 
(8.4%) 
Control: 21.0 vs 23.7 mL·kg-1·min-1 
(12.9%) 
v O2peak between 1 mon and 2 
mon: 
Ex: 24.5 vs 26.4 mL·kg-1·min-1 
(7.8%) 
Control: 23.7 vs 25.0 mL·kg-1·min-1 
(5.5%) 
Daida et al18 
(1996) 
15 M, 2 F 
53±3 y/o, 3 m after 
CABG 
6-8 wk aerobic training, 
3 times/wk, 40 min each 
time, 
at RPE 12-13 
v O2peak between baseline and 9 
mon: 
21.9 vs 27.4 mL·kg-1·min-1 (25.1%) 
↑Exercise time, O2 pulse, peak HR 




18 mon after CABG 
Circuit weight training 
group, (CWT, n=12):10 wks 
CWT at 40-60% max. 
contraction 
Control group (n=14) 
Strength increased by 18% in five 
out of seven exercise in the CWT 
group, but unchanged in the 
control group 
v O2peak : no increase in both 
groups 




5 mon after CABG 
Tai Chi group (n=9): 1-yr TC 
training, 3.8 times/wk, 1 h 
each time, at 48-57% of HR 
reserve 
Control group (n=11) 
v O2peak between baseline and 1 
yr: 
TC : 26.2 vs 28.9 mL·kg-1·min-1 
(10.3%) 
Control: 26.0 vs 25.6 mL·kg-1·min-1 
(-1.5%) 




8-10 wk after CABG 
12-wk of walking program 
Initial intensity at 50-60% of 
v O2peak, then increase to 75-
80% of v O2peak, 5 times/wk, 
45-60 min each session for 3 
m 
v O2peak between baseline and 3 
mon: 
CABG: 19.0 vs 21.0 mL·kg-1·min-1 
(10.5%) 
Ejection Fraction (EF): 
At 40% of v O2peak: 60 vs 63% 
At 70% of v O2peak: 61 vs 64% 






1 wk after CABG 
Exercise group (n=13): 30 
min bicycle exercise, twice 
daily for 2 wk, intensity at 
ventilatory threshold (VeT) 
Control group (n=15): 
walking 200-500 meters for 2 
wk 
v O2peak between 1 wk and 3 wk: 
Ex: 13.1 vs 16.1 mL·kg-1·min-1 
(22.9%) 
Control:13.7 vs 14.8 mL·kg-1·min-1 
(8.0%) 
Peak CO between 1wk and 3 wk: 
Ex: 10.6 vs 13.4 L/min (26.4%) 
Control:11.9 vs 12.0 L/min (0.1%) 
  
Acute Coronary Syndromes 
 
118 
maintenance stage in minimally supervised or unsupervised setting (phase III). 
According to the recommendations of American College of Sports Medicine,13 patients 
with CABG should perform aerobic exercise 3-5 times per week and 20-60 minutes for 
each session, at the intensity of 40-80% of v O2peak. Strength training is suggested to 
perform 2-3 times per week at the intensity of 40-50 % of maximal voluntary contraction 
with 10-15 repetitions.  
For the coronary patients, exercises with moderate intensity have been shown to improve 
functional capacity, and it may provide greater safety during unsupervised training.  Lower 
intensity exercise training also increases the acceptance of exercise program, particularly 
unfit and elderly patients. Therefore, some oriental conditioning exercises deserve more 
attention because they are less intense, easily accessible, low cost and therefore suitable for 
implementation in the community. 
3. Benefits of exercise training 
3.1 Cardiorespiratory fitness 
Cardiac rehabilitation exercise training improves exercise capacity, without significant 
complications or other adverse effects. Peak oxygen uptake is the best indicator for 
cardiorespiratory fitness, and attaining a high v O2peak requires integration of high levels of 
pulmonary, cardiovascular and neuromuscular function. In patient with CAD, the level of 
v O2peak is also a good predictor for mortality rate. Kavanagh et al.14 reported exercise test 
data for 12,169 male rehabilitation candidates, and found the most powerful predictor of 
cardiac and all-cause mortality was v O2peak. Values of <15, 15 to 22, and >22 mL·kg-1·min-1 
yielded respective hazard ratios of 1.00, 0.62, and 0.39 for cardiac deaths and 1.00, 0.66, and 
0.45 for all-cause deaths.  Additionally, the mortality rate might decrease 9% for each 1 
mL·kg-1·min-1 increase of v O2peak.14 For patients with CABG, previous studies reported 
10.5%-48.2% increase of v O2peak in outpatient CR, and the increase of absolute value was 
1.9-6.6 mL·kg-1·min-1 (Table 1),15-32 depended on different exercise protocol and the initial 
level of fitness.  
 
Study Patients Intervention Outcomes 
Haennel et al15 
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24 men 
9-10 wk after CABG 
Cycle training (n=8): cycling 
24 min, 3 times/wk for 8 wk 
Hydraulic circuit training 
(HCT, n=8): 24 min circuit 
training 3 times/wk for 8 wk
Control (n=8) 
v O2peak between baseline and 8 
wk: 
Cycling: 21.4 vs 25.7 mL·kg-1·min-1 
(20.1%) 
HCT: 21.2 vs 23.6 mL·kg-1·min-1 
(11.3%) 
Cardiac output between baseline 
and 8 wk: 
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(17.5%) 
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(15.3%) 
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2-day refresher for 8 m  
Reference group (n=78) 
Maximal work load increased in 
both groups, but the increase is 
greater in rehabilitation group 
than in reference group 12 months 
post-operatively. 
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Study Patients Intervention Outcomes 
Dubach et al17 
(1995) 
42 men 
1 mon after CABG 
Exercise group (n=22): 
walking 1 h twice daily for 1 
m, followed by 1 m of usual 
care 
Control group (n=20): usual 
care for 1 m, followed by 
walking 1 h twice daily for  
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v O2peak between baseline and 1 
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(8.4%) 
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(12.9%) 
v O2peak between 1 mon and 2 
mon: 
Ex: 24.5 vs 26.4 mL·kg-1·min-1 
(7.8%) 
Control: 23.7 vs 25.0 mL·kg-1·min-1 
(5.5%) 
Daida et al18 
(1996) 
15 M, 2 F 
53±3 y/o, 3 m after 
CABG 
6-8 wk aerobic training, 
3 times/wk, 40 min each 
time, 
at RPE 12-13 
v O2peak between baseline and 9 
mon: 
21.9 vs 27.4 mL·kg-1·min-1 (25.1%) 
↑Exercise time, O2 pulse, peak HR 




18 mon after CABG 
Circuit weight training 
group, (CWT, n=12):10 wks 
CWT at 40-60% max. 
contraction 
Control group (n=14) 
Strength increased by 18% in five 
out of seven exercise in the CWT 
group, but unchanged in the 
control group 
v O2peak : no increase in both 
groups 




5 mon after CABG 
Tai Chi group (n=9): 1-yr TC 
training, 3.8 times/wk, 1 h 
each time, at 48-57% of HR 
reserve 
Control group (n=11) 
v O2peak between baseline and 1 
yr: 
TC : 26.2 vs 28.9 mL·kg-1·min-1 
(10.3%) 
Control: 26.0 vs 25.6 mL·kg-1·min-1 
(-1.5%) 




8-10 wk after CABG 
12-wk of walking program 
Initial intensity at 50-60% of 
v O2peak, then increase to 75-
80% of v O2peak, 5 times/wk, 
45-60 min each session for 3 
m 
v O2peak between baseline and 3 
mon: 
CABG: 19.0 vs 21.0 mL·kg-1·min-1 
(10.5%) 
Ejection Fraction (EF): 
At 40% of v O2peak: 60 vs 63% 
At 70% of v O2peak: 61 vs 64% 






1 wk after CABG 
Exercise group (n=13): 30 
min bicycle exercise, twice 
daily for 2 wk, intensity at 
ventilatory threshold (VeT) 
Control group (n=15): 
walking 200-500 meters for 2 
wk 
v O2peak between 1 wk and 3 wk: 
Ex: 13.1 vs 16.1 mL·kg-1·min-1 
(22.9%) 
Control:13.7 vs 14.8 mL·kg-1·min-1 
(8.0%) 
Peak CO between 1wk and 3 wk: 
Ex: 10.6 vs 13.4 L/min (26.4%) 
Control:11.9 vs 12.0 L/min (0.1%) 
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Study Patients Intervention Outcomes 
Adachi et al23 
(2001) 
57 patients 
(46 M/ 11F) 
1 wk after CABG 
Exercise group (n=34): 30 
min exercise, twice daily for 2 
wk, intensity at VeT 
Control group (n=23) 
v O2peak between 1 wk and 3 wk: 
Ex: 13.7 vs 20.3 mL·kg-1·min-1 
(48.2%) 
Control:13.7 vs 14.3 mL·kg-1·min-1 
(4.4%) 
↑Ventilatory efficiency and 
cardiac output in exercise group 
Kodis et al24 
(2001) 
1,042 patients 
6-8 wk after CABG 
Supervised Ex (n=713): 2 
times per wk, at 40-70% of 
functional capacity for 6 m 
Home Ex (n=329) 
Supervised Ex group: ↑23.7% 
in v O2peak , 
↑HDL-C, ↓LDL-C 
Home Ex group: ↑17.2% 
in v O2peak , 
↑HDL-C 




2 mon after CABG 
Aerobic exercise for 3 m, 3 
time/ wk, 30 min each 
session, at 51-59 % of 
functional capacity 
v O2peak between baseline and 3 m: 
Ex: 19.8 vs 26.3 mL·kg-1·min-1 
(32.8%) 
v O2 at VeT between baseline and 
3 m: 
Ex: 11.9 vs 14.7 mL·kg-1·min-1 
(23.5%) 
Chuang et al26 
(2005) 
32 patients 
2-3 mon after CABG 
Virtual reality (VR, n=17) 
group: simulated exercise 2 
times per wk, 30 min for 3 m 
Non-VR (n=15) group: 
exercise without simulation 
v O2peak between baseline and 3 m: 
VR: 17.7 vs 22.5 mL·kg-1·min-1 
(27.1%) 
Non-VR: 15.1 vs 16.8 mL·kg-1·min-
1 (11.3%) 
↑ v O2 at VeT in both groups 
Sumide et al27 
(2009) 
42 patients 
(40 M/ 2F) 
61±8 y/o 
Aerobic and resistance 
exercise for 6 m, 1-2 
time/wk, 60 min each session
v O2peak between baseline and 6 m: 
Ex: 15.1 vs 21.7 mL·kg-1·min-1 
(43.7%) 
↑Peak torque in knee extensor/ 




AIT: 24M/ 4F 
MCT:24M/7F 




4 wk in rehab center, then 
6- m home-based exercise 
v O2peak between baseline and 4 wk: 
AIT: 27.1 vs 30.4 mL·kg-1·min-1 
(12.2%) 
MCT:26.2 vs 28.5 mL·kg-1·min-1 
(8.8%) 
v O2peak between 4wk and 6 m: 
AIT: 30.4 vs 32.2 mL·kg-1·min-1 
(5.9%) 
MCT:28.5 vs 29.5 mL·kg-1·min-1 
(3.5%) 
Onishi et al29 
(2009) 
32 patients with 
metabolic syndrome 
5-14 days after CABG
Supervised CR program for 6 
months, including aerobic 
exercise (60 min) and 
resistance training, at VeT 
v O2peak between baseline and 6 m: 
Ex: 14.2 vs 19.2 mL·kg-1·min-1 
(35.2%) 
↑peak torques of knee extensor 
(13.4%) and knee flexors (15.3%) 
↓Triglyceride, LDL-C and CRP 
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3 mon after CABG 
Ex group (n= 60), 6 wk 
aerobic training, 3 times/wk, 
at 70-80% HRmax 
Control group (n=60) 
Handgrip-induced increases in 
HR, BP, and TPR were lower, 
whereas SV and CO were higher 
(by 13% and 15%, respectively) in 
Ex group. A higher increase in NO 
level and a lower increase in 
noradrenaline in Ex group. 
Shabani et al31 
(2010) 60 women 
Ex group (n=30): 12 wk 
aerobic exercise 
Control group (n=30): usual 
care 
Estimated exercise capacity and 6 min 
walking test increased in Ex group 
Exercise duration time↑49.2% and rate 
pressure product↑10.3% in Ex group 
Smith et al32 
(2011) 196 patients 
Hospital Ex group: aerobic 
Ex 30-50 min per session, 3 
times/wk, at 60-80% HR 
reserve for 6 m 
Home Ex group: walking in 
home 5 times per wk 
MET between baseline and 6 m: 
Hospital Ex: 4.5 vs 6.2 MET 
(37.8%) 
Home Ex: 5.1 vs 6.4 MET (25.5%) 
Home-based exercise maintained 
higher physical capacity during 6 yrs 
follow up than hospital-based exercise 
Table 1. Effect of Exercise Training to Functional Capacity in Patients with CABG 
3.2 Muscular strength 
Traditionally, CR program involving aerobic exercise training such as walking and 
cycling is emphasized. However, muscular strength is important in vocational activities 
and activities of daily living. Previous studies showed that moderate intensity resistance 
exercise might significantly increase muscular strength for cardiac patients.33-34 It is 
recommended that cardiac patient should start a low weight and perform one set of 10-15 
repetitions using 8-10 different exercises.  Some studies reported that resistance training 
might increase aerobic power,15,33-34 but other study found that resistance training can 
only improve muscular strength.19 Therefore, resistance training should be integrated into 
an aerobic exercise program. Sumide et al27 reported a 6-month aerobic exercise and 
resistance training program was beneficial to patients with CABG.  After training, the 
v O2peak and peak lower limb torques significantly increased, and the circumferences of 
thigh and calf were also increased. In a recent study, Onishi et al.29 reported a 6-month 
aerobic and resistance training program also improved v O2peak and isokinetic peak 
torques of knee extensor and flexor in patients after CABG. It appears that a combined 
aerobic and resistance training program significantly increased exercise tolerance and 
lower limb muscle strength. 
3.3 Cardiac function 
Exercise training in healthy individuals may enhance physical capacity by both an increase 
in cardiac output, a central mechanism, and a widening of the arteriovenous oxygen 
difference, a peripheral mechanism. In patients with heart disease, previous studies 
suggested the enhancement of v O2peak only relied on peripheral adaptations,35-37 however, 
recent studies found the increase of v O2peak might be partially attributed to an elevation in 
cardiac output.  
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Study Patients Intervention Outcomes 
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(2001) 
57 patients 
(46 M/ 11F) 
1 wk after CABG 
Exercise group (n=34): 30 
min exercise, twice daily for 2 
wk, intensity at VeT 
Control group (n=23) 
v O2peak between 1 wk and 3 wk: 
Ex: 13.7 vs 20.3 mL·kg-1·min-1 
(48.2%) 
Control:13.7 vs 14.3 mL·kg-1·min-1 
(4.4%) 
↑Ventilatory efficiency and 
cardiac output in exercise group 
Kodis et al24 
(2001) 
1,042 patients 
6-8 wk after CABG 
Supervised Ex (n=713): 2 
times per wk, at 40-70% of 
functional capacity for 6 m 
Home Ex (n=329) 
Supervised Ex group: ↑23.7% 
in v O2peak , 
↑HDL-C, ↓LDL-C 
Home Ex group: ↑17.2% 
in v O2peak , 
↑HDL-C 




2 mon after CABG 
Aerobic exercise for 3 m, 3 
time/ wk, 30 min each 
session, at 51-59 % of 
functional capacity 
v O2peak between baseline and 3 m: 
Ex: 19.8 vs 26.3 mL·kg-1·min-1 
(32.8%) 
v O2 at VeT between baseline and 
3 m: 
Ex: 11.9 vs 14.7 mL·kg-1·min-1 
(23.5%) 
Chuang et al26 
(2005) 
32 patients 
2-3 mon after CABG 
Virtual reality (VR, n=17) 
group: simulated exercise 2 
times per wk, 30 min for 3 m 
Non-VR (n=15) group: 
exercise without simulation 
v O2peak between baseline and 3 m: 
VR: 17.7 vs 22.5 mL·kg-1·min-1 
(27.1%) 
Non-VR: 15.1 vs 16.8 mL·kg-1·min-
1 (11.3%) 
↑ v O2 at VeT in both groups 
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3 mon after CABG 
Ex group (n= 60), 6 wk 
aerobic training, 3 times/wk, 
at 70-80% HRmax 
Control group (n=60) 
Handgrip-induced increases in 
HR, BP, and TPR were lower, 
whereas SV and CO were higher 
(by 13% and 15%, respectively) in 
Ex group. A higher increase in NO 
level and a lower increase in 
noradrenaline in Ex group. 
Shabani et al31 
(2010) 60 women 
Ex group (n=30): 12 wk 
aerobic exercise 
Control group (n=30): usual 
care 
Estimated exercise capacity and 6 min 
walking test increased in Ex group 
Exercise duration time↑49.2% and rate 
pressure product↑10.3% in Ex group 
Smith et al32 
(2011) 196 patients 
Hospital Ex group: aerobic 
Ex 30-50 min per session, 3 
times/wk, at 60-80% HR 
reserve for 6 m 
Home Ex group: walking in 
home 5 times per wk 
MET between baseline and 6 m: 
Hospital Ex: 4.5 vs 6.2 MET 
(37.8%) 
Home Ex: 5.1 vs 6.4 MET (25.5%) 
Home-based exercise maintained 
higher physical capacity during 6 yrs 
follow up than hospital-based exercise 
Table 1. Effect of Exercise Training to Functional Capacity in Patients with CABG 
3.2 Muscular strength 
Traditionally, CR program involving aerobic exercise training such as walking and 
cycling is emphasized. However, muscular strength is important in vocational activities 
and activities of daily living. Previous studies showed that moderate intensity resistance 
exercise might significantly increase muscular strength for cardiac patients.33-34 It is 
recommended that cardiac patient should start a low weight and perform one set of 10-15 
repetitions using 8-10 different exercises.  Some studies reported that resistance training 
might increase aerobic power,15,33-34 but other study found that resistance training can 
only improve muscular strength.19 Therefore, resistance training should be integrated into 
an aerobic exercise program. Sumide et al27 reported a 6-month aerobic exercise and 
resistance training program was beneficial to patients with CABG.  After training, the 
v O2peak and peak lower limb torques significantly increased, and the circumferences of 
thigh and calf were also increased. In a recent study, Onishi et al.29 reported a 6-month 
aerobic and resistance training program also improved v O2peak and isokinetic peak 
torques of knee extensor and flexor in patients after CABG. It appears that a combined 
aerobic and resistance training program significantly increased exercise tolerance and 
lower limb muscle strength. 
3.3 Cardiac function 
Exercise training in healthy individuals may enhance physical capacity by both an increase 
in cardiac output, a central mechanism, and a widening of the arteriovenous oxygen 
difference, a peripheral mechanism. In patients with heart disease, previous studies 
suggested the enhancement of v O2peak only relied on peripheral adaptations,35-37 however, 
recent studies found the increase of v O2peak might be partially attributed to an elevation in 
cardiac output.  
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Nakai et al.38 reported the effects of exercise training on recovery of cardiac function in 115 
patients after CABG. After training, stroke index increased significantly in the exercise 
group, but not in the usual care group. Takeyama et al22 applied a 2-week bicycle program 
to 13 patients with CABG, and they exercised 30-minute twice daily. The peak cardiac 
output increased 22.9% from 10.6 L/min to 13.4 L/min, while the control group showed no 
significant improvement.  Adachi et al.23 assigned 34 patients with CABG to a 2-week 
exercise program, and cardiac output during exercise at 20 watt and at peak exercise 
significantly increased in the exercise group.  In a recent study, Bilinska et al30 reported that 
after 6 weeks of aerobic training at 70–80% of HRpeak, the stroke volume and cardiac output 
were higher (by 13% and 15%, respectively) in trained patients compared with controls.   
Goodman et al.21 has explored central and peripheral adaptations after exercise training in 
31 patients with CABG. Patients underwent 12 weeks of exercise training consisting of 
walking and jogging, at 75% to 80% v O2peak. The results showed a significant improvement 
in v O2peak and an increase of the ejection fraction during submaximal exercise (60 ± 3% vs 63 
± 2% at 40% v O2peak; 61 ± 3% vs 64 ± 3% at 70% v O2peak). Peak ischemic exercise calf blood 
flow and vascular conductance were also increased. The result indicated that exercise 
training in patients after CABG can elicit significant improvements in functional capacity 
that, for the most part, are secondary to peripheral adaptations, with lesser contribution of 
central adaptation.  
3.4 Ventilatory efficiency 
Shortness of breath is a major complaint when ventilation is accelerated during exercise. 
Although exercise training may attenuate exertional dyspnea during exercise, whether 
exercise training improves ventilatory efficiency in patients after CABG was not clear. 
Adachi et al.23 reported the effects of exercise training on ventilatory response and cardiac 
output during exercise in patients following CABG. The minute ventilation–carbon dioxide 
output ( v E– v CO2) slope decreased from 38.9±8.1 to 35.1±6.7 in the exercise group, and 
there was a correlation between improvement of the v E– v CO2 slope and peak cardiac 
output in the exercise group.  The results showed that short-term physical training after 
CABG might improve ventilatory efficiency to exercise.  
3.5 Lipid profile 
Exercise training is not recommended as a sole intervention for lipid modification because 
the inconsistent effect on lipid and lipoprotein levels. Optimal lipid management requires 
dietary and pharmacologic management, in addition to CR exercise training. 
Wosornu et al. 39 compared the effects of 6-month aerobic or strength exercise training after 
CABG. Both groups showed a significant increase in physical capacity, but there were no 
changes in lipoprotein levels.  Brügemann et al.40 randomized 137 men who underwent an 
coronary procedure (111 received CABG) to two types of CR, and blood lipid profile was 
unaffected by exercise training. However, Kodis et al.24 conducted a retrospective review of 
1,042 patients with CABG and found that exercise might induce beneficial changes to lipid 
profile. Following 6 months of exercise training, the supervised exercise group had 
significant lower cholesterol and LDL-cholesterol than the home-based group. Patients in 
the supervised exercise group had significant improvements in triglyceride, LDL-cholesterol 
and HDL-cholesterol, whereas the home-based group showed improvement in HDL-
cholesterol only. In a recent study, Onishi et al.29 also reported CR exercise training might 
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improve LDL-cholesterol and total cholesterol in CABG patients with metabolic syndrome. 
Additionally, metabolic scoring defined by the number of the modified Adult Treatment 
Panel criteria of the US National Cholesterol Education Program was significantly 
improved.  
3.6 Hemodynamic and neurohormonal response 
In order to measure hemodynamic and neurohormonal response to static exercise, Bilinska 
et al30 randomized 120 male patients to either 6 weeks of aerobic training at a 70–80% of the 
HRpeak or to a control group. After 3 months of training, handgrip-induced increases in HR, 
BP, and total peripheral resistance were lower, whereas stroke volume and cardiac output 
were higher (by 13% and 15%, respectively) in trained patients compared with controls. 
Moreover, a higher increase in nitric oxide level (46% vs 14%) and a lower increase in 
noradrenaline (11% vs 20%) were observed in trained patients compared with controls. The 
result showed that short-term dynamic training caused significant improvement of 
hemodynamic and neurohormonal responses to static exercise. 
3.7 Quality of life 
Heather et al.40 recruited 249 patients on a waiting list for elective CABG and randomized 
them into an intervention group and a control group. During the waiting period, the 
training group exercised twice per week, with education and reinforcement. After surgery, 
both groups participated in a CR program. Quality of life was measured by short-form 36 
(SF-36) questionnaire during the waiting period, and patients in the intervention group 
showed a significant increase in the scores of physical role, physical functioning, bodily pain 
and composite physical summary score.  The intervention group displayed better quality of 
life than the control group, but mainly in physical component, and the improvement 
continued up to 6 months after surgery. 
In a recent study, Brügemann et al.41 randomized 137 men to one of two types of CR: 
physical training plus information ('Fit' program) during 6 weeks or comprehensive CR 
which, on top of the Fit-program, included weekly psycho-education sessions and relaxation 
therapy ('Fit-Plus' program) for 8 weeks. The results showed that quality of life improved in 
both treatment groups in the course of time up to 9 months after training, and there was no 
difference between the two types of CR.  
3.8 Graft patency, cardiac events and readmission 
Nakai et al.38 reported the effects of exercise training on recovery of cardiac function and 
graft patency in 115 patients after CABG. The patients were divided into Group I (n = 60) 
with and Group II (n = 55) without a CR program. The rate of graft patency was 98% in 
Group I and 80% in Group II. After training, the exercise stroke index increased significantly 
in Group I, but not in Group II. The result suggested that physical exercise training should 
be started as early as possible after CABG to improve graft patency and recovery of cardiac 
function. 
Perk J et al.42 reported in a study including 49 CABG patients participating in a 
comprehensive CR program and 98 matched patients receiving standard care. During the 
first year after CABG, fewer study group patients were readmitted to hospital (14% vs 32%) 
and on fewer occasions (1.1 vs 2.9). There were no differences in the rates of returning to 
work (59% vs 64%). In a long-term follow-up, the study group patients rated their physical 
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work capacity higher, and more patients had continued with regular physical training (66% 
vs 46%).  Hedbäck et al.43 reported in a study included 49 patients who underwent CABG 
and were offered a CR program consisting of education in risk-factor control and a physical 
training program. After 10 years of follow up, the study group had lower cardiac events 
than in the control group (18.4% versus 34.7%). The number of readmissions to hospital (2.1 
versus 3.5 per patient) and length of admissions (11 versus 26 days per patient) were 
significantly lower in the study group. The result proved that a comprehensive CR program 
after CABG will improve long-term prognosis and reduce the need for hospital care. 
In a recent study, Plüss et al.44 randomized 224 patients with acute myocardial infarction or 
undergoing CABG to expanded CR (a one-year stress management program, increased 
physical training, staying at a 'patient hotel' for five days after the event, and cooking 
sessions), or to standard CR. The number of cardiovascular events was reduced in the 
expanded CR group compared with the standard CR (47.7% versus 60.2%). This was mainly 
because of a reduction of myocardial infarctions in the expanded CR group. Days at hospital 
for cardiovascular reasons were significantly reduced in patients who received expanded 
CR (median 6 days) compared with standard CR (median 10 days). The result showed that 
expanded CR reduces cardiovascular morbidity and days at hospital. 
4. Tai Chi Chuan training 
Tai Chi Chuan (TCC) is a popular Chinese conditioning exercise.  The exercise intensity of 
TCC was low to moderate, depends on its training style, posture and duration. Participants 
can choose to perform a complete set of TC or selected movements according to their needs. 
Previous research substantiates that TC enhances aerobic capacity, muscular strength, 
endothelial function and psychological well-being. In addition, TC benefits to some 
cardiovascular risk factors, such as hypertension and dyslipidemia. Recent studies also 
prove that TC is safe and effective for patients with myocardial infarction, bypass surgery 
and heart failure. Channer et al. 45 reported that the application of TCC for patients with 
acute myocardial infarction was safe and showed benefits to blood pressure. There are 
several reasons to recommend TCC as an exercise program for patients with CABG. First, 
TCC did not need special facility or expensive equipment. Second, TCC is effective for 
enhancing health fitness and improving cardiovascular risk factors. Third, TCC is low cost 
and low technology, and can be easily implemented in the community. We have applied a 
12-month TCC program to patients with CABG as a phase III cardiac rehabilitation 
program.25 After training, the TCC group showed an increase of 10.3% in v O2peak and 11.9% 
in peak work rate. Therefore, TC may be prescribed as an alternative exercise program for 
selected patients with CABG.    
5. Off-pump and minimally invasive CABG 
Off-pump coronary artery bypass grafting (OPCAB) uses fewer resources than conventional 
CABG with cardiopulmonary bypass (CABG-CPB).  It was estimated that 20% of CABG 
operations using OPCAB in western countries, but over 60% of isolated CABG have been 
performed in Japan using the OPCAB technique. OPCAB grafting reduces the risk of 
postoperative morbidity, length of hospital stay than conventional surgery with 
cardiopulmonary bypass. 
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In a recent study, Angelini et al.46 reported the graft patency 6-8 years after CABG was 
similar between OPCAB and CABG-CPB, and the major adverse cardiovascular events or 
death showed no difference between the two groups. The health-related quality of life was 
similar between the OPCAB and CABG-CPB groups.  In addition, with increasing expertise 
and technology, minimally invasive and robotic techniques have been developed to enhance 
post-operative recovery and patient satisfaction.47 However, there is no study compare the 
effect of exercise training on conventional CABG and those new techniques, further study is 
needed to evaluate the difference between conventional and new surgical techniques to the 
outcomes in patients with CABG.  
6. Conclusion 
Short-term exercise training for patients with CABG showed benefits to cardiorespiratory 
function, muscular strength, metabolic profile, cardiac function, ventilatory efficiency, 
hemodynamic function and quality of life. Additionally, exercise training may improve graft 
patency, reduce cardiac events and readmission rate. Thus, CR exercise training is an 
important intervention and should be recommended to most of the patients after CABG. 
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1. Introduction 
The cardiac risk (CR) in noncardiac surgery represents the probability of acute 
cardiovascular conditions appearance, assessed as perioperative complications. 
The most frequent perioperative complications are the acute manifestations of coronary or 
noncoronary ischemia; acute or exacerbated chronic heart failure (CHF); acute rhythm and 
conductive disorders; acute cardiac inflammatory processes; increased arterial blood 
pressure or hypertensive crisis; cardiogenic shock and sudden cardiac death. These 
conditions are either early signs, or represent a manifestation of progress or decompensation 
of present cardiac diseases. Specific indication may be found in their origin, if it is explicitly 
or implicitly associated with the present surgical disease or with a completed surgical 
intervention, giving weight to the special features of the perioperative period [1].  
The major surgical interventions, e.g. in the thoracic cavity and the upper abdominal cavity, 
as well as the neurosurgical and the major orthopedic operations, are related to increased 
CR. Previous myocardial infarction, unstable stenocardia and decompressed chronic cardiac 
insufficiency are powerful predictors for the emergence of acute perioperative 
cardiovascular complications (CVC) and mortality. The patients with such specified 
pathologies need additional evaluation before major surgical intervention.   
The cardiac postoperative morbidity and mortality are closely related to the basic surgical 
disease and the corresponding intervention. Many scientific publications report on the high 
number of complications, accompanying the major surgical abdominal and intrathoracic 
interventions, emergency surgical interventions, surgery of malignant neoplasm, major 
peripheral vascular manipulations [1, 2, 3].      
The CR evaluation will not change the course and the result of the intervention in emergency 
conditions, e.g. rupture of abdominal aortic aneurism, heavy trauma, perforations etc., but 
may have influence upon the care during the early postoperative period. In emergency but 
noncritical states (e.g. biliary obstruction), the evaluation may contribute to risk reduction 
without influence upon the decision about the necessity of the intervention. In some cases, the 
CR evaluation may influence the surgical intervention planning and the choice of less invasive 
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intervention, e.g. the preference for peripheral arterial angioplasty before infrainguinal bypass, 
even though the long-term result of the surgery may be altered. In other cases, the CR 
assessment must support the decision for a given intervention, e.g. for removal of small 
aneurisms from asymptomatic patients with carotidal stenosis, when the compromise is 
between the expected life duration and the risk of the intervention.   
Below are presented some practices for cardiac risk assessment in emergency noncardiac 
surgery, including high risk one. Part of them are discussed on the basis of own studies over 
the applicability of models for CP evaluation in groups of subjects, differentiated upon the 
urgency, the severity of the surgical disease and intervention, with or without 
cardiovascular and other concomitant nonsurgical diseases [4, 5, 6, 7].      
2. Short review of preoperative cardiac risk assessment schemes in major 
noncardiac surgery 
2.1 General preoperative clinical assessment 
The tentative general assessment of the cardiac perioperative risk may be completed on the 
basis of factors with known contribution. 
2.1.1 Risk in patients with ischemic heart disease (IHD) 
The perioperative mortality reaches 9.6% in case of IHD, otherwise it is just about 2.8% [8, 
9]. Besides the hemodynamically induced complication, other manifestations like 
thrombosis, coronary spasm, serious rhythm disorder, spontaneous psychogenic nocturnal 
or preoperative complications, are also possible. The patients with IHD, subjected to major 
noncardiac surgery, can be divided into 3 groups:  
a. Patients with angina pectoris (АP).  
The preoperative assessment of patients with angina, who will be subjected to major noncardiac 
surgery (MNCS), has to clarify the following questions: stable or unstable angina; functional 
class (FC); is the medicamentous treatment adequate; necessity of specific diagnostic tests. 
Except for the surgery of abdominal aortic aneurism, the patients with I-II FC stable 
stenocardia have the resources to bear the stress of MNCS, while this intervention presents 
serious threats to patients with III-IV FC.  
The patients with I-II FC stable AP are with increased risk of cardiac complications after 
MNCS [10] (about 10 times higher relative risk compared to patients without IHD). 
However, this tenfold increase corresponds to a relatively low risk of myocardial infarction 
(MI), approximately of 4%, and of cardiac death, about 1-2% [8, 9]. FC is decisive in 
predicting the risk level of patients with stenocardia. Those of them that succeed to reach 
85% of the maximum cardiac frequency (even with appearance of ST-depression) have no 
complications during surgery [11, 12]. Just the opposite, the presence of ST-depression and the 
bad tolerance of physical stress identify the high-risk patients. 
b. Patients with MI 
The number of perioperative reinfarctions decreases with the improvement of the 
anesthesiologic methods from 30% to 6% after survived MI during the last 3 months, and 
from 15% to 2% after preceding MI during the preoperative 3-6 months.   
The MI manifestation during intra- or early postoperative periods is often preceded by 
prolonged or recidivistic ischemia. There are two important mechanisms in the context of 
the perioperative MI: 
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1. Chronic imbalance between the need and the providing of blood stream that is clinically 
manifested as stable IHD (due to coronary arteries’ stenosis, limiting the blood stream); 
2. Rupture of coronary plaque with clinical manifestation of acute coronary syndrome 
(ACS). 
c. Patients with high risk of asymptomatic IHD.  
Such are the patients with diabetes mellitus (DM) or peripheral vascular disease, when 
either the ECG stress-test cannot be carried out, or the results obtained are not reliable.   
2.1.2 Risk in patients with heart failure (HF) 
The congestive heart failure (CHF) increases the risk of postoperative complications. Here, it 
is important to clarify as far as possible, the HF etiology. For example, HF due to 
hypertension runs a different risk, compared to HF due to IHD [13, 14]. 
Many general anesthetics cause direct myocardial depression. Very often, a large quantity of 
liquids is infused during the perioperative period in MNCS and overburden the patients 
with left ventricular dysfunction or HF. The risk of perioperative cardiogenic pulmonary 
edema among subjects aged over 40 years, who have been subjected to MNCS, vary from 
about 2%, if CHF anamnesis is absent, through about 6% for patients with preceding HF, 
which is not present during physical and X-ray examinations, and reaches up to 16% with 
persisting physical and X-ray data about pulmonary stagnation [8].   
Large abdominal or thoracic surgery, which is followed by CHF that has not been identified 
before the intervention, is usually associated with elderly patients with ECG abnormalities 
or other cardiac symptoms [15]. 
The presence of CHF represents another risk factor for perioperative MI [16, 17, 18, 19]. 
2.1.3 Risk in patients with heart valvular disease 
The patients with heart valvular disease, who have been subjected to MNCS, are subject to 
an increased risk of cardiac complications, mostly because of their susceptibility for 
development of CHF, hypo- and hypervolemia and cardiac arrhythmias in the perioperative 
period [13]. About 20% of the patients with severe heart disease (II or higher FC) either 
evolve new or complicate the present cardiac decompensation during the MNCS [15]. It is 
accepted, that the subjects with aortic stenosis are the higher risk patients among these with 
valvular cardiac disease, as they bear with difficulty hypo- and hypervolemia [20]. 
The patients with combined rheumatic mitral and aortic heart disease represent a 
considerable group. Their risk during noncardiac intervention is high, because of their 
limited resources and capabilities to support changes in pre- and afterloads.   
2.1.4 Risk in patients with cardiac arrhythmias 
The arrhythmias, either atrial or ventricular, are often related to IHD or CHF and specify 
increased risk during MNCS. Although both arrhythmias are pointed out as independent risk 
factors in the perioperative period [20, 21, 22], they probably have significance only as a 
manifestation of serious heart disease, which itself increases the risk of CVC. In similar cases, 
the arrhythmias correlate as a marker of cardiac suffering with ischemic and HF complications 
and do not contribute additional risk during noncardiac surgery. According to Detsky et al and 
Goldman et al, the prognosis in patients with arrhythmias, but without supporting cardiac 
pathology, is usually good and the risk of intervention is very unlikely to be increased, although 
the same authors determine the atrial fibrillation as an independent risk factor [20, 23]. 
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High risk of the supraventricular tachiarrhythmias progress subsists among elderly patients 
subjected to pulmonary surgery, patients with subcrucial valvular stenosis and patients 
with primary anamnesis of similar tachyarrhythmias [24]. 
Patients with anomalies in the conductive system as AV block, fascicular or bundle branch 
block often have cardiac diseases. Many anesthetics suppress the cardiac contractility 
and/or provoke peripheral vasodilatation. The anesthesia may give rise to further 
depression of the automatism and, consequently, of the ventricular frequency in patients 
with heart block. The complication of biphascicular block after MI may progress to a third 
degree AV block, often accompanied by serious hemodynamic disorders [24, 25].    
Patients with bundle branch blocks are not subject to increased risk of third degree AV block 
progress in the perioperative period, although they may acquire it in a long-term context. 
The presence of bundle branch block does not represent an independent predictor of heavy 
postoperative cardiac complications if there is no evidence of other severe disease [15, 20]. 
According to the recommendations of the ACC/AHA the arrhythmias with high risk are as 
followed [2]: 
- high-degree AV block; 
- symptomatic ventricular arrhythmias, combined with presence of cardiovascular 
diseases (CVD); 
- supraventricular arrhythmias at high and out-off-control heart rate (HR). 
2.1.5 Arterial hypertension 
Despite contemporary achievements in arterial hypertension (AH) diagnosis and 
monitoring, a large percent of the subjects with AH remain without diagnosis or have been 
inadequately treated. The patient arterial blood pressure (BP) may increase in a hospital 
environment as a result of a stress. Prys Roberts et al, report higher perioperative BP 
instability among subjects with high preoperative BP [26]. According to Goldman and 
Caldera [8], the mean intraoperative BP, the necessity of infusion and adrenergic agents for 
supporting the pressure during the intervention, as well as the progress of considerable 
postoperative hypertension, practically are not influenced by the fact whether the 
hypertension was not treated, inadequately treated or well monitored.    
Several communications [15, 20, 23, 27] point out that patients with mild through moderate 
hypertension can be subjected to anesthesia and intervention without high risk of CVC [8]. 
Other studies cite as evidence that patients with AH are subjected to higher risks of cardiac 
complications during, or immediately after, MNCS, compared to normotensive subjects. The 
reasons of the increased risk are due to IHD, left ventricular dysfunction, renal failure, or 
other disorders commonly encountered among patients with AH [26]. The subjects with AH 
have increased IHD and CHF risk and tendency towards most frequent manifestations of 
silent myocardial ischemia during surgery [28].    
2.1.6 Cardiomyopathies 
The hypertrophic cardiomyopathy raises some specific problems. The reduction of the blood 
volume, the decreased vascular system resistance and the increased venous volume can 
reduce the left ventricular volume and increase the tendency towards obstruction of the left 
ventricular output tract. In addition, the decreased pressure of the ventricular filling may 
lead to considerable reduction of stroke volume, due to reduced compliance of the 
hypertrophic ventricle. 
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2.1.7 Peripheral vascular diseases 
They add certain perioperative risks, since they are often associated with accelerated 
atherosclerosis and IHD [2]. 
2.1.8 Other risk factors 
2.1.8.1 Age 
Advanced age is an independent risk factor for perioperative complications [2, 17, 18, 25], 
not only because of the increased probability of coronary disease, but also because of the 
senescent effect on the myocardium – decrease of the myocytes number. The mortality 
caused by acute MI considerably increases with the age. The perioperative MI have higher 
mortality among the elderly patients [29].  
2.1.8.2 Sex 
The women have lower cardiac risk except for present early climax or DM [2]. They have 
lower frequency of IHD, and coronary disease is observed 10 years later, compared to men. 
In the case of early climax and DM, the risk is equal to that of men at the same age. 
Mortality, due to acute MI, is greater among women than men, and this difference is even 
more evident with advancement of age and presence of DM.   
2.1.8.3 Diabetes mellitus 
DM increases the probability of IHD appearance, but the myocardial ischemia is often silent. 
DM frequently is considered as a risk factor for cardiac complications in the MNCS 
perioperative period [17, 30, 31].  
2.1.8.4 The chronic pulmopathies  
The chronic pulmopathies present a high perioperative risk [32], which is dependent on the 
severity of the pulmonary disease and the intervention duration. 
2.1.9 Type of surgical intervention 
The surgical risk represents a complex assessment, which includes the severity of the basic 
surgical disease, the treatment method and the patient condition. In addition to the present 
data about cardiovascular pathology that influences the prognosis, other basic surgical 
factors can provoke exacerbation of present chronic cardiac diseases or appearance of 
perioperative CVC. Their number is twice higher with infectious inflammation (sepsis) or 
neoplastic disease [33].  
The basic surgical disease is a leading factor for localization, size and duration of the 
intervention, as well as for the conditions necessary for its performance [34]. The surgery of the 
thoracic and abdominal aorta contributes the highest risk among the noncardiac interventions, 
because of the accompanying problems with the water balance, bleeding and oxygenation. The 
abdominal interventions take the second place in frequency of concomitant CVC, following 
the thoracic ones [35]. The interventions of carotidal and peripheral vessels are also associated 
with increased risk of cardiac complications. It is known, that up to 50% of patients 
undergoing interventions of the peripheral arteries suffer MI in the next 2-3 years [36].      
2.1.9.1 Surgical factors  
Surgical factors, which influence the cardiac risk, are associated with the emergency, the 
complication, the type and the duration of the intervention, as well as with the change of 
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Acute Coronary Syndromes 
 
134 
the body temperature, the loss of blood and the body liquids exchange. The intervention 
emergency represents an issue of special importance. The survival rate increases twofold 
with preoperative intensive cardiac care that is related to eventual delayed emergency 
intervention, whenever that is possible [37]. Each surgery provokes a stress reaction, due 
to tissue damages and is mediated by neuroendocrine factors that may lead to 
tachycardia and hypertension. The perioperative stress reaction includes effusion of 
catecholamine, provoked by the hemodynamic stress, vasospasm, reduced fibrinolitic 
activity, activated trombocytes and extracoagulation. Coronary plaque rupture leads to 
thromboses and subsequent vessel occlusion, which are important factors for the 
occurrence perioperative ACS. The MI among patients with significant IHD may be a 
result of a continuous imbalance between the available and the necessary myocardial 
blood steam (in cases of tachycardia and increased myocardial contractility). Studies on 
performed autopsies, demonstrate that half of the fatal MI have directly destroyed 
plaque fissure, rupture or plaque bleeding. Although the specific patient factors are more 
important for cardiac risk prediction than the surgical ones, the type of the surgical 
intervention cannot be ignored.     
2.1.9.2 Type of the anesthesia 
Recent studies indicate, that the operative period is more reliable than it was in the past, 
mostly because of the careful monitoring of hemodynamics and respiration during the 
anesthesia [20]. No data are available for determining some significant differences in the 
severity of the cardiac complications due to the different anesthesia techniques. However, 
the assessment of the type and the conditions of the anesthesia may have important 
implications for the cardiac risk prognosis. 
2.2 Indices and scales for cardiac risk evaluation and their applicability on cardiac 
risk assessment in patients with emergency high risky noncardiac surgery 
The preoperative assessment of cardiac risk during noncardiac surgery (specifically for 
emergency surgery) is based on quantitative indices and rated scales. They were proposed 
and introduced initially for assessment of the anesthesiology risk and consequently, for the 
cardiac one [20, 23, 38, 39].   
The synthesis of methods for preoperative cardiac risk assessment began intensively at the 
end of the seventies, as a result of the communication by Goldman et al [17, 19, 20, 23, 40, 41, 
42, 43, 44, 45, 46]. The methods and indices for the cardiac risk assessment can be 
characterized as: 
- common for CR [20, 25, 27, 42]; 
- specifically related to the risk of ischemic complications – underestimated by Goldman 
et al, although it is the most dynamic and dangerous risk factor (RF) [17,19, 40, 41, 43, 
44, 45, 46]. 
From another point of view, the methods and indices for cardiac risk assessment are:  
- quantitative [20, 23, 27]; 
- qualitative [17, 19, 40, 41, 42, 43, 44, 45, 46, 47]. 
2.2.1 Quantitative (point) indices 
The CR index in noncardiac surgeries that was introduced by Goldman et al [20] represents 
a point assessment and is still largely applied in practice. This index is derived over data of 
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patients with MNCS, such as aortic, pleural, intraoperational and intrathoracic 
interventions. It includes 9 preoperative assessable indices with own quantitative 
contribution to the amount, which determines the perioperative CVC risk. The risk is 
distributed in 4 classes: I-st class (0 to 5 points) with live-threatening complications and 
cardiac death of 0.9%;  II-nd class (6 to 12 points) with 7% rate of such complications; III-rd 
class (13 to 25 points) with 14% rate; IV-th class (26 and over points) with expected rate of 
live-threatening complications and cardiac death of 77%. The indicator “Poor general 
condition” includes the criteria: PO2 < 60; PCO2 > 50; K < 3; HCO3 < 20; BUN > 50; Creat > 
3; elevated SGOT; chronic liver disease; bedridden. 
Detsky et al [23] modified Goldman’s index on the basis of clinical evaluation and 
monitoring of non-selected patients over 40 years old with MNCS. Within that index, the 
timing of the previous MI is divided into less or more than 6 mounts ago, while the 
influence of the stenocardia is specified according the adopted division as stable (with 
differentiated classes) and unstable; the anamnesis of the pulmonary edema is also included. 
It is accepted, that Goldman’s index is equally informative as the extended index of Detsky 
et al [23], but the first does not include III and IV class stenocardia, while Detsky et al 
introduced such corrections. The atrial fibrillation is included as RF too. Subsequent studies 
establish its significance, whenever this cardiac disorder is currently manifested [53]. AH 
was also evaluated at a later stage, but from the heart defects, only aortic stenosis is 
included.  
The pivotal points of Goldman’s index are the presence of MI and HF. The index of Larsen et 
al [27] includes metabolic deviations in parallel with CVD. Here the volume, the nature and, 
especially, the surgical conditions (emergency or planned) are assessed in greater detail. On 
the basis of that, Larsen et al managed to integrate the CR index with the type of surgical 
intervention. The index of Larsen et al can reach a maximum value of 54 points – divided by 
the level and actuality of HF and IHD, as well as other conditions.   
In 1999, Lee et al [48] reevaluated the significance of some clinic risk factors, associated with 
patients undergoing noncardiac surgery. The revised index sets 6 predictors of major 
cardiac complications: high risk surgery, IHD, HF, cerebrovascular disease, type 1 DM and 
renal insufficiency. The presence of 0, 1, 2 or 3 of the predictors sets the risk level of major 
cardiac complications at 0.4%, 0.9%, 7% and 11%, respectively. The index of Lee et al has 
better prognostic value than those of Goldman et al and Detsky et al, due to the smaller 
number of variable risk factors. For the time being, the clinicians and the researchers accept 
Lee’s index as the most applicable for prediction of the perioperative cardiac risk in 
noncardiac surgery. However, the patients examined by Lee et al do not constitute a 
representative population of patients undergoing noncardiac surgeries, since the thoracic, 
the vessel and the orthopedic cases are over-represented.      
2.2.2 Non-point scales for cardiac risk assessment 
The scale of Kleinman [42] includes remoteness of MI, angina pectoris, valvular disease, 
rhythm disorders, arterial hypertension, abnormal ECG, peripheral vascular diseases.  
The scale of Eagle et al [47] includes age over 70 years, DM, angina pectoris, presence of 
pathological Q-wave in ECG and ventricular extrasystoles.  The presence of one RF 
determines low risk, the presence of 2 to 3 – moderate risk, while more than 3 risk factors 
leads to high risk assessment. 
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Later on, diagrams and tables for risk assessment of ischemic complications [19, 41, 43], life-
threatening ischemic complications [17, 36, 44, 45], tachyarrhythmias [24], and 
ventricular arrhythmias [49] were proposed. The scales and the statements about the 
probability of ischemic complications comprise of several symptoms, derived from 
clinical, laboratory, imaging, and electrophysiological examinations. Hopf and Tarnow 
[41] propose intraoperative ECG monitoring, transesophageal echocardiography, which 
is a semi-invasive and expensive method, cardio-kymography, radio-marked 
erythrocytes and small gamma camera, as well as metabolic parameters. Lette et al [43] 
reach the conclusion that the clinical parameters can not predict incoming ischemic 
incidents. They accentuate on dipyridamole-thallium scintigraphy. Leppo [19] includes 
ECG examinations, treadmill, stress-echocardiography with dobutamine or exercise, 
thallium scintigraphy with test burden in the preoperative assessment. Symptomatic 
angina, CHF, survived MI, ventricular extrasystoles, and age over 70 years, are also 
taken into consideration. 
Mangano et al [50] evaluate the significance of the following clinic symptoms, related to the 
appearance of post-operative ischemic complications: 1) presence of left ventricular 
hypertrophy in ECG; 2) remoteness of the arterial hypertension; 3) diabetes mellitus; 4) 
manifested IHD; 5) HF needing the use of digoxine. According to the presence of the five 
preoperative symptoms for postoperative ischemia, the probability of its perioperative 
appearance is divided into 5 levels: without any symptom presence – 22%; presence of one 
symptom – 31%; 46% with two symptoms; 70% with three; 77% with four symptoms.   
Other studies of the same authors emphasize the significance of the following conditions, 
contributing to unfavorable outcomes from ischemic complications [44, 45]: 
1. intraoperative hypotension and tachycardia (the assessment of hypertension is 
contradictory); 
2. appearance of acute ischemic events in the postoperative period (acute MI), unstable 
stenocarida or ECG ischemia. Note that CHF and ventricular tachycardia are not 
associated with unfavorable outcomes; 
3. instrumentally determined intra- and postoperative changes: appearance of ECG 
ischemia (doubles the MI risk); increases of the endmost left camera diastolic pressure 
that are accepted as evidence of ischemia - note that the mean pulmo-capillary pressure 
and the diastolic pulmonary arterial pressure do not correlate with the incidents; 
segmental disorder of the left camera wall assessed by transesophageal 
echocardiography  - that is accepted as the most sensitive predictor [51], although the 
same authors specify later on, that transesophageal echocardiography weakly correlates 
with postoperative complications; 
4. the presence of AH, heavy limiting lung disease, creatinine clearance lower than 0.8 
ml/s – factors independently associated with high risk of cardiac death [45]. The death 
probability is 80% when two or more factors are present.    
If the total rate of complications with all monitored patients is 12%, then 24% of those with 
old MI or cardiomegaly have postoperative complications – cardiac death, acute MI, 
ischemia. The rate of patients without the mentioned consequences is only 7% [52]. 
A standard for CR assessment during noncardiac surgeries [22, 53, 54] was adopted, on the 
basis of the debates, concerning the applicability of the schemes and indices for CR 
assessment and the ACC/AHA proposals [22, 53, 54]. According to it, CR is further divided 
into three groups – high, moderate, and low, depending on the severity of the perioperative 
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CVC and the probability of a fatal outcome; the significance of the clinical predictors is 
determined, as well as the volume and type of the surgery.  
1. Risk, related to CVD: 
a. high: 
the unstable coronary syndromes – new MI and unstable stenocardia; 
the decompensated HF; 
the significant arrhythmias – high-degree  AV block, symptomatic ventricular 
arrhythmias accompanying cardiac disease, as well as supraventricular arrhythmias 
with uncontrolled HR; 
critical valvular cardiac lesion.  
b. moderate: 
stable stenocardia – I-II FC; 
old MI or present pathological Q wave in ECG ; 
compensated HF;  
diabetes mellitus. 
c. lower: 
advanced in years; 
ECG abnormalities; 
non-sinus rhythm; 
bad functional capacity; 
past apoplexy; 
uncontrolled arterial hypertension. 
2. Risk, related to surgical intervention: 
a. high:  
emergency major interventions, specifically with elderly patients; 
aortic and other major vessel interventions;  
peripherally vessel surgeries;  
extended surgeries, accompanied by loss of many liquids and blood .  
b. moderate: 
carotid endarteriectomy; 
cranial and vertebral surgeries; 





procedures on the body surface; 
cataract and  breast surgeries. 
The ACC/AHA classification merits consist of classification of the risk categories, as well as 
the consideration of the cardiac state and type of surgery. Are specified the rhythm 
disorders, the low risk predictors and the pathological ECG findings. 
There are several investigations and analyses on the applicability of the CR indices 
evaluation [1, 11], including such on large number of patients [23]. Basic disadvantages of 
indices are the high percent of false-positive conclusions [38] and the impossibility of 
obtaining accurate diagnosis and assessment of the most serious and dynamic RF – the 
ischemia, with pain or silent [9, 31, 45, 56]. The CR indices do not determine the appearance 
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assessment and the ACC/AHA proposals [22, 53, 54]. According to it, CR is further divided 
into three groups – high, moderate, and low, depending on the severity of the perioperative 
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CVC and the probability of a fatal outcome; the significance of the clinical predictors is 
determined, as well as the volume and type of the surgery.  
1. Risk, related to CVD: 
a. high: 
the unstable coronary syndromes – new MI and unstable stenocardia; 
the decompensated HF; 
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b. moderate: 
stable stenocardia – I-II FC; 
old MI or present pathological Q wave in ECG ; 
compensated HF;  
diabetes mellitus. 
c. lower: 
advanced in years; 
ECG abnormalities; 
non-sinus rhythm; 
bad functional capacity; 
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uncontrolled arterial hypertension. 
2. Risk, related to surgical intervention: 
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procedures on the body surface; 
cataract and  breast surgeries. 
The ACC/AHA classification merits consist of classification of the risk categories, as well as 
the consideration of the cardiac state and type of surgery. Are specified the rhythm 
disorders, the low risk predictors and the pathological ECG findings. 
There are several investigations and analyses on the applicability of the CR indices 
evaluation [1, 11], including such on large number of patients [23]. Basic disadvantages of 
indices are the high percent of false-positive conclusions [38] and the impossibility of 
obtaining accurate diagnosis and assessment of the most serious and dynamic RF – the 
ischemia, with pain or silent [9, 31, 45, 56]. The CR indices do not determine the appearance 
  
Acute Coronary Syndromes 
 
138 
probability of acute ischemic incidents [9, 31, 57] and that is what significantly affects the 
reliability of the cardiac death prognosis. 
The point indices of Goldman et al and Larsen et al include the emergency and the operation 
volume in the criteria set for the index calculation, but with the lowest possible weights: 4 
and 3 with Goldman et al (in the assessment range from 3 through 11) and 3 and 3 with 
Larsen et al (in the range from 3 through 12). The detailed analysis of the two schemes gives 
a satisfactory answer to both the low discrimination coefficients (used for calculation of the 
emergency and severity of the surgery with both models), and their unavoidable presence 
among the criteria. Table 1.1 details systematically the required data. 
 
Data for investigation of : Goldman et al Larsen et al 
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* Major surgeries: aortic, pleural, intraperitoneal, intrathoracic. 
Table 1.1. Exceeding indices  for emergency and major noncardiac surgery 
The proportion between the cardiac complication rates, accompanying the emergency and 
major surgeries on the one hand, and the total cardiac complication rates for all patients on 
the other, considerably exceeds the corresponding proportion between the emergency and 
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major intervention rates to the total number of interventions. We devoted special attention 
to that fact, in our targeted study [5, 6] introducing the so called “Exceeding Indices.” The 
Exceeding Index, applied to the emergency surgeries (EIES) expresses the quotient (in 
percent) between the relative rate of the heavy cardiac complications (including cardiac 
death) accompanying the emergency surgeries (HCCES), towards the total number of heavy 
cardiac complications (HCC), and the relative rate of the emergency surgeries (ES) towards 
the total number of surgeries (TNS): 
EIES (%) = (HCCES/HCC)/(ES/TNS). 
Respectively, the Exceeding Index of the major surgeries (EIMS) expresses the quotient (in 
percent) between the relative rate of the heavy cardiac complications (including cardiac 
death) accompanying the major surgeries (HCCMS) towards the total number of heavy 
cardiac complications (HCC), and the relative rate of the major surgeries (MS) towards the 
total number of surgeries (TNS): 
EIMS (%) = (HCCMS/HCC)/(MS/TNS). 
The emergency surgeries, representing about 1/5 of a relatively small group used with both 
studies [5, 6], demonstrated a specific rate of cardiac complications that is 2.5-3 times higher 
than the one, observed for the entire group. The same parameter for MNCS indicates an 
increase of 1.5-2 times.  
It is worth noting that the “Exceeding Indices” makes evident the practically total 
coincidence between the results obtained by Goldman et al and Larsen et al about the 
“weights” of the emergency and the intervention volume, despite some differences within 
the constellations of the other criteria used by both point systems. The reason for the 
mentioned emergency and major surgery “classification”, completed by both systems 
becomes clear – on the one hand, they do not predominate over the total number of 
interventions, i.e. they do not determine the nature of the used samples; on the other hand, 
they bring considerable CVC risk in the perioperative period that can not be ignored by the 
used statistical analysis.  
The analysis of the results obtained, when applying both indices of CR assessment towards 
the three specific patient groups, generally indicates a significant discrepancy between the 
formally calculated assessments and the concretely recorded cardiac complications in the 
perioperative period. There are certain possible hypotheses, offering reasons for the limited 
applicability of the index models for CR evaluation under the emergency MNCS conditions: 
1. The criteria with considerable contribution to the total risk assessment (point 
assessment above the mean for a given criterion of the corresponding model) have a 
relatively low rate and/or are weakly informative in emergency surgeries, while the 
criteria with lower contribution (point assessment below the mean for a given criterion) 
have a relatively high rate or are highly informative in emergency surgeries. 
2. More important contribution to the cardiac risk evaluation in cases of emergency 
MNCS have other criteria, which are not included in both models. 
In our opinion, both hypotheses are realistically supported by the analysis performed. We 
reiterate, that the emergency and the surgery severity (markedly demonstrated with the first 
group of patients) dominate as cardiac risk predictors. However, these criteria are not direct 
detectors of the heart status; they specify the surgical heart burdening, which is the reason for their 
predominance in patients with cardiac diseases. The constellation parameters of both models are 
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relatively low rate and/or are weakly informative in emergency surgeries, while the 
criteria with lower contribution (point assessment below the mean for a given criterion) 
have a relatively high rate or are highly informative in emergency surgeries. 
2. More important contribution to the cardiac risk evaluation in cases of emergency 
MNCS have other criteria, which are not included in both models. 
In our opinion, both hypotheses are realistically supported by the analysis performed. We 
reiterate, that the emergency and the surgery severity (markedly demonstrated with the first 
group of patients) dominate as cardiac risk predictors. However, these criteria are not direct 
detectors of the heart status; they specify the surgical heart burdening, which is the reason for their 
predominance in patients with cardiac diseases. The constellation parameters of both models are 
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deficient in direct criteria for cardiac status evaluation; this fact is relevant to a greater extent 
for Goldman’s model.  
The relative advantages of Larsen’s model may be well explained by the adequately 
introduced cardiac status criteria. The IHD assessment criterion includes: 1) MI presence 
during the 3 last months (Goldberger et al specify 6 months); 2) older infarction or angina 
pectoris (missing in Goldberger’s model). The data analysis shows that the second index, 
even appreciated by 3 points only, is significantly more frequent, about 15% of the cases 
with critical patient complications. At the same time, MI presence during the last 3 or 6 
months (indices with high value, 10 and 11 in both models, respectively) is recorded with 
one patient, who did not demonstrate perioperative complications. Our interpretation is that 
the recent (and generally severe) cardiovascular incidents have no explicit contribution to 
the risk evaluation, since they are subject to therapeutic monitoring. This is not the case with 
patients with chronic and mild incidents and generally more distant in time CVD and their 
complications. In emergency cases, the possibilities for correction are missing, that are 
inherent to planed surgery, even when the complications are under- or decompensated.  
Considerable contribution to the cardiac risk assessment in the model of Larsen et al, have 
indices characterizing in aggregate the “heart failure” criterion. Within the investigated by 
us patient group, with present or preceding pulmonary stagnation, heart failure is a 
considerably more frequent postoperative CVC. The conclusion is highly valid among 
patients with stagnations, confirmed by X-ray examination. In such cases, the corresponding 
cardiac risk assessment increases by 12 points (at persistent pulmonary stagnation) or by 8 
points (without stagnation but with preceding pulmonary edema).   
Important for the correct cardiac risk evaluation are the cases, offering indices for combined 
criteria, that are assessed by low point amounts from 2 to 4, such as preceding HF without 
stagnation or edema; preceding IHD with or without old MI; diabetes; increased serum 
creatinine. The combination of three of the mentioned indications, accompanying the 
emergency abdominal surgeries (very common case in practice), leads to a risk increase in 
the range of 12 through 50%.   
Special comment is needed on diabetes, included as a indicator in Larsen’s model. In addition 
to the specific complication, diabetes is associated with the IHD. Introduction of diabetes in 
cardiac risk evaluation is appropriate, bearing in mind its frequency. It was encountered in 
22.4% of the patients, examined by us. The percent of the heavy CVC in patients with diabetes 
is 14.5. In comparison, it is 8 with patients with mild CVC complications.    
The discussion on the applicability of the index models does not cover the problems related 
to the adequate evaluation of the used criteria constellations for CR assessment in 
emergency noncardiac surgery. Evidently, there are other criteria, which reliably predict 
(directly or indirectly) the probability of cardiovascular incidents during the perioperative 
period. 
3. Real and relative myocardial ischemia as a risk factor for appearance of 
acute cardiac complications in emergency noncardiac surgery – Index for 
cardiac risk assessment, through ST-depression in the preoperative ECG 
Most well known studies indicate the manifested myocardial ischemia as a proven predictor 
of perioperative cardiac incidents. Different investigations report preoperative ischemia 
found in 28% through 32% [50, 58] of the examined cases; other refer to a value of up to 60% 
[59]. The preoperative ischemia, established by Holter monitors, is a predictor of the 
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perioperative one [60]. When the preoperative ischemia is determined by two-days of ECG 
monitoring, the perioperative complications are specified as 18%, 21% of them being cardiac 
death, AMI, and unstable stenocardia; 35% are HF; 44% - ventricular tachycardia [9]. The 
influence of the real and relative myocardial ischemia on perioperative CVC appearance is 
evident. Therefore, it is useful to associate the CR evaluation with the ECG determined ST-
depression. The introduction of an index for CR assessment provides an understandable 
and objective method for CVC risk determination in cases of preoperative ECG manifested 
myocardial ischemia (MMI) during emergency noncardiac surgeries. This paragraph 
presents a synthesis of the cardiac risk assessment index (CRI) for CVC prediction in the 
postoperative period, based on ST-depression in preoperative ECG, as an expression of 
real/relative myocardial ischemia. 
Data obtained by monitoring the disease process within a group of 466 patients is used for 
CRI synthesis. The patients have been emergency treated against acute abdominal surgical 
diseases or abdominal traumas. The patient distribution within the investigated surgical 
nosological groups (ING) is presented in increasing order of surgical disease (SD) severity in 
Table 2.1.  
The CRI synthesis is related to assessment and comparison of the CVC rate of patients with 
and without MMI in the ING. CVC appeared in 169 (36.3%) of ING patients: 51 (64.5%) of 
them with MMI and the remaining 118 (30.9%) – without MMI. The statistically significant 
difference (р<0.001) shows that MMI is an important RF. This general evaluation of the MMI 
influence on the patients in the postoperative period has to be specified for ING in 
increasing order of their severity. Table 2.2 presents the CVC rate (in percent) found in ING 
patients with and without MMI.  
The frequency of CVC in patients without MMI marks the anticipated increasing trend in 
accordance with the increased SD severity – from the low 5.5% among patients with acute 
appendicitis, through the significant 33, 34, and 35% for patients with hernia, abdominal and 
biliary-pancreatic diseases, to the high 54% related to acute states, provoked by pathologies 
of the lower part of the gastrointestinal tract.  
The CVC rates in patients with MMI are obviously higher, but as a trend, they do not repeat the 
monotonic CVC rate increase with SD deterioration of patients without MMI. A characteristic 
peak may be observed in group B (77%); high rate in group E (71%); limited increase in С (62%) 
and D (65%) groups. Group A remains with the most rare CVC cases (40%). 
The statistically significant difference between the CVC rates in ING, among patients with 
and without MMI, underlines the specificity of the two trends. Significant, even at different 
levels, are the differences in groups A, B, C and D. The high level (р<0.005) in group B 
corresponds to the highest recorded increase of the CVC rate, when comparing the results of 
patients with and without MMI (from 33% to 77%). The differences in groups A and D 
(р<0.005) are also derived with high significance, due to the considerable CVC percentage 
among the MMI patients. At the same time, the difference in group E between the CVC rate 
among patients with and without MMI is not significant. 
The analysis of the trends in the CVC rates demonstrates the necessity of a detailed 
discussion on the MMI influence as an ING risk factor. 
The CVC are separated as lethal and nonlethal, depending on the recorded disease outcome. 
Nonlethal CVC appeared in 136 (29.2%) patients of the investigated group: 38 (48.1%) of 
them with and 98 (25.3%) without MMI. Lethal CVC were observed in 33 (7.1%) patients, 13 
(16.5%) with and 20 (5.2%) without MMI. 
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Surgical disease Code Number 
Acute appendicitis A 102 
acute phlegmonous appendicitis   
acute gangrenous  and perforated appendicitis   
Complicated hernia B 92 
Incarceration inguinal and ventral hernia without 
complications   
Incarceration inguinal and ventral hernia with intestinal 
necrosis or  intestinal phlegmon   
Gastro-duodenal C 84 
Gastro-duodenal ulcer with perforation   
Gastro-duodenal ulcer with hemorrhage   
Gastro-duodenal ulcer with stenosis   
Gastric neoplasia with perforation or hemorrhage   
Hepatopancreatobiliary D 108 
Acute or chronic exacerbated cholecystitis   
Complicated cysts, tumors and abscess of liver   
Mechanical icterus   
Acute pancreatitis-with edema, necrotic pancreatitis or 
absceding  necrotizing pancreatitis   
Intestinal E 80 
Benignant ileus   
Malignant ileus   
Spontaneous intestinal perforation (including intestinal 
diverticulum, ulcerative or necrotic colitis)   
Colo-rectal neoplasia with perforation or hemorrhage   
Mesenteric thrombosis   
Inflammatory and neoplastic tumors of abdominal wall   
Table 2.1. The patient distribution of the surgical nosological groups in increasing order of 
severity. 
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A 5,5 40 0 0 5,5 40 0 0 0 0 37 58 
B 33 77 4 10 32 69 1 8 3 12 69 75 
C 34 62 8 25 31 46 3 15 10 33 61 68 
D 35 73 21 24 28 50 7 23 25 46 55 63 
E 54 71 32 50 37 35 17 35 50 100 62 72 
Table 2.2. CVC and age profiles in surgical groups 
Lethal CVC were not recorded among patients in group A, either with or without MMI. 
These complications among patients without MMI increase gradually, even weakly in 
groups B (1%), C (3%) and D (7%), but considerably in group E (17%). The trend of the 
lethal CVC rates among MMI patients is also increased, but highly expressed in the range 
of severity groups:  8%, 15%, 23% and 35% in B, C, D and E, respectively. Except for group 
A, there are significantly higher CVC rates among MMI patients, compared to these 
without MMI (р<0.05). The nonlethal CVC rate in patients without MMI increases from 
5.5% in group A to approximately equal levels in groups B (32%), C (31%) and D (28%), 
but more expressively in group E (37%). This rate reaches the peak among MMI patients 
in group B (69%), compared to the almost equal and lower rates in A (40%), С (46%) and 
D (50%). The low rate (35%) of nonlethal CVC patients with MMI in group E is 
impressive, and practically equal to the rate of patients without MMI. This is true also for 
the many times higher CVC rate in group A among MMI patients, comparing to patients 
without MMI (p<0.001). These data determine the high significance of the rate differences 
in group A and the lack of such difference in group E. Nonlethal CVC were observed in 
groups B and D as statistically significant  more often with MMI patients than among 
those without MMI, although the calculated significant level is lower (p<0.05). The 
difference in group C is not significant.    
The consequence of the differentiated analysis on the CVC rates with and without lethal 
outcomes is that the above mentioned specificity of the rate trends of all CVC in patients 
with MMI is totally determined by the rate trend of the low (nonlethal) complications. The 
lethal complications rate in the MMI group follows the increasing trend from group A with 
the low surgical severity to group E with the considerable severity of SD, but this trend is to 
some extent higher in patients without MMI. Among the nonlethal CVC, the most 
significant differences are in the groups A and B with low severity SD, while group A shows 
the highest relative increase in complications (7.3 times). The increased value of 2.2 times in 
group B is obtained with highest absolute percent of 69% of nonlethal complications among 
MMI patients. 
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Surgical disease Code Number 
Acute appendicitis A 102 
acute phlegmonous appendicitis   
acute gangrenous  and perforated appendicitis   
Complicated hernia B 92 
Incarceration inguinal and ventral hernia without 
complications   
Incarceration inguinal and ventral hernia with intestinal 
necrosis or  intestinal phlegmon   
Gastro-duodenal C 84 
Gastro-duodenal ulcer with perforation   
Gastro-duodenal ulcer with hemorrhage   
Gastro-duodenal ulcer with stenosis   
Gastric neoplasia with perforation or hemorrhage   
Hepatopancreatobiliary D 108 
Acute or chronic exacerbated cholecystitis   
Complicated cysts, tumors and abscess of liver   
Mechanical icterus   
Acute pancreatitis-with edema, necrotic pancreatitis or 
absceding  necrotizing pancreatitis   
Intestinal E 80 
Benignant ileus   
Malignant ileus   
Spontaneous intestinal perforation (including intestinal 
diverticulum, ulcerative or necrotic colitis)   
Colo-rectal neoplasia with perforation or hemorrhage   
Mesenteric thrombosis   
Inflammatory and neoplastic tumors of abdominal wall   
Table 2.1. The patient distribution of the surgical nosological groups in increasing order of 
severity. 
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A 5,5 40 0 0 5,5 40 0 0 0 0 37 58 
B 33 77 4 10 32 69 1 8 3 12 69 75 
C 34 62 8 25 31 46 3 15 10 33 61 68 
D 35 73 21 24 28 50 7 23 25 46 55 63 
E 54 71 32 50 37 35 17 35 50 100 62 72 
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Lethal CVC were not recorded among patients in group A, either with or without MMI. 
These complications among patients without MMI increase gradually, even weakly in 
groups B (1%), C (3%) and D (7%), but considerably in group E (17%). The trend of the 
lethal CVC rates among MMI patients is also increased, but highly expressed in the range 
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significant differences are in the groups A and B with low severity SD, while group A shows 
the highest relative increase in complications (7.3 times). The increased value of 2.2 times in 
group B is obtained with highest absolute percent of 69% of nonlethal complications among 
MMI patients. 
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The differentiated MMI evaluation as a risk factor, reveals its different contribution to the 
critical complications structure (lethal and nonlethal) of ING patients with and without 
MMI. Both ratios equal zero due to lack of lethal CVC in group A. In this group, with low 
severity SD, MMI is a risk factor only in cases of mild complications.  
In group B, despite the lesser level of significant difference (р<0.1), MMI stands out as a 
factor emphasizing the CVC and their prognoses. In groups with increased severity SD (C 
and D) this difference is p<0.05,which is convincing proof of the MMI importance for the 
CVC structuring. The significance of the MMI contribution has its logical maximum 
(р<0.001) with the CVC appearances and outcomes in group E, the group with considerable 
surgical severity.    
The results obtained, outlining the role of MMI as a risk factor of increased severity of CVC 
rate in SD with increased severity, need specification of the factor, which underlines the 
specifics of the nonlethal CVC rate trend among MMI patients, reflected also in the structure 
of the total number of CVC.  
The role of age as risk factor in CVC appearance and their complicated duration is known. 
We will limit our scope to clarification of its specific contribution to the CVC structure in the 
ING, thus evaluating the CVC risk among patients with and without MMI. The highest 
mean age of such patients is recoded with the lowest level of significance in group B - 69 
and 75 years, respectively, with the lowest level of significance of  p<0,05. This expressed 
high and near mean age in both types of patients in group B, may be well interpreted by the 
SD nature – the complicated abdominal hernias. The age discrimination among patients 
with and without MMI (37 and 58 years) is most expressed in group A, where the 
significance level of difference is high: p<0.005. Practically the patients of this group are 
clustered in two sets – young without MMI and elderly with MMI. Such clusters have 
considerably nearer values in groups C, D and E (61 and 68 years, 55 and 63 years, 62 and 72 
years, respectively) that determines the lower significance levels of difference. The mean age 
of MMI patients in the very serious SD (group E) is relatively high (72 years) and come close 
to that in group B.        
The low surgical severity group A of MMI patients often contains nonlethal CVC; it is 
characterized by a relatively high mean age. Such age, combined with MMI, determines the 
frequency peak of the nonlethal CVC in group B, which also consists of relatively low 
surgical severity SD. The lethal CVC are more frequent in group E, because of the 
considerable surgical severity SD and the high mean age of the MMI group; the nonlethal 
CVC rates among patients with and without MMI are equaled. In comparison to MMI, the 
age has prevalent importance towards the appearance of nonlethal CVC, in the cases 
discussed above. 
The performed analysis and the results obtained allow quantitative assessment of the 
increasing risk of CVC in patients with MMI in ING, taking into consideration the age 
profile, expressed by indices synthesis: general – for prognosis of all CVC, and specific – for 
the lethal CVC prognosis only. Based on the related to the SD groups content of Table 2.2:   
1. relation between rates of all CVC in patients with and without MMI  
(FAC+MMI/FAC-MMI)SD; 
2. mean ages of patients with and without MMI 
 (MA+MMI/MA-MMI)SD, 
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we can constitute a relation between the rates of all CVC in patients with and without MMI, 
adjusted to the corresponding mean ages: 
TCRISD = (FAC+MMI/FAC-MMI)SD/(MA+MMI/MA-MMI)SD 
The last equation is the total, age-corrected CRI, which gives assessment of the MMI  “net 
contribution” to the increased risk of CVC appearance individually in each SD group, and is 
relevant for a “conditional” patient whose age is equal to the mean age within the group. 
The MMI assessment of a given patient is corrected by the ratio between his own age (PA) 
and the mean age within the MMI group of SD: 
P(TCRISD) = TCRISD*(PA/MA+MMI) 
This formula can be used for interval assessments of the general CRI in ING, according to 
the recommended by the WHO age intervals for patient grouping – Table 2.3.  
Analogously, one may assess the specific CRI, related to lethal CVC prediction by the equation  
LCRISD = (FLC+MMI/FLC-MMI)SD/(MA+MMI/MA-MMI)SD 
and its personalized value 
P(LCRISD) = LCRISD*(PA/MA+MMI), 
where FLC+MMI and FLC-MMI are the presented in Table 2.3 lethal CVC rates of patients with 
and without MMI. 
Table 2.4 contains the age interval assessments (compliant with WHO recommendations) of 
the specific CRI in the SD groups. The trend towards increasing the value of the index can 
be clearly followed as a function of the severity of the SD.   
The research conducted, leads to the following conclusions. The CVC prediction during 
emergency surgeries is very important, due to the exceptionally high CVC rate – 45% in the 
investigated patient groups. In its turn, the significantly higher CVC rate among patients with 
MMI proves that it is an independent, important and leading risk factor. In this context, MMI 
determines not only the probability of occurrence, but also the CVC severity: fully nonlethal 
(group A); predominantly nonlethal (groups B, C, D); predominantly lethal (group E).  
The rate trends of the nonlethal (low severity) and lethal (considerable severity) 
complications among patients in the SD groups with and without MMI take into 
consideration the age influence, since it can not be disregarded in risk factor evaluation. 
Therefore, the MMI presence qualitatively determines the following, influenced by the age 
CVC risks:    
- group A (low surgical severity): rare and mild CVC in young patients, who dominate in 
the group; relatively frequent, but mild CVC among the more elderly; 
- group B (relatively low surgical severity): high rate of mild CVC due to the specific high 
mean age;  
- groups C and D (increased surgical severity): increased probability of mild CVC  with 
the age increase; increased probability of high severity CVC  with the SD severity 
increase;   
- group E (considerable surgical severity): high probability of high severity CVC, due to 
the specific high mean age; the risk of mild CVC is identical in patients with and 
without MMI. 
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the specific CRI in the SD groups. The trend towards increasing the value of the index can 
be clearly followed as a function of the severity of the SD.   
The research conducted, leads to the following conclusions. The CVC prediction during 
emergency surgeries is very important, due to the exceptionally high CVC rate – 45% in the 
investigated patient groups. In its turn, the significantly higher CVC rate among patients with 
MMI proves that it is an independent, important and leading risk factor. In this context, MMI 
determines not only the probability of occurrence, but also the CVC severity: fully nonlethal 
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consideration the age influence, since it can not be disregarded in risk factor evaluation. 
Therefore, the MMI presence qualitatively determines the following, influenced by the age 
CVC risks:    
- group A (low surgical severity): rare and mild CVC in young patients, who dominate in 
the group; relatively frequent, but mild CVC among the more elderly; 
- group B (relatively low surgical severity): high rate of mild CVC due to the specific high 
mean age;  
- groups C and D (increased surgical severity): increased probability of mild CVC  with 
the age increase; increased probability of high severity CVC  with the SD severity 
increase;   
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the specific high mean age; the risk of mild CVC is identical in patients with and 
without MMI. 
  
Acute Coronary Syndromes 
 
146 
Age > 18 - 40 41 -55 56 - 65 66 - 75 76 - 90 > 90 
A 1,4 - 3,2 3,2 - 4,3 4,3 - 5,1 5,1 - 5,9 5,9 - 7,1 > 7,1 
B 0,5 - 1,1 1,1 - 1,5 1,5 - 1,8 1,8 - 2,1 2,1 - 2,5 > 2,5 
C 0,4 - 0,95 0,95 - 1,3 1,3 - 1,5 1,5 - 1,8 1,8 - 2,2 > 2,2 
D 0,5 - 1,2 1,2 - 1,7 1,7 - 2,0 2,0 - 2,3 2,3 - 2,7 > 2,7 
E 0,3 - 0,6 0,6 - 0,8 0,8 - 1,0 1,0 - 1,1 1,1 - 1,4 > 1,4 
Table 2.3. Values of TCRI according to surgery groups and age intervals 
 
Age > 18 - 40 41 -55 56 - 65 66 - 75 76 - 90 > 90 
A 0 0 0 0 0 0 
B 0,06 - 0,13 0,13 - 0,18 0,18 - 0,22 0,22 - 0,25 0,25 - 0,30 > 0,30 
C 0,13 - 0,31 0,31 - 0,43 0,43 - 0,50 0,50 - 0,59 0,59 - 0,73 > 0,73 
D 0,22 - 0,53 0,53 - 0,75 0,75 - 0,88 0,88 - 1,01 1,01 - 1,19 > 1,19 
E 0,30 - 0,60 0,60 - 0,80 0,80 - 1,00 1,00 - 1,10 1,10 - 1,40 > 1,40 
Table 2.4. Values of LCRI according to surgery groups and age intervals 
4. Extended quantitative schemes for risk evaluation of perioperative acute 
coronary syndromes and other cardiovascular complications during 
emergency high risky noncardiac surgery 
The proposed, in the preceding paragraph, index for cardiac risk assessment based on the 
ST-depression has to be interpreted as an express method, applied under the specific 
conditions of emergency noncardiac surgery for prediction of acute CVC during the 
postoperative period. The mentioned index is powerful, as it pays attention to manifested 
myocardial ischemia, which is among the proven factors, determining the high cardiac risk 
in patients with MNCS. This concept, combined with the conclusion about the limited 
applicability of the known schemes for CR assessment under  emergency MNCS conditions, 
raises the actual problem related to the synthesis of extended schemes for risk evaluation 
that offer a compromise between the requirement of highly significant assessment and its 
achievement, based on available patient data. Below, we propose such schemes, synthesized 
on the basis of real patient data undergoing emergency abdominal surgery.  
The study uses data obtained by the same 466 patients with emergency treated acute 
surgical abdominal diseases or traumas (see Table 2.1). The data from large sets of indicators 
have been collected. The pilot investigation on the potential contributions of indicators that 
may reliably characterize the CVC, resulted in the constellation shown in Table 3.1. The data 
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cover the three periods of the disease process: preoperative, intraoperative and 
postoperative. Each indicator has its own structure of category-related or quantitative 
values, appropriately coded to be processed through a multidimensional statistical 
approach. We used discriminant analysis (DA) for the synthesis of rules, allowing 
quantitative evaluation of the CVC risk appearance probability, during the intra- and 
postoperative periods. The categorisation of individual patients to the CVC group with a 
given CR level, or to the group without CVC, is performed by substituting the patient’s 
indicators values in the linear discriminator. The patient belongs to the control group if the 
discriminator value is below the limit. Such are the operated patients without perioperative 
CVC, even only with transient CVD or abnormal values of some indicators related to the 
cardiovascular system. Discriminator value above the limit classified the patient to the 
corresponding risk level group. The hypothesis about CVC appearance with higher risk 
level is verified by the next discrimination rule, which assesses the probability of higher risk 
of CVC. 
 
Age Diabetes mellitus 
Surgical conditions Lung breathing 
Volume of surgery Lung auscultatory 
Duration of anesthesia Systolic blood pressure 
Total duration of intubation Diastolic blood pressure 
Intraoperative surgery complications Central venous pressure 
Intraoperative CVC with low risk Heart rate 
Intraoperative CVC with moderate risk   Heart rhythm 
Intraoperative CVC with high risk Heart  auscultatory 
Postoperative surgery complications Hemoglobin 
Postoperative CVC with low risk Glucose 
Postoperative CVC with moderate risk Urea 
Postoperative CVC with high risk Creatinine 
Cause of death, noncardiac Potassium 
Cause of death, cardiac Enzymes - SGOT 
Arterial hypertension,  class Enzymes - SGPT 
Ischemic heart disease X-ray lung 
Myocardial infarction Exercise ECG 
Arrhythmias Myocardial ischemia - preoperative 
Heart failure Myocardial ischemia - intraoperative 
Chronic pulmonary disease  
Table 3.1. Used indicators 
The level of discrimination significance depends on the patient numbers, correctly or 
incorrectly assigned to the training groups. In our case, training groups are the control 
patient group and the groups with specified CR level. The 446 operated persons are 
distributed in training groups, which correspond almost totally to the ACC/AHA 
classification of intra- and postoperative CVC [2, 20]. Two corrections are introduced, since 
the analysis of the false positive and false negative errors in previous own research, 
following strictly the ACC/AHA classification, showed the expedience of these corrections 
in the specific practice with emergency noncardiac surgeries: 
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the analysis of the false positive and false negative errors in previous own research, 
following strictly the ACC/AHA classification, showed the expedience of these corrections 
in the specific practice with emergency noncardiac surgeries: 
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- the transient hypotension of the intraoperative CVC scheme is re-classified  from low 
risk to moderate risk; 
- the compensated HF of the postoperative CVC scheme is re-classified from high risk to 
moderate risk; the decompensate HF is determined as a high risk complication. 
According to these corrections, the patients are distributed in CVC groups with different CR 
level, as it is shown in Table 3.2 and Table 3.3. The control group consists of 97 patients. The 
intraoperative CVC groups are with: low risk – 42; moderate risk – 206; high risk – 41. The 
postoperative CVC groups are: 1 with low risk; 201 with moderate risk; 40 with high risk (21 
of them with, and 19 without cardiac death). 
Further on, the procedure for optimum discriminator synthesis was applied on the 
already differentiated patient groups. Tables 3.4, 3.5, and 3.6 present the weighting 
discrimination coefficients of the corresponding groups, within the models that determine 
the appearance of the risk of: postoperative CVC, based on data from the preoperative 
period; postoperative CVC based on the pre- and intraoperative data period; 
intraoperative CVC based on data from the preoperative period. The lack of a weighting 
coefficient for a given index in some columns means that the step procedure of the 
discriminant analysis has rejected this index as non-contributing to the correct patient 
distribution in the corresponding groups. 
 
Level of 




Short transient hypertension 





Unprovoced prolonged hypotension  ( > 1 hour) 
Prolonged hypertension ( > 1 hour) 
Supraventricular arrhythmias  (atrial fibrillation, 
supraventricular  tachycardia) 
Increased heart rate ( > 120 bpm) 
Sinus bradycardia 
ECG manifestations of myocardial ischemia 
Frequent ventricular extrasystoles 
High 
Hypotension during sudden heart failure 
41 
Ventricular extrasystoles class IV 
Ventricular tachycardia 
Acute myocardial infarction 
Acute cardiogenic pulmonary edema 
Cardiac arrest 
Table 3.2. Intraoperative cardiovascular complications 
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 Supraventricular arrhythmias  (atrial fibrillation, 
supraventricular tachycardia) 
Angina attack 
Increased heart rate ( > 120 bpm) 
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- the transient hypotension of the intraoperative CVC scheme is re-classified  from low 
risk to moderate risk; 
- the compensated HF of the postoperative CVC scheme is re-classified from high risk to 
moderate risk; the decompensate HF is determined as a high risk complication. 
According to these corrections, the patients are distributed in CVC groups with different CR 
level, as it is shown in Table 3.2 and Table 3.3. The control group consists of 97 patients. The 
intraoperative CVC groups are with: low risk – 42; moderate risk – 206; high risk – 41. The 
postoperative CVC groups are: 1 with low risk; 201 with moderate risk; 40 with high risk (21 
of them with, and 19 without cardiac death). 
Further on, the procedure for optimum discriminator synthesis was applied on the 
already differentiated patient groups. Tables 3.4, 3.5, and 3.6 present the weighting 
discrimination coefficients of the corresponding groups, within the models that determine 
the appearance of the risk of: postoperative CVC, based on data from the preoperative 
period; postoperative CVC based on the pre- and intraoperative data period; 
intraoperative CVC based on data from the preoperative period. The lack of a weighting 
coefficient for a given index in some columns means that the step procedure of the 
discriminant analysis has rejected this index as non-contributing to the correct patient 
distribution in the corresponding groups. 
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Age    8.0  
Arterial hypertension 10.5     
Ischemic heart disease 2.5 15.0  14.0 6.5 
Myocardial infarction   18.5 55.5  
Arrhythmias  4.5    
Heart failure 12.0 17.5 57.0 3.5  
Chronic pulmonary disease 8.5     
Diabetes mellitus   3.0 2.0 4.5 
Lung breathing, preoperative  10.0    
Lung auscultatory, preoperative      
Systolic blood pressure, preoperative   0.5   
Diastolic blood pressure, 
preoperative      
Central venous pressure, 
preoperative     19.5 
Heart rate, preoperative 19.5 6.5 6.0   
Heart rhythm, preoperative      
Heart  auscultatory, preoperative  1.0 4.0  3.0 
Hemoglobin, preoperative 3.0 18.0 11.0  7.0 
Glucose, preoperative 3.5     
Urea, preoperative      
Creatinine, preoperative    13.5 43.5 
Potassium, preoperative      
Enzymes - SGOT, preoperative      
Enzymes - SGPT, preoperative      
X-ray lung, preoperative  27.5  3.5 16.0 
Exercise ECG, preoperative      
Myocardial ischemia - preoperative 40.5     
Limit value for positive test: 40 30 60 35 30 
Table 3.4. Quantitative  models for postoperative CVC risk assessment according to 
preoperative data 
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Age      
 Surgical conditions      
Volume of surgery 1.0   8.0  
Duration of anesthesia   2.0   
Intraoperative surgery complications 0.5   5.0  
Intraoperative CVC with low risk 4.5 5.0 3.5   
Intraoperative CVC with moderate risk   81.0 69.0 41.0   
Intraoperative CVC with high risk 8.5 21.5 43.0 8.5  
Arterial hypertension,  class 2.0     
Ischemic heart disease    3.5 5.5 
Myocardial infarction    7.0  
Arrhythmias      
Heart failure    15.5  
Chronic pulmonary disease   1.5   
Diabetes mellitus    7.5 3.5 
Lung breathing, preoperative      
Lung breathing, intraoperative      
Lung auscultatory, preoperative 1.5  1.5   
Lung auscultatory, intraoperative    6.5  
Systolic blood pressure,  preoperative   0.5   
Diastolic blood pressure, preoperative 0.5     
Systolic blood pressure, intraoperative      
Diastolic blood pressure, preoperative      
Central venous pressure , preoperative    3.5 11.5 
Central venous pressure, intraoperative    17.0 15.0 
Heart rate, preoperative   1.0   
Heart rate, intraoperative    9.0  
Heart rhythm, preoperative      
Heart rhythm, intraoperative   5.0   
Heart  auscultatory, preoperative     2.5 
Hemoglobin     4.5 
Glucose      
Urea      
Creatinine    3.5 30.0 
Potassium      
Enzymes - SGOT      
Enzymes - SGPT      
X-ray lung    2.5 12.5 
ECG LVH  0.5 0.5   
Myocardial ischemia - preoperative      
Limit value for positive test: 20 20 55 65 25 
Table 3.5. Quantitative  models for postoperative CVC risk assessment according to pre- and 
intraoperative data 
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Age 24.0 18.5 7.0 6.0  
Arterial hypertension 22.0 6.5 2.5 9.5  
Ischemic heart disease  5.5 3.0   
Myocardial infarction 11.0  8.0  20.5 
Arrhythmias 42.0   19.5  
Heart failure  12.0 13.0  11.0 
Chronic pulmonary disease  9.0  4.5  
Diabetes mellitus      
Lung breathing, preoperative  8.0 19.0  17.0 
Lung auscultatory, preoperative   8.5   
Systolic blood pressure, 
preoperative      
Diastolic blood pressure, preoperative     7.5 
Central venous pressure, 
preoperative     10.0 
Heart rate, preoperative  23.5  15.5  
Heart rhythm, preoperative      
Heart  auscultatory, preoperative     8.5 
Hemoglobin, preoperative  2.5 20.5  25.5 
Glucose, preoperative   6.0   
Urea, preoperative      
Creatinine, preoperative      
Potassium, preoperative      
Enzymes - SGOT, preoperative      
Enzymes - SGPT, preoperative      
X-ray lung, preoperative 1.0     
Exercise ECG, preoperative   2.0   
Myocardial ischemia - preoperative  12.5 14.5 45.0  
Limit value for positive test: 90 80 40 60 30 
Table 3.6. Quantitative  models for intraoperative CVC risk assessment according to 
preoperative data 
Tables 3.7 and 3.8 show the results of correct and incorrect classification of patients, on the 
basis of the used training groups, ranged according to the CVC risk. The greater informative 
value of the combination of pre- and intreoperative data for prognosis of postoperative CVC 
becomes obvious, and the more distinct significance for prognosis of each higher-risk level 
of the post- and intraoperative CVC.  
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Generally, the proposed models for risk assessment of acute CVC appearances, and of 
incidents with patients undergoing emergency noncardiac interventions, manifest not only 
high significance, but also point out:   
- the importance of the intraoperative CVC (especially that with moderate risk) for 
prognosis of all risk level postoperative CVC, based on preoperative and intraoperative 
data;  
- the obtained discrimination between the groups with cardiac death and high risk 
complications, which is impossible when directly using the ACC/AHA classification of 
intra- and postoperative CVC;  
- certain decrease of the discrimination importance of the preoperatively ECG detected 
myocardial ischemia together with keeping its role in prognosticating the intraoperative 
CVC with moderate and high risk, which are among the factors that determine the rate 
and the severity of the postoperative CVC.    
5. Cardiac risk reduction strategies 
The topical risk assessment of perioperative cardiac incidents during noncardiac surgery, 
attracts the attention of the specialists, and is the reason for permanent updating of the 
practices leading to significant evaluation. It is sufficient to list the handbooks published by 
competent professional societies, including the ESC Guidelines, issued in 2009, on 
preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac 
surgery [61, 62, 63]. The final goal of these strategies for evaluating the cardiac risk and the 
optimization of heart management during noncardiac surgery, based on this evaluation, is the 
reduction of perioperative acute cardiac incidents. The strategies can be summarized, without 
reiteration of the available algorithms, in following three directions. 
5.1 Pharmacological strategy 
Surgeries of patients with moderate and low FC and moderate CR can be performed by 
inclusion of statins and low dose beta-blockers. ACE inhibitors are recommended to be 
introduced before intervention on patients with LV dysfunction (EF less than 40%). 
Continued use of beta-blockers is advised with patients having positive preoperative stress-
tests. The latest cardioprotection concepts recommend the use of cardio-selective beta-1-
blockers without internal simpatico-mimetic activity and long half-life time, e.g. bisopropol. 
The statins induce coronary plaque stabilization. Multiple clinical investigations show the 
positive effect of the perioperative use of statins. 
The inhibition of ACE may prevent myocardial ischemia and LV dysfunction, therefore the 
perioperative treatment with ACE inhibitors is expedient.  
Aspirin is widely taken by patients with IHD, especially after intracoronary stent 
implantation. The apprehension of perioperative hemorrhaging complications often leads to 
suspension of the aspirin in the perioperative period. However, this is related to triplicate 
the risk of heavy cardiac incidents. The aspirin admission has to be interrupted only if the 
bleeding risk exceeds the cardiac benefit.  
5.2 Noninvasive stress-tests 
Patients with one or more cardiac risk factors are advised to be ECG monitored for changes 
in the postoperative period. Noninvasive testing is recommended for patients with 3 or 
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more risk factors. The last can be accomplished during each surgery, depending on the 
change in the perioperative strategy – the intervention type and the anesthetic technique.   
Patients without stress-induced moderate or heavy ischemia (orienting towards single- or 
two-branch coronary disease) can continue with the planned intervention by inclusion of 
statins and low dose beta-blockers. Individual approach is recommended for patients with 
heavy stress-induced ischemia, after discussing the potential benefit of the advised surgery 
in comparison with the bad prognosis. It is necessary to specify the effect of the 
medicamentous therapy and/or coronary revascularization not only in the postoperative 
plan, but also in a long-term plan. 
5.3 Revascularization 
When a life-threatening state, requiring surgical intervention, is combined with ACS, it is 
advisable to give advantage to the surgery. However, a second stage necessities aggressive 
medicamentous therapy and revascularization, according to the NSTEMI and STEMI-ACS 
recommendations. 
ACS without ST-elevations is interpreted as a high risk clinical state, requiring accurate 
diagnosis, risk stratification and revascularization. That means that if no life-threatening 
surgical state is present, advantage has to be given to the diagnosis and the appropriate 
treatment of the unstable angina. The corner-stones of the treatment are the double 
antiaggregating therapy, the beta-blocker and the revascularization.    
The antiaggregation and the anticoagulations have to be carefully appreciated before 
applying to patients with unstable AP and forthcoming surgery state, in order to avoid the 
risk of subsequent enhanced bleeding. Most of the patients with unstable AP need 
interventional revascularization and advantage must be given to metal stents, in order not 
to delay the surgery more than three months. 
The main goal of the prophylactic myocardial revascularization is the prevention of lethal 
perioperative MI. As far as the revascularization may be only partially effective in treatment 
of high risk stenosis, it cannot prevent the rupture of vulnerable plaque during the surgery 
stress. This one is found at least in the half of the perioperative MI cases, and can explain the 
lack of specificity in the stress-imaging methods for infarct-related coronary lesions 
discovery. Patients with previous PCI can be with higher risk during or after noncardiac 
surgery, especially in the cases of unplanned or emergency surgery that follow coronary 
stent setting. The intervention duration and the specificity of the process (malignant tumor, 
vascular aneurism, etc.) have to be adequately balanced against the risk of stent-provoked 
thrombosis during the first year after the implantation of drug emitting stent. Careful 
discussion is recommended in every individual case by a team, including a surgeon, an 
anesthesiologist and a cardiologist.        
Despite the specific strategies for risk reduction, the perioperative CR assessment gives an 
opportunity for optimized control of all cardiovascular risk factors.  
6. Index 
-A- 
ACC/AHA classification for CR assessment during noncardiac surgeries 
acute cardiac inflammatory process  
acute conductive disorders 
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acute cardiovascular complications 
acute heart failure  
acute myocardial infarction 
acute rhythm disorders 
angina pectoris (АP) 
arterial hypertension (AH) 
-C- 
cardiac arrhythmias 
cardiac risk (CR) 
cardiogenic shock 
cardiomyopathies 
cardiovascular complications (CVC) 
CR assessment in emergency noncardiac surgery 
CR assessment schemes in major noncardiac surgery  
CR reduction strategies 
-E- 
ECG manifested myocardial ischemia 
emergency high risky noncardiac surgery 
emergency major surgical interventions 
exacerbated chronic heart failure 
Exceeding Index of the Emergency Surgeries (EIES) 
Exceeding Index of the Major Surgeries (EIMS) 
extended quantitative schemes for CR evaluation 
-F- 
functional class (FC) 
-H- 
heart failure (HF) 
heart valvular disease 
hypertensive crisis 
-I- 
indices for CR evaluation 
intraoperative CVC 
investigated surgical nosological groups (ING) 
ischemic heart disease (IHD) 
-M- 
major noncardiac surgery (MNCS) 
major surgical interventions 
manifested myocardial ischemia (MMI) 
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Early Evaluation of Cardiac Chest Pain – 
Beyond History and Electrocardiograph 
Ghulam Naroo and Aysha Nazir 
Rashid Hospital, Dubai 
United Arab Emirates 
1. Overview 
Acute Coronary Syndrome (ACS) represents a continuous spectrum of disease including 
Unstable Angina (UA), acute non-ST elevation myocardial infarction (NSTEMI), and acute 
ST elevation myocardial infarction (STEMI). In spite of major advances in prevention and 
treatment, Acute Coronary Syndrome remains a leading cause of death as well as a major 
cause of hospital admissions both within Europe and worldwide.[1-3] 
Recent advances have allowed for early detection and disposition of patients with Acute 
Coronary Syndrome. The first step in the management of patients with ACS is prompt 
recognition. The diagnosis of ACS is largely based on the history, the electrocardiogram 
(ECG) and changes in cardiac biomarkers. It is a universally acknowledged fact that history 
remains the most essential tool in directing the need for further workup which includes 
serial ECGs and measurement of cardiac biomarkers. 
2. Diagnostic challenges 
The ECG is an important diagnostic and risk stratification tool. Most patients who have 
UA/NSTEMI have some ECG changes, although the ECG may be normal in 1% to 6% of 
patients who have NSTEMI and in approximately 4% of patients who have UA.[4]ST 
elevation myocardial infarction (STEMI) is diagnosed by the symptoms and the 
characteristic ST elevation on the ECG. The other two variants of ACS, non-ST elevation 
myocardial infarction and unstable angina are differentiated from each other by the 
presence of positive cardiac biomarker in the former and the treatment varies 
accordingly.[5-7] 
Of the number of available markers and assays that detect myocardial necrosis, the cardiac 
troponins T and I and the creatinine kinase–MB (CK-MB) isoform are the most commonly 
used, with troponins gaining acceptance as the markers of choice in ACS. These have 
achieved an important role in diagnostic, prognostic, and treatment pathways by virtue of 
their high degree of sensitivity and specificity and their relative ease of use and 
interpretation. However, troponins are detectable only 6 hours after myocardial injury and 
are measurable for up to 2 weeks. 
For a patient presenting with a suspected acute MI, the characteristics of the chest pain and 
the ECG findings permit initial risk stratification. The gold standard in the care of a patient 
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with cardiac chest pain is that an ECG and an abbreviated history and physical examination 
be obtained within 10 minutes of patient arrival.[8] 
The early diagnosis of acute myocardial infarction (AMI) is however sometimes difficult due 
to: [9] 
1. Equivocal electrocardiogram (ECG) changes and other conditions with ECG changes 
that mimic acute myocardial infarction. Atypical chest pains with many differentials 
confuse to make a diagnosis. 
2. Acute myocardial infarction patients without ST-segment elevation. 
3. Delayed liberation and detection of cardiac markers of myocardial necrosis such as 
troponin and creatine kinase (CK). 
Cardiac troponin is frequently not detected until after 4-6 hours and in many cases, repeated 
measurement is needed 8-12 hours after admission. The importance of early risk 
stratification in the management of acute myocardial infarction is emphasized in the 
American Heart Association task force guidelines.[10]Risk stratification is an important 
objective in the evaluation of patients with ACS. The presence of positive biomarkers 
indicates higher risk and worse prognosis.[11] 
When initiating reperfusion therapy, door-to-needle time of less than or equal to 30 minutes 
for initiation of fibrinolytic therapy and a door-to-balloon time of less than or equal to 90 
minutes for percutaneous coronary perfusion is the standard of care.[12-14]Although, more 
and more hospitals are meeting this benchmark, diagnosing and excluding ACS often poses 
a diagnostic challenge to the clinicians.[15]A misdiagnosis may lead to considerable increase 
in morbidity and mortality. An ideal marker which can predict the onset of the disease, 
could aid in reducing the deaths due to ACS. 
3. Cardiac biomarkers 
Acute myocardial infarction refers to irreversible myocardial necrosis caused by an 
imbalance between oxygen supply and demand. In 75% cases, plaque rupture or erosion 
leading to thrombus formation are the causes of acute coronary syndromes. Early diagnosis 
and subsequent reperfusion therapies within 4 to 6 hours of onset of symptoms can salvage 
myocardium at risk. Therefore, optimal markers of myocardial necrosis need to be rapidly 
detectable in blood. 
Myocardial injury causes release into the extracellular space of intracellular constituents 
including detectable levels of a variety of biologically active cytosolic and structural proteins 
such as troponin, creatine kinase, myoglobin, lactate dehydrogenase, etc. 
Cardiac biomarkers have characteristic release and clearance kinetics. However, the time to 
presentation and comorbidities that affect clearance may confound the interpretation of 
biomarkers. Myoglobin is the earliest biochemical marker of myocardial cell damage, and it 
is detectable in blood within 1 to 2 hours of myocyte damage. Blood levels of CK-MB may 
be detectable in blood after 4 to 6 hours of myocardial ischemia. [16] Cardiac troponins are 
elevated within 4 to 12 hours of symptom onset and remain elevated for 4 to 10 days. [17] 
Based on these patterns of release and clearance, a diagnostic algorithm of serial biomarker 
measurements has been developed. Serial sampling of multiple cardiac markers beginning 
at the time of presentation is recommended currently. The sensitivity of serial 
measurements of multiple markers nears 100%, whereas the sensitivity of a single 
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measurement of any biomarker at the time of presentation is poor. The recommended time 
between the rst and second blood draw is 6 to 7 hours. [18] If cardiac marker levels are not 
elevated but clinical suspicion remains high, a third set of markers should be drawn at 12 to 
24 hours after presentation. [19] The markers currently used in this multimarker approach are 
myoglobin, CKMB, and troponin. 
3.1 Myoglobin 
Myoglobin is a heme protein found in the cytoplasm of cardiac and skeletal muscle cells that 
rises most rapidly after myocardial injury but is not cardiac-specic. [16] Myoglobin levels 
are frequently elevated in patients who have renal failure, skeletal muscle injury, trauma, 
and other diseases. Myoglobin is not used in most hospital laboratories. 
3.2 Creatine kinase-MB isoform 
CK-MB is an enzyme present primarily in cardiac muscle and active in energy 
generation. CK-MB is released rapidly after myocardial injury and is more cardiac-
specic than myoglobin. However, CK-MB also comprises up to 5% of skeletal muscle 
and can be elevated in noncardiac disease states. Before the use of troponin, CK-MB was 
the gold standard for the biochemical diagnosis of AMI. CK-MB is released early during 
AMI, and it plays an important role in dening infarct size, infarct expansion, and 
reinfarction.[20] 
3.3 Cardiac troponins 
Cardiac troponins and tropomyosin form the thin lament component of the contractile 
structure in striated muscle. Troponins are released into the blood stream following 
irreversible ischemic myocardial cell injury and remain elevated for a prolonged time. 
There is no clinical difference between TnT and TnI for diagnosing cardiac necrosis. There 
are separate cardiac and skeletal isoforms of both TnI and TnT, allowing for the 
development of highly cardiac-specic assays. [17, 21] Troponin assays can detect as little as 
1 g of myocardial tissue necrosis, and even minute elevations in cardiac troponins have 
been associated with myocardial necrosis and increased rate of short- and long-term 
mortality. [19,22-24] 
Cardiac troponins have been studied in symptomatic and asymptomatic patients who have 
renal dysfunction. It is important that emergency physicians include the patient’s history 
and physical examination when considering an elevated troponin level in patients who have 
renal dysfunction. In patients in whom acute coronary syndrome is not suspected, renal 
failure may be associated with chronic elevations of TnI and TnT, without evidence of acute 
myocardial necrosis. However, an acute increase from baseline troponin levels may be 
associated with increased mortality[25, 26] 
Therefore, baseline troponin levels are helpful when differentiating between acute and 
chronic elevations in cardiac troponins. Elevated levels of cardiac troponins in patients who 
have renal dysfunction may be attributable to decreased renal clearance and increased 
release from cytoplasm because of the loss of membrane integrity. TnT is of higher 
molecular weight and is more commonly present in the free, unbound form in the 
cytoplasm, potentially explaining why TnT is more frequently elevated than TnI. [25] A study 
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with cardiac chest pain is that an ECG and an abbreviated history and physical examination 
be obtained within 10 minutes of patient arrival.[8] 
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for initiation of fibrinolytic therapy and a door-to-balloon time of less than or equal to 90 
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biomarkers. Myoglobin is the earliest biochemical marker of myocardial cell damage, and it 
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elevated within 4 to 12 hours of symptom onset and remain elevated for 4 to 10 days. [17] 
Based on these patterns of release and clearance, a diagnostic algorithm of serial biomarker 
measurements has been developed. Serial sampling of multiple cardiac markers beginning 
at the time of presentation is recommended currently. The sensitivity of serial 
measurements of multiple markers nears 100%, whereas the sensitivity of a single 
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measurement of any biomarker at the time of presentation is poor. The recommended time 
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and other diseases. Myoglobin is not used in most hospital laboratories. 
3.2 Creatine kinase-MB isoform 
CK-MB is an enzyme present primarily in cardiac muscle and active in energy 
generation. CK-MB is released rapidly after myocardial injury and is more cardiac-
specic than myoglobin. However, CK-MB also comprises up to 5% of skeletal muscle 
and can be elevated in noncardiac disease states. Before the use of troponin, CK-MB was 
the gold standard for the biochemical diagnosis of AMI. CK-MB is released early during 
AMI, and it plays an important role in dening infarct size, infarct expansion, and 
reinfarction.[20] 
3.3 Cardiac troponins 
Cardiac troponins and tropomyosin form the thin lament component of the contractile 
structure in striated muscle. Troponins are released into the blood stream following 
irreversible ischemic myocardial cell injury and remain elevated for a prolonged time. 
There is no clinical difference between TnT and TnI for diagnosing cardiac necrosis. There 
are separate cardiac and skeletal isoforms of both TnI and TnT, allowing for the 
development of highly cardiac-specic assays. [17, 21] Troponin assays can detect as little as 
1 g of myocardial tissue necrosis, and even minute elevations in cardiac troponins have 
been associated with myocardial necrosis and increased rate of short- and long-term 
mortality. [19,22-24] 
Cardiac troponins have been studied in symptomatic and asymptomatic patients who have 
renal dysfunction. It is important that emergency physicians include the patient’s history 
and physical examination when considering an elevated troponin level in patients who have 
renal dysfunction. In patients in whom acute coronary syndrome is not suspected, renal 
failure may be associated with chronic elevations of TnI and TnT, without evidence of acute 
myocardial necrosis. However, an acute increase from baseline troponin levels may be 
associated with increased mortality[25, 26] 
Therefore, baseline troponin levels are helpful when differentiating between acute and 
chronic elevations in cardiac troponins. Elevated levels of cardiac troponins in patients who 
have renal dysfunction may be attributable to decreased renal clearance and increased 
release from cytoplasm because of the loss of membrane integrity. TnT is of higher 
molecular weight and is more commonly present in the free, unbound form in the 
cytoplasm, potentially explaining why TnT is more frequently elevated than TnI. [25] A study 
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of asymptomatic patients who had renal failure did not show TnI levels to be elevated in 
this population. The previously noted false-positive TnI results in patients who have renal 
failure were measured during acute disease states, including sepsis or pulmonary embolism, 
which may independently cause elevated troponin levels. [27] 
In symptomatic patients who have chest pain and renal dysfunction, elevated levels of 
cardiac troponin predict patients at an increased risk for adverse cardiovascular outcomes. 
In a study of 7033 patients who had suspected acute coronary syndromes, the elevated 
levels of TnT were predictive of death or myocardial infarction across the spectrum of 
creatinine clearance. [28] 
Despite the value of cardiac troponin as a very sensitive marker for myocardial damage, 
elevated troponin levels do not reect the mechanism of damage and should not be used 
alone to diagnose myocardial infarction. Troponin levels may be elevated in patients who 
have myocarditis, pericarditis, decompensated heart failure, and septic shock. The use of 
troponin measurements as a screening tool in patients whose conditions have a low 
suspicion for ACS lowers the sensitivity and positive predictive value to 47% and 19%, 
respectively. A high sensitive troponin could be available in future to turn out an ideal 
biomarker for ACS. [29] 
4. Heart-type fatty acid-binding protein 
Heart-type fatty acid-binding protein (h-FABP) has been researched since 1988, due to its 
high potential as an early marker for myocardial infarction. It bears considerable 
resemblance to myoglobin in terms of size, location within the cell, release and clearance 
kinetics. It is a relatively low molecular mass cytoplasmic protein (15 kDa) available in 
abundance in myocardial tissue. [30-32]It is important for myocardial homeostasis since 50 – 
80% of the heart’s energy is provided by lipid oxidation and h-FABP ensures intracellular 
transport of insoluble fatty acids. It is released from the heart during cell necrosis, it diffuses 
much more rapidly than troponins through the interstitial space and appears in the 
circulation as early as 90 minutes after the onset of symptoms, reaching its peak within 6 
hours and clearing within 24 hours. 
This combination of early h-FABP release after symptom onset, rapid kidney clearance from 
the circulation and high cardiac specificity suggests great potential for its clinical use.[30-
32]Therefore,it can be derived that h-FABP may not only be of value in detecting myocardial 
injury in the early hours of the insult but may also be ideal for the diagnosis of reinfarctions. 
H-FABP has been found to be superior to troponins due to its higher sensitivity.[33, 34]A 
recent study showed h-FABP had a sensitivity of 75.76% and a specificity of 96.97% 
compared with 58.59% and 98.94% for cTnT and 68.69% and 97.54% for CK-MB in the initial 
6 hours after the onset of chest pain. [35]Recent data also suggests h-FABP may provide some 
prognostic information which appears superior to that of troponins. [36].   
4.1 h-FABP in the pre-hospital setting 
There is some evidence to suggest the utility of h-FABP in the pre-hospital 
setting.[37]According to the literature, early assessment of H-FABP in patients presenting 
with chest pain improves the diagnosis of an ongoing myocardial infarction. An h-FABP 
self-testing kit can be helpful in the pre-hospital setting. Though an h-FABP testing kit (h-
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FABP Quanta) is used for the quantitative measurement, especially in next one hour of the 
initial testing to see if there is a rise of titre. This kit is more useful in emergency 
department/CCU and ICU setting. ConformitéEuropéenne (CE) certification approving it 
for sale in the European Union member countries. 
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of asymptomatic patients who had renal failure did not show TnI levels to be elevated in 
this population. The previously noted false-positive TnI results in patients who have renal 
failure were measured during acute disease states, including sepsis or pulmonary embolism, 
which may independently cause elevated troponin levels. [27] 
In symptomatic patients who have chest pain and renal dysfunction, elevated levels of 
cardiac troponin predict patients at an increased risk for adverse cardiovascular outcomes. 
In a study of 7033 patients who had suspected acute coronary syndromes, the elevated 
levels of TnT were predictive of death or myocardial infarction across the spectrum of 
creatinine clearance. [28] 
Despite the value of cardiac troponin as a very sensitive marker for myocardial damage, 
elevated troponin levels do not reect the mechanism of damage and should not be used 
alone to diagnose myocardial infarction. Troponin levels may be elevated in patients who 
have myocarditis, pericarditis, decompensated heart failure, and septic shock. The use of 
troponin measurements as a screening tool in patients whose conditions have a low 
suspicion for ACS lowers the sensitivity and positive predictive value to 47% and 19%, 
respectively. A high sensitive troponin could be available in future to turn out an ideal 
biomarker for ACS. [29] 
4. Heart-type fatty acid-binding protein 
Heart-type fatty acid-binding protein (h-FABP) has been researched since 1988, due to its 
high potential as an early marker for myocardial infarction. It bears considerable 
resemblance to myoglobin in terms of size, location within the cell, release and clearance 
kinetics. It is a relatively low molecular mass cytoplasmic protein (15 kDa) available in 
abundance in myocardial tissue. [30-32]It is important for myocardial homeostasis since 50 – 
80% of the heart’s energy is provided by lipid oxidation and h-FABP ensures intracellular 
transport of insoluble fatty acids. It is released from the heart during cell necrosis, it diffuses 
much more rapidly than troponins through the interstitial space and appears in the 
circulation as early as 90 minutes after the onset of symptoms, reaching its peak within 6 
hours and clearing within 24 hours. 
This combination of early h-FABP release after symptom onset, rapid kidney clearance from 
the circulation and high cardiac specificity suggests great potential for its clinical use.[30-
32]Therefore,it can be derived that h-FABP may not only be of value in detecting myocardial 
injury in the early hours of the insult but may also be ideal for the diagnosis of reinfarctions. 
H-FABP has been found to be superior to troponins due to its higher sensitivity.[33, 34]A 
recent study showed h-FABP had a sensitivity of 75.76% and a specificity of 96.97% 
compared with 58.59% and 98.94% for cTnT and 68.69% and 97.54% for CK-MB in the initial 
6 hours after the onset of chest pain. [35]Recent data also suggests h-FABP may provide some 
prognostic information which appears superior to that of troponins. [36].   
4.1 h-FABP in the pre-hospital setting 
There is some evidence to suggest the utility of h-FABP in the pre-hospital 
setting.[37]According to the literature, early assessment of H-FABP in patients presenting 
with chest pain improves the diagnosis of an ongoing myocardial infarction. An h-FABP 
self-testing kit can be helpful in the pre-hospital setting. Though an h-FABP testing kit (h-
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FABP Quanta) is used for the quantitative measurement, especially in next one hour of the 
initial testing to see if there is a rise of titre. This kit is more useful in emergency 
department/CCU and ICU setting. ConformitéEuropéenne (CE) certification approving it 
for sale in the European Union member countries. 
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1. Introduction 
Many patients who present with acute coronary syndrome (ACS) are candidates for 
coronary artery bypass grafting (CABG). Approximately 500,000 CABG operations are 
performed each year in the United States, and many of these patients present with acute 
coronary syndrome. In the Bypass Angioplasty Revascularization Investigation (BARI) trial 
comparing CABG and percutaneous coronary intervention for coronary artery disease, 64% 
of the patients presented with unstable angina (Rosamond, Flegal et al. 2008). According to 
2007 ACC/AHA guidelines (Anderson, Adams et al. 2007), left main stenosis greater than 
50% and three-vessel coronary artery disease represent a class I indication for coronary 
artery bypass grafting in patients with unstable angina or non-ST elevation myocardial 
infarction. In addition, patients with 2-vessel coronary artery disease and either diabetes or 
left ventricular dysfunction may benefit from coronary artery bypass grafting (Class II 
recommendation). Regardless of the modality of revascularization, patients with acute 
coronary syndrome benefit from antagonists of platelet activity such as aspirin and 
clopidogrel since these agents reduce the risk of major adverse events. However, antiplatelet 
agents also increase the risk of bleeding in patients who will ultimately proceed to coronary 
artery bypass graft surgery. Usually the benefits of early initiation of antiplatelet therapy 
outweigh the risks. The purpose of this review is to summarize current antiplatelet therapy 
in acute coronary syndrome, with particular emphasis on patients who will undergo 
coronary artery bypass, and the appropriate operative strategies will be discussed. We will 
also review the current recommendations for secondary prevention after coronary artery 
bypass grafting. 
2. Antiplatelet therapy 
Platelet activation and aggregation play a critical role in the pathogenesis of coronary 
thrombosis, and antiplatelet therapy has become a central tenet of the treatment strategy in 
acute coronary syndrome. Platelet aggregation and activation can be inhibited 
pharmacologically at several points in the cascade leading up to platelet aggregation, and 
several of these antiplatelet agents are commonly used perioperatively in the setting of acute 
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coronary syndrome. Aspirin inhibits the formation of thromboxane A2 thereby preventing 
glycoprotein (Gp) IIb/IIIa-mediated activation of platelets. Ticlodipine and clopidogrel 
inhibit ADP release from platelets and thereby prevent Gp IIb/IIIa activation, and 
eptifibatide blocks GpII B/IIIa-mediated platelet aggregation. The pharmacokinetics of 
platelet inhibition and inactivation by each type of agent is of particular importance 
regarding the timing of CABG because of the bleeding risk associated with antiplatelet 
therapy. However, the timing of CABG in the setting of ACS is often flexible, with perhaps 
less than 1% of patients with ACS requiring emergent CABG (Serebruany, Malinin et al. 
2004), so much of the bleeding risk associated with antiplatelet therapy can often be 
mitigated by waiting several days before CABG is performed. 
Regardless of whether patients with ACS undergo percutaneous coronary intervention or 
CABG, the overwhelming body of evidence supports the use of antiplatelet therapy in ACS. In 
one large meta-analysis of studies of patients with ACS (Seshadri, Whitlow et al. 2002), the risk 
of serious vascular events including non-fatal myocardial infarction or stroke was reduced by 
25%. Although aspirin was associated with a significantly reduced risk of major vascular 
events, the adenosine diphosphate (ADP)-receptor antagonists ticlodipine and clopidogrel 
were associated with an additional 10-12% risk reduction. In a direct comparison of aspirin 
and clopidogrel in the randomized Clopidogrel versus Aspirin in Patients at Risk for Ischemic 
Events (CAPRIE) trial, clopidogrel was associated with an 8.7% relative reduction of risk of 
ischemic stroke, myocardial infarction, or vascular death compared with aspirin, with no 
signicant difference in the safety profiles of the two drugs (1996). Furthermore, the beneficial 
effects of aspirin and clopidogrel in ACS are additive. In the Clopidogrel in Unstable angina to 
prevent Recurrent Events (CURE) trial, unstable angina and non-ST elevation myocardial 
infarction (NSTEMI), patients taking both clopidogrel and aspirin had less chance of cardiac 
death, non-fatal MI, or stroke at 30 days and 1 year compared to those only taking aspirin 
(Yusuf, Zhao et al. 2001). Taken together, these studies all confirm that antiplatelet therapy 
with both aspirin and clopidogrel should be intitiated early in ACS. 
In patients with ST-elevation myocardial infarction (STEMI), clopidogrel in addition to 
aspirin improves outcomes. In the Clopidogrel and Metoprolol in Myocardial Infarction 
(COMMIT) trial, clopidogrel in addition to aspirin was associated with a significant 
decrease in the composite endpoint of death, reinfarction, or stroke compared to aspirin 
alone (Sabatine, Cannon et al. 2005). The Clopidogrel as Adjunctive Reperfusion Therapy- 
Thrombolysis In Myocardial Infarction (CLARITY-TIMI) compared aspirin alone to 
clopidogrel in addition to aspirin in patients with STEMI and demonstrated a 36% reduction 
in relative risk of the early composite endpoint of occlusion of the infarct-related artery, 
recurrent MI, or death, and there was a 20% relative risk reduction of the late composite 
endpoint of death from cardiovascular cause, recurrent MI, or recurrent ischemia leading to 
urgent revascularization (Sabatine, Cannon et al. 2005). Importantly, there was no increase 
in bleeding complications in either the COMMIT or the CLARITY-TIMI trial. Based on such 
compelling findings, the current AHA/ACC guidelines for patients with ACS recommend 
that aspirin and clopidogrel be given as soon as possible (Anderson, Adams et al. 2007). The 
typical loading dose for clopidogrel is 300mg or 600mg. Usually for patients undergoing 
stent placement, 600mg of clopidogrel is given, while patients who are found to be 
candidates for CABG are given 300mg of clopidogrel. 
New ADP-receptor antagonist antiplatelet agents include prasugrel and ticagrelor. Both 
decrease the relative risk of ischemic events when used with aspirin (Ebrahimi, Dyke et al. 
Coronary Bypass Grafting in Acute Coronary  
Syndrome: Operative Approaches and Secondary Prevention 
 
173 
2009; Wallentin, Becker et al. 2009). However, prasugrel is associated with increased risk of 
bleeding complications, especially related to CABG. In contrast, ticagrelor was not 
associated with increased risk of bleeding related to CABG. 
Several clinical trials have examined the outcomes of patients with ACS who were treated 
with antiplatelet therapy before undergoing CABG. In the CURE trial, patients who 
proceeded to CABG after receiving clopidogrel as opposed to placebo had a decreased 
relative risk of the composite endpoint of death, MI or stroke prior to CABG (RR 0.56 95% CI 
0.29-1.08, absolute risk reduction 1.8%). As long as clopidogrel was stopped 5 days prior to 
CABG there was no increase in risk of life-threatening bleeding. The CLARITY-TIMI trial 
and the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trials 
demonstrated similar improved outcomes without increased risk of bleeding in patients 
who underwent CABG after being treated with clopidogrel (Ferraris, Ferraris et al. 2005). 
3. Coronary artery bypass grafting and acute coronary syndrome 
Using antiplatelet agents in patients with ACS raises the risk of bleeding in those patients 
that undergo CABG, however several factors including the pharmacokinetic profile, 
individual patient sensitivity to the agent, and timing of the surgery determine the exact risk 
posed. Clinical trials are often difficult to compare because of varying classification of 
bleeding complications leading to differing conclusions. The Aspirin Guideline Taskforce of 
the Society of Thoracic Surgeons reviewed 21 studies examining the effect of preoperative 
aspirin on bleeding after CABG (Ebrahimi, Dyke et al. 2009). The dose of aspirin varied 
significantly between studies, so comparison of the findings is difficult. However, there 
appears to be a small increase in chest tube drainage and blood loss and a small increase in 
need for blood transfusion associated with preoperative aspirin, all of which may be dose 
related. Nonetheless, the mortality benefit of aspirin preoperatively in ACS outweighs the 
small risk of bleeding, leading to a class IIa recommendation to continue aspirin for 
urgent/emergent CABG patients. Some studies have shown an increased risk of 
perioperative bleeding in patients treated with both aspirin and ADP receptor antagonists 
such as clopidogrel who proceed to CABG (Yende and Wunderink 2001; Hongo, Ley et al. 
2002; Genoni, Tavakoli et al. 2003). Therefore, clopidogrel should be stopped for 5-7 days 
before CABG when possible (ACC/AHA class I recommendation). 
Because of the increased risk of bleeding after CABG in patients on dual antiplatelet 
therapy, one strategy would be to wait until coronary anatomy is defined on coronary 
angiography. However, this would delay antiplatelet therapy for all patients with a 
decrement in the benefit for all patients, most of whom do not end up undergoing CABG. 
The number of patients with ACS who proceed to CABG is probably between 7-14% (Bhatt, 
Roe et al. 2004; Fox, Anderson et al. 2007), and salvage CABG after failed percutaneous 
coronary intervention is relatively uncommon. The risk of bleeding after CABG, as well as 
the risk of reoperation for bleeding, overall is fairly low. Thus, the vast majority of patients 
will benefit from starting dual antiplatelet therapy early in ACS, and many patients would 
be harmed by delaying therapy. 
4. Operative strategies 
Usually CABG can be delayed in ACS to allow ADP-receptor blockers to be metabolized 
and excreted allowing platelet function to recover. If anticoagulation is critical, as is usually 
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the case in ACS, short acting anticoagulants such as unfractionated heparin and Gp IIb/IIIa 
inhibitors can be used up until shortly before going to the operative room. Patients with 
ACS who have ongoing ischemia or are hemodynamically unstable and have received ADP-
receptor antagonists may benefit from bridge percutaneous coronary intervention or intra-
aortic balloon pump insertion. An algorithm for the management of patients with ACS that 
undergo CABG is presented in Figure 1.  
 
 
Fig. 1. Algorithm or the management of patients with ACS and indications for CABG. 
Patients with ACS who are stable are observed while ADP receptor blockers are held for 5 
days prior to surgery to eliminate the increased risk of bleeding and mortality (Ferraris, 
Ferraris et al. 2005; Ebrahimi, Dyke et al. 2009). Aspirin is continued up to the time of 
surgery. If there is particular concern about the grade of coronary stenosis or evidence of 
ongoing ischemia, the patient may be continued on unfractionated heparin and/or Gp 
IIb/IIIa inhibitors up until the time of surgery. The bleeding time or platelet function time 
can be used to assess platelet function and the bleeding risk preoperatively. This may be 
useful in assessing bleeding risk and planning for CABG. The dose of clopidogrel may be 
proportional to the risk of bleeding after CABG. In patients who receive the 600 mg loading 
dose of clopidogrel, CABG should be delayed 5-7 days for the platelet function to recover. 
However, in patients who received the lower 300 mg loading dose and are maintained on 75 
mg per day of clopidogrel, CABG may be safely performed after holding clopidogrel for 1-3 
days. A logical strategy is to administer 300mg of clopidogrel in addition to aspirin at the 
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time of presentation in patients with ACS. When coronary angiography is performed, an 
additional 300mg of clopidogrel may be given if percutaneous coronary intervention is 
performed, while in those that will undergo CABG, no additional clopidogrel is given and 
low dose aspirin is continued. 
In patients with ACS and high grade left main coronary artery stenosis or left main 
equivalent who have received high dose clopidogrel or thrombolytics, insertion of an intra-
aortic balloon pump (IABP) will improve coronary perfusion and decrease cardiac demand 
by afterload reduction. Preoperative IABP insertion in these situations provides 
hemodynamic stability and reduces hospital mortality (Wiviott, Braunwald et al. 2007). 
CABG may be performed on cardiopulmonary bypass with cardioplegic arrest or off-pump 
(OPCAB). The advantages and disadvantages of OPCAB have been studied and reviewed 
extensively, yet remain controversial (Moore, Pfister et al. 2005). OPCAB avoids full 
heparinization and the systemic inflammatory response syndrome associated with 
cardiopulmonary bypass. Early studies suggested that off-pump CABG is associated with 
fewer adverse cardiovascular events and reduced early postoperative morbidity and 
mortality (Rastan, Eckenstein et al. 2006; Magee, Alexander et al. 2008). However, more 
recent data demonstrate a slightly higher rate of incomplete revascularization and a greater 
need for subsequent revascularization, as well as slightly reduced long-term mortality 
(Puskas, Kilgo et al. 2008). However, much of the outcome after OPCAB may be surgeon 
and center dependent, and this should be taken into account when formulating operative 
plans for patients with ACS undergoing CABG. 
5. Secondary prevention 
CABG for patients with ACS reduces angina, reduces the risk of myocardial infarction, 
and improves long-term survival, particularly when the internal thoracic artery is grafted 
to the left anterior descending artery (Anderson, Adams et al. 2007). However, secondary 
prevention strategies are critical for the long-term benefit of revascularization to be 
realized. Lifestyle modification such as diet modification, an exercise regimen, and 
smoking cessation are necessary. Pharmacologic secondary prevention consisting of lipid-
lowering agents, antihypertensives (primarily with beta blockers), and antiplatelet 
medications is also required to decrease the risk of progression of coronary artery disease 
and graft occlusion. A strategy for antiplatelet therapy after CABG in patients with ACS is 
presented in Figure 2. All patients should be continued on aspirin postoperatively to 
reduce the risk of vein graft occlusion (ACC/AHA class I recommendation). This also 
protects against the risk of future cardiovascular, cerebrovascular, and peripheral 
vascular ischemic events. In patients with ACS who have undergone coronary artery stent 
placement, clopidogrel is required in addition to aspirin to reduce major cardiac events 
(Muller, Buttner et al. 2000). In the CURE trial, patients with ACS treated with clopidogrel 
in addition to aspirin had decreased cardiac events, stroke and hospitalizations at 1 year 
regardless of whether they underwent PCI or CABG (Yusuf, Zhao et al. 2001). Therefore, 
in our practice, patients with ACS who undergo on-pump CABG or OPCAB are treated 
with 600mg aspirin suppository upon postoperative admission to the intensive care unit. 
When they are extubated, clopidogrel 75mg daily is administered, in addition to aspirin 
81mg daily. Dual antiplatelet therapy is continued in all patients with ACS for 9-12 
months. 
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proportional to the risk of bleeding after CABG. In patients who receive the 600 mg loading 
dose of clopidogrel, CABG should be delayed 5-7 days for the platelet function to recover. 
However, in patients who received the lower 300 mg loading dose and are maintained on 75 
mg per day of clopidogrel, CABG may be safely performed after holding clopidogrel for 1-3 
days. A logical strategy is to administer 300mg of clopidogrel in addition to aspirin at the 
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time of presentation in patients with ACS. When coronary angiography is performed, an 
additional 300mg of clopidogrel may be given if percutaneous coronary intervention is 
performed, while in those that will undergo CABG, no additional clopidogrel is given and 
low dose aspirin is continued. 
In patients with ACS and high grade left main coronary artery stenosis or left main 
equivalent who have received high dose clopidogrel or thrombolytics, insertion of an intra-
aortic balloon pump (IABP) will improve coronary perfusion and decrease cardiac demand 
by afterload reduction. Preoperative IABP insertion in these situations provides 
hemodynamic stability and reduces hospital mortality (Wiviott, Braunwald et al. 2007). 
CABG may be performed on cardiopulmonary bypass with cardioplegic arrest or off-pump 
(OPCAB). The advantages and disadvantages of OPCAB have been studied and reviewed 
extensively, yet remain controversial (Moore, Pfister et al. 2005). OPCAB avoids full 
heparinization and the systemic inflammatory response syndrome associated with 
cardiopulmonary bypass. Early studies suggested that off-pump CABG is associated with 
fewer adverse cardiovascular events and reduced early postoperative morbidity and 
mortality (Rastan, Eckenstein et al. 2006; Magee, Alexander et al. 2008). However, more 
recent data demonstrate a slightly higher rate of incomplete revascularization and a greater 
need for subsequent revascularization, as well as slightly reduced long-term mortality 
(Puskas, Kilgo et al. 2008). However, much of the outcome after OPCAB may be surgeon 
and center dependent, and this should be taken into account when formulating operative 
plans for patients with ACS undergoing CABG. 
5. Secondary prevention 
CABG for patients with ACS reduces angina, reduces the risk of myocardial infarction, 
and improves long-term survival, particularly when the internal thoracic artery is grafted 
to the left anterior descending artery (Anderson, Adams et al. 2007). However, secondary 
prevention strategies are critical for the long-term benefit of revascularization to be 
realized. Lifestyle modification such as diet modification, an exercise regimen, and 
smoking cessation are necessary. Pharmacologic secondary prevention consisting of lipid-
lowering agents, antihypertensives (primarily with beta blockers), and antiplatelet 
medications is also required to decrease the risk of progression of coronary artery disease 
and graft occlusion. A strategy for antiplatelet therapy after CABG in patients with ACS is 
presented in Figure 2. All patients should be continued on aspirin postoperatively to 
reduce the risk of vein graft occlusion (ACC/AHA class I recommendation). This also 
protects against the risk of future cardiovascular, cerebrovascular, and peripheral 
vascular ischemic events. In patients with ACS who have undergone coronary artery stent 
placement, clopidogrel is required in addition to aspirin to reduce major cardiac events 
(Muller, Buttner et al. 2000). In the CURE trial, patients with ACS treated with clopidogrel 
in addition to aspirin had decreased cardiac events, stroke and hospitalizations at 1 year 
regardless of whether they underwent PCI or CABG (Yusuf, Zhao et al. 2001). Therefore, 
in our practice, patients with ACS who undergo on-pump CABG or OPCAB are treated 
with 600mg aspirin suppository upon postoperative admission to the intensive care unit. 
When they are extubated, clopidogrel 75mg daily is administered, in addition to aspirin 
81mg daily. Dual antiplatelet therapy is continued in all patients with ACS for 9-12 
months. 
  




Fig. 2. Strategy for antiplatelet therapy for secondary prevention of CAD after CABG. 
All patients with a history of a cardiovascular event should be started on a beta blocker and 
3-hydroxy-3-methylglutaryl coenzyme A (MHG –CoA) reductase inhibitors (statins) for 
secondary prevention of cardiovascular events unless otherwise contraindicated (1994; 
Sacks, Pfeffer et al. 1996; 1998). Angiotensin converting enzyme inhibitors should be 
initiated in all patients with CAD and a left ventrticular ejection fraction less than 40%, 
diabetes, hypertension, or chronic kidney disease (Smith, Allen et al. 2006). ACE inhibitors 
may be considered in lower risk patients with well-controlled risk factors. If ACE inhibitors 
are not tolerated or are contraindicated, angiotensin receptor blockers (ARBs) may be 
considered. Patients with heart failure may also benefit from ARBs. Medication compliance 
is required for successful secondary prevention and must be ensured to reap the benefits of 
revascularization. 
6. Conclusions 
Antiplatelet therapy with aspirin and clopidogrel imparts a clear benefit in major adverse 
cardiovascular events and mortality after acute coronary syndrome. Although these agents 
may pose additional bleeding risk in the small percentage of patients with ACS that proceed 
to CABG, the risk is far outweighed by the benefits, and much of the bleeding can be 
diminished by delaying CABG when possible. Short acting anticoagulants and IABP 
insertion may temporize while allowing platelet function to recover after discontinuing 
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clopidogrel. Following bleeding times postoperatively can clarify the need for platelet 
transfusion in the event of bleeding.  OPCAB may have offer some benefits by avoiding full 
heparinization and avoiding the inflammatory response associated with cardiopulmonary 
bypass. Secondary prevention with antiplatelet therapy, beta blockade, lipid lowering 
therapy, and ACE inhibitors or ARBs is critical to the long term success of revascularization. 
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1. Introduction 
Atherosclerosis is increasingly considered as a low grade inflammatory response of the 
arterial wall to a variety of stimuli [Fuster&Lewis, 1994; Libby, 2001]. It is accepted that 
the adhesion of circulating leukocytes and monocytes to endothelial cells (EC) and 
subsequent transendothelial migration are an important step in the initiation and the 
development of atherosclerotic lesions [Hillis&Flapan, 1998; Jang, 1994]. This process is 
mediated by receptors expressed on the surface of vascular EC – cell adhesion molecules 
(CAM) under the action of an enhanced oxidative stress, lipopolysaccharide and 
proinflammatory cytokines. Vascular cell adhesion molecule (VCAM-1) and intercellular 
adhesion molecule (ICAM-1) are two members of the immunoglobulin gene superfamily 
that play important but different roles in the adhesion of blood cells to the vascular 
endothelium.  The significance of these molecules in the course of atherogenesis is 
confirmed by their immunohistochemically established elevated expression in the 
atherosclerotic plaques [Cybulsky&Gimbronejr, 1991; O’Brien et al., 1993] and by 
experimental models proving a delayed lesion development in case of their absence 
[Cybulsky et al., 2001].  
Circulating forms of adhesion molecules that have been described are probably generated 
by cleavage to a site close to membrane insertion. The amount of ICAM-1 released has been 
demonstrated to be directly correlated with the surface expression of ICAM-1 in EC in 
culture and a correlation between plasma VCAM-1 and VCAM-1 mRNA has been reported 
in human atherosclerotic aorta [Leuwenberg et al., 1992; Pigott et al., 1992]. 
Levels of soluble cell adhesion molecules have been postulated to be useful risk predictor of 
cardiovascular events in healthy populations and various settings of ischemic heart disease 
[de Lemos et al., 2000; Hwang et al., 1997; Mulvihill et al., 2000, 2001; O’Malley et al., 2001; 
Ridker et al., 1998]. Nonetheless, the pathologic role of different soluble adhesion molecules 
in various stages of coronary artery disease is not fully defined.  
Two electrocardiographic markers - ventricular arrhythmias (VA), [Bigger et al., 1981; 
Farrell et al., 1991; Kostis et al., 1987] and impaired cardiac autonomic function, as indicated 
by depressed heart rate variability (HRV), [Bigger at al., 1992; Farrell et all, 1991; 
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by depressed heart rate variability (HRV), [Bigger at al., 1992; Farrell et all, 1991; 
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Hartikainen et al., 1996; Kleiger  et al., 1987; Lanza et al., 1998, 2006; La Rovere et al., 1998] 
have been shown to predict mortality among patients recovering from acute myocardial 
infarction (MI). However there are only limited data about the prognostic value of 
depressed HRV in the whole spectrum of patients with ACS and few attempts to quantify 
the exact value of soluble adhesion molecules and HRV in the cumulative risk assessment of 
patients with ACS [Kennon et al., 2008; Lanza et al., 2006]. 
Previous studies have shown that statin treatment improve the prognosis in patients with 
acute coronary syndromes [Kinlay et al., 2003; Ridker at al., 2005]. The reduction of clinical 
events secondary to lipid lowering has traditionally been attributed to reduction of 
cholesterol deposition and facilitation of cholesterol efflux from coronary plaques. However, 
several studies have recently suggested that the beneficial effects of statins in atherosclerotic 
disease may not be limited to the lipid-lowering effects of these drugs. Possible explanations 
for the observed reduction of morbidity and mortality with statin use include improvement 
of endothelial function, plaque stabilisation, and inhibition of the inflammatory response 
associated with atherosclerosis [Liao 2003; Ray&Cannon, 2005]. In the last years an 
antiarrhythmic effect of statins has been suggested and reported as a possible contributing 
mechanism. 
The aim of this study was:  
1. To assess heart rate variability and soluble adhesion molecules ICAM-1 (intercellular 
adhesion molecule-1) and VCAM-1 (vascular cells adhesion molecule-1) in patients 
with coronary artery disease and healthy control and to evaluate the usefulness of the 
markers of impaired autonomic function and endothelial activation as predictors of 
adverse prognosis in patients with acute coronary syndromes.  
2. The impact of early initiation of low and moderate-dose rosuvastatin treatment on 
autonomic function and concentrations of soluble adhesion molecules during the first 
12 weeks post ACS without ST segment elevation. 
2. Methods 
2.1 Study protocol 
The study consisted of two phases. In the first phase two groups of patients with coronary 
artery disease (acute coronary syndromes without ST segment elevation and stable angina 
pectoris) and one control group of subjects were included for comparisons of soluble 
levels of adhesion molecules and heart rate variability. Between December 2001 and July 
2002, a total number of 136 patients were involved in the study. Patients were divided 
into three groups according to the clinical diagnosis. The first group consisted of 75 
patients with non-ST segment elevation ACS (unstable angina and non ST elevation 
myocardial infarction). Unstable angina (UA) patients (n=57) had ischemic chest pain at 
rest within the preceding 48 hours that had developed in the absence of an extracardiac 
precipitating cause with either ST segment depression of >0.1 mV or T wave inversion in 
two or more contiguous leads on the presenting 12 lead ECG. Patients with non ST 
elevation myocardial infarction (n=18) had similar diagnostic criteria along with elevation 
of serum creatine kinase, without the evolution of pathological q waves. The second 
group consisted of 36 patients with stable angina pectoris (SAP) who had typical 
exertional angina pectoris and positive stress test. Patients with angina at rest were 
excluded from this group. The control group comprised of 25 healthy volunteers in the 
same age of distribution, without angina symptoms and with normal physical 
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examination and stress test. Subjects with acute or chronic inflammatory diseases, 
malignancies, renal insufficiency, and severe liver disease, on immunosuppressive and 
antibiotic treatment were excluded from the study. Also excluded were patients with 
acute ST elevation myocardial infarction, diabetes mellitus, and history of myocardial 
infarction, surgical intervention or major trauma within the preceding month.   
A six months follow-up of patients with ACS was assessed by regular clinical examination 
for every month. Primary outcome was defined as cardiac death, non-fatal myocardial 
infarction or recurrent hospital admission for severe unstable angina. After the 6-month 
period of observation the study population was divided into two groups – with favorable 
course of the disease and with occurrence of adverse coronary events. 
In the second phase other 30 patients with ACS were allocated into two groups, and 
received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 
mg/day (n =14, mean age  57.64±3.1 years). The randomization was carried out by the 
adaptive dynamic random allocation method irrespective of serum lipids levels. A follow-
up assessment of both HRV on ambulatory ECG monitoring and adhesion molecules levels 
was performed during study period of 12 weeks. All patients were under treatment with the 
same medications during the acute phase of the episode (aspirin, nitrates, beta blockers, 
ACE inhibitors), according to the guidelines. 
2.2 Biochemical analysis 
Blood samples from ACS patients were collected after admission in the ICU prior to the 
onset of the antiischemic and anticoagulant therapy with a closed Vacutainer system 
(Beckton Dickinson, NJ, USA) and after 12 weeks for patients included into the second 
phase of the study. In SAP group and in controls, blood samples were collected at the time 
of clinical admission. The serum was separated after centrifugation at 3000 g for 10 min until 
1 hour after taking the samples and sent in Department of Clinical Laboratory, Saint Anne 
University hospital for analyses of creatine kinase, cholesterol and triglycerides levels as a 
part of routine patient management. Two aliquots of the serum were centrally stored at -
80°C and sent in batches to the Department of Clinical Laboratory and Clinical 
Immunology, Medical university, Sofia (for analyses of cTnT and hsCRP) and to the Section 
of Molecular Immunology, Bulgarian Academy of Sciences, Sofia (for analyses of VCAM-1 
and ICAM-1). Determination of cTnT, hsCRP and soluble adhesion molecules levels was 
performed at the end of the study period, blinded to patients’ histories and allocated 
treatment.  
Quantitative detection of serum concentrations of sVCAM-1 and sICAM-1 was performed 
using an enzyme linked immunosorbent assay (ELISA) technique employing a 
commercially available assay kit (BenderMed Sysytems, Vienna, Austria). The intra- and 
interassay coefficients of variation were 3.1%, 5.2% for VCAM-1 and 4.1%, 7.6% for ICAM-1 
respectively. The levels of cardiac troponin T (cTnT) were determined by a third generation 
troponin STAT electrochemiluminescent immunoassay on the ELECSYS 1010 (Roche 
Diagnostics, Basel, Switzerland) with the detection limit at 0.01 ng/ml and a total coefficient 
of variation (CV) of 6% at 5.07 ng/ml and 9.3% CV at 0.10 ng/ml. High-sensitivity C-
reactive protein was measured with a CardioPhase hsCRP immunonephelometric assay 
(Dade Behring Inc) on BN systems. The detection limit was 0.175 mg/l with a total CV of 
7.6% at 0.41 mg/l.  
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2.3 Holter monitoring 
Patients underwent 24 h ECG Holter monitoring within 24 h of admission with two-channel 
tape recorders and monitoring two bipolar chest leads.  Cardiac autonomic function was 
assessed by frequency-domain HRV analyses for the entire 24 hours. Frequency domain 
HRV was assessed in the frequency range of 0 to 0.5 Hz by fast-Fourier transform spectral 
analysis, with a spectral resolution of 0.0005 Hz. The amplitude of the following frequency-
domain HRV variables was obtained: very low frequency (0.0033 to 0.04 Hz), low frequency 
(0.04 to 0.15 Hz), and high frequency (0.15 to 0.40 Hz). Further, the ratio of low to high 
frequency was calculated. 
2.4 Statistical analysis 
Any quantitative parameters under investigation were presented as a mean value and 
standart deviation. Any qualitative parameters under investigation were presented as a 
number and percentage. Student’s t test or paired sample t-test was used to compare the 
quantitative parameters in the groups with a normal distribution. Mann-Whitney’s or 
Wilcoxon signed rank non-parametric analysis is applied to compare the quantitative 
parameters of non-Gaussian distribution such as cTnT, hsCRP, sICAM-1, sVCAM-1 and 
parameters of HRV. Comparison of the categorical variables was performed by Pearson’s 
x2test and Fisher’s test. Receiver-operating characteristics (ROC) analysis was performed to 
estimate the potential of the variable tested to discriminate between patients with and 
without cardiovascular events during follow-up. To identify variables as independent 
predictors of CV events we calculated various multivariate Cox regression models with 
stepwise adjustment for univariate predictors possibly confounding the examined variable. 
Probability values of p<0,05 were considered statistically significant. All analyses were 
performed with SPSS, 9.0 version for Windows. 
3. Results 
3.1 Markers of endothelial activation and impaired autonomic function in patients with 
acute coronary syndromes – Potential prognostic implication 
3.1.1 Characteristics of the study population 
Table 1 demonstrates clinical characteristics and biochemical data of all study groups. There 
were no significant differences among study groups regarding age, gender, family history 
and smoking status. The patients with coronary artery disease (acute coronary syndromes 
and stable angina) had significantly higher rates of hypertension and dyslipidaemia 
compared with healthy control group. The presence of coronary risk factors was equal 
among groups with acute coronary syndromes and stable angina pectoris. Eight of the 
patients in the control group (32%) were on antihypertensive medications. The 
corresponding number of patients on antihypertensive medications in ACS group was 48 
(64%) and 21 (61%) in stable angina pectoris group. All soluble ICAM-1, VCAM-1 and 
hsCRP significantly discriminated between patients with ACS and SAP (p=0.014, 0.05 and 
0.025 respectively) and control subjects (p<0.001, 0.05 and 0.048).  Soluble ICAM-1 and 
hsCRP were also elevated in patients with SAP compared with control group whereas no 
difference in sVCAM-1 was found (p<0.001, 0.05 and 0.4). In opposite, all the parameters of 
the frequency domain HRV tented to be lower in patients with ACS compared with stable 
angina and control group. In healthy subjects VLF, LF and HF were elevated, but LF/HF 
ratio was lower in comparison with stable angina patients (p=0.006).   
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Variable ACS Group 1 
Stable AP 
Group 2 Р1 
Control 
Group 3 Р2 Р3 
Number 75 36  25   
Age 57.8±8.8 57.8±8.7 1 55.6±9.2 0.3 0.4 
Male gender 41 (54.7%) 15(41.7%) 0.2 12 (48%) 0.7 0.8 
Family history 36 (48%) 15(41.7%) 0.5 11 (44%) 0.8 1 
Hypertension 51 (68%) 27 (75%) 0.5 11 (44%) 0.05 0.01 
Smoking 38 (50.7%) 14(38.9%) 0.31 11 (44%) 0.65 0.8 
Cholesterol 
mmol/l 6.24±1.25 6.21±1.41 0.92 5.41±0.79 0.002 0.01 
Tryglycerides 
mmol/l 1.94±1.06 1.82±1.21 0.62 1.27±0.42 0.003 0.03 
BMI>25 43 (57.3%) 26(72.2%) 0.15 12 (48%) 0.49 0.06 
Preivious MI 19 (25.3%) 4 (11.1%) 0.13 0 (0%) 0.003 0.14 
sVCAM-1 
ng/ml 1447.3±52.9 1362.4±114.9 0.05 1318.6±78.4 0.05 0.419 
sICAM-1 
ng/ml 465.5±15.9 387.2 ±29.2 0.014 108.6 ±14.7 <0.001 <0.001 
hsCRP mg/l 15.5 ±3.95 2.33 ±0.39 0.025 1.45±0.24 0.048 0.05 
VLF ms 101.4±9.3 195.2±45.3 0.003 213.9±45.1 <0.001 0,78 
LF ms 71.1±8.05 187.6±46.7 <0.001 199.7±43.5 <0.001 0.85 
HF ms 42.1±8.6 87±27.6 0.04 128.4±37.1 0.001 0.37 
LF/HF ms 2.67±0.3 4.09±0.7 0.03 2.12±0.39 0.43 0.06 
Р1 group 1 vs group 2 
Р2 group 1 vs group 3 
Р3 group 2 vs group 3 
Table 1. Baseline characteristics of study population 
3.1.2 Baseline characteristics of patients with ACS according to clinical outcome 
During the six month follow-up of the patients with acute coronary syndromes three 
patients (4%) died suddenly, seventeen (22.7%) suffered a non-fatal myocardial infarction 
and eight (10.7%) had recurrent UA, for a major adverse cardiovascular event rate of 37.3%. 
The majority of ischemic events occurred within 30 days of the initial episode of non ST 
elevation acute coronary syndrome – 16 (57.14%). Simultaneously, the risk of development 
of non-fatal AMI and rehospitalization for recurrent UA remained significant even during a 
longer period of observation as 12 (42,8%) of the subsequent complications occurred during 
the period between the 30th day and the 6th month. 
On Table 2 the demographic, clinical and laboratory data of the patients with major 
cardiovascular events were compared with those of the patients with favorable outcome. 
Both groups do not differ concerning the classical risk factors for the development of 
ischemic heart disease such as age, gender, history of arterial hypertension, tobacco 
smoking, obesity, familial history and indices of lipid profile. The patients have received 
identical drug therapy including heparin (97,3%), acetysal (90,7%), β-blocker (73,3%), nitrate 
(100%), ACE-inhibitor (48%) and diuretics (17,3%). The patients with subsequent 
complications presented more often with Killip class over 1 (28,6% versus 8,5%, p=0,047) 
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and with a significantly lower left ventricular ejection fraction on the echocardiographic 
examination performed between day 3 and day 7 of the hospitalization (54,6% versus 60,4%, 
p=0,003). Concentrations of sVCAM-1 (1488,75 ng/ml versus 1071,45 ng/ml, p<0,001),  
sICAM-1 (516,7 vs 433,3 ng/ml, p=0,010), hsCRP (32.6 vs 5.31 mg/l, p=0.001) and cTnT (0,72 
vs 0,115 ng/ml, p<0,001) at presentation were significantly raised in patients who went on 
to have ischemic events during the six months of follow-up. None of the parameters of HRV 
was significantly associated with the occurrence of the composite endpoint. Although the 
prognostic information of frequency domain HRV indices was low, we found out that 2 
variables – reduced LF (27±1.7 vs 65.1±10 ms, p=0.05) and LF/HF ratio (0.5±0.2 vs 2.94±0.4, 
p=0.004) were significantly predictive of death, but no for other endpoints (Fig 1) 
 
 No event n (%) 
Event 
n (%) p 
Number 47 28  
Males 26 (55.3) 15 (53.6) 1 
Age, y 57.36 ±8.2 58.6 ±10.1 0.559 
Hypertension 34 (72.3) 17 (60.7) 0.318 
Smoking 23 (48.9) 15 (53.6) 0.812 
Previous MI 12 (25.5) 7 (25) 1 
Family history 20 (42.6) 16 (57.1) 0.242 
BMI>25 25 (53.2) 18 (64.3) 0.470 
Kilip>1 4 (8.5) 8 (28.6) 0.047 
Cholesterol mmol/l 6.30 ±1.22 6.13 ±1.31 0.581 
Triglycerides mmol/l 2.07 ±1.19 1.70 ±0.75 0.145 
Ejection fraction % 60.4 ±7.65 54.6 ±8.45 0.003 
Тroponin Т ng/ml 0.115 ±0.01 0.72 ±0.16 <0.001 
hsCRP mg/l 5.31 ±1.66 32.59 ±9.45 0.001 
sVCAM-1 ng/ml 1071.5 ±54.08 1488.8 ±90.3 <0.001 
sICAM-1 ng/ml 433.3 ±20.01 516.7 ±23.8 0.010 
VLF ms 114.5±13.4 89.2±11.6 0.16 
LF ms 73.7±12.2 65.2±10.1 0.62 
HF ms 56.6±16.4 32.5±6.5 0.143 
LF/HF ms 1.98±0.3 2.98±0.4 0.07 
Table 2. Baseline characteristics of patients with and without cardiovascular events during 
follow-up 
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Fig. 1. LF and LF/HF in patients according to the prognosis during the study period 
Table 3 presents the associations between soluble adhesion molecules, high sensitivity C-
reactive protein and troponin T in patients with ACS. There is a moderately strong positive 
correlation between the levels of sICAM-1 and sVCAM-1 (Spearman's r=0,205, p=0,028). 
Levels of sICAM-1 showed a strong correlation with hsCRP. The correlation between 
sVCAM-1 and hsCRP was r=0.144, p=0.11. In acute coronary syndromes levels of the 
myocardial necrosis marker troponin T correlated highly significant with hsCRP (r=0.451, 
p=0.001), but showed no interdependence with sVCAM-1 (r=0.106, p=0.383) and sICAM-1 
(r=0.129, p=0.286).  
 
  sVCAM-1 sICAM-1 hsCRP 
sVCAM-1 r 1 0,205 0,144 
 p - 0,028 0,11 
sICAM-1 r 0,205 1 0,438 
 p 0,028 - <0,001 
hsCRP r 0,144 0,438 1 
 p 0,11 <0,001 - 
cTnT r 0,106 0,129 0,451 
 p 0,383 0,286 <0,001 
Table 3. Associations between soluble adhesion molecules, high sensitivity C-reactive 
protein and troponin T 
A nonsignificant inverse correlation was found between sVCAM-1 levels and all HRV 
variables studied with the strongest association with low frequency amplitude. The 
correlation coefficients of hsCRP and cTnT with HRV parameters were low and without 
clinical significance. (table 4) 
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p=0.001), but showed no interdependence with sVCAM-1 (r=0.106, p=0.383) and sICAM-1 
(r=0.129, p=0.286).  
 
  sVCAM-1 sICAM-1 hsCRP 
sVCAM-1 r 1 0,205 0,144 
 p - 0,028 0,11 
sICAM-1 r 0,205 1 0,438 
 p 0,028 - <0,001 
hsCRP r 0,144 0,438 1 
 p 0,11 <0,001 - 
cTnT r 0,106 0,129 0,451 
 p 0,383 0,286 <0,001 
Table 3. Associations between soluble adhesion molecules, high sensitivity C-reactive 
protein and troponin T 
A nonsignificant inverse correlation was found between sVCAM-1 levels and all HRV 
variables studied with the strongest association with low frequency amplitude. The 
correlation coefficients of hsCRP and cTnT with HRV parameters were low and without 
clinical significance. (table 4) 
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  VLF LF HF LF/HF 
hsCRP r 0,128 -0,02 0,16 -0,19 
 p 0,35 0,87 0,24 0,16 
sVCAM-1 r -0,10 -0,24 -0,12 -0,06 
 p 0,46 0,08 0,41 0,67 
sICAM-1 r -0,08 0,014 0,03 0,009 
 p 0,55 0,92 0,82 0,95 
cTnT r 0,125 0,017 0,15 -0,07 
 p 0,36 0,9 0,27 0,57 
Table 4. Associations between HRV and soluble adhesion molecules, high sensitivity C-
reactive protein and troponin T 
3.1.3 Soluble adhesion molecules and cardiovascular events 
The ROC analysis was performed to provide an index for assessment of the accuracy of the 
variable investigated to discriminate between subjects with cardiovascular complications 
and those without it. The data obtained from it demonstrate threshold concentrations of 0,01 
ng/ml for cTnT (area under the curve 0,803, p=0,001), 4 mg/l for hsCRP (AUC 0,859, 
p=0,001),  1153,4 ng/mL for sVCAM-1 (AUC 0,786, p=0,001) and 438 ng/mL for sICAM-1 




































Variable AUC SE 95% Confidence Interval 
CRP 0,859 0,045 0,770 0,948 
cTnT 0,803 0,057 0,692 0,914 
VCAM-1 0,786 0,059 0,669 0,902 
ICAM-1 0,671 0,066 0,542 0,800 
AUC – area under the curve, SE – standard error 
Fig. 2. Receiver-operator characteristic curves of the investigated biomarkers as a test for 
predicting major adverse coronary events in patients with acute coronary syndromes 
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A total of 37 patients (49.3%) had a concentration of sVCAM-1>1153.4 ng/ml and the ischemic 
event rate for these patients was 78.6%. The remaining 38 patients had sVCAM-1 
concentrations <1153.4 ng/ml and the ischemic event rate in this group was 21.4% (Pearson 
x2= 15,28, p<0,001). As Figure 3 A shows the difference was mainly driven by an increased 
rate of non-fatal myocardial infarction and rehospitalsation for unstable angina in the group of 
patients with high sVCAM-1 levels. Although the incidence rate of the ischemic complications 
in the patients with sICAM-1>438 ng/ ml was 66,7% while in the patients with subthreshold 
concentration of this parameter it was only 33,3%, a statistically reliable difference was lacking 
(Pearson x2=2,71,p<0,140, Figure 3 B). The sensitivity of a concentration of sVCAM-1>1153.4 
ng/ml for predicting future ischemic events was 79%, with a specificity of 68%. The negative 
predictive value was 84%. The sensitivity of sICAM-1>438 ng/ml for predicting a future 




























































Fig. 3. Cardiovascular events in patients according to concentration of sVCAM-1 (A) and 
sICAM-1 (B) 
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Fig. 3. Cardiovascular events in patients according to concentration of sVCAM-1 (A) and 
sICAM-1 (B) 
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3.1.4 Multivariate risk stratification 
In a multivariate analysis that included baseline characteristics and biochemical markers 
(Table 5) sVCAM-1 remained an independent and powerful predictor of increased cardiac 
risk at 6 months follow-up. The odds ratio associated with the highest value of sVCAM-1 
was 4.62 (95% CI 1.8-11.4, p=0.0009) without adjustment and remained significantly elevated 
after adjustment for Killip class and left ventricular ejection fraction in model 2 (RR 4.63, 1.8-
11.7, p=0.0012), troponin T in model 3 (RR 3.93, 1,5-10, p=0.04) and C-reactive protein in 
model 4 (RR 2.22, 0.8-5.7, p=0.05) Figure 4.   
 
 Odds ratio 95% CI Р 
Sex - Males 0.93 0.44 – 1.97 0.86 
Age > 65 y 1.48 0.68 – 3.21 0.31 
Hypertension 1.38 0.64 – 2.96 0.39 
Smoking 1.11 0.52 – 2.34 0.77 
BMI > 25 1.38 0.6 – 2.9 0.41 
Hypercholesterolemia 1.11 0.45 – 2.76 0.80 
Family history 1.58 0.7 – 3.34 0.23 
Previous MI 1.00 0.42 – 2.37 0.98 
ST depression > 0.5 mm 2.11 0.85 – 5.2 0.10 
Killip > 1 2.73 1.19 – 6.22 0.016 
EF < 50% 2.75 1.24 – 6.11 0.0125 
IСАМ-1 > 438 ng/ml 1.81 1.82 – 4.04 0.15 
VСАМ-1 > 1153.4 ng/ml 4.62 1.86 – 11.4 0.0009 
hsСRP > 4 mg/l 9.85 3.39 – 28.5 <0.0001 
cTnТ > 0.01 ng/ml 5.29 2.13 – 13.1 0.0003 


















CRP>4 mg/l cTnT>0.01 ng/ml Killip>1&EF<50% VCAM>1153.4 ng/ml
 
Fig. 4. Multivarate Cox regression models on VCAM-1 as predictor of major adverse 
coronary events during 6 month follow-up 
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In order to assess the exact role of the increased soluble adhesion molecules levels we 
analyzed the combined predictive value of these two molecules with that of the already 
established prognostic indicators among ACS patients – troponin T and hs C-reactive 
protein. Division of the patients into 4 groups based on their sCAM and cTnT levels 
revealed that sVCAM-1 is an independent prognostic indicator of major adverse coronary 
events during the six months follow-up. In the patients admitted to the ICU without any 
detectable levels of the marker of cardiomyocyte necrosis (n=39) the incidence rate of the 
ischemic events was 1,3% when combined with low levels of sVCAM-1 and 6,7% when 
combined with sVCAM-1> 1153,4 ng/ml (Pearson χ2=6,03, p<0,024, Figure 5 A). 
Simultaneously, the high sICAM-1 levels do not improve the prognostic value of troponin T 
as there was no statistically significant difference in the incidence rate of the complications 
in the patients with a negative cTnT test in dependence on the low or high sICAM-1 levels 







































Fig. 5. Incidence of cardiovascular events according to soluble VCAM-1 and cTnT levels (A) 
and soluble ICAM-1 and cTnT levels (B) 
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Fig. 5. Incidence of cardiovascular events according to soluble VCAM-1 and cTnT levels (A) 
and soluble ICAM-1 and cTnT levels (B) 
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Furthermore, the predictive value of VCAM-1 was independent of systemic inflammation as 
evidenced by C-reactive protein. High VCAM-1 serum levels indicated increased cardiac 
risk both in patients with high CRP serum levels (25.3%% vs 6.7%, p=0.024) and in those 















































Fig. 6. Incidence of cardiovascular events according to soluble VCAM-1 and hsCRP levels 
(A) and soluble ICAM-1 and hsCRP levels (B) 
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3.2 Markers of endothelial activation and impaired autonomic function in patients with 
acute coronary syndromes – Potential therapeutic implication 
3.2.1 Characteristics of the study population 
During the second phase of the study 30 patients with ACS were allocated into two groups, 
and received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 
mg/day (n =14, mean age 57.64±3.1 years) for 12 weeks. Baseline characteristics for each 
group are presented in Table 6, showing no significant differences between the two 
treatment groups. Furthermore, no significant differences in lipids, HRV and markers of 










Age 57,25±2,22 57,64±3,1 0.34 
Male gender 7 (23%) 9 (30%) 0.22 
Hypertension 9 (30%) 9 (30%) 0.72 
Smoking 7 (23.3%) 6 (20%) 0.62 
Family history 5 (16.7%) 7 (23.3%) 0.46 
cTnT 0,29±0.13 0,46±0,18 0.91 
EF % 58,5±2,1 58,8±2,6 0.46 
BMI 26,8±1 26,9±1 0.34 
Cholesterol mmol/l 5,66±0,28 6,07±0,32 0.4 
Tryglycerides mmol/l 1,76±0,17 1,93±0,25 0.6 
HDL-C mmol/l 0,99±0,03 0,91±0,03 0.14 
LDL-C mmol/l 3,86±0,29 4,27±0,28 0.3 
sVCAM-1 ng/ml 1235(831.3-1476.3) 1327,4(1039.5-1989.7) 0.21 
sICAM-1 ng/ml 476,8(424,3-516,8) 439,4(362,1-607,3) 0.92 
VLF ms 97±18,7 90,7±16,7 0.80 
LF ms 43,3±8,2 44,5±7,1 0.91 
HF ms 19,8±5,8 20,9±6,7 0.89 
LF/HF ms 3,34±0,5 3,58±0,5 0.77 
Table 6. Baseline characteristics 
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3.2.2 Effects of rosuvastatin on lipid profile and markers of endothelial and autonomic 
activation 
The changes in lipid values from baseline to 12 weeks in the two treatment groups are 
shown in Table 7. 
 
 Rosuvastatin 10 mg Rosuvastatin 20 mg 
 Baseline 3 months p Baseline 3 months p 
Cholesterol 
mmol/l 5,66±0,28 4,49±0,18 <0.001 6,07±0,32 4,24±0,16 <0.001 
Tryglycerides 
mmol/l 1,76±0,17 1,3±0,13 <0.001 1,93±0,25 1,37±0,18 <0.001 
HDL-C mmol/l 0,99±0,03 1,05±0,04 <0.001 0,91±0,03 1,06±0,03 <0.001 
LDL-C mmol/l 3,86±0,29 2,67±0,2 <0.001 4,27±0,28 2,27±0,11 <0.001 
Table 7. Effects of rosuvastatin on lipid profile 
Serum levels of total cholesterol, triglycerides and LDL-cholesterol in patients decreased after 
3 months of treatment with rosuvastatin. The decrease in total cholesterol and LDL cholesterol 
was significantly larger in the more aggressively treated group (p<0.05 for all comparisons). 
 
 Rosuvastatin 10 mg Rosuvastatin 20 mg 












































VLF ms 97±18,7 99,5±16,5 0,8 90,7±16,7 113,3±20,5 0,35 
LF ms 43,3±8,2 63,8±14,9 0,2 44,5±7,1 56,7±13,4 0,23 
HF ms 19,8±5,8 37±11,6 0,23 20,9±6,7 42,2±7,2 0,009 
LF/HF ms 3,34±0,5 2,87±0,5 0,31 3,58±0,5 1,73±0,2 0,003 
Table 8. Effects of Rosuvastatin on Adhesion Molecules and HRV levels 
After 3 months, patients in the 20 mg rosuvastatin group demonstrated a significant 
decrease in serum levels of sICAM-1 and sVCAM-1 (Table 8, Figure 7 and 8). Also in the 10 
mg-rosuvastin group, there was a significant decrease of sICAM-1 (Figure 9). However, no 
changes in sVCAM-1 levels were observed in this group of patients (Table 8, Figure 10). 
There were no significant differences in changes between the two treatment groups for 
either soluble adhesion molecules levels, but for sICAM-1 we found out a trend towards 
lower concentrations in the moderately treated group (p=0.07). 
No correlations were found between changes in LDL-cholesterol over 12 weeks and changes 
in s-ICAM-1 (r=0.198, p=0.29), sVCAM-1 (r=0.193, p=0.31) and HRV during the same period. 
The Spearman’s correlation coefficients between hsCRP and sICAM-1 (r=0.059, p=0,7) and 
sVCAM-1 (r=0.15, p=0,4) are low and not statistically significant. 
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Fig. 8. Intra-individual changes in levels of s-ICAM-1 in patients during the study. 
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Fig. 8. Intra-individual changes in levels of s-ICAM-1 in patients during the study. 
  






































Fig. 10. Mean changes ± 2 SD of sVCAM-1 in the two rosuvastatin treated groups 
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In ACS group, a significant inverse correlation was observed between markers of 
endothelial activation and HRV variables, with the strongest association being found for 
sVCAM-1 and HF amplitude (r =−0.506, p= 0.004) and LF amplitude (r=-0,4, p=0.02). In 
addition, sympathovagal balance was shifted to greater vagal predominance with 20 mg 
rosuvastatin (increase of HF and decrease of low frequency/ high frequency ratio) when 
compared to lower dose of 10 mg, p=0.05, Table 9. 
 
   LDL vcam 1 
icam 





Coefficient 1,000 ,193 ,198 ,049 ,029 ,130 -,098 
Sig. (2-tailed) . ,308 ,294 ,804 ,882 ,509 ,620 
vcam 1
Correlation 
Coefficient ,193 1,000 ,384(*) -,158
-
,423(*) -,506 ,207 
Sig. (2-tailed) ,308 . ,036 ,405 ,020 ,004 ,273 
icam 1
Correlation 
Coefficient ,198 ,384(*) 1,000 ,089 -,144 -,234 ,210 
Sig. (2-tailed) ,294 ,036 . ,654 ,465 ,231 ,284 
VLF 
Correlation 
Coefficient ,049 -,158 ,089 1,000 ,694 ,431(*) ,125 





,423(*) -,144 ,694 1,000 ,656 ,091 
Sig. (2-tailed) ,882 ,020 ,465 ,000 . ,000 ,634 
HF 
Correlation 
Coefficient ,130 -,506 -,234 ,431(*) ,656 1,000 -,649 
Sig. (2-tailed) ,509 ,004 ,231 ,017 ,000 . ,000 
LF/HF
Correlation 
Coefficient -,098 ,207 ,210 ,125 ,091 -,649 1,000 
Sig. (2-tailed) ,620 ,273 ,284 ,511 ,634 ,000 . 
* Correlation is significant at the 0.05 level (2-tailed). 
Table 9. Associations between HRV and soluble adhesion molecules and LDL cholesterol 
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The measurement of ICAM-1 and VCAM-1 in prospective studies is based on the presence 
of an inflammatory process in the artery wall which increases the expression of adhesion 
molecules and on the hypothesis that the serum levels of these molecules reflect their 
expression by the endothelial cells. In this study we had measured the two main 
representatives of the immunoglobulin gene superfamily of CAM and found significantly 
higher levels of both sVCAM-1 and sICAM-1 in patients with ACS as compared with those 
with SAP and healthy controls. Our finding that soluble adhesion molecules and especially 
sVCAM-1 are strongly and independently predictive for future CV events in patient with 
ACS extends previous observations describing the predictive value of inflammatory 
markers on future cardiac events. However, whereas the causative role of C-reactive protein 
in promoting the inflammatory component in development of plaque rupture remains 
controversial, our data implicate a direct mediator of an inflammatory vessel wall process. 
Several arguments support the hypothesis that sCAM may be more useful than other 
markers of inflammation in predicting clinical outcome: 
First, all sICAM-1 and sVCAM-1 measured in our study are elevated in patients at risk for 
future cardiovascular events. Second, sCAM levels did not correlate with cTnT, a specific 
marker of cardiomyocyte necrosis and the most established prognostic marker in patients 
with ACS. The risk related to the high sVCAM-1 concentrations is independent of the cTnT 
that is evident from the increasing rate of complications in the groups with negative and 
positive cTnT in dependence on sVCAM-1 levels. These data suggest that VCAM-1 release 
actually precedes myocardial injury and that VCAM-1 elevation identifies patients with 
unstable atherosclerotic plaque formation even before complete microvascular obstruction. 
In contrast, we do not find any relationship between sICAM-1 and the risk of subsequent 
events in the course of the follow-up and we do not read any enhanced incidence rate of 
vascular events in the patients without laboratory evidence of a cardiomyocyte necrosis in 
dependence on the levels of this parameter. Third, sVCAM-1 levels did not correlate with C-
reactive protein, a systemic marker of inflammation. Because hsCRP correlated with cTnT 
levels elevated CRP serum levels most likely reflect both a robust vascular inflammatory 
response and myocardial injury. The measurement of sVCAM-1 added to the predictive 
value of hsCRP in determining the risk of future cardiovascular events. Even patients with 
low hsCRP levels were found to be at significantly higher risk with elevated sVCAM-1 
levels which suggest that endothelial activation and proteolytic cleavage of sCAM is a 
primary event and is followed by release of other systemic mediators and acute phase 
proteins such as C-reactive protein. 
Prospective data of soluble adhesion molecules are sparse. The results of our study 
correspond to the data published in the literature about the relationship between sCAM and 
the risk of cardiovascular events and they find their explanation in some differences 
between the two adhesion molecules studied. In the large prospective trials ARIC and PHS 
of healthy individuals, sICAM-1, but not sVCAM-1 appears consistently related to incident 
CAD [de Lemos et al., 2000; Hwang et al., 1997; Ridker et al., 1998]. ICAM-1 expression is 
not only endothelial and ICAM-1 is constitutively expressed by a variety of cell types 
including cells of the hematopoietic lineage and fibroblasts. sICAM-1 correlates with acute 
phase reactants like CRP and provides similar predictive information to CRP in settings of 
primary prevention [Blankenberg et al., 2003; Mulvihill et al., 2002; Ridker et al., 1998; 2000]. 
sICAM-1 therefore appears as a general marker of a proinflammatory status with little 
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prognostic information in patients with ACS after controlling the data for troponin T and C-
reactive protein (Figure 5 and 6). By contrast, VCAM-1 is not expressed in baseline 
condition, but is rapidly induced by pro-atherosclerotic conditions in animal models and 
humans [Cybulsky&Gimbronejr, 1991; O’Brien et al., 1993]. It seems that sVCAM-1 
represents an appropriate marker of plaque burden or activity of a potential clinical 
importance as a prognostic indicator under the conditions of secondary prevention rather 
than in healthy individuals without endothelial dysfunction [Blankenberg et al., 2003; 
Mulvihill et al., 2002]. A similar hypothesis is supported by the data proving the 
independent predictive value of sVCAM-1 in the patients with angiographically proven 
coronary artery disease [Blankenberg et al., 2001], with diabetes mellitus [Jager et al., 2000] 
and with ACS [Mulvihill et al., 2001, 2002] as well as its absence in healthy individuals [de 
Lemos et al., 2000]. 
The relationship between depressed HRV and mortality is difficult to ascertain as the 
exact physiological mechanisms responsible for the various HRV components are still 
incompletely known [Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology, 1996; Tsuji et al., 1996]. Decreased 
values of HRV variables, including LF, may reflect reduced vagal tone or predominant 
sympathetic influence to the heart. The presence of frequent or complex non-sustained VA 
in the context of sympathovagal imbalance can increase the susceptibility to fatal VA, in 
particular during myocardial ischaemia [Kent et al., 1973; Lanza et al., 1998, 2006; 
Schwartz et al.,1988]. On the other hand, VA and depressed HRV are unlikely to be 
associated with the triggers of acute MI, as they were not predictive of non-fatal MI in 
hospital or at six-month follow up. 
Recent experimental findings have suggested that the nervous autonomic system can 
significantly modulate inflammatory reactions [Wang et al., 2003]. In particular, vagal 
stimulation has been shown to decrease inflammatory reactions in animals by inhibiting 
tissue macrophage activation, an effect mediated by stimulation of the alpha-7 subunit of 
the macrophage nicotine receptor by the vagal neurotransmitter acetylcholine, whereas 
adrenergic activity has been reported to favor sympathectomy and towards inflammatory 
reactions. Conversely, several products of inflammation have been shown to have potential 
influence on nervous autonomic activity by central and/or peripheral mechanisms [Lanza et 
al.,2006; Tracey,2002]. The low and no significant correlations between markers of 
endothelial activation and HRV in the present study emphasize that neural influence 
unlikely explained the observed predictive value of soluble adhesion molecules in patients 
with ACS. 
ACS is a diffuse process involving the entire coronary vasculature [Buffon et al., 2002]. 
Although mechanical revascularization by percutaneous coronary intervention may address 
the culprit lesion, recurrent events may reflect disease progression or instability elsewhere 
in the vascular tree. Stabilization of vulnerable plaques or modulation of the so-called 
vulnerable patient is becoming recognized as an important target for systemic therapy 
[Libby&Aikawa 2003; Naghavi et al., 2003a, 2003b]. The rapid pleiotropic effects of statins 
on inflammation, endothelial function, and coagulation are likely to be particularly 
beneficial in patients with ACS in whom these systems are deranged. 
Inhibition of HMG CoA reductase by statins inhibits cholesterol synthesis and isoprenoid 
production. This results in reduced prenylation of small G-proteins such as Rho and, in turn, 
NF-κB activation. By inhibiting HMG CoA reductase, statins can prevent the biosynthesis of 
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production. This results in reduced prenylation of small G-proteins such as Rho and, in turn, 
NF-κB activation. By inhibiting HMG CoA reductase, statins can prevent the biosynthesis of 
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isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. Inhibition 
of Rho geranylgeranylation by statins can reduce leukocyte adhesion and fibronolytic 
activity [Rasmussen et al., 2003; Yoshida et al.,2001]. A recent report suggests additional 
mechanism which is independent of mevalonate production - statins bind to a novel 
allosteric site within the ß2-integrin leukocyte function–associated antigen–1 (LFA- 1), 
preventing binding to the counterreceptor on the endothelial surface (ICAM-1) [Weitz-
Schmidt et al., 2001]. 
In addition, statins can induce endothelial nitric oxide synthase (eNOS) accumulation in 
endothelial cells, an effect dependent on the inhibition of Rho geranylgeranylation, reduce 
the activation of monocyte/macrophage system, the cytotoxicity of T-lymphocytes and the 
balance between Th-1/Th-2 subclass. Hence, statins modify the immune response in ACS 
via reductions in inflammatory cell number, adhesion, and activation at potentially 
vulnerable sites along the wall [Liao, 2002; Libby&Aikawa 2003]. 
In animal models HMG-CoA reductase inhibitors have been shown to reduce renal 
sympathetic nerve traffic [Pliquett et al., 2003]. To date, the underlying mechanism by which 
statins reduce sympathetic outflow has not been elucidated. An effect on central nitric oxide 
(NO) and reactive oxygen species (ROS) formation, as well as regulation of the AT1-receptor 
expression, have been proposed as possible explanations [Gao et al., 2005; Gomes et al.,  
2010; Hirooka et al., 2010; Patel et al., 2001]. 
Contradictory results have been published about the effect of statins on sICAM-1 and 
sVCAM-1 plasma/serum concentrations in patients with various clinical manifestation of 
ischemic heart disease. In a number of small population studies, different authors have 
noted that treatment with statins diminished sICAM-1 concentrations in subjects with 
hypercholesterolemia or CHD [Ascer et al., 2004; Patti et al., 2006]. However, Wiklund et 
al., 2002 observed a small and inconsistent effect of simvastatin and atorvastatin treatment 
in hypercholesterolemic patients. Furthermore, Jilma et al., 2003, demonstrated that 
atorvastatin, simvastatin, or pravastatin did not modify sICAM-1 concentrations after 3 
months of treatment in subjects with moderate hypercholesterolemia. Blanco-Colio et al. 
2007, investigate the effect of 10-, 20-, 40- and 80 mg Atorvastatin on sICAM-1 and MCP-1 
levels in 2117 patients with CHD in Achieve Cholesterol Targets Fast with Atorvastatin 
Stratified Titration Trial and didn’t found statistically significant differences between the 
various doses used. Although atorvastatin had a weak effect on sICAM-1 concentrations 
in the whole population [-2.2 % change (95% confidence interval -3.8 to -0.6%); P =.006], in 
the highest quartile all doses of atorvastatin diminished sICAM-1 plasma levels by more 
than 10% in subjects at high cardiovascular risk, indicating that atorvastatin has a greater 
effect in subjects with higher systemic inflammation. In the large PROVE-IT TIMI 22 
study Ray et al. 2006 didn’t found significant difference between intensive (80 mg 
Atorvastatin) and standart (40 mg Pravastatin) regiment on sICAM-1 levels at 30 days. 
However, when considered the relation among statin therapy, sICAM-1 levels, and 
clinical outcomes, the authors found that the risk of adverse events for patients with a 
sICAM-1 level >231 ng/ml appeared more marked among those allocated to standard 
dose statin therapy (each odds ratio >2.1). The observed pattern raises the hypothesis that 
the risk associated with sICAM-1 may be attenuated by treatment with intensive statin 
therapy (each odds ratio <1.5). 
In this study we have analyzed the effect of two rosuvastatin regimens on sICAM-1 and 
sVCAM-1 concentration in patients with high risk ACS defined by the levels of soluble 
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adhesion molecules. We observed that the treatment with rosuvastatin diminish both 
markers of endothelial activation during 12 week follow-up. We found out a trend towards 
lower concentrations of sICAM-1 in patients randomized to 20 mg Rosuvastatin, in addition 
to the previously observed significant lowering of low-density lipoprotein and C-reactive 
protein. There was no correlation between sCAMs and low-density lipoprotein and hsCRP 
at month 3 and the effect of rosuvastatin on soluble CAMs did not appear to be explained by 
changes in lipids or inflammatory markers.  
However, standart statin therapy did not significantly alter sVCAM-1 levels at 3 months. 
The present observations with sVCAM-1 are analogous to the observations with aspirin 
and clopidogrel in which each drug decreases the risk of adverse clinical events in 
subjects with high CRP levels but do not decrease CRP significantly [Chew et al., 2001; 
Kennon et al., 2001; Ridker et al., 1997]. A potential mechanistic explanation for our 
clinical observations is, that among subjects with increased endothelial activation, a more 
potent statin regimen could bind to lymphocyte function-associated antigen-1 on 
inflammatory cells to a greater extent, thus interfering with downstream effects of 
increased endothelial activation rather than decreasing endothelial activation itself. This 
hypothesis raises the possibility that novel therapeutic strategies that target inhibition of 
adhesion molecules may be of benefit in ACS, as has been demonstrated in animal 
models and in patients with inflammatory bowel disease [Gill et al., 2005; Van Assche et 
al., 2005]. 
An interesting finding was the observed beneficial effect of more intense statin regiment 
on some parameters of autonomic function. During the study period we found out a 
significant increase of high frequency component with represents the parasympathetic 
contribution to the spectrum, whereas low frequency remained unchanged. As a result, 
the LF/HF ratio, measure of autonomic balance was reduced significantly in patients 
received 20 mg Rosuvastatin. The results of the correlation analysis clearly suggest that 
some of the beneficial effects of more potent statin dose may be driven by the effect on 
endothelial and autonomic function [Lanza et al., 2006; Patti et al., 2006]. Supports for this 
hypothesis are the results of the meta-analysis of Patti et al, who found that high-dose 
statin pretreatment before percutaneous coronary intervention leads to a significant 
reduction in periprocedural myocardial infarction and 30-day adverse events. It is 
noteworthy that the effect is most pronounced, but is not limited in patients with elevated 
markers of inflammatory activity [Patti et al., 2011]. Our findings must be confirmed by 
larger studies. It may contribute to the achievement of specific treatment goals for each 
patient with proper drug selection and dose titration in high risk patients such as those 
with elevated markers of endothelial activation and depressed HRV. 
5. Conclusions 
In patients with ACS, soluble adhesion molecules are independent predictors of subsequent 
MACE and reduced HRV of medium-term mortality, suggesting that markers of endothelial 
activation and impaired autonomic function should be taken into account in the risk 
stratification of these patients. 
Our findings support the hypothesis that statins decrease endothelial injury and activation 
in patients with acute coronary syndromes. In addition we found that more aggressive 
regiment with early initiation of 20 mg Rosuvastatin significantly decreases sICAM-1 levels 
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and better preserve parasympathetically mediated variable of HRV. Future studies are 
required to elucidate the optimal dose of statin treatment in patients with ACS and high 
levels of markers of inflammatory and endothelial activation or impaired autonomic 
function. 
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1. Introduction 
Acute coronary syndrome (ACS), i.e. acute myocardial infarction (MI) and unstable angina, 
is a life threatening disease, and its treatment after onset has greatly improved; however, we 
are not satisfied with the long-term outcome of the patients with ACS. Furthermore, we 
cannot adequately prevent the onset of ACS, although we know many risk factors of ACS, 
e.g. diabetes mellitus, dyslipidemia, hypertension, obesity, and smoking. 
As plaque disruption and thrombosis is known as the major cause of ACS, many 
investigations to identify vulnerable plaques that are prone to disrupt have been performed 
but failed to identify high-risk lesions of future ACS event. Major reason for this failure may 
be that disruption of plaques does not always cause ACS and probably very few percentages 
of disrupted plaques may actually cause ACS. In order to know adequately about the 
mechanisms for the onset of ACS and to prevent it effectively, we have to clarify those 
missing factors that are essential for the disrupted plaques to cause ACS. 
In this chapter, we would like to elucidate and discuss on the known and unknown 
mechanisms for the onset of ACS from the angioscopic point of view. 
2. Culprit lesions of acute coronary syndrome 
The culprit lesions of ACS1, 2 have disrupted yellow plaque and thrombus in >90% of cases. 
The surface of the yellow plaques is irregular and has the adhesion of white or mixed 
thrombus. The plaque is defined as ruptured3, 4 if the protrusion of yellow necrotic core is 
observed; otherwise, it is defined as eroded (or non-ruptured). Thrombus2 directly adhering 
to the plaque surface is usually white, and it becomes reddish when blood flow is disturbed 
by massive white thrombus and the fibrin network captures many red blood cells in it, i.e. 
mixed or red thrombus. In the same way, thrombus becomes yellow when the fibrin 
network of white thrombus contains protruded necrotic core, i.e. yellow thrombus. 
After reperfusion therapy1 or coronary intervention with balloon or stent, the culprit lesion 
of ACS gradually loses its thrombogenicity. In the patients with acute MI, 64% of patients 
still have thrombus at their culprit lesion at one month after reperfusion, while it becomes as 
low as 5% at 6 months. The prevalence of thrombus at one month is higher in the patients 
with diabetic patients than in the non-diabetic patients (78% vs. 45%), suggesting that the 
healing process of disrupted plaque is deteriorated in the diabetic patients. 
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As >90% of ACS patients have disrupted yellow plaque in their culprit lesions, both 
ruptured and eroded plaques, which are detected in about 70% and 30% of cases, 
respectively, by pathologic studies, should be detected as yellow plaques5. We have recently 
revealed4 that both ruptured and non-ruptured yellow plaques detected by angioscopy have 
similar atherosclerotic characteristics including thin-cap fibroatheroma (TCFA) when 
examined by VH-IVUS (Figure 1). 
3. Detection of vulnerable plaques by angioscopy 
Because the majority of ACS culprit lesions have disrupted yellow plaques, yellow plaques 
should be the vulnerable plaques that are prone to disrupt. Yellow plaques are classified 
into 3 grades6 according to its yellow color intensity: grade 1, slight yellow; grade 2, yellow; 
and grade 3, intensive yellow (Figure 2). We have revealed that yellow plaques of higher 
yellow color grade have the higher incidence of having thrombus on it, i.e. higher incidence 
of disruption, suggesting that those plaques are more vulnerable. Furthermore, the yellow 
plaques of higher yellow color grade have the higher incidence of positive remodeling and 
the thinner fibrous cap7, which supports the idea that those yellow plaques are more 
vulnerable. 
Although we have experienced >5,000 cases of angioscopic examinations and found huge 
number of yellow plaques, it was quite rare that the plaque caused ACS shortly after the 
examination. However, the prospective follow-up of the angioscopically examined patients 
have revealed8 that patients with more than 2 yellow plaques per vessel have the higher 
incidence of ACS event than the patients with 1 or no yellow plaque per vessel during the 
mean follow-up interval of 4.8 years. Formation of yellow plaques occurs equally in the 
culprit and non-culprit vessels of MI as it is regarded pan-coronary process of 
atherosclerosis progression9 (Figure 3). Therefore, the patients who have many yellow 
plaques in their coronary arteries are regarded as vulnerable patients. Judging from the 
results of this and other angioscopic studies, the probability of each yellow plaque to disrupt 
and to cause ACS may be estimated5 as 25%/year and 0.3-1%/year, respectively.  
4. Silent plaque disruption and missing factors for the onset of acute 
coronary syndrome 
Disrupted yellow plaques are sometimes found in the asymptomatic patients or in the non-
culprit segments of ACS patients, which are called silent plaque disruptions10, 11. Factors 
required for the disrupted plaques to cause symptomatic ACS are unknown, which is an 
important but unsolved issue for clarifying the mechanism of ACS onset. However, 
thrombogenic potential of blood, thrombogenic potential of necrotic core that would be 
exposed to blood by plaque rupture, underlying stenosis or stenosis caused by the 
protrusion of necrotic core at the site of plaque rupture, and/or vasoconstriction may play a 
role for the onset of ACS after the disruption of vulnerable plaques12. Investigations to 
clarify the contributions of these or other factors have not been reported adequately. 
Although the thrombogenicity of blood, i.e. vulnerable blood, has been regarded one of 
important factors, reports on this issue are limited. We have recently reported13 that 
originally defined parameter of blood thrombogenicity (blood vulnerability index) is 
significantly and extremely higher in the patients with acute MI than in the patients with 
stable coronary heart disease. 
 








Most of ACS culprit lesions have disrupted yellow plaque, which is classified into ruptured or non-
ruptured yellow plaque by angioscopy.  Non-rupture would include small rupture and erosion of 
pathologic classifications.  Both of ruptured and non-ruptured yellow plaques have similar 
atherosclerotic characteristics by VH-IVUS.  (From reference #4) 
Fig. 1. Culprit lesions of ACS 
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Yellow plaques are classified into 3 grades according to these standard colors: grade 1, slight yellow; grade 2, 
yellow; and grade 3, intensive yellow.  Grade 0 indicates white color.  Yellow plaques of the higher grade are 
regarded more vulnerable as they have higher frequency of plaque disruption.  (From reference #6) 
Fig. 2. Classification of yellow plaques according to their color 
 
The yellow plaque at the culprit lesion is disrupted having thrombus on it.  There are multiple yellow 
plaques in the non-culprit segments both in culprit and non-culprit vessels.  The formation of yellow 
plaques is regarded pan-coronary process.  (From reference #9) 
Fig. 3. Coronary arteries in acute MI patients 
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5. Stent thrombosis and atherosclerosis 
Bare metal stent (BMS) is gradually covered by neointima and the coverage is usually 
completed by 3-6 months after implantation14. Neointima at 3-6 months is generally white 
and its surface is smooth; and stent is not seen buried under neointima. Yellow plaques 
under stent are also covered and buried under the neointima. Neointima becomes thinner 
and rather transparent at about 3 years again15, although its surface is smooth and 
thrombus is not detected on its surface. Therefore, the implantation of BMS stabilizes the 
vulnerable plaques by the formation of thick fibrous neointima over the plaques, which is 
called sealing effect of BMS. It takes about 10 years for the formation of vulnerable 
plaques in the fibrous healthy neointima over BMS leading to its disruption and onset of 
ACS. Very late stent thrombosis (VLST) in the BMS is indeed quite rare especially within a 
few years after implantation. 
On the other hand, neointima formation over drug-eluting stent (DES) is generally very 
poor16, 17; and stent is usually seen through very thin neointima or partly uncovered in the 
majority of cases (Figure 4). The incidence of thrombus at the stented lesion is 
significantly higher in the 1st generation DES (Cypher and Taxus DES) than in BMS. 
Furthermore, the stented lesions become yellow after Cypher DES implantation17, 18, 
suggesting that DES promotes progression of atherosclerosis (Figure 5). However, 
Endeavor DES is known to have larger late loss but have as good neointima formation as 
observed in BMS; and thrombus is rarely detected in this DES. Although the angioscopic 
findings on the newer DES has not been fully clarified, Xience V and Nobori DES appear 
to have as thin neointima as 1st generation DES but have lower incidence of thrombus 
than 1st generation DES. 
The mechanisms for the onset of VLST have not been fully clarified; however, uncovered 
stent strut, uncovered disrupted plaque, new disruption of uncovered yellow plaque, and 
new disruption of newly formed yellow plaque may be the probable thrombogenic 
sources19 that can cause VLST. After BMS and Endeavor DES implantation, thick and 
white fibrous neointima completely covers stent and plaques; and the incidence of VLST 
is known to be very low. However, as the neointima over Xience V and Nobori DES is thin 
and may not reduce the risk of new yellow plaque disruption, we should be careful about 
the incidence of VLST after the implantation of these stents. From the angioscopic point of 
view, Endeavor DES would be the safest DES among the DES examined by angioscopy. 
BMS that has not developed restenosis would be the best condition that should be 
achieved by newly developed DES in the future, i.e. complete coverage by rather thick 
white smooth neointima. 
6. Regression of vulnerable plaques by statin treatment 
Statin treatment is known to reduce both plaque volume evaluated by IVUS and yellow 
color evaluated by angioscopy20, 21. However, it has not been clarified which of plaque 
volume and plaque color is more directly associated with the risk of plaque disruption or 
the risk of ACS. According to the results of TWINS study20, yellow color of plaques 
regressed significantly from baseline to 28 weeks but did not change thereafter until 80 
weeks under atorvastatin treatment; on the other hand, plaque volume decreased gradually 
but significantly from baseline to 28 weeks and to 80 weeks. Early effect of statin treatment 
to reduce the risk of ACS might be reflected by the early regression of yellow color. 
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Various conditions of neointima coverage are observed at 1-year follow-up after DES implantation.  A: 
White and good (grade 2) neointima coverage is observed without thrombus formation.  B: Thin (grade 1) 
neointima coverage is observed without thrombus formation; and the vessel wall under stent is white.  C: 
Thin (grade 1) neointima coverage is observed without thrombus formation; however, the vessel wall 
under stent is yellow.  D: Neointima coverage grade is partly 1 and partly 2.  Both of vessel wall under 
stent and neointima over stent are yellow.  Yellow atherosclerotic neointima is often observed after Cypher 
stent implantation but never after BMS implantation.    E: Uncovered stent strut is observed on the yellow 
disrupted plaque.  Thrombus is detected on the yellow plaque and on the stent strut.  (From reference #17) 
Fig. 4. Angioscopic appearance of DES implanted lesions at follow-up 
 




Cypher stent was implanted on a white vessel wall (A).  However, at 1-year follow-up (B), neointima that 
covered the stent was yellow, suggesting the early formation of atherosclerosis in the neointima.  Yellow 
arrow indicates where the stent was implanted.  Red arrow indicates the stent strut.  (From reference #17) 
Fig. 5. Rapid progression of atherosclerosis in the neointima after DES implantation 
7. Investigation of missing factors and hypothesis on the mechanisms of 
ACS onset 
According to the results of PROSPECT trial22, in addition to the presence of TCFA, large 
plaque burden and narrow minimum lumen area were the risk of future coronary event. 
Although ACS is known to occur from angiographically mild to moderate stenosis, findings 
in PROSPECT trial may be consistent with this. Underlying stenosis that can be detected 
only by IVUS and large plaque burden that may cause abrupt progression of stenosis on 
rupturing may be important for the onset of ACS. Presence of relatively severe stenosis 
might be essential for the formation of occlusive thrombus at the disrupted plaque. The 
larger necrotic core might possibly have the higher thrombogenicity; however, there are 
very few investigations on the difference of necrotic core thrombogenicity. Vasoconstriction 
has been speculated to play an important role, although no investigation has ever 
demonstrated its contribution to the onset of ACS. We have reported13 that blood 
thrombogenicity (blood vulnerability index) is significantly and extremely higher in the 
patients with acute MI than in the patients with stable coronary heart disease. This high 
blood thrombogenicity might be either a cause or a result of ACS. However, none of stable 
coronary heart disease patients including those who had silent plaque disruption had that 
high blood vulnerability index. Therefore, silent plaque disruption will never result in the 
extreme increase of blood vulnerability index. Furthermore, ACS patients who were taking 
dual antiplatelet therapy also had high blood vulnerability index, suggesting that dual 
antiplatelet therapy was not adequately effective to prevent this increase of blood 
vulnerability index and thus failed to prevent the onset of ACS. 
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Process of positive feedback and cyclic flow variation might play an important role for the 
onset of ACS: i.e. a plaque disruption causes thrombus formation that increases 
thrombogenicity of blood and more thrombus would be formed; if the occlusive thrombus is 
formed, it may cause cyclic flow variation depending on the severity of stenosis and the 
amount of thrombus formed, which may further increase the thrombogenicity of blood; and 
the thrombus may finally occlude the artery. In this process, the amount of thrombus must 
be influenced by the thrombogenicity of both blood and exposed necrotic core; and the 
severity of stenosis would be determined by the underlying stenosis, the stenosis increased 
by the protrusion of necrotic core on plaque rupturing, and the stenosis caused by 
vasoconstriction that may be induced by thrombus formation. 
It is well known that silent plaque disruption is frequently detected in the patients with 
ACS23, suggesting that plaque disruption and/or thrombogenesis is generally promoted in 
ACS patients (Figure 6). Blood thrombogenicity would be increased in ACS patients as 
mentioned above. Another idea is that coronary vessels generally have inflammation in ACS 
patients, i.e. coronary flu syndrome, which might possibly be the initiation mechanism of 
ACS. 
These mechanisms should be examined more intensively by clinical and basic 
investigations; and blocking some of these steps may be able to prevent the onset of ACS. 
 
 
In a patient with acute MI (culprit lesion at red arrow), a silent plaque disruption (at yellow arrow) was 
detected. The healing process of silently disrupted yellow plaque was observed as the regression of 
yellow color intensity and the disappearance of thrombus by 6 months.  (From reference #23) 
Fig. 6. Silent plaque disruption and its healing in the non-culprit segments in acute MI 
patients 
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Process of positive feedback and cyclic flow variation might play an important role for the 
onset of ACS: i.e. a plaque disruption causes thrombus formation that increases 
thrombogenicity of blood and more thrombus would be formed; if the occlusive thrombus is 
formed, it may cause cyclic flow variation depending on the severity of stenosis and the 
amount of thrombus formed, which may further increase the thrombogenicity of blood; and 
the thrombus may finally occlude the artery. In this process, the amount of thrombus must 
be influenced by the thrombogenicity of both blood and exposed necrotic core; and the 
severity of stenosis would be determined by the underlying stenosis, the stenosis increased 
by the protrusion of necrotic core on plaque rupturing, and the stenosis caused by 
vasoconstriction that may be induced by thrombus formation. 
It is well known that silent plaque disruption is frequently detected in the patients with 
ACS23, suggesting that plaque disruption and/or thrombogenesis is generally promoted in 
ACS patients (Figure 6). Blood thrombogenicity would be increased in ACS patients as 
mentioned above. Another idea is that coronary vessels generally have inflammation in ACS 
patients, i.e. coronary flu syndrome, which might possibly be the initiation mechanism of 
ACS. 
These mechanisms should be examined more intensively by clinical and basic 
investigations; and blocking some of these steps may be able to prevent the onset of ACS. 
 
 
In a patient with acute MI (culprit lesion at red arrow), a silent plaque disruption (at yellow arrow) was 
detected. The healing process of silently disrupted yellow plaque was observed as the regression of 
yellow color intensity and the disappearance of thrombus by 6 months.  (From reference #23) 
Fig. 6. Silent plaque disruption and its healing in the non-culprit segments in acute MI 
patients 
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